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Introduction: Muscle fiber and motor unit typing
Muscle fiber types can be described using morphological, histo-
chemical, immunohistochemical and biochemical characteristics. 
Clear morphological differences were seen in birds, with fast 
muscles appearing white and slow muscles appearing red. The 
redness of the slow muscle is due to the greater myoglobin 
and capillary content that permits a greater oxidative capacity 
of the muscle (Staron, 1997).  Research has long shown that 
there is a clear correlation between myosin ATPase activity and 
muscle contraction speed.  Studies in rats, measuring isolated 
muscle units, lead to initial classification of muscle fibers based 
on their isometric twitch contraction speed as fast, interme-
diate and slow (Pette et. al., 1999). Presently, muscle fibers are 
classified by means of 3 different techniques: histochemical my-
osin ATPase staining, immunohistochemical myosin heavy chain 
isoform identification, and biochemical identification of meta-
bolic enzymes.
Histochemical Classification
Myosin ATPase histochemical staining confirmed the diversity 
of muscle fibers.  The stain’s intensity differs based on the my-
ofibrillar differences in pH sensitivity.  Type I fibers were found 
to be alkali labile (lighter stain, low ATPase activity) and acid 
stable (intense stain, high activity), while type II fibers were alkali 
stable and acid labile (Staron, 1997, Sieck, Prakash, 1997).  At 
first, fibers were identified as slow type I, and fast types IIA and 
IIB (Pette et. al., 1999).  However, advances in the histochemical 
staining technique has led to the identification of a total of 7 
human muscle fiber types (Staron, 1997).  The newly identified 
fibers, types IC, IIC, IIAC, and IIAB, have intermediate myosin 
ATPase staining characteristics.  Type IC, the slowest fiber, stains 
most similarly to type I fibers, while type IIAB fibers have inter-
mediate staining characteristics between type IIA and IIB fibers. 
Thus, the 7 human muscle fiber types (from slowest to fastest), 
as identified by myosin ATPase histochemical staining are: types 
I, IC, IIC, IIAC, IIA, IIAB, and IIB (Pette et. al., 1999). As seen in 
the literature, some researchers do not use all 7 fiber types, 
but rather place all fibers into the original 3 categories (Staron, 
1997).
Immunohistochemical Classification
A second fiber type classification is based on the identification 
of different myosin heavy chain (MHC) isoforms (Pette et. al., 
1999). Immunohistochemical analysis of human muscle began 
after scientists discovered antigenic differences between the 
myosin types of different human muscle (Staron, 1997). Isoforms 
were identified using antimyosin antibodies or by sodium do-
decyl sulfate-polyacrylamide gel electrophoretic (SDS-PAGE) 
separation (Pette et. al., 1999).  A general correlation was dis-
covered between the histochemically classified fiber types and 
the MHC isoforms they express (Sieck, Prakash, 1997, Fry et. al., 
1994).  The original 3 myosin isoforms identified were MHCI, 
MHCIIa, and MHCIIb, corresponding to those identified by my-
osin ATPase staining as pure types I, IIA, and IIB, respectively. 
However, each muscle fiber can contain more than one myosin 
heavy chain isoform, forming hybrid fibers.  This phenomenon 
explains the existence of more muscle fiber types than the 
amount of pure isoforms. These mixed fibers almost always 
contain “neighboring” myosin heavy chain isoforms (i.e., MHCI 
and MHCIIa or MHCIIa and MHCIIb) (Pette et. al., 1999).  Type 
IIAB fibers that have a predominance of the MHCIIa isoform 
stains more like type IIA fibers, but fibers that have a predom-
inance of the MHCIIb isoform stains more like type IIB fibers 
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(Staron, 1997). Consequently, the histochemical myosin ATPase 
types express their isoform genes to varying degrees, according 
to the variable ratio of isoforms present in the fiber.  Due to 
its quantitative nature, the SDS-PAGE technique is perhaps the 
best method for muscle fiber typing, as electrophoretic separa-
tion permits the recognition of the relative concentrations of 
different myosin heavy chain isoforms in mixed muscle fibers 
(Pette et. al., 1999, Fry et. al., 1994).
A fourth myosin heavy chain isoform, MHCIIx or MHCIId, and 
its corresponding fiber type IIX, is present in small mammals. 
Evidence shows that MHCIIb in humans in homologous to 
MHCIIx/d of small mammals (Pette et. al., 1999, Hilber et. al., 
1999). In actuality, MHCIIb in humans is really MHCIIx/d, as hu-
mans do not express MHCIIb, the fastest myosin heavy chain 
isoform (Pette et. al., 1999).  In fact, recent data shows that 
fibers that were histochemically identified as type IIB in humans 
contain low amounts of MHCIIa, and therefore, in reality, are 
hybrid type IIAB fibers (Staron, 1997).  Therefore, the 3 myosin 
heavy chain isoforms present in human limb muscles are (from 
slowest to fastest): MHCI, MHCIIa, and MHCIIx/d (previously 
incorrectly known as MHCIIb).
Biochemical Classification
A third classification technique reflects the energy metabolism 
of the muscle fibers.  Histochemical myosin ATPase fiber typ-
ing of type I or type II corresponds to slow and fast muscle 
fibers, respectively, and the enzymes involved reflect the meta-
bolic pathways that are either aerobic/oxidative or anaerobic/
glycolytic (Pette et. al., 1999). This classification scheme leads to 
3 fiber types: fast-twitch glycolytic (FG), fast-twitch oxidative 
(FOG), and slow-twitch oxidative (SO) (Pette, Staron, 1997). 
Type I and IIA fibers have a greater mitochondrial density and 
oxidative capacity than type IIB and IIX fibers (Sieck, Prakash, 
1997).  Accordingly, there is a good correlation between type I 
and SO fibers, but correlations between type IIA and FOG and 
type IIB and IIX and FG fibers are more diverse (Hamalainen, 
Pette, 1995).  This can be explained by the fact that changes 
in oxidative capacity can take place without changes in MHC 
isoforms (Staron, 1997).  Generally, type I fibers rely primarily 
on aerobic/oxidative energy metabolism and type II fibers rely 
primarily on anaerobic/glycolytic metabolism,  but as it cannot 
be assumed, the terms type IIB and FG or type IIA and FOG 
cannot be used interchangeably (Pette et. al., 1999).
Myosin Light Chains
The myosin light chains also exist in different isoforms, slow 
and fast, and affect the contractile speed of the fiber (Talmadge, 
Pette, 1995). A homogeneous/pure myosin heavy chain isoform 
can be heterogeneous in regard to its myosin light chain iso-
form.  Usually, however, fast heavy chain isoforms fuse with fast 
light chain isoforms, and slow heavy chain isoforms fuse with 
slow light chain isoforms (Pette et. al., 1999, Jostarndt-Fogen et. 
al., 1998).
Motor Unit Classification
The proper functional unit of the neuromuscular system, the 
motor unit, reflects the characteristics of its individual fibers. 
Motor units are categorized based on their contractile speeds 
and fatigue characteristics.  Contractile speed classifies motor 
units into slow-twitch (S), usually comprised of type I fibers, or 
fast-twitch (F), usually comprised of type II (Burke, 1999). The 
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F motor units are additionally classified by their type II fiber 
subdivisions.  Fast-twitch fatigue-resistant (FR) are comprised of 
type IIA fibers, fast-twitch fatigue-intermediate (Fint) are com-
prised of type IIX, and fast-twitch fatigable (FF) are comprised 
of type IIB (Burke, 1993).  The fatigue resistance of the muscle 
unit is explained by the mitochondrial density and oxidative ca-
pacity of the muscle fibers.  The motor unit typically reflects 
the function of the muscle.  The diaphragm muscle employs its 
fatigue-resistant S and FR units to produce normal breathing, 
but must recruit its Fint and FF units for actions that require 
greater force, such as gagging or sneezing.  Contrariwise, the 
extensor digitorum longus muscle of the limb, which is used for 
motor activities demanding short periods of greater force pro-
duction, is composed mostly of FF type IIB fibers.  Consequently, 
type I and IIA fibers are intended to sustain longer periods of 
activation, while type IIX and IIB fibers are intended to produce 
shorter bursts of activation (Sieck, Prakash, 1997).
Therefore, the overall properties of a muscle reflects the prop-
erties of its heterogeneous collection of fiber types and their 
overall proportions.  It is this range of fiber types that allows for 
the wide range of muscle function a single muscle can display. 
Muscle fibers adapt to their motor unit’s changing stimuli not 
only by changing their size, but by converting their fiber type 
composition to suit the functional demands. This muscle plas-
ticity serves as the physiologic basis for the adaptions of skeletal 
muscle to resistance and endurance exercises.
Methods
EBSCO multi-search, ProQuest Medical Library, Wiley Library, 
Journal of Applied Physiology, MEDLINE, and PubMed databases 
were used to find material for this paper.  Access was gained to 
these databases through the Touro College Online Library and 
Einstein Online Library websites.   Key words, such as “muscle 
fiber types” and “effects of exercise on muscle” were used to 
search for scientific articles. After reading through these articles, 
other key words were identified, such as “fiber-type shifting”, 
and “resistance vs endurance”.  Additionally, sources listed as 
references for review articles on the APTA website (American 
Physical Therapy Association) were searched for to find the 
original papers. 
Discussion
The plasticity of the heterogeneous composition of muscle 
fibers allows for adaptations in the contractile and metabolic 
properties of skeletal muscle.  Various phenotypes are there-
fore possible in response to different workloads. This plasticity 
has practical implications, both for athletes and rehabilitation 
patients alike.
This range of myosin form expression in response to exercise 
regimes is evident in the vastus lateralis.   In untrained, physically 
active subjects, the vastus lateralis is made up of roughly 50% 
of slow type I fibers and 50% type II fibers (40% type IIA and 
10% IIX).  Power athletes, such as sprinters, power weight lifters 
and throwers, are constituted chiefly of IIA and IIX fibers, with 
a percentage of type I as little as 20%.  Ultra-endurance athletes, 
such as long-distance runners, have a 95% constitution of type 
I fibers. The variability of the composition of the vastus latera-
lis muscle is due to fiber type shifting.  Long-term endurance 
training induces a substantial transformation from fast muscle 
fibers to slow muscle fibers. Slow muscle fibers rely mainly on 
aerobic metabolism and, for that reason, are vital for endurance 
activities such as swimming, cycling and marathon running.  The 
shift in MHC isoform type depends on changes at the molecular 
level.  New slow MHC polypeptides, which are still categorized 
as type IIA fibers, are produced, marking the start of their tran-
sition towards the slow type I fibers (Zawadowska et. al., 2004). 
In response to training, the most common fiber conversions are 
between type IIB and type IIA.  Slow to fast/ type I to type II 
conversions are possible in response to the loss of function re-
lated to deconditioning, as shown in studies on humans with spi-
nal cord injury and microgravity exposure during their time in 
space. Detraining in humans (i.e., decreased use of skeletal mus-
cle following a formerly high activity level) leads to shifts MHCIIa 
to MHCIIx/d and possibly MHCI to MHCIIa.  Additionally, there 
is a related decrease in aerobic-oxidative metabolic enzymes 
(Pette, Staron, 1997). In short, immobilization of skeletal muscle 
may cause conversions in the slow to fast direction.  Scientists 
assumed that power training may also cause the transformation 
in slow to fast direction. This was a logical assumption, since fast 
muscle fibers depend mainly on anaerobic metabolism and are 
consequently essential for power training, such as sprinting and 
weight lifting. Additionally, IIX fibers produce a greater maximal 
power output than IIA fibers and are therefore essential for 
such activities.   However, studies have proven that all methods 
of training (both endurance and power/resistance) cause a con-
version toward the slow direction (Zawadowska et. al., 2004).
Endurance
Many studies have proven that endurance exercises (low-resis-
tance, repeated contractions that require the muscle to produce 
a high aerobic metabolic rate) lead to several adaptations within 
the muscle to augment aerobic metabolism and resistance to fa-
tigue (Staron et. al., 1990). Firstly, the oxidative capacity of all fiber 
types will increase by increasing the amount of mitochondria, oxi-
dative/aerobic enzymes and capillaries in the muscles being trained 
(Holloszy, Booth, 1976, Fitts, Widrick 1996).  Based on metabolic 
classification scheme, there is a transition from the FG fiber type 
to the FOG fiber type without, necessarily causing a change in the 
myosin heavy chain composition (Pette, Staron, 1997).
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Secondly, there are alterations in myosin heavy chain isoform. 
It has been suggested that there is an increase in the percent-
age of type I fibers following aerobic training, and a subsequent 
decrease following detraining in elite endurance athletes. 
Additionally, within type II fibers, MHCIIx/d (IIB) are converted 
to MHCIIa (IIA).  In other words, there is a decrease in the 
population of pure type IIB fibers and an associated increase in 
the population of pure type IIA fibers. It also seems that there 
is an increase in the hybrid population of type I and type II fi-
bers, known as type IIC (Staron et. al., 1990).  Evidence as to 
the conversion of type II to type I fibers, as stated previously, 
is lacking (Ricoy et. al., 1998).  The transformation of type IIB 
fibers to type IIA in response to endurance training is fairly 
logical.  Although there are variations on the oxidative capacities 
within a muscle type, as a class, type IIA fibers generally have a 
greater oxidative capacity than type IIB fibers.  Therefore, an 
increase in the population of type IIA fibers makes the muscle 
more oxidative. In fact, there is a negative correlation between 
the percentage of type IIB fibers and maximum oxygen intake. 
Therefore, as stated previously, detraining and immobilization 
cause a conversion in the slow to fast direction, from type IIA 
to type IIB (Staron et. al., 1990).
Thirdly, there can be a transformation in myosin light chain iso-
forms.  Type I fibers show an increase in contractile speed in 
response to endurance exercises, but show a decrease following 
deconditioning in humans. Logically, this change cannot be ex-
plained by a conversion of fiber type, but rather, by a conversion 
in the myosin light chain isoforms from slow to fast and from fast 
to slow, respectively (Larsson et. al., 1996, Widrick et. al., 1996). 
The conversion from slow to fast allows the fibers to maintain 
their properties of efficient energy usage while increasing their 
contractile speed to keep up with the demands of the exercise 
(Fitts, Widrick, 1996).  Such a conversion would not be detected 
by the histochemical technique, as there is no change in the my-
osin ATPase (Pette, Staron, 1997).  To summarize, muscle fiber 
adaptations to endurance exercise varies based on fiber type. 
In all types, the oxidative capacity of the fibers increases.  Type 
II fibers shift in the type I direction, leading to slower, oxidative 
types.  Type I fibers convert their myosin light chains to increase 
their contractile speeds.
Resistance/Power
High-intensity resistance strength training involves short, max-
imal contractions that require the muscle to produce a large 
amount of anaerobic energy (Staron et. al., 1990).  Resistance 
training, such as high-load–low-repetition exercises, leads both 
to the fiber type shifting seen with endurance training and to 
muscle hypertrophy, which plays a significant role in increas-
ing force production (Kraemer et. al., 1996).  Initial strength 
gains made with high-intensity resistance training are caused 
by neural factors, rather than hypertrophy of the actual mus-
cle fibers.  However, adaptations may also be occurring in the 
contractile proteins of skeletal muscle within a short duration 
of training, even two weeks, with sufficient intensity (McArdle 
et. al., 1994). Visible hypertrophy is not evident until later in 
the training period (>8 weeks) (Kraemer et. al., 1996), around 
the same time researchers found a shift in muscle fiber type 
composition from MHCIIx/d to MHCIIa (Staron et. al., 1994, 
Kraemer et. al., 1995, Staron et. al., 1990). 
To explore this plasticity, twenty four male subjects were cat-
egorized into three groups according to their sports/physical 
activity.  Group A was made up of untrained students, group 
B of national and sub-national level endurance athletes (7.8+/-
2.9 years of specialized training) and group C of sprint-power 
athletes (12.8+/-8.7 years of specialized training). Biopsies of 
the vastus lateralis muscle were obtained and immunohisto-
chemically analyzed for fast/slow MHC composition. This mus-
cle is easily accessible and easily trained.  Most importantly, it 
expresses all three myosin isoform types at specific amounts, 
and so its phenotype visibly mirrors any adaptive modifications 
that occur after different forms of exercises. Unpredictably, 
group C sprint-power athletes (such as ice hockey, volleyball, 
karate, soccer players and modern dancers), who were ex-
pected to display the highest percentage of MHCIIX, were no 
different in this aspect from group B endurance athletes (such 
as marathon runners, cyclists and cross country skiers). The 
muscle phenotypes of both groups were similar, containing a 
small proportion of the MHCIIX isoform and a predominance 
of slow MHCI isoform. Clearly, the muscle phenotype was 
adapted for long lasting, sustainable activities (similar to what 
happens in endurance athletes), rather than activities that re-
quire a maximum power output in minimal time. Moreover, 
the fastest isoform, MHCIIX, was relatively lower in group C 
athletes than in group A students. This myosin profile in group 
C athletes is unfavorable to their sport. Muscles that contain 
a higher percentage of type IIX fibers have a greater maxi-
mum shortening velocity, which is the most important factor 
in maximum power output and therefore vital for their sports 
regime.  This is a possible explanation for why, despite years 
of training, these athletes could not reach international level 
(Zawadowska et. al., 2004).
A study performed on women proved similar to the results 
shown by  men.  To examine the adaptations that take place 
following a high-intensity resistance strength training program 
(i.e. hypertrophy and fiber type shift), twenty-four women 
participated in a 20- week program for the lower extremi-
ty.  Biopsies were obtained both before and after the training 
program from the superficial part of the vastus lateralis.  Once 
again, this muscle was chosen due to its easy accessibility, broad 
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fiber type composition, and potential for training (Staron et. al., 
1990).
Based on staining intensities using MATPase histochemistry, 
six fiber types (I, IC, IIC, IIA, IIAB, and IIB) were distinguished, 
and three groups were determined based on fiber type (I, IIA 
and IIA+IIB) . Dramatic hypertrophy of all three groups (I= 
15%, IIA= 45%, and IIAB +IIB= 57%) following a high- intensi-
ty strength training regime showed that fast twitch fibers are 
not the only fibers affected.  There appears to be an increase 
in contractile elements within the muscle fibers, leading to 
an increase in both muscle strength and size, similar to the 
adaptations found in men following strength exercises (Staron 
et. al., 1990).   
Additionally, the data shows that strength training causes mus-
cle fiber-type conversions.  In the pre-training biopsy sample, 
group 1 (type I) had the largest cross-sectional area (4253±949 
µm2), group 2 (type IIA) had intermediate (3370±1048 µm2), 
and group 3 (type IIAB+IIB) had the smallest (2697±931 µm2). 
Despite a hypertrophy of all three groups, the “hierarchy of 
fiber sizes” was changed following training.  The areas of group 
1 and 2 were not significantly different from each other (type I 
= 4893±770 µm2, type IIA = 4888±967 µm2), and the area of 
group 3 was still significantly smaller (4233±1433 µm2) than 
the areas of both group 1 and 2.  Therefore, despite the fact 
that the total area of type IIB fibers increased, the percentage 
of IIB fibers (MHCIIx/d) significantly decreased, with a con-
comitant increase in the percentage of IIA (MHCIIa) fibers 
(Staron et. al., 1990, Figure 1).  
It is assumed that the recruitment of the infrequently activated 
IIB fibers caused their transformation to type IIA fibers.  This 
increases the oxidative capacity of strength-trained muscle, as 
supported by the findings of significantly greater volumes of 
mitochondria in weightlifters’ muscles compared to untrained 
subjects.  This also explains the observation of an increase in 
short-term endurance following an intense-resistance training 
routine (Staron et. al., 1990).  As a result of this shifting, reduc-
tions in myosin heavy chain “coexpression” has been reported 
both after endurance and resistance training, with a corre-
sponding increase in pure fibers (Williamson et. al., 2000). 
Conclusion
The study of muscle fiber types has constantly been evolving 
over the past several decades.  New systems of classification 
that categorize the fibers into more specific groups enables 
researchers to accurately track the changes that occur within 
a muscle’s fibers.  Endurance training is known to increase the 
muscle’s endurance by increasing the oxidative capacity of its 
fibers, as supported by the increase in type I fibers. Resistance/
power training is known to increase the volume of the contrac-
tile proteins in the muscle fibers, promoting hypertrophy of the 
muscles.  However, research shows that rather than increasing 
the percentage of fast muscle fibers, as expected, resistance ex-
ercises leads to fiber type shifting in the slow direction, increas-
ing the oxidative capacity of the muscle.  
While research has proven that resistance exercises leads to 
hypertrophy and muscle type shifting in both men and women, 
such studies are fairly new.  Research conducted on the effects 
of endurance exercises far exceeds the research conducted on 
the effects of resistance exercises.  As such, studies pertaining to 
resistance exercises do not always agree, and the pool of avail-
able research is not large enough to evaluate which studies are 
most accurate.  For example, some papers claim that fiber type 
shifting causes type IIB to convert to type I fibers, while other 
papers say that type IIA is the farthest it can go.  Therefore, ad-
ditional research must be conducted to shed light on this topic 
and determine which theory is correct.  However, it is clear 
that just like endurance exercises, resistance exercises lead to 
conversions in the fast to slow direction, and not in the slow to 
fast direction (as was originally assumed). 
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Millions of people across the globe are exposed each day to acous-
tic overstimulation – noise – in their daily activities, whether at 
their jobs or during their leisure activities.  Noise is one of the 
most common sources of environmental stress, and it can cause 
both mechanical and metabolic damage to an individual’s ear. As a 
result, noise-induced hearing loss (NIHL) is a disability that is wide-
spread among individuals exposed to either prolonged loud noise 
or excessively loud noise. More than 600 million people around the 
world endure excessive noise at their jobs and are thus at risk for 
NIHL. Millions more expose themselves to excessive noise during 
leisure activities, particularly when listening to or playing music, and 
they too place themselves at risk to developing NIHL.
The susceptibility to NIHL has been shown to have both environ-
mental and genetic factors. Environmental variables that increase 
a person’s likelihood of developing NIHL include noise exposure 
that is combined with extreme temperatures, chemical solvents, 
and prolonged vibration. Individual environmental factors including 
smoking, high blood pressure, and high cholesterol levels, have also 
been shown to increase an individual’s risk of developing NIHL. 
Currently, the genetic factors that increase a person’s susceptibility 
to NIHL are largely unknown. Many animal studies are currently 
ongoing to identify genetic polymorphisms linked with NIHL.
This paper will explore how noise impacts both the mechanical 
structure of the ear and the metabolic processes within the ear. 
Additionally, it will examine recent and ongoing studies regarding 
the genetic factors that increase a person’s susceptibility to de-
veloping NIHL, as well as the preventative and therapeutic inter-
ventions that are currently in use or being tested in experimental 
stages.
Methods
The information in this paper was synthesized from literature 
reviews and studies published in peer-reviewed journals. The 
articles were selected using databases, primarily the Academic 
Search Complete (EBSCO) database made available through the 
Touro College virtual library. Data was extracted according to 
relevance, with special attention given to NIHL statistical data; 
mechanical and metabolic disruption in the ear as a result of 
noise trauma; and the diagnosis, treatment, and genetic factors 
related to NIHL.
Discussion
The word noise is derived from the Latin word nausea, which 
means “impulsive, unwanted, and unpleasant” (Taneja, 2014). 
In medical terms, noise has been defined as a “physical agent 
capable of causing damage to the human body with the short 
and medium term effects” (Metidieri et al., 2013). Sound is 
measured in units known as decibels (dB), and normal sounds 
are generally less than 75 dB and are unlikely to cause any 
damage to the ear or cause hearing loss. However, sounds 
that are higher than 85 dB can cause physical damage to the 
structures of the ear. This includes excessively loud noises 
that are short and sudden, such as gunshots or explosions. 
Moreover, an individual who is frequently exposed to noises 
that are continuously and moderately loud can experience 
damage to hearing structures that results in NIHL.NIHL can 
involve functional limitations for a number of hearing process-
es, including “changes in frequency selectivity, temporal and 
spatial resolution, recruitment, and tinnitus as well as changes 
in hearing sensitivity” (Metidieri et al., 2013). NIHL is the sec-
ond most common hearing loss after age-related hearing loss 
(Levey et al., 2012).
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Excessive noise in public areas has been called noise pollution, 
and it is considered an environmental problem along with other 
forms of pollution, such as smog or water pollution. In fact, noise 
pollution affects the largest number of people worldwide,ac-
cording to the World Health Organization (WHO) (Metidieri 
et al., 2013). In research on NIHL, noise is classified in three 
categories: (i) continuous noise, which is noise that persists for 
minutes or hours at about the same level of intensity; (ii) impact 
noise, which is a high level but short duration noise that occurs 
when two objects collide; and (iii) impulse noise, which is a high 
level but short duration noise that results from an explosion or 
gunfire(Bielefeld, 2015).NIHL can be diagnosed as either acous-
tic trauma or chronic NIHL. Acoustic trauma is defined as a sud-
den but permanent hearing loss caused by a one-time exposure 
to a forceful sound, with sound pressure levels of approximately 
130-140 dB. The extent of damage after an acoustic trauma will 
vary from mild to profound. In contrast, chronic NIHL results 
from gradual exposure to less forceful noise over an extended 
period of time, and this to can result in either mild or profound 
hearing loss (Rajguru 2012). 
Approximately 25% of workers across the globe are exposed 
to noise levels that can induce NIHL. It is the most common 
work injury (Metidieri et al., 2013). Noise exposure is often ex-
perienced with other causal agents of NIHL, including chemical 
exposure. For example, when an individual is exposed to car-
bon monoxide and noise simultaneously, he has a higher risk of 
developing NIHL, even though exposure to carbon monoxide 
alone rarely induces hearing loss (Kashani et al., 2011). Smoking 
cigarettes while being exposed to noise both raises the risk of 
NIHL and increases the extent of the hearing damage. This may 
be due in part to the carbon monoxide exposure related to 
cigarette smoke (Liuyan et al., 2013). Other causal agents in-
clude vibrations, medications, and one’s individual susceptibility 
to hearing loss (Metidieri et al., 2013).  
The National Institute for Occupational Safety and Health 
(NIOSH) estimates that in the United States alone, there are 
5–30 million workers who are exposed to dangerous noise levels 
each year (Bielefeld, 2015).NIHL is an insidious condition, as those 
exposed to loud noise are generally unaware that damage is oc-
curring until it is too late (Levey et al., 2012). It is characterized 
by a decrease in hearing sensitivity to sounds that fall between 
3000–6000 Hz (known as the “notch”). The decrease in hearing 
sensitivity is often asymmetric. Typically, there is greater hearing 
loss in the left ear than in the right ear (Phillips et al., 2010).
Individuals from all segments of the population are at risk for 
NIHL, though there is a higher prevalence among men (Pelosi, 
2014). Among Americans aged 20-69, there are 23 million peo-
ple (12.8% of this demographic) who have NIHL (Bielefeld, 
2015).However, the risk of developing NIHL is unrelated to 
age (Phillips et al., 2010).In fact, the pervasiveness of NIHL rises 
steadily over childhood and adolescence (Pelosi, 2014).The 
American Academy of Audiology estimated in 2008 that one in 
eight children has sustained NIHL. In 2010, a similar estimate 
was made in which 16% of teenagers were thought to have sus-
tained NIHL.Among younger demographics, NIHL is typically 
caused by exposure to excessively loud music over an extended 
period of time, particularly on personal listening devices such 
as iPods, MP3 players, or CDs. Children’s toys that emit loud 
sounds have also been found to cause NIHL. A study conducted 
with 329 student musicians between the ages of 18 to 25 years 
found that 45% of the students had sustained NIHL, with 78% 
of the hearing loss happening at 6000 Hz (Levey et al., 2012).
Noise exposure at work is often associated with factory work-
ers who spend their working hours in cramped spaces with 
loud, industrial machinery. However, there are less conventional 
occupations that have high risk of NIHL as well. As many as 
60 percent of military personnel involved in active duty re-
turn home with NIHL or tinnitus, and have both (Pelosi, 2014). 
This is likely due to their excessive gun use (Berg et al., 2014). 
Firefighters, too, are at high risk for NIHL, as the noise they are 
exposed to regularly is usually high in intensity and short in 
duration (Hong et al., 2013).
Individuals who do not work in noisy environments or listen 
to loud music can also be at risk for NIHL in their daily lives. 
Neitzel et al. found that New York City subway riders are ex-
posed to noise louder than the limits recommended by WHO 
and the United States Environmental Protection Agency (EPA). 
This presents a heightened risk for NIHL to those who use 
mass transit often, especially those who remain on the subways 
for a longer period of time (Nietzel et al., 2009). 
Mechanical Structure and Metabolic  
Processes of the Ear
The prevalence of NIHL demonstrates how the ear is a complex 
and vulnerable organ. The cochlea is the inner ear organ that con-
verts sound for the process of hearing. The cochlea holds the organ 
of Corti, which is comprised of hair cells that serve as the sensory 
receptors of sound. There are two types of hair cells: inner hair cells 
and outer hair cells. The inner hair cells use the auditory nerve to 
communicate with the brain to create sound perception. The outer 
hair cells amplify sound, increasing hearing sensitivity by ∼40 dB. The 
organ of Corti also contains a number of supporting cells that form 
the physical structure of the ear that is necessary for the mechani-
cal movement that occurs when sound waves reach the ear.
The organ of Corti requires metabolic homeostasis to properly 
convert sound waves and auditory signals. Noise exposure can 
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Figure 3:
Movements of the basilar membrane and the deflection of the 
stereocili:
A. Upward movement of the basilar membrane (arrow) deflects 
hairs away from the modiolus.
B. The basilar membrane is at rest is 
C. Downward movement (arrow) deflects hairs toward the modiolus. 
(Klinke, 1978)
damage the cochlea both metabolically and mechanically, and NIHL 
can occur from either metabolic or mechanical deterioration, as 
well as from a combination of both (Bielefeld, 2015). (Figures 1 
and 2)
Normal Ear Function
The hearing process is a complex series of steps that occurs 
when a sound is emitted. Sound waves travel to an individual’s 
ear, where the hair cells act as receptors for the energy from 
sound waves and then convert the sound waves into nerve 
signals that reach the brain (Pelosi, 2014). Sound waves first 
enter the outer ear and then traverse the ear canal to reach the 
eardrum. When the sound waves strike the eardrum, it begins 
to vibrate, and the vibrations reach the middle ear. In the middle 
ear, bones (also known as “ossicles”) called the malleus, incus, 
and stapes, amplify the sounds. The vibrations are then sent to 
the inner ear, known as the cochlea, which is a fluid-filled organ 
with an elastic membrane known as the basilar membrane. 
Attached to the basilar membrane, there are sensory cells, 
known as outer and inner hair cells. The vibrations that reach 
the inner ear generate a traveling wave that runs along the bas-
ilar membrane as a result of the electromotility of the outer 
hair cells. The movement induces stereocilia, spiky structures 
on the apical surface of the inner hair cells, to rub up against 
the tectorial membrane and thus release neurotransmitters 
that travel across the synapse between the inner hair cell and 
the auditory nerve. Figure three depicts these movements. This 
process allows for sound waves to change into electrical signals 
that are carried to the brain by the auditory nerve, and the 
brain allows the individual to perceive the sound he is hearing 
(Levey et al., 2012).
Development of NIHL
Most cell populations in the cochlea are vulnerable to noise 
damage. Noise can impair or kill: the pillar cells, which provide 
the structural support for the organ of Corti; thefibrocytes of 
the lateral wall, which allow potassium recycling necessary for 
the depolarization of the hair cells; and the outer and inner 
hair cells, which are vital for reducing hearing thresholds, dis-
criminating between sound frequencies, and delivering auditory 
information to the brain. The synapses between the inner hair 
Figure 1: Diagram of the cochlea cut through along the modiolus. 
Arrows demonstrate the pathway of pressure waves that originate 
in the oval window.
(Curtis et al., 1970)
Figure 2: Cochlear partition and the organ of Corti. 





cells and afferent auditory nerve neurons are also susceptible 
to noise damage, and damage to these synapses can result in 
long-term auditory nerve neuropathy (Bielefeld, 2015). An in-
dividual with NIHL will experience deterioration of the ciliat-
ed cells of the organ of Corti (Metidieri et al., 2013). Figure 4 
shows the destruction of a region of the organ of Corti. The 
noise exposure induces overproduction of free radicals. While 
free radicals are often present in cells, they can be destructive 
when they are overproduced, resulting in an overpowering of 
the ear’s antioxidant defense systems. These free radicals are 
made up of reactive oxygen species (ROS) (Levey et al., 2012). 
ROS are molecules with an odd number of electrons and thus 
highly reactive and destructive to the body. The accumulation of 
ROS causes damage to the mitochondria, which is the driving 
force of the cell and produces more than 98% of the energy 
used in our bodies. When ROS impair the mitochondria, they 
lose their capacity to produce energy. Ultimately, this reduces 
the amount of energy available for normal inner ear function, 
causing hearing loss(Seidman, 1999).
When the ear is exposed to excessive noise, the outer hair 
cells in the cochlea require high levels of energy and consume 
more oxygen. This generates a number of byproducts that mix 
with other molecules in the cochlea to generate high levels of 
ROS. This upsets the metabolic homeostasis of the cochlea. 
Additionally, the ROS then destroy cell membranes and hair cell 
nuclei, which causes tissue death (necrosis) and apoptosis (cell 
self-destruction), ultimately leading to hair cell death. Once it 
is dead, the hair cell will break into pieces, and this upsets the 
mechanical structure of the ear. Eventually, the hair cells are 
replaced with scar tissue. While the scar tissue ensures that the 
basilar membrane of the ear remains intact, it cannot play a role 
in the hearing process, and thus the individual with NIHL will 
experience hearing loss (Levey et al., 2012).
Cochlear microcirculation is vital for hearing transduction. 
Sensory hair cells of the cochlea are at risk of ischemia during 
noise exposure, and studies have shown that inadequate blood 
flow is associated with the development of NIHL. An important 
component of cochlear microcirculation is the diameter of the 
spiral modiolar artery, a branch of the anterior inferior cere-
bellar artery, which meets the lateral cochlear wall to form the 
striavascularis. The spiral modiolar artery has been shown to 
constrict during and after noise exposure (Arpornchayanon et 
al., 2013), and this is an additional cause of NIHL.
Another contributing factor in the development of NIHL is 
calcium homeostasis in the cochlea. Calcium plays the role of 
second messenger in a cell’s physiological activities, and an upset 
calcium homeostasis has been linked to trauma-induced neuro-
nal injury(Bao et al., 2013).In the cochlea, calcium participates 
in a number of functions, including mechano-electric transduc-
tion, hair cells’ voluntary contractions, the inner ear’s frequency 
selection, basal membrane vibration, and the release of neu-
rotransmitters (Liu et al., 2012). Calcium homeostasis is sus-
tained through a number of different calcium channels, including 
voltage-gated calcium channels (VGCCs). VGCCs are comprised 
of two groups:  high-voltage-activated (L-type) and low-volt-
age-activated calcium channels (T-type) (Bao et al., 2013).L-type 
VGCCs provide access for calcium to enter hair cells and are 
essential for the regulation of calcium homeostasis. After noise 
exposure, the levels of calcium in hair cells have been shown to 
increase, and an excessive amount of calcium in a cell has been 
linked to cell injury and cell death. Thus, too much calcium in 
the cochlea, brought on by excessive noise, has been linked to 
NIHL (Liu et al., 2012).
Genetic link
Although there is much research about the link between en-
vironmental agents and NIHL, less is known about the genetic 
basis for the impairment. Various animal studies have provid-
ed significant evidence of a genetic predisposition for NIHL. 
Mitochondrial dysfunction and ROS production have been 
shown to play significant roles in neurodegenerative conditions. 
As ROS overproduction is a result of noise exposure, mito-
chondrial genes and endogenous antioxidant defense-related 
genes have been thought to be the genes associated with NIHL. 
There are a number of antioxidant enzymes at work in the co-
chlea. Glutathione-S-transferase (GST) enzymes catalyze the 
conjugation of glutathione with xenobiotics and are vital for 
antioxidant protection. GST is comprised of a number of gene 
classes (GSTA, GSTM, GSTP, GSTT, GSTZ, GSTS, GSTK, GSTO). 
Humans have genetic variability of GSTM1 and GSTT1. For ex-
ample, approximately half of the European population has null 
genotypes for GSTM1, and 25–40% of Europeans do not have 
GSTT1. A person with a null genotype is unable to conjugate 
certain metabolites for these enzymes, and this makes him or 
her more susceptible to damage from oxidation. Therefore, it 
has been suggested that an individual with a null genotype is 
more likely than his peers to develop NIHL when exposed to 
excessive noise (Liu et al., 2012). 
There are also genetic mutations that reduce susceptibility 
to NIHL. A1555G in MTRNR1 is the mitochondrial mutation 
most frequently linked to hearing loss, typically with aminogly-
coside-induced deafness and non-syndromic deafness. MTTS1 
is another mitochondrial gene with a number of mutations. 
A1555G or other mitochondrial variants in the MTRNR1 and 
MTTS1 have been suggested as factors that lessensusceptibility 
to NIHL.
Abreu-Silva et al. conducted a study to evaluate genetic factors 
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in susceptibility to NIHL. The researchers compared persons 
with NIHL and persons without NIHL, as well as their family 
history of hearing loss and whether they had genetic mutations 
that have been linked with hearing loss (including deletions in 
GSTM1 and GSTT1, A1555G in the MTRNR1 gene. Their sam-
ple was comprised of 255 bus drivers and workers at a printing 
facility in Sa˜o Paulo, Brazil. Both groups were regularly exposed 
to excessive noise.  The subjects of the study included 107 
people whose audiograms showed NIHL, 44 people with hear-
ing impairment and audiograms that did not show NIHL, and 
104 people with normal hearing. Data was collected regarding 
each subject’s age, regularity of noise exposure, family history 
of hearing loss, alcohol consumption, smoking habits, and geo-
graphic origin of their ancestors. Subjects also provided blood 
samples for DNA screening and genotyping. The researchers 
found that family history of hearing loss is significantly associat-
ed with NIHL, which supports a genetic susceptibility to the im-
pairment. Moreover, the researchers found that the existence of 
at least one allele in both genes (GSTM1 = 1/? and GSTT1 = 1/?) 
increases the risk of NIHL, and that individuals of mitochon-
drial haplogroup L1 were disproportionately affected byNIHL. 
However, no significant findings were made regarding variants in 
the MTRNR1 and MTTS1 genes(Abreu-Silva et al., 2011).
Additional research on the genetic susceptibility to NIHL has 
focused on Human 8-oxoG DNA glycosylase1 (hOGG1), a key 
enzyme in the human base excision repair pathway. NIHL occurs 
as a result of DNA damage to cochlear hair cells, causing necrosis 
and apoptosis. At the same time, a number of DNA repair path-
ways, including base excision repair, help to maintain the integrity 
of the cell and stave off cell death. This DNA repair has been 
shown to be essential in maintaining hearing after noise exposure.
The 8-oxoguanine (8-oxoG) DNA lesion, which is caused by 
the overproduction of ROS, is a common cause of oxidative 
damage associated with NIHL.  HOGG1 in the base excision 
repair pathway eliminates 8-oxoG.  Reseach has suggested 
that the Ser326Cys polymorphism (rs1052133) in exon 7 of 
hOGG1 gene can impact the activity of hOGG1 enzyme and 
thus may be useful as a genetic marker for vulnerability to differ-
ent diseases. Shen et al. conducted a study to evaluate whether 
there is a link between the hOGG1 Ser326Cys polymorphism 
in the human base excision repair pathway and susceptibility 
to NIHL. The researchers genotyped 615 workers with NIHL 
and 615 normal hearing workers in China. The workers had not 
been regularly exposed to any other causal agents of NIHL, like 
chemical solvents, heat, or vibrations, and they had no other 
medical conditions that could have impacted their hearing.
The researchers found that the hOGG1 Cys/Cys genotype was 
statistically associated with NIHL. Therewas a higher number 
of persons with the hOGG1 Cys/Cys genotype among NIHL 
workers than among normal hearing work, suggesting the 
hOGG1 Cys/Cys genotype may have a lesser capacity for re-
storing 8-oxoG damage, and thus a higher susceptibility for 
NIHL. The researchers also found that the hOGG1 Ser326Cys 
polymorphism had a synergistic effect when combined with 
noise exposure time, noise exposure level, whether the indi-
vidual is a smoker, and whether the individual drinks alcohol 
regularly (Shen et al., 2014).
Diagnosis
Early detection of NIHL would help decrease the social and 
economic burdens related to the condition (Meinkeet al., 2013). 
Moreover, early detection can help stop the progression of 
hearing loss and prevent damage to speech frequencies (i.e., 
500, 1000, 2000 and 3000 Hz) (Mehrparvar, 2011). NIHL is 
diagnosed when an individual is found to have a hearing level 
change, compared to a baseline audiogram, of an average of 10 
dB or more at 2000, 3000, and 4000 Hz in either ear (Levey et 
al., 2012). Generally, NIHL results in hearing loss in the higher 
frequencies (3000-6000 Hz), so during hearing tests, hearing 
loss is observed at 4000 Hz with improvement in hearing at 
8000 Hz. However, among elderly patients, the improvement at 
8000 Hz is often lost, and this presents difficulty in determining 
whether the hearing loss is from NIHL, age, or another cause. 
Tympanometry is used to test the condition of the middle ear. 
Asymmetric hearing losses are evaluated using a brainstem au-
ditory evoked response or a high resolution CT scan of the 
inner ear and internal auditorycanal (Seidman, 1999).
Researchers are currently evaluating a potential new means of 
diagnosing and monitoring NIHL known as distortion prod-
uct otoacoustic emission (DPOAE) level mapping. The goal of 
DPOAE is to detect early signs of cochlear damage and then 
track changes in cochlear function, but the maps have mostly 
been used in trials with animals.A study was conducted in which 
they performed DPOAE level mapping on 17 individuals with-
out a history of noise exposure and then compared the results 
to maps created with 19 individuals with mild moderate NIHL. 
The DPOAE maps presented accurate data in a color pattern, a 
“visual snapshot” of cochlear function between the frequencies 
of 0.5 kHz and 6.0 kHz. This graphic form of data presentation 
enables for more detailed data collection and supports rapid 
comparison of maps for an individual. With further research, 
DPOAE maps may become the standard tool for detecting and 
monitoring NIHL (Meinke et al., 2013).
Prevention
NIHL is not a new phenomenon. Reports from as early as 600 
B.C. tell of the Sybarites, who prohibited metal-working or the 
possession of roosters within their city limits due to the dangers 
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of excessive noise. Other historical documents show that indi-
viduals living near the waterfalls of the Nile River experienced 
more hearing loss than those at a greater distance from the wa-
terfalls’ noise (Seidman, 1999).NIHL is an impairment that is both 
avoidable and foreseeable (Metidieri et al., 2013).The implications 
of NIHL can extend beyond hearing loss; it can result in the de-
velopment of a range of secondary diseases, including hyperacu-
sis (over-sensitivity to certain frequency and volume ranges of 
sound), tinnitus, or depression related to social isolation (Tziridis 
et al., 2014).
The federal government has long sought to regulate noise expo-
sure and prevent NIHL. In 1936, the Walsh-Healey Public Contracts 
Act was instituted to oversee workplace noise exposure, though 
it was not properly enforced. In 1970, the Occupational Safety 
and Health Administration (OSHA) wasfounded to both monitor 
and regulate workplace noise exposure. Currently, OSHA allows 
for exposure to 90 dB for 8 hours a day, while the EPA allows 
for a level of 85 dB. However, on-the-job inspections are typically 
infrequent, and fines for noise-level violations are often low.
The key to preventing NIHL is avoiding damaging noise expo-
sure (Seidman, 1999), beginningwith an assessment of risk of an 
environment. It is advisable to have workers rotate tasks to en-
sure that no individual is exposed to continuous hazardous noise 
over an extended period of time (Singh et al., 2012).Additionally, 
acoustic attenuation devices or engineering controls can be 
used to reduce the noise dose to which an individual is exposed 
(Bielefeld, 2015). If sounds often go above 85 dB, hearing pro-
tection is essential to preventing damage. OSHA mandates the 
distribution of free hearing protective devices (HPDs) in work 
places such as these. Protective devices may include ear plugs or 
ear muffs (Pelosi, 2014). Earplugs can reduce between 10 dB and 
22 dB of sound diminution, and protective earmuffs can reduce 
sound by 20-55 dB. When earplugs are used together with ear-
muffs, the benefit is additive (Seidman, 1999).
However, there are a number of barriers to the use of HPDs. 
First, many work sites require ongoing communication with 
colleagues, and this is hindered by the use of ear protectors. 
Additionally, Reddy et al. (2012)conducted surveys with work-
ers in high-noise environments, and their findings suggest that 
there is a “fatalist belief among workers that noise is an accept-
able and unavoidable part of the job.” This perception often leads 
workers to avoid using HPDs, not recognizing that these devices 
can prevent permanent hearing loss (Reddy et al., 2012).Hong 
et al. (2013) explain that the perceptual factors involved in HPD 
use include perceived self-efficacy, perceived benefits, perceived 
barriers, perceived susceptibility to hearing loss, and perceived 
severity of hearing loss. In a study conducted by Nodoushan et al. 
(2014), HPDs were found to be used more frequently and more 
effectively when workers received training about the reasons for 
HPD use, as well how they can be properly fitted in the ear.
In addition to HPD use, scientists continue to investigate a num-
ber of less conventional approaches to reducing the damage 
from noise exposure. Experimental methods for preventing 
NIHL include reducingbody temperature, stimulating a number 
of neural structures, treatment of the ear with a number of 
compounds, increasing oxygenation, interfering with ROM ac-
tivity, and sound conditioning. In some cases, these alternative 
approaches have achieved partial protection. In particular, the 
concept of sound conditioning has received a lot of attention 
from scientists. Conditioning allows for the toughening of the 
cochlea through exposure to non-damaging levels of sound 
before being exposed to noise trauma. Resistance can develop 
after the exposure to stimuli that varies in duration, frequency, 
and continuity. This is due to brain and nerve adaptability; during 
sound conditioning, the cochlea’s outer hair cells perform simi-
larly to a muscle (Seidman, 1999).
Treatment
Research has also focused on the use of pharmacological 
agents in the prevention and treatment of NIHL. While there 
is no widely-accepted protocol for pharmacological treatment 
of NIHL, there are a number of ongoing research studies that 
are testing substances on both animals and humans, including 
antioxidants that decrease oxidative stress byeliminating ROS; 
glucocorticoids; and agents that improve cochlear blood flow, 
stimulate inhibitory transmitter systems, or obstruct apopto-
sis pathways in hair cells (Tziridis et al., 2014).
There are a number of antioxidants currently being tested for 
their efficacy in both preventing and treating NIHL. The anti-
oxidant α-tocopherol has been shown to reduce the noise-in-
duced damage in guinea pigs (Kashani et al., 2011).N-Acetyl-
L-Cysteine (NAC), an antioxidant which has been shown to 
inhibit lipid peroxidation and destroy ROS by increasing levels 
of glutathione within the cell, has been found in a number of 
animal studies to be effective in treating NIHL if given immedi-
ately after noise exposure (Rajguru, 2012).
Antiepileptic drugs and glucocorticoids are also being tested 
in the treatment of NIHL. Bao et al. conducted a study re-
garding prophylactic treatment of NIHL. Their study sought 
to reduce the risk of NIHL by administering anticonvulsant 
drugs to block T-type calcium channels in the organ of Corti, 
and thus prevent an injurious disturbance to calcium homeo-
stasis that may occur after exposure to noise. This approach 
had been found to be effective in protecting neurons after a 
stroke. The researchers administered to mice two anticonvul-
sant drugs - ethosuximide and zonisamide – to block T-type 
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calcium channels, and then exposed them to high levels of 
noise. The mice were also administered synthetic glucocor-
ticoids, dexamethasone and methylprednisolone (Bao et al., 
2013). Glucocorticoids were used because they activate the 
enzyme Na, K-ATPase, which has been linked to restoring 
cellular osmolarity and neuronal conduction. Additionally, glu-
cocorticoids have been found to be effective in both cells and 
dendrites (Rajguru, 2012).
In Baoet al.’s (2013) study, the anticonvulsant drugs and the 
glucocorticoids were administered after the noise exposure as 
well to assess whether the drugs had any therapeutic effect after 
noise-induced trauma. The researchers found that anticonvulsant 
and glucocorticoid drugs could have both a prophylactic and 
therapeutic effect, and that there was a synergistic prophylactic 
effect when the drug families were used together (Bao et al., 
2013). Further studies are necessary to ascertain whether the 
drugs would have the same effect in preventing and treating NIHL 
in humans.
Vitamins and minerals are also being tested in the prevention 
and treatment of NIHL. Studies show that magnesium has both 
a prophylactic and therapeutic effect on noise-induced injuries. 
In the cochlea, levels of magnesium are essential for preventing 
disruption in cochlear microcirculation and oxygenation and for 
protecting against free radicals. Clinical trials are ongoing to as-
sess whether application of magnesium to the inner ear, together 
with the administration of an antioxidant, can prevent and reduce 
hearing damage after a noise-related trauma (Rajguru, 2012).
Tziridis et al (2014) conducted a study on the use of ginkgo bi-
loba extract EGb 761 to prophylactically treat NIHL and tinnitus 
in the Mongolian gerbil.  Their study results demonstrate the 
neuroplastic effects of EGb 761 on central and peripheral levels 
of auditory processing when given prophylactically to gerbils ex-
posed to noise. The researchers posit that the antioxidant effect 
of EGb 761 provides protection against NIHL. Additionally, EGb 
761 was shown to increase blood flow, so it provides a protective 
effect against noise exposure, which can decrease blood flow in 
the cochlea. While EGb 761 has not yet been tested on humans, 
the results of the gerbil study are promising (Tziridis et al., 2014).
Another agent being tested in the prevention and treatment of 
NIHL is vitamin B12.Vitamin B12 is an essential cofactor in meth-
ylation of myelin basic protein and cell membrane phospholipids 
and also important in methionine synthesis from homocysteine. 
There have been studies that have shown that individuals who 
have low levels of vitamin B12 and folic acid are more susceptible 
to hearing loss caused by noise exposure. When there is a B12 
deficiency, there can be axon degeneration and neuronal loss. 
Kibar et al. (2013) theorize that supplementary B12 can decrease 
homocysteine synthesis in the cochlea, increase concentration of 
nitric oxide, and thus cause the blood vessels to dilate. As such, 
the B12 may be able to induce increased vascular perfusion and 
cellular metabolism within the cochlea. In a study Kibar et al. 
(2013) conducted with guinea pigs, they were not able to show 
a significant decrease in hearing loss when the guinea pigs were 
treated with B12. However, studies are ongoing to determine the 
efficacy of B12 treatments in preventing and minimizing the dam-
age of NIHL (Kibar et al., 2013).
Hyperbaric oxygen therapy (HBOT) is also being considered for its 
use in treating NIHL. HBOT can be used to improve oxygenation 
in the inner air, and thus improve microcirculation and attenuate 
injured cochlear hair cells. HBOT can infuse hypoxic areas of the 
cochlea with oxygen, which can work to speed up cellular mech-
anisms necessary for recovery. There are ongoing studies that are 
evaluating the impact of HBOT on NIHL, as well as the combined 
use of HBOT and glucocorticoids (Rajguru, 2013).
Conclusion
Though the effects of noise exposure have been known within 
the medical community since the 1960s, the general public re-
mains largely unaware of the long-term effects of both sudden 
and gradual noise trauma. In a study conducted with American 
respondents, only 16% of those surveyed reported that they 
had read about or heard about NIHL in newspapers or other 
media forums. In another American-based study, 72% of respon-
dents admitted that they never wear hearing protection when 
they are exposed to loud noises, even though they are aware 
that noise exposure can be harmful (Ramma, 2011).
It has been said that an ounce of prevention is worth a pound of 
cure, and this maxim is especially relevant in regards to NIHL. It 
is essential that the general public is made aware of the damag-
ing effects of noise exposure, both on the job and during recre-
ational activities. While studies related to the prophylactic and 
therapeutic intervention for NIHL are promising, there is cur-
rently no widely-accepted treatment protocol and no known 
cure. As such, it is imperative that OSHA and EPA guidelines are 
adhered to in all areas of work, and that HPDs are employed 
during occupational hazards and leisure activities. Moreover, it 
is essential that people recognize that their ears are vulnerable 
to injury, and they should be protected from unnecessary – and 
often irreversible – damage.
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Introduction
Sleep was once thought of as a process during which the both the 
body and brain are at rest and inactive. But in modern times, starting 
in approximately 1950, sleep has been studied and discovered to be 
an active process, necessary to maintain many of the body’s functions 
(National Institute of Neurological Disorders and Stroke, NINDS, 
2014).
In 1937, Alfred Loomis, along with E. Newton Harvey, and Garret 
Hobart, used the EEG to map out what they considered five stages 
of sleep, A-E. In 1953, Eugene Aserinsky and Nethaniel Kleitman 
established the REM sleep stage. In 1957 Dement and Kleitman 
mapped out the sleep stages as they are known today, dividing 
sleep into NREM (non-rapid eye movement) and REM (rapid eye 
movement) sleep. NREM sleep consists of four stages, each with 
varying brain wave activity, and increasing in depth as the stage 
number increases. These stages are cyclical, repeating throughout 
the night. Following the four stages, there is a period of REM sleep 
(Shepard et al., 2005).  REM sleep is associated with rapid eye 
movements, increased heart rate, and dreaming (NINDS, 2014).
With vast research and many studies conducted since, the under-
standing of the roles that sleep plays in the body has been greatly 
advanced and its necessity has been studied extensively (Shepard 
et al., 2005).  
Sleep is both a circadian rhythm and a homeostatic cycle. A circa-
dian rhythm is natural rhythm, approximately twenty-four hours 
long, and controlled primarily by the suprachiasmatic nucleus. The 
natural timing of the cycle is based on the light-dark cycle (NIGMS, 
2012). Though they are naturally occurring, circadian rhythms can 
be altered and affected by environmental factors. One of the cir-
cadian rhythms is the body’s drive for alertness and wakefulness, 
which gets higher throughout the daytime hours and decreases 
during the night. The circadian sleep-wake cycle, along with the 
body’s homeostatic drive for sleep, which increases based on the 
amount of prior wakeful hours, keep the body in a proper rhythm, 
maintaining the appropriate amount of necessary sleep (Dijk and 
Lockley, 2002).
The necessary amount of sleep in humans varies with age, rang-
ing from 16–18 hours in infancy to 7-8 hours in the average 
adult (NINDS, 2014). In the last century, America has seen an 
approximate 20% decrease in the amount of sleep it gets. This 
has had economic, social, and health consequences. Sleep de-
ficiency has been associated with numerous health risks such 
as hypertension, stroke, obesity, and diabetes. Sleep is neces-
sary to support many vital systems in the body, and adequate 
sleep is necessary for optimal cognitive performance, without 
which many accidents may occur (Institute of Medicine (US) 
Committee on Sleep Medicine and Research, 2006).
Parallel to the decrease in sleep, the incidence of obesity in 
America has drastically increased. Studies conducted by the 
National Health and Nutrition Examination Survey (NHANES) 
show that more than one third or 34.9% of adults over age 
20 are considered obese. Additionally, of American children and 
adolescents ages 2–19, approximately 16.9% are obese (Ogden 
et al., 2014). Obesity is a result of excessive weight gain, which 
occurs primarily when the energy expenditure of the body is 
less than energy intake, resulting in a net gain. Over time, if the 
gain continues, the weight accumulates and results in obesity. 
Other factors that may cause obesity are environmental factors, 
genetics, illnesses, and medications (CDC 2011). 
The correlation between sleep deficiency and weight gain has 
been examined and many cross sectional and epidemiological 
studies found a relationship of sleep deprivation with obesity. 
Studies show an association of a higher body mass index (BMI) 
in individuals who generally sleep fewer hours than the recom-
mended sleep time. Over all, the studies point at a relationship 
Abstract
The obese population in America has grown during the last century. During these years as well, American’s have been 
sleeping less. Cross sectional studies show that there is a correlation of the two factors, and indeed find a greater 
number of overweight individuals amongst the sleep-deprived population. Though they are unclear, studies attempt to 
establish possible mechanisms through which weight gain occurs. Results of studies show that sleep deprivation may 
influence leptin and ghrelin levels, which can cause hunger, and excessive caloric intake. Sleep-deprived individuals also 
have an increased opportunity to eat during the wakeful nighttime hours. In the sleep-restricted state, activity levels 
may decrease, and though the extra hours spent awake also cause a small increase in energy expenditure, there is over-
compensation in energy intake, leading to weight gain. Obstructive Sleep Apnea also plays a role in obese individuals’ 
sleep patterns, and may lead to further weight gain. Without excessive caloric intake it may be possible to maintain 
weight in the sleep-deprived state. This paper will review a number of studies and give an overview of some of the 
possible methods though which sleep-deprivation causes obesity.
The Mechanisms of Weight Gain in Sleep-Deprived 
Individuals
By Chaya Rosen
Chaya Rosen will graduate in January 2016 with a B.S. degree in Biology.
17
Weight Gain in Sleep-Deprived Individuals
of sleep deprivation to obesity primarily in the pediatric and 
young adult population (Beccuti and Pannain, 2011). Though 
these results were most evident in the young and middle-aged 
population, one study found that there is a greater likelihood 
(3.7 times in men and 2.3 times in women) for obesity in older 
individuals who sleep less than 5 hours per night (Patel et al., 
2008). Though the data is evident of a correlation between the 
two, there are many factors that may contribute to the obesity 
and the findings are not entirely conclusive (Patel and Hu, 2008). 
This paper will investigate the mechanisms involved in sleep 
deprivation that result in weight gain and obesity? 
Methods
Information was obtained online with access to many online 
publications through the Touro College library. Key words in-
cluded sleep-deprivation, obesity, weight gain, leptin, ghrelin, 
energy expenditure, OSA. Additionally, references made by lit-
erature reviews were helpful in conducting research.
Discussion
Many studies have been performed in an effort to establish 
the relationship of decreasing sleep with increasing likelihood 
of obesity. The studies examine whether the shortened sleep 
times have an effect on weight, and via which mechanisms this 
may occur. Three commonly discussed factors that may con-
tribute to the weight gain in sleep-deprived individuals are 
energy intake (consumption of food), energy expenditure, and 
hormonal leptin and ghrelin levels. 
Leptin and ghrelin
Leptin and ghrelin are two essential hormones in the maintenance 
of the body’s energy balance. These two hormones have oppo-
site effects on the body. Leptin induces a satiety and fullness, and 
ghrelin, hunger and appetite. Leptin is primarily released by adipose 
tissue into the bloodstream and send the brain signals regarding 
the energy state of the body. Leptin signals receptors at the hypo-
thalamus, which affect hypothalamic neurons and various neuro-
peptides. Leptin is known to have anorexic (appetite suppressing) 
effects. Ghrelin, is released primarily by the stomach and signals 
the hypothalamus, which thereafter has orexic (appetite inducing) 
effects (Klok et al., 2007). Because of the correlation found be-
tween sleep and weight gain, it is presumed that perhaps leptin and 
ghrelin, which are closely related to food intake and regulation, are 
affected by sleep restriction. Studies examine this detail, and show 
inconsistent results. 
One study that examined the sleep-weight gain relationship was 
performed on 12 average men, 22 +/- 2 years of age, and with 
average BMIs 23.6+/- 2 kg/m2. The participants did not smoke or 
take any medication. They all regularly slept 7 to 9 hours, and they 
had not crossed time zones in the last four weeks before the study. 
The study consisted of two randomized periods, six weeks apart. 
Weight did not change during the time between the two studies. 
For the first night of study, participants were given a restricted 
diet, while during the day, they ate their regular diets. During the 
second day of study, they received a glucose infusion of 5 g/kg/ 24 
hours. After both periods of the study- two nights of 10 hours in 
bed, and two nights of 4 hours in bed, blood samples were taken 
at 20-minute intervals, from 8 am to 9 pm. Results showed that in 
the sleep deprived state, leptin levels were 18% lower and ghrelin 
levels 28% higher than in the normal sleep state (Spiegel et al., 
2004). These results accounted for the elevated hunger levels in 
the sleep-deprived state. Consequently, increased hunger usual-
ly causes increased food intake. However, these studies did not 
measure exact food intake of the participants, so there is no clear 
evidence of the increased energy intake.
Another study performed on 1,024 volunteers in the Wisconsin 
Sleep Cohort Study found a decrease in leptin levels with sleep 
deprivation. They underwent polysomnography and answered 
questionnaires to measure sleep. In the sleep-deprived state, (5 
hours versus 8) a morning blood test showed a 15.5% decrease 
in leptin and 14.9% higher ghrelin levels (Taheri et al., 2004). 
Consistent with the findings by Spiegel et al. these results can likely 
cause increase in hunger and food intake, leading to weight gain.
Though these results show a clear effect of sleep on leptin and 
ghrelin, not all studies yielded such results. Numerous reasons 
may be responsible for the discrepancy in the results. One 
reason might be that in the study by Spiegel et al., the blood 
samples were taken after participants underwent constant glu-
cose infusion, which could perhaps yield results that differ from 
those of a regular food diet. 
Another study was in search of a relationship of partial sleep 
deprivation to weight gain and insulin sensitivity in women. It 
was performed on 14 healthy women, age 23-38, who were 
weight stable, with no recent illness, non- smoking, non-lac-
tating, and not on any medication besides oral contraceptives. 
They were all in the follicular phase of the menstrual cycle, 
slept 7.5 to 9 hours on an average night, did not cross time 
zones in last month, and had no sleep complaints. Participants 
were studied after 2 nights of 8 hours of sleep, after 4 nights 
of consistent decrease in sleep (minus one additional hour 
nightly) and then 2 nights of recovery sleep. Food was not re-
stricted, though alcohol was. Their diet was carefully recorded 
using computer software. After performing a glucose toler-
ance test, blood was collected in 15-minute intervals for 90 
minutes. Leptin levels showed a 24% increase after 2 nights of 
approximately 5.5 hours in bed versus 9 hours in bed. Ghrelin 
levels were stable. This may be due to the extra caloric intake 
during those days of study, as will be discussed below. Insulin 
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sensitivity did not appear to be affected by sleep restriction 
(Bosy-Westphal et al., 2008).
Numerous other studies also yielded results that were inconsis-
tent with each other. Certain studies show increase in leptin, others 
show a decrease, while others do not show any significant change. 
One study was performed on eleven people, men and women, 
with an average BMI of 26.5, for two two-week periods in ran-
dom order. In the restricted sleep they slept 5.5 hours, com-
pared to 8.5 hours in the habitual sleep. They had an unrestrict-
ed diet throughout the study. The results showed that in the 
sleep deprived state, leptin and ghrelin levels were not affected 
significantly. These results show that perhaps in response to 
sleep loss, the body may have an altered response to restricted 
food, and the hormonal levels remain more stable than in the 
body’s usual state. This would account for the stable leptin and 
ghrelin levels across the two periods of study (Nedeltcheva et 
al., 2009).
One other study observed that in nine average weight men 
after one night of normal sleep, one of partial sleep restriction 
and one total sleep deprivation, leptin levels did not show a 
significant change, while ghrelin levels were 22% higher in total 
sleep deprivation than in normal sleep (Schmid et al., 2008).
Clearly, many studies yield conflicting results on the effect of 
sleep on leptin and ghrelin. Two studies we discussed show en-
tirely opposite results (Spiegel et al. 2004 and Bosy-Westphal 
et al., 2008). Why are the observations to the various studies 
inconsistent? 
Perhaps it is the fact that certain factors were sometimes 
unaccounted for in these particular studies, such as genetics, 
individual’s environment, race, and height (Spiegel et al., 2004). 
Additionally not all of the studies measured and accounted for 
precise weight of the participants, which is perhaps necessary 
to determine the effect of one factor on another. Additionally, 
as mentioned above, the diets of the participants in the studies 
were not consistent with each other, which may have had an 
effect on the body’s endocrine response.
The inconsistent results of the many studies suggest that the 
leptin and ghrelin levels may or may not change and contrib-
ute to weight gain in response to sleep restriction. However, 
even studies that do not show a direct change in leptin and 
ghrelin, do show greater caloric intake, likely due to hunger and 
increased opportunity to eat. 
The effect that sleep has on energy expenditure must also 
be taken into account. Intuitively, in the sleep-deprived state, 
because of fatigue, energy expenditure should decrease. 
However, studies show that a sleep deprived individual expe-
riences extra wakeful hours during which he/she is burning 
more calories than if he/she had been sleeping. However, be-
cause during those wakeful hours the individual is likely fatigued, 
activity levels are lower than regular wakeful hours. Therefore, 
the overall energy expenditure in the sleep-deprived state may 
increase only slightly. 
Energy intake versus expenditure
To maintain weight one must be in energy balance, when ener-
gy consumed is equal to energy expended. Weight gain occurs 
when the body is in positive energy balance, when the person 
takes in more calories than they burn. Perhaps even without 
an observed hormonal change, the body reacts to sleep depri-
vation with increased hunger, and thus increased caloric intake. 
Sleep may also have an effect on metabolism and energy ex-
penditure? Many of the studies mentioned above, searched for 
the effect of sleep deficiency on hunger levels, energy intake, 
and energy expenditure, in addition to its role in leptin and 
ghrelin levels. 
According to Spiegel et al. participants recorded their hunger 
levels after both periods of the study- restricted and normal 
sleep times- by answering how hungry they felt at every hour 
from 9 am to 9 pm, after the second night of sleep. They were 
also asked to describe their appetite, answering how much 
they would like to eat 7 different foods (sweet, salty, starchy, 
fruits, vegetables, meat, dairy etc.) Results showed that con-
sistent with the decreased leptin and elevated ghrelin levels 
found in this study, 24% higher hunger levels were found, as 
well as 23% higher appetite levels, in the sleep deprived state. 
The appetite increase was highest for calorie and carbohy-
drate dense foods. Increased appetite for protein rich foods 
was not significantly increased in sleep-deprived state (Spiegel 
et al., 2004). The study by Schmid et al. also showed an increase 
in average hunger ratings of 3.9 after total sleep deprivation 
as opposed to 1.7 after a 7-hour time in bed, consistent with 
increased ghrelin (Schmid et al., 2008). 
Presumably, the increase in hunger accounts for greater ca-
loric intake in sleep-deprived individuals, causing weight gain. 
However, in the studies by Spiegel et al. (2004) and Schmid 
et al. (2008), exact caloric intake during the study periods 
was not measured, and thus we cannot necessarily assume 
that there was extra consumption of calories or how many. 
Additionally, during the study periods, activity levels were kept 
low (reclining, sitting etc.), and they did not examine wheth-
er or not there is a change in energy expenditure or energy 
balance. Without this information we cannot determine if 
there would be a theoretical net weight gain. To examine these 
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details, further study on energy expenditure is needed. 
Energy expenditure can be measured using indirect calorimetry, 
metabolic chambers, heart rate and other methods. Indirect cal-
orimetry and metabolic chambers measure the level of carbon 
dioxide production to assess energy expenditure.
In the study by Bosy-Westphal et al. careful measurement of ca-
loric intake was measured during the entire study via computer. 
Resting energy expenditure was measured using indirect calo-
rimetry, and total energy expenditure was measured using 24-
hour heart rate monitoring. Physical activity was also measured 
with pedometers. Energy intake significantly increased from 
baseline to sleep deprived state, while energy expenditure did 
not show a significant change. The average increase in calories 
was 415 +/- 471 kcal/day, and caused a net weight gain (Bosy-
Westphal et al., 2008). Because there was no change in ener-
gy expenditure seen, we can assume that in prolonged sleep 
deprivation the individuals would experience significant weight 
gain. This provides further evidence that sleep deprivation caus-
es an increase in caloric intake and body weight, despite the 
fact that there was no significant endocrine response to sleep 
deprivation. 
However, the study did observe a change in thyroid hormone 
levels, so further research is required to examine more spe-
cific results of the effect sleep restriction may have on ener-
gy expenditure, such as measuring total energy expenditure 
using a caloric chamber (Bosy-Westphal et al., 2008).
This leads us to another study that did indeed measure spe-
cific total energy expenditure, using a caloric chamber. The 
study shows a significant increase in energy expenditure in 
the sleep-deprived state due to the extra hours of time spent 
awake. Ten women, with average BMIs were studied under 
shortened sleep and habitual sleep, 4 and 8 hours, 3 days 
of each, while kept on a strictly controlled diet. The results 
showed significantly greater energy expenditure of approx-
imately 92 kcal in the shortened sleep period. This study 
provides evidence that there may be an increase in energy 
expenditure in the sleep deprived state, however, there is an 
overcompensation of energy intake, which leads to weight 
gain (Shechter et al., 2013). 
Another study that measured energy intake versus expen-
diture found that with unlimited food allowance, the partic-
ipants did not consume a significant amount of extra calo-
ries during meals, however, they did increase their intake of 
snack calories between the hours of 7pm-7am, with more 
carbohydrates and less protein/fat snacks (Nedeltcheva et al., 
2009). The fact that the increase was only significant between 
7pm-7am, not 7am-7pm, highlights the fact that during the 
nighttime hours when sleep is restricted participants found 
time to consume significantly more snacks, leading to an in-
crease in daily calories. 
When one is sleep deprived and awake during nighttime 
hours, not only is there elevated hunger during the day, but 
there is also increased opportunity to eat during the extra 
hours spent awake. More so, the nature of nighttime eating 
is snacking, which can cause unintentional excessive caloric 
intake. 
The total energy intake was 297 kcal more in sleep-deprived 
state. Additionally, during both sleep deprived and habit-
ual sleep state, there was a surplus of calories, due to the 
participants’ eating habits. Some individuals had a greater 
‘propensity’ to eat, while others not .The study also found a 
slight change in energy expenditure between the two sleep 
states. The difference, which they considered insignificant, was 
136 +/- 437 kcal more per day in the restricted sleep period 
(Nedeltcheva et al., 2009). Even if the change in total energy 
expenditure was considered significant, there is a surplus of 
an average 160 kcal per day in the sleep-deprived state. If 
we were to apply this information to a general population 
one can assume that the overcompensation in calories would 
cause weight gain in individuals who are consistently sleep 
deprived.
Perhaps if participants were more active, the studies would 
find a significant increase in energy expenditure, and there 
would no longer be the overcompensation of calories. 
However, because of fatigue and sleepiness, activity levels 
should presumably be lower when one is sleep-deprived. 
Studies show that the activity levels of sleep-deprived individ-
ual are indeed lower.
Another study involved 30 men and women, ages 30-49, and 
with BMIs between 22-26. No shift workers, or individuals 
that had travelled across time zones within 4 weeks of the 
study were allowed. Smokers, diabetics, those with excessive 
caffeine intake, or neurologic issues were also disqualified. 
The study was divided into two stages of 6 days each. In the 
shortened and normal sleep stages, the participants were 
given 4 hours in bed and 9 hours in bed, respectively, with no 
naps during the day. They measured sleep by polysomnogra-
phy. For the first 4 days of each period, their food intake was 
allotted and strictly measured. The last two days were also 
carefully measured, but participants were allowed to make 
their own food choices. On day 4 they were asked how they 
would rate their hunger, how full they felt, how energetic, how 
much they could eat, and how much they would like to eat 
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foods that were sweet, salty, savory etc. After measuring the 
energy intake and expenditure, results showed that women 
consumed 15.3% more in the restricted sleep period, with a 
39% increase in fats. Men consumed 9.2% more. Additionally 
they ate more often in the sleep-restricted stage. While they 
consumed more, no significant change in energy expenditure 
was found, though the point of peak activity observed was 
higher in the normal sleep period. In the normal sleep period, 
participants spent a greater percentage in sedentary activity, 
a lesser percentage in light activity, and a significantly greater 
percentage of time doing heavy activity, than in the restrict-
ed sleep period. Overall the study showed greater feelings 
of sluggishness and less energy during the shortened sleep 
period and there was no significant change in total energy ex-
penditure over the course of the study (St.-Onge et al., 2011).
 This is intuitive, as a sleep-deprived individual is tired and con-
sequently has less energy for intense activity. Low intensity 
activity leads to less energy expenditure, and opportunity for 
more weight gain.
Surprisingly, there was no net change in energy balance ob-
served, after controlling for phase order and gender. However, 
like Nedeltcheva et al., this study showed an increase of approx-
imately 300 kcal per day in the shortened sleep period. Due 
to the fact that they are primarily due to the increase in fat 
and saturated fat calories, the people would also be at risk for 
cardiovascular disease (St-Onge et al., 2011).
Even though, unlike previous studies, this study did not show 
a significant effect on participants hunger ratings, there was an 
observed increase in energy intake. This suggests that the rela-
tionship of sleep deprivation and obesity is one primarily based 
on excessive food intake.  The continuous surplus of calories in 
the sleep-deprived state may eventually lead to obesity, if not 
coupled with an increase in energy expenditure (St-Onge et 
al., 2011).
Obstructive Sleep Apnea
There is reason to believe that perhaps the relationship of poor 
sleep and obesity is a reverse process. The cross sectional data 
showing a relationship between obesity and sleep deprivation 
may be due to the fact that as a result of being overweight, obese 
individuals experience shortened sleep, with poorer quality. This 
is indeed true in the case of Obstructive Sleep Apnea (OSA). 
Obese people are twice as likely to experience Obstructive 
Sleep Apnea, a significantly higher risk, than average weight indi-
viduals. OSA occurs in approximately 45% of obese individuals. 
Additionally, their risk for OSA is increased six times, if they 
gain even 10% of their normal (baseline) weight. On the other 
hand, the OSA can show an improvement with weight loss of 
the same amount. One reason that obesity increases the risk 
for OSA is that fat situated in the upper airways can cause an 
increase in the collapsibility of the airway, and increase the risk 
for apnea. A patient with sleep apnea has interrupted sleep and 
decreased sleep quality. This leads to sleep deprivation, and the 
sleep deprivation leads to additional weight gain. The process is 
cyclical. An obese individual is at risk for OSA. OSA causes sleep 
deprivation and an increased risk for weight gain. The weight 
gain causes further worsening of OSA symptoms. Studies pro-
pose that weight loss can effectively help the obesity, as well as 
help improve symptoms of OSA (Romero-Corral et al., 2010).
In light of the above, we can say that the relationship between 
sleep deprivation and obesity is indeed cyclical. However, as our 
discussion shows, even amongst the average weight population, 
individuals who are sleep deprived tend to increase energy in-
take and gain weight. 
Further Research
Though studies have established correlation of the above factors, 
further research would be helpful to provide more conclusive 
evidence of the mechanisms involved in sleep deprivation that 
cause obesity. Discrepancies amongst the studies may be due to 
environmental factors, genetic predisposition, and metabolic dif-
ferences that vary with each individual participant. Additionally 
as mentioned above, participants each have varying propensity 
to eat more, and gain or lose weight, independent of sleeping 
habits. Furthermore, the studies discussed were performed 
on relatively small samples of people. Additional studies with a 
greater number of participants, and in a broader population of 
ages could perhaps provide more conclusive results. Moreover, 
perhaps there is a way to study populations in a free-living en-
vironment, rather than in a lab setting, and assess under those 
circumstances, which mechanisms resulting from sleep depriva-
tion lead to the development of obesity.
Conclusion
Obesity is an epidemic that has many economic, social, and 
health costs. The effects it has on health and healthcare costs 
are tremendous. Obesity not only requires treatment itself, but 
it also leads to many health problems such as cardiovascular 
disease, hypertension, type two diabetes, stroke, osteoarthritis, 
gallstones, certain types of cancer, fertility problems in women, 
as well as other health issues (Kopelman, 2007). 
Studies show that if the growing obesity epidemic continues, 
86.3% of American adults will be overweight or obese, with 
51.1% obesity by year 2030. This could lead to health care 
costs projected at 860.7-956.9 billion dollars (Wang et al., 
2008). Obesity also has many social costs, amongst adults and 
children alike. Obese people may experience limitations on 
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physical activity, and there are stigmas associated with being 
heavily overweight that may cause obese people to be treated 
differently in the workplace and social forums (Seidell, 1998). In 
light of the above, if sleep deprivation has a role in the growing 
obese population, not only is intervention necessary to treat 
obesity and its side effects, but there must also be intervention 
to counsel people regarding positive sleeping habits. Beginning 
with school aged children, they must be educated regarding the 
benefits of getting enough sleep. Parents should try to assist 
children in creating healthy sleeping habits. Adults should be 
careful to try to generally maintain a proper sleep schedule, 
when social and work responsibilities do not demand late bed 
times. Overall, a greater awareness must be made to the public 
that sleep deprivation has serious negative side effects.  
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MDMA, known scientifically as 3, 4-methylenedioxymetham-
phetamine, is an amphetamine derivative drug increasing in 
popularity amongst teenagers and young adults (Broening, et al., 
2001). Amphetamines are a class of molecules that have stimu-
lating effects on the central nervous system (CNS). MDMA is 
known by recreational users as ‘Ecstasy’ because it has stimu-
lating and hallucinogenic effects on the CNS while engender-
ing immediate feelings of ecstasy and openness upon ingestion 
(Singer, et al., 2012). 
Studies show that adults taking MDMA have a decrease in sero-
tonin (5-HT) in the brain, a reduction in 5-hydroxyindoleacetic 
acid (5-HIAA), a main metabolite of serotonin, and a reduction 
in tryptophan hydroxylase (TPH), an enzyme involved in the 
synthesis of serotonin (Broening, et al., 2001). This serotonergic 
reduction is harmful to the exposed adult. Interestingly, though 
the effects of MDMA on adults have been well researched, few 
studies have been conducted on the effects of MDMA on pre-
natally exposed children and on the reasons for these effects. 
Due to its popularity amongst teenagers and young adults, it 
has become increasingly prevalent to find developing fetuses 
exposed to MDMA while in utero. Scientists are determining 
the long term neurological effects of Ecstasy-exposed fetuses by 
conducting post parturition studies on both rats and children 
that have been prenatally exposed to MDMA. Some long term 
neurotoxic effects include sequential and spatial learning delays 
(Broening, et al., 2001) milestone delays at 4 months of age, and 
poorer mental development index scorings at 12 months of age 
(Singer, et al., 2012). The question stands as to why these and 
other neurotoxic effects develop  in both rats and children that 
have been exposed to MDMA in utero. Scientists are hypoth-
esizing numerous reasons for these effects, including serotonin 
(5-HT) reduction (Broening, et al., 2001), elevated levels of cor-
tisol (Parrott, et al., 2014), changes in the norepinephrine (NE) 
system (Thompson, et al., 2011) and in the dopamine (DA) sys-
tem (Thompson, et al., 2009), an increase in autophagy protein 
5 (Atg5) (Chae, et al., 2009), and embryotoxicity due to MDMA 
metabolites (Barenys, et al., 2012). This paper explores various 
venues theorized to be the cause of the cognitive and neuronal 
impairment observed in Ecstasy-exposed fetuses.
Methods
Research on the topic of the biological reasons for the neuro-
toxic effects of MDMA on the developing fetus was compiled 
from various sources found in the Touro database. Information 
was obtained regarding general usage of MDMA as well as 
the observations noted in children of women who ingested 
MDMA while pregnant. Finally, data about various experiments 
performed on rats was obtained in order to gain insight into 
possible biological causes for the neurotoxic deficits noted in 
MDMA exposed fetuses. The information was arranged into a 
comprehensive order and edited by the author.
Discussion
One strong hypothesis as to how Ecstasy induces long term 
brain damage in a fetus is that MDMA-exposed fetuses are 
harmed due to a decrease in 5-HT in the brain. This hypothesis 
is based on the established fact that MDMA causes serotonergic 
reductions in the adult brain. In a study done on Sprague-Dawley 
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rats, researchers in the University Of Cincinnati College Of 
Medicine sought to determine whether the effects of MDMA 
on exposed fetuses are indeed caused by a 5-HT reduction. 
Sprague Dawley rats were mated and their litters were reduced 
to 8 pups, 4 males and 4 females, with parturition day termed P0. 
The rats were divided into 2 groups. One group received two 
subcutaneous injections of MDMA daily on P1-P10 while the 
second group received similar MDMA injections on P11-P20. 
These intervals of P1-P10 and P11-P20 correspond to early and 
late third trimester development in humans, respectively. 
Between P60 and P80, the rats were tested in various assigns. 
The results of the tests illustrated that the rats in the P11-P20 
group had significant decreases in sequential learning, spatial 
learning, and memory abilities, while those in the P1-P10 group 
did not show significant decreases in any of these areas. Neither 
group showed a significant decrease in cued learning. These 
tests demonstrate that the neurotoxic effects that MDMA has 
on a developing fetus are more likely to occur when MDMA is 
taken during late third trimester development and that these 
effects are long term, as seen from the presence of the impair-
ments in rats that had already reached adulthood.
The researchers sought to determine whether these cognitive 
impairments in the rats were due to serotonergic decreases 
in the rat brains. In order to investigate this hypothesis, the 
rats were decapitated on P105 and their brains were dissected. 
Reductions in 5-HT in the hippocampus were found for both 
the P1-P10 and P11-P20 groups, findings that do not correlate 
with the cognitive impairments seen only in the P11-P20 groups. 
In addition, the frontal cortex of the rats displayed 5-HT reduc-
tions only in the P11-P20 group, but these reductions were in-
significant as seen with a correlation coefficient between these 
reductions and the spatial learning deficits exhibited by the rats 
that did not approach significance. Therefore, while this study 
shows that MDMA has long term negative effects on spatial 
and sequential learning and memory, it also illustrates that these 
cognitive deficits are not due to serotonergic reductions. The 
cause of fetal brain damage by MDMA must be via a mechanism 
other than the 5-HT reduction that causes MDMA induced 
damage in the adult brain (Broening, et al., 2001).
This idea that prenatal MDMA exposure and the long term 
damage that it causes is not due to 5-HT reduction can be sup-
ported by the mechanism via which MDMA causes 5-HT reduc-
tion in the adult brain. Studies indicate that MDMA metabolites 
form free radicals upon further metabolism and thereby dam-
age serotonergic neurons. This is supported by the presence 
of malondialdehyde in rat brains after exposure to MDMA. 
Malondialdehyde is an end product of lipid peroxidation, the 
process during which lipids in cell membranes are broken down 
via free radicals. Because free radicals are hard to measure due 
to their short half-lives, the by-products of these radicals known 
as TBARS (thiobarbituric acid reacting substances) are used to 
measure the damage induced by the free radicals. The TBARS 
Assay is a test that reacts thiobarbituric acid with malondial-
dehyde in order to quantify the amount of free radicals found 
in a specimen. This reaction yields a florescent product that 
indicates the presence of free radicals. Thus, a high yield of 
malondialdehyde from a TBARS Assay found in adult rats ex-
posed to MDMA indicates the presence of free radicals in these 
rats. Another indication of the presence of free radicals in rats 
exposed to MDMA is that 5-HT reduction is prevented from 
occurring in MDMA-exposed rats that are injected with alpha-
phenyl-N-tert-butyl nitrone (PBN), a free radical scavenger. This 
indicates that the 5-HT reduction occurring in adult rats may 
be happening in part because of free radicals. A study exposing 
both neonate and adult rats to MDMA showed no significant 
increase in the presence of malondialdehyde in the hippocam-
pus and cortex of the neonate rats while the adults’ brain cor-
tices did demonstrate a significant increase in malondialdehyde 
(Figure 1). Free radicals cause the serotonergic reduction in 
adult rats, and it can be inferred that cognitive defects found 
in adult humans exposed to MDMA are caused by this 5-HT 
reduction. In contrast, neonatal rats and, by inference, humans 
prenatally exposed to MDMA, have cognitive impairments that 
cannot be attributed to 5-HT reductions (Colado, et al., 1997). 
Other factors must be explored to lend reason for these long 
term neurotoxic effects.
Another possible cause for the cognitive deficits recognized 
in children prenatally exposed to MDMA is elevated levels of 
Figure 1 - Formation of thiobarbituric acid reacting substances 
(TBARS) in the hippocampus and cortex of adult rats and cortex of 
neonate rats 3 h (hatched columns) and 6 h (cross-hatched columns) 
after MDMA (40 mg kg71, i.p.) administration. Results show % 
change in brain malondialdehyde (MDA) formation compared to 
saline-injected control animals (open columns), as mean+s.e.mean, 
n=8± 10. *Significantly different from saline (Colado, et al., 1997).
Figure 1
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cortisol caused by ingestion of Ecstasy. As noted, MDMA has 
been shown to cause impairments in long term memory, learn-
ing, and locomotor activity in children exposed to this drug in 
utero. Researchers hypothesize that these impairments may be 
due to the increase in cortisol that is present. Individuals in-
gesting Ecstasy display higher levels of cortisol in comparison 
to drug-free individuals with baseline cortisol levels. In addition, 
increased cortisol levels may be damaging to fetal development. 
Therefore, if the Ecstasy user is a pregnant woman, her MDMA 
usage may put her fetus at risk (Parrott, et al., 2014).
Cortisol is a glucocorticoid steroid hormone produced by the 
adrenal cortex in response to bodily stress and/or low blood 
glucose levels. The body releases this hormone in order to pro-
vide additional metabolic resources that enable an individual to 
function properly while under stress. The hypothalamic- pitu-
itary-adrenal (HPA) axis is a systemic interaction of endocrine 
glands that utilize a negative feedback mechanism in order to 
control the hormonal activities of the adrenal cortices (Mosby’s 
Medical Dictionary, 2009). 
In a recent study performed on MDMA users, light usage of 
MDMA (ingestion of MDMA 1-4 times within the past 3 
months) led to a mean increase of 50% in cortisol levels, in con-
trast with a control group of MDMA-free individuals. Heavier 
Ecstasy users (ingestion of MDMA 5+ times within the past 3 
months) were noted to have a mean increase of 400% in their 
cortisol levels in comparison with a control group. While these 
statistics definitely illustrate radical increases in cortisol levels 
in MDMA users, a 10% increase of maternal cortisol leads to a 
mere 1% increase in fetal cortisol. This is due to the placental 
glucocorticoid barrier that prevents most of the cortisol from 
reaching the fetus. However, while a small increase in maternal 
cortisol levels may not cause damage to a fetus, a 400% increase 
in maternal cortisol can possibly have long term deleterious ef-
fects on the child. 
According to the scientific review by Parrott, et al.(2014), “…
HPA basal hyperactivation…may represent a complex neuro-
endocrine dysfunction associated with MDMA use.” They imply 
that elevated cortisol levels caused by MDMA ingestion may 
lead to HPA axis impairments, specifically in a developing fetus. 
This idea is supported by a study on the effects of maternal 
stress on a fetus, because researchers have found that similar 
to ingestion of MDMA, an increase in a mother’s stress level 
causes more cortisol to be produced, and this hormone is then 
passed to the fetus via the placenta. As noted, although most 
of the cortisol is prevented from reaching the fetus due to the 
placental glucocorticoid barrier, about 1/10th of the cortisol 
will still reach the fetus. This hormone may then reprogram the 
HPA axis activity of the developing fetus which can cause long 
term damaging effects on the child. Studies illustrate that the 
negative effects of stress on the developing fetus include poorer 
attention spans, sleeping, feeding, and activity problems, great-
er impulsivity, and a higher pervasiveness of Attention Deficit 
Hyperactivity Disorder (ADHD). Because ingestion of MDMA 
causes an increase in cortisol in the same way that maternal 
stress does and because cortisol has been shown to cross the 
placental barrier, researchers infer that it is the elevated cortisol 
levels found in MDMA users that are responsible for the neu-
rotoxic deficits found in Ecstasy-exposed fetuses and that the 
long term effects of MDMA may mirror the effects of maternal 
stress on a fetus.
It is interesting to note that increased cortisol levels can be seen 
in an individual for up to 3 months after he/she has stopped 
using MDMA. Thus, it follows that a woman who stops MDMA 
usage prior to pregnancy may still be liable to inflict lasting 
damage to her fetus unless she has had several months of drug 
abstinence prior to conception (Parrott, et al., 2014).
A study researching the connection between elevated cortisol 
levels and memory problems supports the idea that elevated 
cortisol levels may be the cause of long term damage in MDMA-
exposed fetuses, specifically in the area of memory impairment. 
Researchers tested healthy individuals with a mean age of 61.8 
years to determine if memory problems are linked to elevated 
cortisol levels. This study used a special testing method in order 
to control for any stress that would develop in the subjects 
because of the inherent knowledge of their memory loss. The 
study demonstrated that women with memory complaints 
had significantly higher levels of cortisol than women without 
memory complaints, although no such difference was seen in 
men. In addition, individuals who complained of memory issues 
also had increased activity of their HPA axes (Wolf, et al., 2004). 
Similar to the adults in this study, fetuses exposed to MDMA 
also had elevated cortisol levels and hyperactivity of their HPA 
axes (Parrott, et al., 2014). In a similar vein, a study performed 
on cocaine dependent individuals served to analyze the cause 
for the learning and memory dysfunctions observed in these 
drug addicts. Researchers determined that cocaine dependent 
individuals have higher levels of cortisol than individuals in a 
‘cocaine-free’ control group, and this increase was associated 
with the poorer learning and memory skills observed in these 
individuals (Fox, et al., 2009).Thus, it can be inferred that the 
memory impairments noted in children prenatally exposed to 
MDMA may be caused by the elevated cortisol levels that these 
fetuses are exposed to.
Another hormone that may be linked to the damage induced 
by MDMA in the developing fetus is norepinephrine (NE). NE 
is a noradrenergic hormone and neurotransmitter made from 
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dopamine (DA) by the enzyme dopamine beta hydroxylase 
(DBH). It is released from the adrenal medulla into the blood-
stream and acts as a systemic hormone, and it is also released 
from noradrenergic neurons in the locus ceruleus of the brain 
where it acts as a neurotransmitter. Scientists have found that 
a correlation exists between prenatal exposure to MDMA in 
rats and changes in the structure and function of the NE sys-
tem in these prenatally exposed rats. NE system dysfunction 
has been associated with exaggerated behavioral responses to 
new stimuli as well as a decrease in habituation to these stim-
uli, impairments which are attributed to attentional processing 
deficits. Because researchers have observed these behaviors in 
prenatally exposed rats, they  infer that the damage induced by 
MDMA exposure to a developing fetus may be linked to abnor-
mal wiring of the fetus’s NE system (Thompson, et al., 2011).
In order to test this hypothesis, pregnant Sprague-Dawley rats 
were randomly assigned to two groups. One group was injected 
with 15mg/kg of MDMA twice a day at 8 hour intervals, a dose 
consistent with the typical MDMA dosage taken for human 
consumption, while the other group received subcutaneous 
injections of saline two times a day at corresponding 8 hour 
intervals. These injections were administered from embryonic 
day 14 (E14) to embryonic day 21 (E21). The pups were born on 
E21 and the first day after parturition was termed postnatal day 
1 (P1). The litters were reduced to 4 males and 4 females for the 
MDMA group and 5 males and 5 females for the saline group. 
The pups were anesthetized on P21 and their brains were re-
moved and cut into specific sections for observational analysis.
Among the different areas of the brain that were analyzed, three 
sections of the rostral hippocampus, CA1, CA2, and CA3, were 
scrutinized for NE abnormalities. This section of the brain was 
studied because it is receives noradrenergic innervation from 
the locus ceruleus and because it is involved in spatial memory 
and responses to novelty, abilities that have been found lack-
ing in MDMA exposed fetuses. The rats prenatally exposed to 
MDMA exhibited a 32.1% increase in DBH fiber density in the 
CA1 region of the hippocampus in comparison with the control 
group. In addition, norepinephrine transporter (NET), a mole-
cule that regulates NE signaling by clearing NE from the synaptic 
cleft, increased in MDMA rats by 39.3% in the CA1 region and 
32.1% in the CA3 region. In spite of these increases, the rostral 
hippocampus displayed no elevation in NE levels and levels of 
3-methoxy-4-hydroxyphenolglycol (MHPG), a main metabolite 
of NE. The locus ceruleus displayed no increase in DBH fibers, 
and NET binding did not increase in this area. However, in the 
prelimbic (Cg3) region of the prefrontal cortex, there was a 
69.2% increase in DBH neurites. This was accompanied by a 
15% increase in NE in the prefrontal cortex as a whole, although 
there was no increase in NET binding or MHPG levels in the 
prefrontal cortex.
These findings suggest that MDMA can cause NE system dys-
function in the developing fetus. As an example, the increase 
in NET binding observed in the CA1 and CA3 regions of the 
hippocampus illustrate that MDMA caused more NE to con-
tinue to be present in these areas even after exposure, or that 
the high levels of NE found in the hippocampus during MDMA 
exposure led to a sustained increase in NET binding in these 
areas as a form of systemic regulation. Because NE in the CA1 
region of the hippocampus plays a big role in communication 
signaling between the hippocampus and entorhinal cortex, NE 
abnormalities in this region may lead to communication deficits 
which in turn may lead to impairments in spatial learning and 
working memory. In fact, as illustrated in other studies pre-
viously mentioned, these deficits have been found in rats ex-
posed to MDMA while in utero. Also, as mentioned previously, 
NE increases have been related to exaggerated responses to 
novelty and attentional processing impairments. These deficits 
also correlate with a study that observed that rats exposed to 
MDMA while in utero had increased levels of responsivity to a 
new cage at P21, an increase that persisted into adulthood as 
far as P61-P62. Therefore, it can be theorized that NE system 
changes caused by rat embryonic exposure to MDMA, and, by 
inference, NE system changes caused by human fetal exposure 
to MDMA, lead to many of the impairments observed in chil-
dren prenatally exposed to MDMA. Changes in the noradren-
ergic system that develop in the fetus as a result of MDMA ex-
posure have direct links to the deficits noted in these children 
post-parturition. 
It is worth mentioning that the results of the MDMA exposure 
are noted on P21, and that this corresponds to the early teen-
age years in humans. Thus, NE system changes and the resulting 
impairments can be effective in this time period. These system-
ic deficits may be the cause of the impulsivity and ‘search for 
novelty’ that is present amongst many young adults that often 
leads to substance abuse or reckless behavior (Thompson, et 
al., 2011). Perhaps the mothers ingesting MDMA while preg-
nant are unknowingly setting the stage for substance abuse in 
their children many years down the line.
In a similar study, scientists determined that fetal rat exposure 
to MDMA affects the fetus’s dopamine (DA) system. These ef-
fects can be seen by a five-fold increase in dopamine neuron 
fibers in the prefrontal cortex of the rat brain as well as by 
smaller increases in DA fiber density in the striatum and nu-
cleus accumbens of rats exposed to MDMA while in utero. 
DA has many pathways in the brain, one of which is the meso-
cortical tract, a pathway that transports DA from the ventral 
tegmentum to the frontal cortex. The pathway is known to 
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influence exploratory behaviors, impulsivity, and a search for 
novelty. When this system is impaired, the results can cause hy-
peractivity and are sometimes linked to behavioral issues such 
as ADHD. Because changes in the DA system of both humans 
and rats is associated with decreased habituation to novelty 
and increased locomotor activity, this study sought to discover 
whether the changes in the DA system noted in the rats ex-
posed to MDMA could be correlated with significant changes 
in these particular behavioral areas (Thompson, et al., 2010). 
The study tested Sprague Dawley rats that were injected with 
MDMA on embryonic day 14-20, as well as a group of ‘control’ 
rats, and measured their behavior on postnatal day 21. Many 
behavioral areas such as home cage locomotor activity, running 
wheel activity, gravitation towards a high fat diet, and cocaine 
self-administration levels where tested. However, the only areas 
of behavior that had significant results in comparison with the 
control group were the rats’ decreased acclimation to new 
environments, increased perseverance to find a cued platform, 
and increased locomotion in the center of an open field which 
served as an indication of the rats’ decreased levels of anxi-
ety. Thus, the researchers hypothesized that the rats exposed 
to MDMA in utero had alterations in their dopamine systems, 
specifically in the mesocortical pathway. They conjectured that 
a possible cause for the decreased habituation to novelty and 
increased perseverance seen in the rats was caused by impair-
ments that the MDMA wreaked on the fetal rats’ developing 
DA systems (Thompson, et al., 2010).
Another study researching deficits found in fetuses exposed 
to MDMA explores impairments in neuronal differentiation 
that arise due to an increase in an autophagy-related protein 
5 (Atg5). Autophagy is an intracellular process that involves 
packaging unneeded cytoplasm and organelles into vesicles 
known as autophagosomes in preparation for degradation 
so that the cell can recycle these particles. After an isolation 
membrane elongates and surrounds unneeded cellular parti-
cles, an autophagosome is formed which fuses with a lysosome, 
eventually leading to the catalytic breakdown of the extraneous 
cellular particles. Seven proteins known as autophagy-related 
proteins regulate this process. These proteins are grouped into 
two distinct categories – the Atg12 system (comprised of Atg 
5, 7, 10, and 12) which involves regulating the elongation of 
the autophagosome isolation membrane, and the Atg8 system 
(comprised of Atg 3,4,7, and 8), a system involved in regulating 
the attachment of the phospholipids in the autophagosome 
membrane (Chae, et al., 2009). 
Defects in the autophagy system have been linked to various 
physiological impairments. In this study, researchers discovered 
that rats embryos injected with MDMA had elevated levels of 
Atg5. The study explanted rat embryos after 8.5 days of gestation 
and administered dos es of 2.5, 5, and 10 micrograms of MDMA 
to the embryos. When the embryonic mRNA was sampled, it was 
noted that Atg5 expression had doubled after 48 hours of MDMA 
exposure and that extreme teratogenesis and fetal brain damage 
was observed in the rats (Figure 2). In order to determine if this 
brain damage occurred due to impairment of neuronal differen-
tiation, human neuroblastoma SH-SY5Y cells were divided into 
two groups, a control group and a group injected with 10 micro-
grams of MDMA. The group of cells administered with MDMA 
illustrated an increase of 1.8 times the amount of Atg5 mRNA 
expression after 48 hours. Furthermore, when a sample of SH-
SY5Y cells was induced with a green florescent protein vector 
(GFP), a protein used as a marker of genetic expression, in the 
presence of a plasmid encoding for Atg5, the cells did not express 
This diagram illustrates images of fetal brain development of various rat embryos that received specific doses of MDMA on gestational 





any neurite extensions or arborizations (fine branching at the 
end of the neurite fiber). This was in the presence of retinoic 
acid, a metabolite of vitamin A that usually aids in growth and 
development. In contrast, a control group of SH-SY5Y cells in-
duced with a GFP vector and retinoic acid in the absence of Atg5 
exhibited extensive neurite extension and arborization (Figure 
3). This demonstrates that an increase in Atg5 impairs neuronal 
growth and differentiation. Therefore, because an increase in Atg5 
is found to impair the differentiation of SH-SY5Y neuroblastoma 
cells, it can be inferred that the teratogenesis observed in rats ex-
posed to MDMA that is accompanied by an increase in Atg5 can 
be attributed to a similar mechanism of impairment of neuronal 
differentiation (Chae, et al,. 2009).
An additional area that can be explored in order to explain the 
neuronal impairments discovered in fetuses exposed to MDMA 
is the metabolites that MDMA forms upon ingestion. As stat-
ed previously, when MDMA enters the body, it is broken down 
into substances that are further metabolized into free radicals. 
This is supported by the presence of malondialdehyde (MDA) 
in rat brains after exposure to MDMA, because MDA is one of 
the end products of lipid peroxidation, a process during which 
lipids in cell membranes are broken down via free radicals. 
However, MDMA forms other metabolites aside from MDA, 
depending on which enzymes are present to break it down. 
Therefore, while the formation of the MDA metabolite ac-
counts for the breakdown of 20-90% of MDMA ingested by rats, 
3, 4-Dihydroxymethamphetamine (HHMA) is a metabolite of 
MDMA that is formed upon human consumption and accounts 
for 53-81% of MDMA metabolism in humans. The difference in 
MDMA metabolism that results in the formation of MDA or 
HHMA is very slight. Ortho-demethylenation of MDMA, which 
occurs in humans, leads to the formation of HHMA, while 
N-demethylation, occurring in rats, leads to the formation of 
MDA (Figure 4). MDMA does metabolize into MDA in humans, 
as does MDMA metabolize into HHMA in rats, but only trace 
amounts of these metabolites are found in humans and rats, 
respectively (Barenys, et al., 2012). 
Researchers have found that the presence of HHMA or MDA 
while a fetus is developing can lead to embryonic defects in the 
fetus. Scientists explanted embryos from Sprague Dawley rats 
after 9.5 days of gestation and injected various embryos with 
MDMA, MDA, and HHMA. The concentrations of the injections 
for each substance were 5, 15, 25, and 50 micrograms. They 
discovered that the embryos injected with 25 and 50 micro-
grams of MDMA had a decrease in crown-rump length (CRL), a 
measurement of the fetus from the top of the head (crown) to 
the bottom of the buttocks (rump). In addition, abnormal tissue 
formations, known as dysmorphogeneses, were observed in the 
rats injected with 50 micrograms of MDMA. These dysmor-
phogeneses displayed themselves as an opening in the superior 
frontal tissue of the head, termed an open cranial neural pore, 
an abnormal prominence in the inferior frontal part of the head, 
termed a protuberant nasal placode, and a disproportionately 
small forebrain in comparison with the midbrain and hindbrain 
(Barenys, et al., 2012). 
Similarly, the embryos injected with doses of MDA displayed a 
decrease in their CRL after receiving a dose of 50 micrograms 
of MDA. These rats also exhibited dysmorphogeneses such as 
the posterior part of the embryonic trunk located behind the 
embryo instead of in front of it, termed an abnormal flexion, 
an abnormal caudal part of the embryo that was marked by a 
bend in the distal part of the embryo’s trunk, abnormally shaped 
somites, and unusual narrowing of the otic vesicles that repre-
sented the formation of irregular ears (Barenys, et al., 2012). 
The embryos injected with doses of HHMA also displayed 
This figure depicts the SH-SY5Y cells that were induced with GFP 
vector and retinoic acid for 5 days. The control group (top row) was 
imaged after 5 days while the test group (bottom row) was induced 
with Atg5 and also imaged after 5 days. Neurite extension and 
arborization is present and can be seen in the control group while no 
extension and arborization is present in the test group (Chae, et al., 
2009).
Figure 3
Figure 4 - This diagram illustrates the two main metabolic 
pathways of MDMA. O-demethylenation produces HHMA and is 
the main pathway that occurs in humans while N-demethylation 
produces MDA and is the main metabolic pathway that occurs in 
rats (Barenys, et al., 2012).
Figure 4
29
Biological Reasons for the Neurotoxic Effects of MDMA
similar anomalies. Interestingly, the group of embryos injected 
with 50 micrograms of HHMA died upon exposure to this 
concentration of metabolite. Therefore, the doses were mod-
ified to 10, 20, 30, and 40 micrograms of HHMA per group of 
embryos. At both 30 and 40 micrograms of HHMA, the CRL of 
the embryos significantly decreased. Additionally, dysmorpho-
geneses such as abnormal flexion, a protuberant nasal placode, 
and an abnormal yolk sac (an anomaly marked by a yolk sac that 
was not properly rounded or was missing vasculature) were 
noted in the embryos injected with 40 micrograms of HHMA 
(Barenys, et al., 2012). 
This research indicates that MDMA severely damages a de-
veloping fetus due to the toxic metabolites that are formed 
upon MDMA ingestion. However, it must be addressed why the 
dysmorphogeneses noted in the fetuses exposed to MDMA 
differed from those noted in the fetuses exposed to MDA 
and HHMA. While some of the abnormalities such as a pro-
tuberant nasal placode and decreased CRL were seen in both 
the MDMA-exposed embryos and the MDA and/or HHMA-
exposed embryos, there were anomalies noted in the MDA and 
HHMA-exposed embryos that were not found in the MDMA-
exposed embryos. This presents a problem, because MDA and 
HHMA are metabolites of MDMA and therefore, all of the 
anomalies found in an embryo exposed to these metabolites 
should be found in an embryo exposed to MDMA. Perhaps this 
can be explained by the fact that MDMA forms many metabo-
lites upon ingestion, aside from MDA and HHMA. It is possible 
that the ‘other’ metabolites of MDMA interact with one anoth-
er and ‘change’ the irregularities noted in embryos exposed to 
MDA or HHMA to represent those seen in embryos exposed 
to MDMA. 
Additionally, it is worth focusing on the fact that the HHMA 
killed the embryos that received injections of 50 micrograms 
while this did not occur to the embryos receiving injections 
of 50 micrograms of MDA. HHMA is the main metabolite of 
MDMA in humans, and this finding suggests that it is more toxic 
than MDA, the main metabolite of MDMA that is found in rats. 
Because many of the studies available today about MDMA and 
its harmful effects have used rats as their method of research, 
perhaps humans need to be extra cautious when ingesting 
MDMA. This is because the negative effects that MDMA has 
been shown to display in rats is probably greater in humans 
since HHMA is the main metabolite of MDMA in humans and 
appears to be a more toxic metabolite than MDA.
Conclusion
MDMA is an illicit, amphetamine derivative drug known as 
‘Ecstasy’ that causes harm to a developing fetus exposed to 
this drug while in utero. Scientists have confirmed that fetus-
es exposed to MDMA exhibit shorter attention spans, poorer 
memory, decreased habituation to novelty, poorer mental de-
velopment index scorings, and other neurological impairments. 
While researchers have determined the negative effects that 
MDMA has on a fetus, the biological reasons for these effects 
are still being researched extensively. Scientists have determined 
that these deficits are not due to 5-HT reductions in the brain. 
However, these defects may be caused by changes in the fetuses’ 
cortisol levels, systemic NE or DA changes that are caused by 
exposure to MDMA, an increase in Atg5 that leads to inhibi-
tion of neuronal growth and differentiation, or the embryotoxic 
effects of HHMA and MDA, two main metabolites of MDMA. 
These explanations require further research to determine how 
they interrelate with one another. Additional studies can inves-
tigate the interactions of all of the systemic changes caused by 
fetal exposure to MDMA to explore how these interactions 
bring about the cognitive deficits noted in MDMA-exposed 
fetuses. While this area of research has yet to be explored, indi-
viduals should take note that the harmful effects of MDMA have 
already been determined with certainty and that consumption 
of this drug should be avoided. 
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Introduction
A primary goal in biological research is to understand human de-
velopment, however research on humans in restricted. Although 
isolation of human embryonic stem cells (hESCs) and the gener-
ation of human induced pluripotent stem cells, have led to more 
options in the field of human biology, there is still need to ana-
lyze these cells in an in vivo setting. As a result, many researchers 
are now turning to human animal chimera research (Hermerén, 
2015). The definition of a chimera, suggested by Lensch et al. 
(2007), is an organism containing cells from two or more individ-
uals of the same or different species. Behringer (2007) proposed, 
that a chimera is an organism with two cell lines, where the in-
dividual is “composed of somatic and, in certain cases, germline 
tissues derived from more than one zygote.” 
There are different types of chimeras, Tetragametic chimeras, 
arise in many cases from in vitro fertilization (IVF), a route of 
fertilization, in which an egg and sperm are combined in a lab-
oratory dish, and the resulting embryo is then transferred into 
the uterus. Because the ensuing embryos were grown in close 
contact, Tetragametic chimeras can result (Granzen, R.R, 2014). 
Tetragemetic chimeras also occur when twin zygotes fuse to-
gether and develop into one body. As a result, the individual’s 
tissues are derived from more than one zygote, and contain 
two sets of DNA. There have been cases where this happened, 
and affected the individual later on in life, when she has her 
own child and if a DNA test is done, it might not match up. It 
can be her ‘sisters’ genes that she fused with that matches her 
children’s. Further testing will prove it’s her child by matching 
the same genotype in some parts of her body. A person who has 
two different eye colors, can be from the fusion of two zygotes, 
among other causes. Consequently, someone born with male 
parts and female parts can be male and female early embryos 
that merged together (Norton and Zehner, 2008). But here, 
chimeras spoken about are human animal chimeras, which are 
being studied more by scientists in the hope to discover cures 
for diseases, such as Alzheimer’s and Parkinson’s and to develop 
vaccines, for example to help fight HIV.
Human animal chimeras have been created by “grafting human 
cells and tissues into the embryos, fetuses, or adults of vertebrate 
model organisms (Behringer, 2007).” Currently researchers and 
scientists are experimenting how the use of chimeras can ad-
vance the field of medicine. Scientists are utilizing the unique 
ability of stem cells to proliferate and differentiate into various 
cells. They are using the idea of stem cell research, but with a 
twist. Scientists are injecting human stem cells (hCSs) into ani-
mal embryos for the purpose of studying human diseases. When 
a fetus is forming, the immune system is not mature enough to 
attack anything foreign, therefore modifications can be made 
in an embryo. For example, early discovery of an abnormality 
can be treated with stem cell administration. The injected cells 
can freely proliferate and/or differentiate into new cells, replace 
the diseased ones, and regenerate damaged tissue. Although this 
concept might sound relatively new, the idea of chimeras are al-
ready being practiced today, by using pig heart valves for humans 
and using animals for skin grafts (Cooper, 2012).
The study of biological systems in humans is largely regulated to 
in vitro models that lack the mechanisms and intricacy of living 
organisms. The complexity of a biologic structure can only be 
precisely and realistically replicated by an in vivo system. In vivo 
studies in laboratory animals are routinely used to model human 
biology and disease but they are not human and therefore can-
not fully replicate human functioning. Transplanting human cells 
into animals provides a way to study human systems in vivo (Sun 
et al., 2007). Humanizing an animal, by implanting human blood, 
neurons, germ cells and other tissues into it, results in a chimera. 
Human animal chimeras, containing animal and human cell lines 
have been generated for decades to facilitate human biological 
studies and therapeutic strategies for disease (Behringer, 2007).
This paper reviews studies done using human animal chimeras. 
Although research with chimeras shows great potential for in-
sight into diseases and medicine, it also raises unique ethical 
issues that must be considered. Are the benefits of using human 
animal chimeras for therapeutic protocols worth the possible 
risks?
Materials and Methods
In order to answer the question proposed above, many re-
search papers and journal articles with relation to this area 
have been read. Touro College’s library data base (tourolib.org) 
was utilized to search for relevant studies and reviews, with 
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databases such as ProQuest, and EBSCO. Further research was 
done by looking up references cited from review articles to find 
original papers. All research accumulated was used in an attempt 
to determine if the benefits of humanized animals outweigh the 
possible risks.
Discussion
There have been a number of studies using human animal chime-
ric mice as an in vivo system to study how stem cells proliferate, 
to test diseases, and to study in more detail the biologic systems. 
Often mice are used, however fetal sheep and fetal goat, during 
the pre-immune stage of development, have also been used as a 
surrogate animal model for human stem cells.  The pre-immune 
stage allows for the transplant of human stem cells, and the 
resulting human animal chimera serves as a unique and clinically 
relevant xenograft animal model for assessing the differentiation 
potential of hSCs in vivo. However from a scientific perspective, 
large animals are not a suitable model for mechanistic research 
and the experiments reviewed here utilize mice, as a host for 
human cells. Small animal models, such as mice and rats accord-
ing to scientists are ideal models to use. The advantages of using 
small animals is that they contain naturally occurring migration 
patterns of stem cells, and provide the availability of extending 
homing and engraftment sites. Additionally, the presence of tis-
sue and organ specific signals from niche, greatly facilitate the 
widespread distribution of human donor cells. It is these rea-
sons that compelled scientists to develop an influential small 
animal model, also known as a humanized animal for pursuing 
hSC basic research (Sun et al., 2007).
Stem Cells
In one study, a human/rat xenograft animal model was gener-
ated by transplanting human low-density mononuclear cells 
(hMNC’s) from human umbilical cord blood (hUCB) into fetal 
rats to study how the human donor stem cells behave in vivo. 
Numerous methods including flow cytometry, Polymerase 
Chain Reaction (PCR), and immunohistochemistry (IHC) 
assay were used to test the human donor contribution. Flow 
cytometry detected that out of 29 recipients, 19 had human 
leukocyte common antigen, CD45+ cells in peripheral blood 
(PB). PCR analysis on 11 different adult tissues showed that 14 
out of 19 CD45+ animals possessed donor derived human en-
graftment in multiple tissues for example, the liver, spleen and 
thymus. The differentiation of human donor cells in the liver 
was assessed by IHC with the use of human specific antibody 
against the hepatocyte marker; CK18. The recipient liver, and 
the human liver had cells that expressed human CK18, while 
normal control rats did not.  IHC examination revealed that 
in the chimeric adult spleen of recipients, many donor derived 
human cell populations expressed CD45 marker indicating the 
human spleen- specific differentiation of donor derived human 
cells. Differentiation of hMNC’s was evaluated in the rat thy-
mus using IHC with a human specific antibody against CD45. 
At 3 weeks, 2 months and 6 months after in utero transplan-
tation, multiple human cells recognized in the recipient thymus 
strongly expressed CD45. Human umbilical cord derived cells 
expressing CK18  underwent site specific differentiation into 
CK18+ human cells in the recipient liver and CD45+ human 
cells in the recipient spleen, which demonstrates that after in 
utero transplantation of hMNC’s, they successfully engraft into 
the liver and spleen of recipients. “Subsequently, the long term 
that survive in these organs are then actively influenced by niche 
signals to contribute in organogenesis (for example liver and 
spleen) recipients in the xenogeneic competitive settings.” This 
experiment concluded that a human rat chimera was successful-
ly developed in which xenogeneic human cells exist for up to 6 
months. This provides a great in vivo model to study how stem 
cells work (Sun et al, 2007).
In another study, hESCs were implanted into the brain ventricles 
of embryonic mice, and found to differentiate into functional 
neural lineages, generating mature active human neurons that 
successfully integrate into the adult mouse forebrain. This study 
reveals insights to recognition of common signals for neural 
differentiation throughout mammalian evolution. The results 
showed that hESCs, when transplanted into the ventricle of the 
developing mammalian brain, can give rise to neuronal and glial 
lineages, suggesting that they are “responsive to environmental 
cues that regulate cell fate determination and differential migra-
tion.” This human animal chimera model provides an in vivo ap-
proach to study human neural development. An approach which 
can be used to study human neurodegenerative and psychiatric 
diseases, and a prospective technique to speed up the screening 
process for therapeutic drugs in the future (Muotri et al., 2005).
Disease Model
In another experiment, an animal with a humanized immune 
system was used to serve as a human disease model for Human 
Immunodeficiency Virus type 1 infection (HIV-1). Rag2−/−vc−/− 
mice, when neonatally injected with human CD34+, develop a 
functional human immune system, with human hematopoiet-
ic cells found in the thymuses, PB, spleen, and bone marrow 
(BM) of the animals. Rag2−/−v c−/− mice become infected with 
HIV-1 when injected with CCR5 tropic HIV-1. HIV-1 infection 
is characterized by constant virus replication and a gradual loss 
of CD4+ T cells and T-cell function. After being injected with 
CCR5 tropic HIV-1, there was a productive infection of human 
cells in PB, thymus, spleen tissue, and BM, and ratios of CD4 (+) 
T cells to CD8 (+) T cells declined. Infection of the mice with 
5000 TCID50 of R5 HIV-1 resulted in a productive infection 
in 3/3 animals. HIV replication was detected in PB, thymuses 
and spleen and BM was also positive for HIV-1. When a 10 fold 
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smaller amount 500 TCID50 was used for infection, only 2/5 
were found to be productively infected with HIV 1 in PB and 
all lymphoid organs. This study demonstrated that HIV-1 can be 
detected in multiple lymphoid tissues of Rag2−/−vc−/− mice, 
using low doses of CCR5- tropic HIV-1. This mouse, consisting 
of a human hematopoietic system, can serve as a small animal 
model for investigating HIV-1 pathogenesis and testing potential 
HIV-1 therapies (An et al., 2007).
In the next study, a chimeric mouse, that sufficiently mimics the 
pathophysiological micro-environment in human liver, was es-
tablished as a unique experimental model to study human liver 
cancer metastasis (Fujiwara et al., 2012). This was discovered 
by expression of an albumin-urokinase plasminogen activator 
(Alb-uPA) transgene in the mouse that is hepatotoxic, resulting 
in the progressive destruction of the mouse liver. It was found 
that when primary healthy normal human hepatocytes were 
transplanted into this mouse, the human hepatocytes were ca-
pable of reconstituting the host liver, highlighting the generous 
capacity of hepatocytes to regenerate. This liver reconstitution 
mouse model has led to a mouse with a humanized liver, by the 
development of mice with livers that are reconstituted by en-
grafted human hepatocytes. This model can be useful for in vivo 
testing of anti-cancer drugs and for studying the mechanisms of 
human cancers (Behringer, 2007). Based on this, scientists theo-
rized that the chimeric mouse can be used as an animal model 
to investigate the underlying mechanisms of tumor metastasis 
into the liver, where the “parenchyma is composed largely of 
normal and healthy human hepatocytes (Fujiwara et al., 2012).”
Human Organs
Human animal chimeras can be used to create complete human 
organs by growing organs made exclusively from human cells in 
a chimeric animal, such as a pig, that could potentially be used 
for organ transplants (Hermerén, 2015).  It was shown, that 
when a mouse that is deficient in T and B cells was injected with 
mouse embryonic stem cells, the T and B cells generated were 
the donor derived mouse embyonic stem cells.  The donor stem 
cells compensated for the lack of T cells by producing T cells. It 
was hypothesized that the same may be true for organs. That if 
an animal that is deficient in an organ is injected with stem cells, 
the stem cells might compensate for what its lacking and grow 
into that organ. 
A study was done where mouse wild-type pluripotent stem 
cells (PSCs) were injected into Pdx1−/− mouse blastocysts, 
(pancreatogenesis-disabled) and found that they developmen-
tally compensated vacancy of the pancreatic “developmental 
niche,” generating almost entirely PSC-derived pancreas. The 
organ generation system described may be useful to treat 
organ failure in humans if pigs or other large animals are used. 
However, several concerns have to be addressed first to bring 
this idea into practice. For example, if interspecific chimeras be-
tween mouse and rat were to be generated, their “embryonic 
lethality is high and maturation into adulthood is uncommon 
(Kobayashi et al., 2010).”
In another study the immune-deficient athymic nude mouse was 
used as a recipient of human tissue grafts, to generate human 
animal chimeras. Because this mouse lacks T cells, it allows for 
many types of xenograft tissues to survive and grow (Behringer, 
2007). Four to seven grafting experiments using human fetal 
material in the nude mouse have been successful. In 1969 the 
first successful transplantation of human malignant tumor tissue 
in the nude mouse was reported. Since then, the number of tu-
mors transplanted has increased steadily. The nude mouse with 
transplanted malignant tumors is a new alternative model in 
oncologic research. It can be applicable to: “basic studies of the 
genesis of cancer tissue, immunology, and cell kinetic research 
(Spang-Thomsen and Visfeldt, 1976).” The nude mouse was used 
as a model for cancer, by grafting pieces of human tumors under 
the skin of the nude mice, in that way, providing a “bio incu-
bator” for tumor growth. This bio incubator gives scientists a 
glimpse into how to treat diseases in humans. The introduction 
of the nude mouse significantly enabled these types of studies 
and this in vivo assay is one of the fundamental experimental 
models for cancer research (Behringer, 2007).
Other experiments include studying mice with human germ 
lines. By subcutaneously transplanting human pre-pubertal and 
adult testicular tissue fragments into immune deficient mice, it is 
seen that human spermatogonia can survive in mice. Hopefully 
with more research, it may be possible to come up with a strat-
egy to preserve the germline of young boys undergoing chemo-
therapies and radiotherapies that cause sterilization (Behringer, 
2007). This study utilized Nude mice and severe combined im-
munodeficiency- non-obese diabetic mice, (SCID-NOD), two 
immunodeficiency recipients to compare the grafting of pre-pu-
bertal and adult murine and adult human testicular tissue. The 
survival of pre-pubertal and adult murine testicular tissues, and 
of adult human testicular tissue was evaluated after subcutane-
ous grafting to immune deficient mice. This xenograft model in 
an immune deficient mouse with pre-pubertal human testicular 
tissue is a theoretical strategy for restoring fertility in childhood 
cancer patients, while circumventing the risk of malignant recur-
rence (Geens et al., 2006).
Ethical issues
These different types of human animal chimeras have provid-
ed important insights into fundamental biological mechanisms 
and the development of therapeutic protocols for human dis-
ease. Chimeras have compensated as human animal models for 
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the study of human processes in vivo. However there has been 
a lot of ethical debate concerning this research. These exper-
iments reviewed have been approved, because the carefully 
transplanted human cells aren’t large enough to make the ani-
mal human. They only humanize certain parts, and the resulting 
chimeras are euthanized after a number of days. Many bound-
aries had to be set with this type of research. In these studies, 
the human donor contribution is very low compared to the 
animal host. Although cells express an evidently higher degree 
of activity than genes, they also are intricately dependent on 
their surroundings. When hSCs are transplanted into animals, 
although they are free to proliferate and differentiate they are 
still in an animal body, and are reliant on their environments. 
They help to humanize an immune system if the animal is 
lacking one, however the host still remains an animal, with a 
distinct cell line of human cells, resulting in a chimera. Only 
in a receptive host, local niches regulate key developmental 
changes for several adult stem cell types, termed as an “insep-
arable relationship”, besides for bone marrow transplantation, 
in which the hematopoietic stem cell is an “agent” in blood 
reconstitution (Hyun, et al 2007). 
Research with human animal chimeras become a problem 
when cognitive capacities of the animal is changed, and when 
the germ line is affected. Therefore, boundaries have been put 
into place. Precautions in this field of research include, using 
progenitors rather than PSCs to avoid germ line contribution, 
which pose the risk of producing human embryos in animals. 
And treating the humanized mice, as a modified crop, by keep-
ing it isolated to prevent it from mating with other mice, as 
well as euthanizing it immediately when research is concluded 
(Hermerén, 2015).
Conclusion
The above studies reviewed involved reconstituting animal 
models by transplanting human stem cells, HIV, cancer, and 
growing human organs in mice. The experiments resulted in a 
human animal chimera, an animal with two cell lines. Human an-
imal chimeras, animals carrying human tissues were used as an 
alternative model to investigate human specific biological pro-
cesses without experimentation on human individuals. Although 
human animal chimeras provide numerous possibilities, there 
is still a lot of controversy and risk associated with it. Since 
research is developing rapidly, and people’s values and percep-
tion of risk and benefit change, not all issues can be settled. 
This approach to studying human pathways in animals concerns 
many people, however with the proper care and thought-out 
methods, research should be able to proceed without extreme 
regulation, and more experiments using human animal chimeras 
for therapeutic protocols should be approved.
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Introduction
A young woman walks into her doctor’s office complaining of 
what seems to be a pimple that does not go away. She initially 
treated it with over counter creams, then a facial and many der-
matologist visits. Upon a more extensive examination the spe-
cialist realized that this was not the average case of adolescent 
acne and ordered blood work. The test revealed that this girl 
has type-one diabetes. Her plans to go to college were placed 
on hold and her life completely changed. What if diabetes didn’t 
have to be a life altering disease? What if glucose monitoring 
and insulin injections were replaced with a one-time stem cell 
therapy that could replace the damaged cells? This example did 
occur and the girl is being treated with subcutaneous insulin 
infusion therapy. Stem Cell Research has not reached this break-
through but the hope is that in the future stem cells will be used 
to test medical treatments and replace cells lost by devastating 
diseases that currently have no sustainable cure. 
The first several divisions of the mammalian fertilized oocyte 
give rise to totipotent cells. These cells can form cells in the 
placenta, embryotic sack, and any cell in the body. Once cells are 
designated for the body they are termed pluripotent cells. These 
embryotic stem cells have virtually limitless potential and are an 
invaluable resource for the biomedical community. Along with 
the importance of these cells arises a responsibility of using 
them correctly. The process of understanding how these stem 
cells work and the services they can provide has not been an 
easy feat. This battle has been fought in both the courtrooms 
and laboratories. The legal system bears the responsibility of 
creating a system in which guidelines are being followed and 
ethics upheld. This is an ongoing battle, and there is no under-
mining this work. Regardless of several ongoing debates and 
some legal verdicts, the biomedical community is addressing 
stem cell research, cell regeneration, and organ construction 
from two different perspectives. There is ongoing promising 
research being done on organ and cell regeneration with the 
use of somatic stem cells. Specific mature, undifferentiated, adult 
cells are reprogramed to function as stem cells and referred to 
as induced pluripotent stem cells (iPSC). These cells, generally 
found in the epithelial cells  of an adult organ, have already been 
assigned a task and are therefore limited to the regeneration of 
that particular cell or organ. However, being that they are ex-
tracted from the patient, it is assumed, although not tested, that 
these cells will face less rejection after implantation because 
of the body’s familiarity with the cells. An alternative form of 
adult stem cells is activation of somatic stem cells (Stem Cell 
Information, n.d.) within the body. These cells reside within a 
healthy body and function as a natural maintenance system by 
regenerating aged or damaged tissue and replacing lost cells. 
Examples of the somatic stem cells are cord blood and bone 
marrow. The third of these general stem cell approaches allows 
for more potential but at a greater risk; pluripotent embryotic 
stem cells (ESC) can be used to create any cell or organ but at 
a higher probability for tumor growth. There are several distinct 
differences between embryotic and adult stem cells. Adult stem 
cells are rare cells that require extraction, isolation, and then in 
vivo cell culturing, to multiply. This cell culture process has not 
fully developed and is a great deal more complicated than the 
growth of ESCs (Herberts et. al. 2011., Shanthly et. al. 2006).
This paper will explore the potential of regenerating tissue by 
means of pluripotent stem cells, as well as discuss literature on 
growth of these cells to build tissues and replace cells. Upon ex-
ploring the processes of in vitro and in vivo differentiation, in 
both induced pluripotent stem cells (iPSC) and human embryonic 
stem cells (hESC), one can question the technology needed to 
operate these cells. Is it possible to limit stem cells to differen-
tiate, as they would in utero, to create a select tissue or organ?
Abstract
It would seem that differentiation of stem cells is the remedy of modern times. Yet stem cell research is more complex 
that the public may recognize and is still in the developmental stage. Recent breakthroughs show promise; various 
guidelines provide structure to this growing field but it is not ready for gross public application. The objective of this 
paper is to research various different methods of stem cell production and application. Methods included reviewing 
articles and studies to evaluate the process in production of affective stem cells. There are many therapies that illustrate 
this research. Upon completing and explaining this phase, further analysis of research presented risk factors such as 
negative immune responses, tumor, and teratoma formation are discussed. This paper further examines the different 
complications that may be triggered by stem cell therapy. The danger analysis is briefed to describe the risks involved 
in stem cell therapy while explaining the ongoing research and discoveries to assist in limiting these risks. This paper 
culminated with the success of the most affective form of therapy to date. There are ongoing studies directed to limiting 
stem cell therapy for safe and risk-free application. Nevertheless, no definite conclusion can be reached as to how stem 
cells can be limited to the point of remaining simultaneously pluripotent and effective.
Human Stem Cells: Is it Possible to Limit Pluripotent 
Human Stem Cells to Differentiate into a  
Specific Tissue or Organ?
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Methods
This document was amassed by referencing original research and 
peer reviewed scholarly articles. US government websites and 
portions of scholarly articles were accessed to gain knowledge 
about the background, history, and general methods involved in 
stem cells therapies. Specific topic information, regarding the re-
search question, was collected, reviewed, and analyzed. Google 
Scholar, and databases that are made accessible through the 
Touro College online library, such as Proquest and Ebsco, were 
used to search and access documents related to the research 
topic. The following are examples of key words were used: stem 
cell and apoptosis, c-myc, tumorigenic factors, in vivo growth, 
nodal signaling. There was no discrimination made regarding the 
date of publication on articles. 
History
Initial stem cell research dates back to 1870, with in vitro fertil-
ization of an oocyte. Any form of promising finding were slow 
until research intensively propelled in the late nineteen seven-
ties. Notable accomplishments include cloning of mammals in 
1997 and development of the first stem cell culture in 1998. 
The virtually simultaneous discovery of cloning and stem cells 
were the building block of forthcoming research. Stem cells cul-
tured in today’s laboratories are removed from the blastocyst 
early in differentiation and frozen in their state until they are 
differentiated into the cells required for a specific medical ther-
apy (Shanthly et. al. 2006). Research is ongoing and promising; 
the biomedical community has only scratched the surface of 
the untapped potential of stem cells. There are various issues 
and setbacks that are limiting stem cell potential (Stem Cell 
Information, n.d.). 
Stem cell research raised sharp scientific, technological, ethi-
cal, and political controversies. The United States federal and 
state governments enforced laws to enhance and restrict actual 
stem cell research. States such as Florida and New York agree 
to provide state funding while other states such as Arkansas 
and Michigan have placed bans on the creation and use of ESC 
for biotech research (Vestal 2008). Some forms of stem cell 
research and experimentation are more disputed than others; 
stem cells derived from oocytes are more controversial than 
induced adult cells. For example, in 2006 the Senate passed a 
law allowing federal money to benefit the specific research of 
iPSC, umbilical blood and bone marrow treatments but not 
ESC. However, in 2011 President Obama removed all bans that 
restricted federal funding from being assigned to new lines of 
embryotic stem cells. Regardless of the origin of the cell, human 
stem cells research raises ethical sensitivities. The ethical poli-
cies are continuously evolving and the biomedical community is 
attempting to overcome the challenges to ensure that research 
is carried out in an appropriate manner (Levin et. al. 2013).
In addition to legal constraints the anatomical components that 
comprise stem cells are intrinsically a hindrance. The same fac-
tors, enzymes, and transcription that insure the cell’s ability for 
self-renewal cause biomedical complications (Li et. al. 2015).
Differentiations
Some mammalian tissues, such as the skin and liver, have the 
ability to regenerate yet others cannot. The capability of bioen-
gineering and sustaining all organs, regardless of their regenera-
tion factor, will be invaluable; this can ultimately circumvent the 
transplant system ensuring that patients don’t die waiting for an 
organ. Regeneration capability is reliant on stem cells. For the 
purpose of this paper stem cells are divided into two catego-
ries, embryonic stem cells (ESC) and induced pluripotent stem 
cells (iPSC). In more recent years, researchers have developed 
methods of directly reprograming differentiated cells to pro-
duce iPSC. iPSCs are rare and found in only some differentiated 
tissues throughout the human body. A common use for iPSC 
is bone marrow transplants to fight leukemia. Although only 
one in every one hundred thousand cells is stem cell, advanced 
techniques allow for harvesting and collecting those cells in 
concentration to be donated by injecting the donor with colo-
ny-stimulating factor 3 (CSF 3). This glycoprotein stimulated the 
bone marrow to produce more stem cells; a necessary tool to 
collecting these otherwise dispersed cells. Such techniques can 
be used to collect adult stem cells but the process is tedious and 
does not allow for the unlimited potential hESC offer (Shanthly 
et. al. 2006). Although iPSC involves complications, such as the 
complexity of collection, it also provides therapeutic potential 
because these cells are harvested from a patient’s own cells. This 
can alleviate tissue and cell rejection complications. 
Since adult stem cells cannot give rise to all cells and tissues 
in the body, the ideal regenerative cell is embryotic stem cell. 
There are three different forms of embryonic stem cells used 
for medical research. The foremost method, true embryotic 
stem cells, is made from fertilized eggs generally donated by 
patients undergoing in vitro fertilization. Somatic cell nuclear 
transfer (ntES cell) is the process of creating an embryotic cell 
by inserting the nucleus of a general human cell into an egg cell. 
Although this technology has not been tested on higher mam-
mals, it can be of great use because the nucleus of the cell will be 
a genetic match to the patient. The third form of ESC, not ready 
for clinical use, is called parthenogenetic embryonic stem cells 
(pESC). Through the process of parthenogenesis, an unfertilized 
egg is stimulated into differentiating as an embryotic cell would 
(Shanthly et. al. 2006). 
Stem Cell Links to Tumorigenic Cells
Regardless of the types of ESC, these stem cells are derived from 
the core of mammalian blastocysts and can multiply infinitely 
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and differentiate into three germ layers: mesoderm, endoderm 
and ectoderm.  However, there are stem cells that have been 
documented to have significantly more genetic mutations as 
they grow in vitro. Research performed on zebra fish indicates 
that nodal signaling and pathways are found in both metastasized 
cancerous cells and embryotic stem cells yet not in healthy skin 
cells (Topczewska et. al. 2006). Nodal proteins are growth fac-
tors important to pattern formations needed for the embryotic 
differentiation, specifically as it relates to the formation of the 
mesoderm and endoderm .(Shen 2007). Activation of the nodal 
pathways is tightly regulated and prompts self-gene inscription 
with positive and negative feedbacks .(Cheng, Sun, 2014). The 
similarities between ESC and tumorigenic cells may lead to dis-
coveries that can limit the association between stem cells and 
cancer. Nodal signaling pathways are not the only unique link 
between stem cells and metastasized tumor cell; telomerase is 
an enzyme that facilitates growth and development of DNA in 
ESC but also found in upwards of fifteen times more often in 
cancer cells than in healthy cells .(Hiyama, Hiyama, 2007).
Nonsense-mediated mRNA decay (NMD) is been known to 
clean RNA in order to protect from early termination. At the 
PTC site, the location where early termination would com-
mence, the NMD complex is assembled. This complex balances 
and regulates the proteins and is essential for homeostasis and 
overall survival of not only the embryonic cell, but organisms as 
a whole. One factor of the NMD complex is Smg5, this factor 
is involved in telomere and telomerase maintenance. Thus this 
NMD factor and Telomerase protein are both essential compo-
nents that regulate cell viability. They may cause cell fatality or 
paradoxically, cancer (Li et. al. 2015).
Understanding the similarities between these cells help with 
limiting ESC. This process is called clinical transitions; scientific 
knowledge is gathered, understood and then turned into medi-
cal treatments. Regardless of these setbacks, the utility of these 
cells should not be undermined; simple laboratory practices 
such as freezing can assist with excess cell growth. Chemicals 
have been tested to determine if ESC can be treated to induce 
certain forms of apoptosis. Apoptosis is the shrinking of a com-
plete cell and its membrane. Apoptosis differs from the generic 
form of cell death by the fact that it does not leave residue. 
Excess cell components that did not shrivel; undergo phago-
cytosis. The purpose of these chemicals would be to generate 
cell death and on the specific component of the cell that may 
lead to complications, while leaving the remainder of the stem 
cell unharmed. Research performed on these compounds and 
chemical were published in 2012 and these findings claim to 
identify compounds that altered the viability of ESC (Conesa 
et. al. 2012).
Research In Vivo/ In Vitro
A ten-year research program beginning in the late 1980’s studied 
soft tissue engineering using totipotent stem cells. The experi-
ment used mouse embryotic stem cells to attempt to build lym-
phatic tissue, among other structures. Prior to commencement 
the researchers set out to establish what would be an ideal 
environment for embryogenesis. Building tissues in vivo requires 
an environment that mimics all aspects of uterus or in vitro de-
velopment; components such as nutrient and culture conditions 
are key. However, the physical creation of such an environment 
is quixotic, at best (Chen et. al. 1997, Shanthly et. al. 2006). A 
later study characterizes the complexity of stem cells by ex-
plaining the conditions for maintaining undifferentiated status. 
This study dictates that FGF2 and conditioned medium (CM) 
support hESC in an undifferentiated state. In 2005 undifferen-
tiated hESC were maintained with either FGF2 or CM. These 
stem cells remained in undifferentiated colonies apposed to the 
hESC that were maintained without these factors. Maintenance 
of the undifferentiated cells is an extremely delicate process, 
indicating that the steps from that point forward, toward proper 
differentiation, is that much more complex (Sumi et. al. 2007, 
Umar et. Al. 2014).
Development of any tissue, regardless of its origin requires 
three steps: cell differentiation, complex tissue formation, and 
the building of a three-dimensional, three-layered germ celled 
organ (Chen et. al. 1997). The most complex portion of com-
plete in vitro embryogenesis is the maintenance of a live culture 
throughout this process. As it is with a fetus, tissues, and organs 
can only function if the fetus is alive. Considerable research has 
been completed, and is ongoing, on many different forms of tis-
sue growth. To better understand the processes of building cells 
and tissues with stem cells, this paper will only be discussing 
two different tissues developed in culture, cardiac myocytes and 
lymphoid tissues. The decision to use these specific examples is 
based on varied dates of the research and the difference in tis-
sue complexity, due both to function and development of each 
cell.
Cardiac Myocytes
The differentiation of stem cells to cardiac myocytes is a rath-
er complex. Cardiac muscle is a prime example of a complex 
tissue due to the various forms of specific muscular tissues 
and their functions as it relates to an efficiently operating 
heart. Cardiac tissue is made up of interlocking, single nuclei, 
striated, muscle fibers. The unique and complex aspect of this 
tissue includes the intercalated disc, which assist in conduction 
speed, and autorythmicity, the ability to set its own contrac-
tions.  Research published in April of 2011 suggests promising 
potential of differentiation of cardiac myocytes from hESC. By 
inhibiting Bone Morphogenic Proteins (BMP), a growth factor, 
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during cardiac differentiation, cardiogenesis is initiated.  This 
step is far from the only one that is needed to allow for ESC 
to be transplanted for therapeutic uses. Additional research 
is required such as the study of the regulation of retinoid sig-
naling, the key that defines the difference between ventricular 
and arterial myocytes (Zhang et. al. 2011, Hartman et. al. 2014).
Lymphatic Tissue
The microenvironment needed for embryogenesis is delicate. 
Being that lymphoid cells develop toward the end of this pro-
cess, it was difficult to assume that the microenvironment need 
for ES cultures could be sustained until that point. Initiation of 
the research began with mice. Through the use of viral vectors, 
oncogenes were inserted and developed in vivo to produce B 
and T cells.  Many attempts and adjustment were made. The gen-
eration of B and T cells from lymphatic tissue was rare at the 
time publication of this journal but at the end of the research it 
was confirmed that lymphoid precursor cells could be derived 
from ESC. These years of research, experiments, and analysis of 
data only begins to explain the complexity of building tissues, 
regardless of their origin (Chen et. al. 1997).
Complications
Regardless of the difficulty of building tissues from stem cells 
and the improvements to cell cultures explained in cardiomy-
ocytes formation, there are other complications that require 
attention. In fact, some stem cell therapies such as bone marrow 
transplants with somatic stem cell, do not involve the intricate 
complexities that tissue growth requires. Yet even these ther-
apies must be addressed as it relates to the other risk factors 
involved in such a therapy. Risk factors begin in procurement 
and linger through the many phases involved, beginning with cul-
turing and injection. Subsequent to any initial success, long-term 
affects must be analyzed. There is deficient clinical experience 
in embryonic and adult stem cells. This lack of experience is an 
inevitable aspect of relatively new, current, and ongoing research 
and results in a variety of complications, after stem cell injection 
(Herberts et. al. 2011). 
General observations of the three most common forms of stem 
cells are summarized in Table 1. Improved comprehension of 
the differences and characteristics of these cells will assist in 
establishing their risk analysis.
An example of a consequence is tumor formation. This is a 
known complication that is being investigated from different 
standpoints. Understanding cell growth and death is crucial to 
such an analysis. The Myc gene family encompassed both factors. 
It is for that reason that this paper uses c-Myc as an example 
of a protein that may help limit tumor genesis. In addition fifty 
percent of tumor formation found in mouse research of iPSC is 
attributed to c-Myc.
Tumor Formation
The basic and universal self-renewal factors that assist in 
feedback and feed forward loops is Oct4, Sox2 and Noanog. 
However, the Myc gene family is additional self-renewal proteins 
and factors that affect intrinsic stem cell existence and apoptosis. 
Research published in 2007 investigated the function of c-Myc in 
stem cells regulation, differentiation, and apoptosis. Initially the 
tests were performed on mouse stem cells and later applied to 
hESC. It was widely known that that c-Myc is required to reg-
ulate normal cell development. However, the application of this 
factor in hESC regulation was confirmed and verified as being 
expressed as three different factors of the same family (Myc, 
Mycn, MycL1). Each of these Myc proteins were tested and found 
in the mRNA of hESC. Furthermore, just as c-Myc was present in 
regulation of mice cells, it was traced in undifferentiated human 
stem cells. Testing of this protein suggests that c-Myc is a factor 
of self-renewal. This research further investigated if c-Myc would 
also affect apoptosis and differentiation (Sumi et. al. 2007).
The properties of the c-Myc protein are best explained when 
looking at cancer cells. The protein factor c-Myc is found to be 
uncontrolled in end-stage cancers. This overexpression in tum-
origenic cells helps explain the role it plays in normal cell growth, 
stem cell proliferation, differentiation, and apoptosis. Even prior 
to a complete discovery of the potential of c-Myc, it was known 
that increased levels of c-MYC indicated the initiation of cell 
death. There are various pathways in which apoptosis is initiated. 
The first is by the regulator p53 ultimately activating BAX. The 
second is activation of PI3’K-AKT. The third and final pathway to 
cell apoptosis is through cell ligations that activate c-Myc. The 
activation and increase of this protein then caused apoptosis 
(Prendergast 1999).
ESC: iPSC: SSC:
Derived from inner 
mass of blastocyst
Derived from somatic 
cells





Autologous or  
Allogenic material
Pluripotent Pluripotent Multipotent
Can differentiate into 
all three germ cells
Can differentiate into 
all three germ cells
Can differentiate to 
limited cell types.
Self-renewal Self-renewal Limited Self-renewal






Serious Ethical Issues Serious Ethical Issues Serious Ethical Issues





Being that this factor plays a role both in the differentiation of 
stem cells and the death of tumor cells, it must be assumed 
that investigations on regulation of this protein may be vital to 
advancements in stem cell therapy. With better control of this 
protein a clinical laboratory scientist may be able to use it in 
either furthering the differentiation of cells or leaving them in an 
undifferentiated state when deemed necessary. The link between 
the Myc gene family and oncogenic cells will additionally assist 
with the considerable complications facing stem cell therapy, 
tumorgenesis.
Aside for the risk of essentially causing tumor formation, stem 
cell therapy may also affect the growth and formation of existing 
tumor cells. If, for example, a patient has a dormant tumor of 
cancerous cells, stem cell therapy may active it. This has not 
been proven but is under investigation with the use of mouse 
stem cells. 
Immune Response
Any donation requires proper human leukocyte antigen match-
ing (HLA); stem cell therapy is no different. Taking care to ensure 
that the donor and recipient match decreases the risks of Graft 
Verse Host Disease (GVHD). As detailed in table one, some 
forms of stem cell therapy are allogeneic. Therapies that are not 
recognized by the body risk immune rejection. Even those that 
are immune privileged (hESC) may be subject to rejection and/
or an inflammatory response due to the increase in response 
stimulus, caused by the actual stem cell therapy induction. For 
that reason, stem cell therapy may be administered while the 
patient is on immune suppressants. Placing a patient on immune 
suppressants runs the risk of adverse drug reactions. There are 
ongoing studies investigating different methods of stem cells 
growth in vivo that will limit the risk of rejections and GVHD. 
Such studies include introduction of mesenchymal stem cells 
in vivo. Data from such research indicated that these stem 
cells tranquilize the immune system and regulate its responses 
(Herberts et. al. 2011).
Teratoma
A teratoma is a benign mass composed of a hazardous mix-
ture of tissues, generally resembling remnants of all three germ 
layers. It is established in vivo and assumed to be congenital. 
Being that pluripotent stem cells can create all three layers, 
this therapy is susceptible to such a risk. In fact the same char-
acteristics that defines stem cell, pluripotency, are the same 
trait that creates teratomas.  Research produced in 2011 
details the comparative affects of tumor formation on both 
hESC and iPSC. The research indicates that because iPSC is a 
stem cell engineered in vitro and thus a more controlled cell 
than hESC, iPSC is less susceptible to tumor genesis. In fact 
the reason that teratomas are found less frequently in iPSC is 
because the heterogeneity of this cell causes slower growth 
rate (Zhang et. al. 2012).  
In addition to cell type effects on teratomas, injection sites may 
also influence distinctive increase or decrease levels of forma-
tion. Although not enough clinical research and analysis can con-
fidently support this claim, it is reasonable (Zhang et. al. 2012). 
More research has been performed on mouse stem cells to 
detect the correlation of the environment in which the stem 
cells are injected into and malignant tumors. Although tumor 
growth differs from teratomas, these discoveries may lead to 
additional exploration into the plausible affect of increased ter-
atomas based off of site administration (Herberts et. al. 2011).  
Success
Success is a complicated term to define when associating 
it with ongoing scientific research. Success can be attributed 
to a research breakthrough or a clinical accomplishment; it’s 
simply relative. Longevity is fundamental determinate of suc-
cess.  Pluripotent haematopoietic stem-cell transplantation for 
cancer therapy has made significant stride since initial investi-
gations over sixty years ago. It progressed from research that 
was plagued with complications and hurdles to a standard form 
of treatment. This blood forming stem cell is the only therapy 
approved for standard use because of sufficient understand-
ing of the cells, possible complications, and long term affects. 
Expansion of this therapy for use other than replacement of 
blood and immune cells causes similar complications mentioned 
throughout this document. There are many trials taking place 
and success may be recognized within each trial but a complete 
understanding of overcoming challenges and complications can 
only be determined by continual research and the test of time 
(Stem Cell Information, n.d.).
Conclusion
Research, along with case studies and accounts show there are 
far more complications with stem cells than would appear at 
first glance; they require numerous forms of adjustments to 
insure an innocuous treatment. Limiting stem cell therapies is 
a promising prospect, and in some therapies it has been suc-
cessful. However, there is insufficient research completed at this 
time to form a definite universal response for limiting any form 
of stem cell for every therapy application. 
Researchers are investigating the factors that cause the risks 
involved in various therapies and consequently exploring rem-
edies and suggestive solutions. However, stem cell therapies 
involve a multitude of complexities, some yet to be ascertained. 
The reason for these uncertainties appears to be based on the 
varied potential administrations, forms of stem cells (hESC, iPSC, 
ntES), their associated risks, and the limitless therapies they can 
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produce. This research is a relatively new and revolutionary 
field of study. With increase research, funding, and integration 
of continual findings, selectively listed in this paper, scientists 
are advancing to the goal of utilizing all that stem cells have 
to offer. This includes the capability to understand its potential, 
related limitations, and safely developing the two in an effort to 
advance medicine. Stem cell therapy is the promise for infinite 
preventative care and treatment options.
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Cancer is a disease characterized by the presence of mutated 
cells that continue to divide uncontrollably. Cancerous, or ma-
lignant, tumors, can spread to other parts of the body especially 
via the lymph system which can act like a cancer highway, and 
new tumors can then form in places far from the original tumor 
source (What is Cancer 2015). These tumors can have negative 
health effects and in many cases can be life threatening.
According to the World Health Organization more than 14 mil-
lion new cancer cases were diagnosed in 2012 and there were 
more than 8 million deaths attributed to cancer. Additionally, 
the American Cancer Society projects the number of new can-
cer cases in the United States in 2015 to exceed 1.5 million and 
the number of deaths to exceed a half million. 
Radiotherapy, a common cancer treatment, works by directing 
high energy beams, including x-rays and gamma rays, at cancer 
cells to disrupt their DNA and ultimately result in cell death 
(“Radiation Therapy”). Although radiation therapy can be suc-
cessful at eradicating cancerous cells, relapse is a common 
problem because a few cells, or even just one cell, left behind 
can continue to divide and pose a serious health risk (Wayteck 
et. al., 2014). 
To combat the problem of relapse, chemotherapy is com-
monly prescribed to ensure that all cancerous cells are erad-
icated. Chemotherapy works by killing all rapidly dividing cells 
(“Chemotherapy”). However, chemotherapy has many unwanted 
side effects as it does not differentiate between healthy rapidly di-
viding cells and cancerous rapidly dividing cells. This effects many 
different systems within the body and can cause anemia, hair loss, 
infection and other unhealthy and unwanted symptoms. 
Another form of treatment, immunotherapy, works by using 
immune elements to target cancerous cells through recogni-
tion of cancer antigens. There are two different ways of rec-
ognizing cancerous cells through antigens. One way is through 
tumor specific antigens which are expressed solely in cancer-
ous tumor cells, while the other involves overexpressed anti-
gens which more abundant in cancerous tumor cells than in 
healthy cells. This method of treatment aims to avoid the side 
effects of chemotherapy by targeting only cancerous cells and 
to also thwart the problem of relapse seen in radiation therapy 
(Wayteck et. al., 2014). 
Passive immunotherapy uses stimulatory factors such IL-2 
which is injected into the tumor area to stimulate anti-tumor 
T cells to proliferate, activate, and increase effector functions 
(Wayteck et. al., 2014). Active immunotherapy, on the other 
hand, involves CD 8 and CD4 T cells that are primed to rec-
ognize specific cancerous antigens and thereby direct immune 
cells to target and kill these cancerous cells. This report dis-
cusses the effectiveness of active immunnotherapy in general 
and, specifically, a branch of active immunotherapy called adop-
tive cell transfer. 
Methods
To research the effectiveness of active immunotherapy and spe-
cifically adoptive cell transfer, relevant information was gathered 
from many databases and journals. Those databases included: 
the Touro College Library database, Proquest Science Journals, 
Pub MEDLINE (EBSCO), and Oxford Journals. The information 
gathered was narrowed further and analyzed to glean an un-
derstanding of the effectiveness of these treatment protocols.
Abstract
There are many ways to fight cancer using the body’s own immune system. Some methods include the administration of 
vaccines while others involve stimulatory factors injected near tumors. One promising method is enlisting the help of T cells. 
To fight cancer effectively, T cells must be able to recognize cancerous antigens and the environment in which these T cells 
reside must be conducive to their function, survival, and proliferation. This paper discusses a method of providing such an en-
vironment called adoptive cell transfer, as well as the elements that effect this protocol and the ways in which the environment 
can be manipulated to increase the effectiveness of adoptive cell transfer. 
Many factors contribute to the observation that the effectiveness of adoptive cell transfer increases as immunodepletion in-
creases, namely, the depletion of regulatory T cells. Additionally, the existence of natural killer cells during adoptive cell transfer 
has been shown to decrease its effectiveness. Also, increased levels of cytokines IL-7 and IL-15 enhance the function, survival 
and proliferation of transferred T cells which would increase their effectiveness. Moreover, the results of adoptive cell transfer 
are more positive when patients’ own T cells are used. 
These findings show that T cells can be used through adoptive cell transfer as an effective treatment for metastatic melanoma 
patients, and that there is potential for adoptive cell transfer to be adopted as a widespread effective treatment for cancer. 
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Discussion
A recent study indicates that active immunotherapy can be an 
effective treatment for cancerous tumors (Raez, et. al. 2003). This 
study assessed the impact and response of CD8 T cells to tumor-
cell-based allogeneic vaccines in patients with advanced non-small-
cell carcinoma, commonly known as lung cancer. However, the 
selection of patients with advanced stages of non-small-cell car-
cinoma may have resulted in reduced effectiveness of treatment, 
as cancerous cells may have been too numerous for the body’s 
immune system to handle. Similarly, as only patients previously 
unresponsive to conventional treatments like chemotherapy and 
radiation therapy were studied, the results may have been lower 
than they might be had the body’s ability to fight off harmful cells 
not already been undermined.
Vaccinations were delivered in three courses.  After com-
pletion of the first course, only patients with stable disease 
progression or positive response against non-small-cell car-
cinoma as determined by CT scan, coupled with low toxicity, 
continued to a second course of vaccination. Again, patients 
with no tumor progression and non-life threatening levels of 
toxicity continued on to a third course of vaccination (Table 
1). The patients were evaluated at the beginning and end of 
each course to study clinical effects and to determine toxicity 
levels (Raez, et. al. 2003). 
The results of the above study, as shown in Table 2, indicate an 
increase in CD8 T cell response in all but one patient. Clinically, 
however, the results were less profound. Only 27% of the patients 
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1012 A1 NE NE C 15 - 0.2 ND ND ND
1001 A2 PD 25 C+S 18 - 0 25 ND ND
1002 A2 PD 1.6 C+S 22 - 41 65 ND ND
1009 A2 PD 6.5 C 3 - 2 13 ND ND
1010 A2 PR 41 S 27+ 3 3.8 46 88 157
1011 A2 PD 19 C 11 - 3 30 57 ND
1013 A2 PD 34 C+R+S 2 - 5.2 164 178 ND
1014 A2 SD 19 C+S 13+ 3 1.6 30 30 25
1015 A2 PD 0 C+R 7 - 0 0 ND ND
1003 non SD 134 S 31+ 26+ 1 134 113 84
1004 non SD 424 C+R 23 11 0 424 232 >450
1006 non PD 9.3 C+S 30+ - 16 150 ND ND
1007 non SD 14 C+R+S 29+ 23+ 1.2 2.8 0.8 0/17
1008 non PD 32 C 6 - 5.6 178 ND ND
PD=progressive disease; PR=partial response; SD=stable disease; ND=not determined; C=chemotherapy; R=radiation therapy; S=supportive 
care; NE=not evaluable
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showed stable disease progression while another 7% showed a 
partial response. This total clinical response of 33% suggests that 
immunotherapy may be a viable option but requires further study 
to assess clinical effectiveness. (Raez, et. al. 2003)
The vaccine used in this study was developed by Dr. N. Savaraj 
through modification of a cell line harnessed from a patient in 1994. 
The cells were rendered incapable of colonizing ensuring they 
would not cause any harm to study participants. However, perhaps 
a more effective albeit more expensive method, demonstrated at 
the Johns Hopkins School of Medicine (Perica, et.al. 2015), may be 
to extract a patient’s own CD8 T cells from the vicinity of the 
tumor and subsequently culture them in vitro. This would ensure 
that the T cells would be reactive to the patient’s own cancerous 
cells. Using pharmaceuticals to regulate the patient’s regulatory T 
cells, the CD8 T cells harnessed in vitro can be reinserted with free 
rein to target cancerous cells (Perica, et.al. 2015). 
Adoptive cells transfer is a treatment in which immune cells 
harnessed in vitro are transferred to a patient to give him spe-
cific immune functions. To treat cancer patients using adoptive 
cell transfer, a piece of a tumor is removed from the body, so 
that T cells can be removed from the tumor, and stimulated to 
grow rapidly in vitro. These T cells are then infused back into the 
patient to target and kill cancer cells (Figure 1).
When attempted on patients with metastatic melanoma, adop-
tive cell transfer showed potential as an effective treatment 
although admittedly it had limited clinical results. A trial of 20 
metastatic melanoma patients were treated with adoptive cell 
transfer and given IL-2 to stimulate the transferred T cells. The 
results revealed tumor regression in multiple sites in 11 of the 
20 patients studied (Phan, Rosenberg, 2013). However, it should 
be noted that although IL-2 promotes the growth and function 
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suppress these transferred T cells thus countering the intended 
effect and perhaps limiting the overall effectiveness of the treat-
ment. This indicates that adoptive cell transfer may have a place 
in the pursuit of a cure for cancer but it does require some 
further fine tuning. 
Depletion of immune cells and other immune elements before 
adoptive cell transfer of CD 8 T cells in mice has been shown to 
increase the effectiveness of transferred T cells (Gattinoni et. al., 
2005).  It has been proposed that depleting the immune system 
of its natural elements keeps regulatory T cells from turning off 
anti-cancer CD 8 T cells transferred during adoptive cell trans-
fer. Additionally, adoptive cell transfer helps lower the immune 
system’s tolerance of the cancerous “self-antigens” by selecting 
and activating highly specific T cells, mostly CD 8 T cells, and by 
changing the body’s internal environment to one that is more 
receptive to these cells. 
A recent study looked at 13 metastatic melanoma patients who 
received immunodepleting chemotherapy specifically targeted 
to regulatory T cells. The patients were then injected with in 
vitro cultured T cells as well as IL-2. Because the patients first 
received immunodepleting chemotherapy, in this study the addi-
tion of IL-2 avoided the adverse effect of activating regulatory T 
cells. This allowed for highly favorable results (Table 3) that were 
significantly more efficient than the results of the study involving 
non-small-cell carcinoma patients. Of the 13 patients, 6 showed 
positive clinical responses, and 4 showed mixed responses con-
sisting of considerable shrinkage of at least one tumor. Although 
the study was relatively small and was limited to melanoma pa-
tients, it nevertheless demonstrates the potential of adoptive 
cell transfer in treating cancer patients (Dudley et. al., 2002).
In a similar trial, metastatic melanoma patients were treated with 
different levels of immunodepletive therapy prior to adoptive cell 
Patient Demographics, Treatments Received, and Clinical Outcomes. 


























3 43/F 4.0 44/58 gp100 5 Brain, cutaneous, 
liver,lung
NR None
4 57/F 3.4 56/52 gp100 9 Cutaneous, subcu-
taneous
PR (2) None
5 53/M 3.0 16/85 Other 7 Brain, lung, lymph 
nodes
NR-mixed None
6 37/F 9.2 65/35 Other 6 Lung, intraperitoneal, 
subcutaneous
PR (15+) None
7 44/M 12.3 61/41 MART-1 7 Lymph nodes, subcu-
taneous
NR-mixed Vitiligo
8 48/M 9.5 48/52 gp100 12 Subcutaneous NR None
9 57/M 9.6 84/43 MART-1 10 Cutaneous, subcu-
taneous
PR (10+) Vitiligo
10 55/M 10.7 96/2 MART-1 12 Lymph nodes, cutane-
ous, subcutaneous
PR (9+) Uveitis
11 29/M 13.0 96/3 MART-1 12 Liver, pericardial, 
subcutaneous
NR-mixed Vitiligo
12 37/F 13.7 72/74 MART-1 11 Liver, lung, gallbladder, 
lymph nodes
NR-mixed None
13 41/F 7.7 92/8 MART-1 11 Subcutaneous NR None
PR = Partial Response, NR = No Response
Table 3
Dudley et. al., 2002 
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transfer in order to establish a level of immunodepletion that would 
best enhance this treatment protocol (Rosenberg et. al., 2011). One 
group of 43 patients received a nonmyeloablative preparative regi-
men, a less toxic method of immunodepletion. A second and third 
group of 25 patients each, received a more toxic total body irradi-
ation of 2 Gy and 12 Gy (Dept. of Homeland Security 15), respec-
tively, in addition to a non-myeloablative preparative regimen. All 
three groups were subsequently treated with adoptive cell transfer 
(Rosenberg et. al., 2011). 
The results of this study (Table 4) showed that at higher levels of 
immunodepletion positive clinical outcomes following adoptive 
cell transfer increased. In the group that received only a non-my-
eloablative preparative regimen, 49% of subjects showed an overall 
response while 5% showed complete response. The group that 
received 2 Gy of total body irradiation exhibited slightly higher in-
cidence of overall response at 52%, but showed a large increase in 
complete response at 20%. The group that received 12 Gy of total 
body irradiation showed a marked overall response of 72% with 
complete response at 40%, indicating that the greater the immuno-
depletion the greater the clinical outcome of adoptive cell transfer 
(Rosenberg et. al., 2011). 
One possible method to increase the overall effectiveness of 
adoptive cell transfer and such positive results is to harness 
a patient’s own CD 8 T cells to ensure that the T cells are as 
specific to the cancer cell antigens as possible to. However, this 
is likely a complicated task as it would require development 
of a “new drug” for every patient. Another method that may 
enhance the results of adoptive cell transfer is to take a sample 
of the patients own cancer cells and test CD 8 T cell reactivity 
to the cancer antigens thereby ensuring a highly reactive T cell 
response.  In another experiment, 20 metastatic melanoma pa-
tients received a less intense form of immunodepletion called 
nonmyeloablative preparative regimen. However, no patient re-
ceived total body irradiation. In this trial, however, T cells were 
taken directly from the actual patients’ tumor and grown quick-
ly in vitro, as opposed to using previously developed anti-tumor 
T cells. This may have helped ensure T cells would be highly 
specific and highly reactive to the patients’ own cancerous cells. 
Of the 20 patients treated, 10 had an overall response, of 
which 2 had a complete remission and 8 had a partial remis-
sion. Additionally, 4 patients had stable disease, and 6 had pro-
gressive disease for an overall response of 70%  (Besser et. 
al., 2010). The results show that nonmyeloablative preparative 
regimen, coupled with adoptive cell transfer that uses cells 
harnessed from patients own tumors can be an effective treat-
ment. Furthermore, analysis of the results may show that the 
results are more positive then what is seen on the surface.  Of 
the 6 patients with progressive disease after treatment, all 6 
started with stage M1c melanoma, which represents the stage 
in which the tumor has traveled to vital organs (excluding the 
lungs) or when the tumor has traveled to other areas and 
the patient shows elevated levels of low-density lipoprotein 
(“How is Melanoma Staged”). At this stage the cancer cells 
may have been too numerous for the transferred T cells. 
However, all patients with stages below M1c melanoma and 
even some patients with stage M1c melanoma showed at least 
some response to adoptive cell transfer, either complete re-
sponse, partial response, or stable disease. This indicates that 
adoptive cell transfer using patient’s own T cells, combined 
with nonmyeloablative preparative regimen for immunodeple-
tion is an effective treatment for early stages of metastatic 
melanoma patients. 
This trial, in which patients received only nonmyeloablative 
preparative regimen for immunodepletion prior to adoptive 
cell transfer, significantly outperformed the previously men-
tioned trial in which patients received only nonmyeloablative 
preparative regimen for immunodepletion prior to adoptive 
cell transfer. One possible explanation may be that this trial 
used T cells taken from removed portions of the patients own 
tumor, ensuring that the T cells used were highly reactive to 
the patients cancerous cells.
As previously stated, immunodepletion prior to adoptive cell 
transfer increases the effectiveness of the treatment. However, 
immunodepletion effects the entire immune system, which can 
have life threatening side effects. Therefore further study to 
determine key components that effect the effectiveness of 
adoptive cell transfer and how to precisely block them may 
be helpful. 
The most obvious immune element that would reduce the 
effectiveness of adoptive cell transfer is regulatory T cells. 
When developing T cells and B cells, the body has mechanisms 
through which it ensures than no immune cell is released that 
reacts to self-antigens; however, the system is not foolproof. 
Regulatory T cells restrain the few immune cells that get 
through those mechanisms and suppress them ensuring that 













No TBI 43 16 (37) 5 (12) 21 (49)
2 GY TBI 25 8 (32) 5 (20) 13 (52)
12 GY TBI 25 8 (32) 10 (40) 18 (72)
Total 93 32 (34) 20 (22) 52 (56)
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It has been shown that regulatory T cells suppress anti-cancer 
CD 8 T cells in vitro (Antony et. al., 2005). It would be logical 
to hypothesize that regulatory T cells would also effect the T 
cells transferred during adoptive cell transfer. To test for a cor-
relation between regulatory T cells and adoptive cell transfer, 
tumor bearing mice were treated with adoptive cell transfer. 
Some mice were then injected with anti-Thy-1.2 antibody and 
complement to suppress function of regulatory T cells, while 
others were given active regulatory T cells. The results showed 
that when regulatory T cell function was turned off the trans-
ferred T cells destroyed the cancerous cells. However, when 
active regulatory T cells were added the size of the tumors 
continued growing exponentially (North, 1982). This shows 
that regulatory T cells have a large impact on the effectiveness 
of adoptive cell transfer. 
Although regulatory T cells decrease the effectiveness of adop-
tive cell transfer, simply turning them off while leaving the rest 
of the immune system intact would allow surviving immune 
cells that recognize self-antigens to attack patients’ healthy 
cells causing autoimmune disease. 
One method to reduce the effect of regulatory T cells on adop-
tive cell transfer without effecting the entire immune system 
may be to induce apoptosis only in regulatory T cells in close 
proximity to the tumor. This would allow the transferred T 
cells to operate in an environment conducive to their function, 
while allowing regulatory T cells in other areas of the body to 
operate freely avoiding autoimmune disease. 
Recently, it was suggested that the protein FasL-Fc can be used 
to deplete regulatory T cells located only in tumors (Chen et. 
al., 2007). To confine the protein FasL-FC to the tumor, a pro-
tein is incorporated into cell membranes and acts as a trap 
for the Fc portion of FasL-Fc, not allowing it to escape the 
confines of the tumor (Chen, Zheng, Tykocinski, 2000). To test 
this suggestion, tumor bearing mice were injected with FasL-Fc 
in the tumor region. The results showed a significant increase 
in apoptosis of regulatory T cells in the tumors treated with 
FasL-Fc, indicating this may be a viable option to decrease the 
regulatory T cell effect on adoptive cell transfer without effect-
ing the entire immune system (Chen et. al., 2007). 
To test the actual effect of the protein FasL-Fc on adoptive cell 
transfer, tumor bearing mice were treated with both FasL-Fc 
and adoptive cell transfer. The results were a significant retar-
dation of tumor growth in a large portion of mice. Additionally, 
complete tumor regression was seen in 53% of the mice (Chen 
et. al., 2007). This indicates that using the protein FasL-Fc may 
be a viable option to eliminate the effect of regulatory T cells 
on adoptive cell transfer while allowing the immune system to 
operate regularly and without the risk of autoimmune effects. 
To determine the impact of other immune elements on adop-
tive cell transfer, tumor bearing mice were tested and the re-
sults analyzed. In many studies, after irradiation of cancer bear-
ing mice lacking regulatory T cells, effectiveness of adoptive cell 
transfer increased. This indicates that regulatory T cells are not 
the only elements responsible for decreased effectiveness of 
adoptive cell transfer (Gattinoni et. al., 2005). 
One hypothesis is that Natural Killer cells act as sinks for cy-
tokines responsible for survival, proliferation, and function of 
transferred CD 8 T cells (Gattinoni et. al., 2005). Host Natural 
Killer cells, also in need of cytokines, compete for the same 
cytokines necessary to support the transferred T cells lead-
ing to a limited amount of cytokines available to support the 
transferred T cells. To test this hypothesis, tumor bearing mice 
lacking endogenous B cells and T cells, including regulatory T 
cells, were treated with anti-NK1.1 antibody to decrease the 
number of Natural Killer cells to the number found after irra-
diation of the entire immune system. They were then treated 
with adoptive cell transfer and compared to mice not given 
the anti-NK1.1 antibody and treated with adoptive cell trans-
fer. The results showed that removal of Natural Killer cells 
increased the effectiveness of adoptive cell transfer, indicating 
that Natural Killer cells play an important role in the function 
of transferred CD 8 T cells (Gattinoni et. al., 2005). 
One way to avoid the effects of cytokine sinks may be to pre-
cisely determine which cytokines the Natural Killer cells sink, 
and stimulate an increase of their production giving the trans-
ferred T cells access to those cytokines. 
To determine the effects of cytokines on adoptive cell transfer, 
different cytokines were removed and added to tumor bearing 
mice treated with adoptive cell transfer. Results indicated that 
the cytokline IL-7 was needed to maintain survival and con-
tinued growth of transferred T cells, but was not necessary to 
maintain function of the T cells. Conversely, IL-15 was neces-
sary to maintain function, but did not play a part in survival and 
proliferation of transferred T cells. This shows that increasing 
both IL-7 and IL-15 at the same time increases the transferred 
T cells effectiveness against tumors, while decreasing both IL-7 
and IL-15 at the same time would decreases the transferred T 
cells effectiveness against tumors (Gattinoni et. al., 2005). 
These findings indicate that there may be a path by which reg-
ulatory T cells can be eliminated from the area of the tumor 
(Chen et. al., 2007), and transferred CD 8 T cells can be stimu-
lated to proliferate and enhance their effector functions with-




In conclusion, increasing CD 8 T cell count alone is not the most 
effective way to use T cells to fight cancer. Instead immunode-
pletion together with an increase in anti-cancer T cells delivered 
through adoptive cell transfer is an effective approach that has 
been shown to be effective in humans with metastatic mela-
noma. Other factors besides immunodepletion also effect the 
results of adoptive cell transfer such as cytokines, and the origin 
of the T cells injected. The key to adoptive cell transfer success 
with limited side effects, is the balance of all elements involved 
which is a large task and requires further study but does seem 
possible in the future.
However, for now, adoptive cell transfer is still a relatively new 
method of treatment and still requires immunodepletion for 
its effectiveness. This can bring with it its own problems, such 
as an increased risk of infection and a limited ability to fight 
infection. Additionally, most trials of adoptive cell transfer on 
humans have been limited to melanoma patients, making further 
research necessary for it to be used to fight other cancers. To 
that effect, further studies are currently underway to broaden 
this treatment to fight other cancers including, lymphoma, leu-
kemia, and neuroblastoma (Deng et. al., 2014) giving hope to 
cancer patients all over the world.
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Introduction
Traumatic brain injury serves as a major cause of death and 
disability. Over one million people are treated for traumatic 
brain injury in emergency rooms in America each year. Fifty 
thousand die as a result, while seventy to ninety thousand are 
left with debilitating long term neurological impairment. Among 
men under the age of 35, traumatic brain injury as a result of 
vehicular accident is the leading cause of death and disability 
(Shear, et al. 2002). Besides for the direct effects of the primary 
injury, outcomes are affected by the onset of secondary insult. 
Such insult includes the onset of hypoxia, hypotension, and an 
increase in intracranial pressure, which is often due to cranial 
edema. Hypotension has been correlated with a mortality rate 
which is double that of patients without the condition (Cooper, 
et al. 2004; Cooper, et al. 2012; Shackford, et al. 1998). As yet, no 
pharmacologic agent has been proven to improve the outcome 
of traumatic brain injury, notwithstanding the intense efforts of 
many researchers. To date, the management of traumatic brain 
injury consists of preventing further neurologic insults, manag-
ing intracranial pressure, and instituting surgical procedures to 
minimize damage (Shear, et al. 2002; Wright, et al. 2007; Xiao, et 
al. 2008). 
The severity of a traumatic brain injury is universally measured 
according to the Glasgow Coma Scale, which assesses eye, ver-
bal and motor condition following the injury. The scale which is 
most often used is the Extended Glasgow Coma Scale, which 
ranges from 3 to 15, awarding points for various functions which 
can be achieved. A score on the Glasgow Coma Scale of 3 in-
dicates death or a deep coma, while a 15 indicates complete 
consciousness. 
The outcome of traumatic brain injury is universally assessed 
according to the Extended Glasgow Outcome Scale, which is 
highly sensitive. It consists of eight diagnoses, which are: Dead, 
Vegetative State, Lower Severe Disability, Upper Severe Disability, 
Lower Moderate Disability, Upper Moderate Disability, Lower 
Good Recovery, and Upper Good Recovery This study aims to 
analyze and assess the effectiveness of three of the current acute 
responses to traumatic brain injury, including both chemical and 
surgical options. Methods used to decrease intracranial pressure 
include hypertonic saline resuscitation and the administration of 
progesterone, which has been touted as a neuroprotector. The 
performance of decompressive craniectomy has also been fac-
tored into this study. 
Hypertonic Saline
Hypertonic saline is administered intravenously, often en route 
to the hospital. The underlying claim to the administration of 
hypertonic saline is that it restores systemic blood pressure 
and cardiac output to manageable levels with less volume being 
necessary than when using the standard Lactated Ringer’s solu-
tion. The hypertonic saline extracts water from the intracellular 
space in order to restore intravascular losses and it has a positive 
inotropic effect on cardiac output. In addition, hypertonic saline 
has been shown to improve oxygen transport, mesenteric and 
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Eye Opening Response
Spontaneous-open with blinking at 
baseline
4 Points
Opens to verbal command, speech, 
or shout
3 Points




Confused conversation, but able to 
answer questions
4 Points
Inappropriate responses, words 
discernable
3 Points
Incomprehensible speech 2 Points
None 1 Points
Motor Response
Obeys commandes for movement 6 Points
Purposeful movement to painful 
stimulus
5 Points
withdraws from pain 4 Points
Abnormal (spastic) flexion, decorti-
cate posture
3 Points




Extended Glasgow Outcome Scale
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coronary blood flow, myocardial contractility, and redistribu-
tion of extracellular and interstitial fluid (Mattox, et al. 1991; 
Shackford, et al. 1998).
Progesterone
Progesterone is administered in a similar fashion to hypertonic 
saline. The concept of using progesterone to alleviate problems 
caused by traumatic brain injury was discovered when research-
ers noticed a significant sex difference in trauma outcome in 
correlation to hormonal cycling. Female rats with elevated 
levels of progesterone showed reduced tissue damage and im-
proved behavioral recovery (Shear, et al. 2002). As progesterone 
has been used safely on humans for years, it was hoped that 
it would have a positive effect on people with traumatic brain 
injury (Wright, et al. 2007). While the mechanism is unknown as 
of yet, progesterone has been shown to reduce cerebral edema, 
prevent neuronal loss, improve functional outcome, and inhibit 
oxidative damage in the central nervous system. It might also 
promote peripheral remyelination of axons following injury. 
Progesterone is lipid soluble, so it rapidly crosses the blood-
brain barrier to reach equilibrium within an hour of adminis-
tration (Shear, et al. 2002; Wright, et al. 2007; Xiao, et al. 2008). 
Decompressive Craniectom
Decompressive craniectomy is a surgical measure which is taken 
when patients present with dangerously high intracranial pres-
sure. Part of the skull is removed to allow room for the brain 
to swell. Proponents of decompressive craniectomy state that it 
can relieve uncontrollable intracranial pressure by increasing the 
volumetric capacity of the intracranial cavity. Craniectomies have 
been performed since the early nineteenth century, with varying 
degrees of success (Akyuz, et al. 2010; Morgalla, et al. 2008).
Methods
This study was performed through analyzation of published orig-
inal studies on the effects of hypertonic saline, progesterone, and 
decompressive craniectomy on traumatic brain injury. Sources 
include TouroLib databases, PubMed databases, and the archives 
of Lancet.
Discussion
Hypertonic saline was found in all cases to be safe for use. 
Shackford, et al. (1998) do caution that solutions that are too 
hypertonic are liable to reversibly open the blood-brain barri-
er, cause cerebral edema, and increase intracranial pressure. 
However, great care is taken to assure that proper proportions 
are used. Solutions that are 7.5% hypertonic saline have been 
shown to be both safe and effective (Bulger, et al. 2010; Cooper, 
et al. 2004; Mattox, et al. 1991). Administration of hypertonic sa-
line causes a slight increase in intracranial compliance, as shown 
by a decrease in mean intracranial pressure in patients receiving 
hypertonic saline, as compared to a positive trend in the intra-
cranial pressure of patients receiving Lactated Ringer’s solution. 
This data was observed on the second day following trauma 
(Shackford, et al. 1998).
When administering hypertonic saline, fluid input must be 
increased, as the saline decreases the fluid balance. No cases 
of renal failure or neurological complications due to hyperna-
tremia or hyperosmolarity have been found, but precautions 
should be taken all the same (Shackford, et al. 1998).
Patients receiving hypertonic saline showed a higher rate of nos-
ocomial infection due to the increased rate of the bloodstream. 
The increased amount of fluid output also led to a higher in-
cidence of urinary tract infections. In addition, administration 
of hypertonic saline might cause regulation of the A3 receptor 
on neutrophils, which would cause an increase in susceptibility 
to infection (Bulger, et al. 2010). Patients receiving hypertonic 
saline required a greater number of interventions to lower in-
tracranial pressure over the course of their hospitalization, but 
the difference was not significant (Shackford, et al. 1998).
While many studies have attempted to prove the superiority of 
hypertonic saline over other standard protocols, such as manni-
tol and Lactated Ringer’s solution, most have been unsuccessful. 
Out of five studies analyzed, only one study conclusively stated 
that hypertonic saline was universally preferable to mannitol. In 
that study, Battison, et al. (2005) administered four doses each 
to nine patients. Two doses were of hypertonic saline and two 
were of mannitol, in no particular order. The minimum intracra-
nial pressure was measured ten minutes before each treatment 
and was compared with the minimum intracranial pressure an 
hour after each treatment. While hypertonic saline reduced 
the intracranial pressure slightly more than mannitol did, there 
was no significant difference. The duration of the effect, how-
ever, was seen to be significantly longer in hypertonic saline. 
This study cannot be seen as conclusive, though, as it was only 
done on nine patients. In addition, the patients received both 
mannitol and hypertonic saline over a set period of time. As 
such, the effect could be due to the presence of both mannitol 
and hypertonic saline in their systems, and cannot be attributed 
solely to the hypertonic saline. 
Hypertonic saline has been shown to work slightly faster than 
controls. Cooper reports that patients receiving hypertonic sa-
line had a faster rate of decrease in intracranial pressure than 
those in the control group. However, the study also states that 
standard protocols are equally effective. All studies concur that 
there is no significant difference in favorable outcomes of pa-
tients who receive hypertonic saline and those who are treated 
with standard measures (Battison, et al. 2005; Bulger, et al. 2010; 
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Cooper, et al. 2004; Mattox, et al. 1991; Shackford, et al. 1998). 
While it may improve physiologic parameters, the long term 
benefit of administering hypertonic saline is negligible. Patients 
who received 7.5% hypertonic saline and those who received 
Lactated Ringer’s solution showed identical neurologic function 
after six months. The percentage of patients who survived to 
hospital discharge was similar. Studies found no significant dif-
ference in intracranial pressure for the duration of hospital stay, 
and there was no discernible difference in Glasgow Outcome 
Scale values. (Bulger, et al. 2010; Cooper, et al. 2004; Mattox, et 
al. 1991; Shackford, et al. 1998). 
Patients who were to undergo surgery showed a far better out-
come when given hypertonic saline in dextran (Mattox, et al. 
1991). However, at this time, hypertonic saline in dextran is quite 
expensive, as compared to the cost of standard treatments, such 
as Lactated Ringer’s solution and mannitol (Battison, et al. 2005). 
Therefore, rather than staying as a first tier response to trau-
matic brain injury, perhaps hypertonic saline should be relegated 
to a measure which is used only when surgery is indicated.
Progesterone
Aside from its long history of safe use, progesterone has been 
proven to be completely safe for use in humans. A study was 
performed with the express purpose of determining the safe-
ty of progesterone as a response to traumatic brain injury 
(Wright, et al. 2007). It was found that administration of pro-
gesterone was in no way harmful to patients, and it was indi-
cated that it might be beneficial to their recovery. Furthermore, 
endogenously released progesterone causes a 1° F increase 
in core body temperature. This deviation from standard basal 
temperature might hinder neurologic outcome in a patient with 
traumatic brain injury. However, the study found that no such 
increase in body temperature manifested in relation to admin-
istered progesterone. 
Multiple studies have found immense short term and long term 
benefits from the use of progesterone as an acute response 
to traumatic brain injury. Patients receiving progesterone had 
significantly fewer deaths due to neurologic causes. At 30 days 
postinjury, the mortality rate of patients receiving progester-
one was less than half of that of the control group (Wright, 
et al. 2007). A significant difference in neurologic outcome was 
evident up to six months post-treatment, with the experimen-
tal group having a 58% favorable outcome as compared to the 
control’s 42% (Xiao, et al. 2008). In addition, treated patients 
showed a decrease in cerebral edema, necrotic cavity forma-
tion, and neuronal loss as compared to control groups, which 
presented with neuronal and glial shrinkage and neutrophil in-
filtration. For example, necrotic cavity formation decreased by 
approximately 20% in treated patients. A decrease in apoptosis 
was noted, as well as an increase in peripheral remyelination of 
axons, an inhibition of oxidative damage in the central nervous 
system, and an overall enhanced recovery from cortical, cere-
bral, and spinal cord injury (Pan, et al. 2007; Shear, et al. 2002; 
Wright, et al. 2007; Xiao, et al. 2008). 
There has been much speculation as to the mechanism behind 
progesterone. It has been ascertained that it works, but not how 
it works. Progesterone down-regulates the inflammatory cyto-
kine cascade, which can increase the damage caused by trauma. 
Trauma causes a release of amino acids, which cause neuronal 
exitotoxicity. Progesterone might act at the GABA receptor to 
diminish that exitotoxicity (Shear, et al. 2002). The study by Pan, 
et al. (2007) posits that progesterone acts as a sigma-1 receptor 
antagonist, which can initiate the opioid-like capabilities of the 
receptor. In addition, progesterone inhibits nuclear factor kappa 
B, which is known to be a pro-inflammatory transcription factor. 
Nuclear factor kappa B is the activator of numerous inflamma-
tory cytokines, including tumor necrosis factor alpha, interleu-
kin-1 beta, C3, and glial fibrillary acidic protein. Thus, inhibition 
of nuclear factor kappa B decreases system-wide inflammation 
(Pan, et al. 2007).
The timing and duration of administration are key to the ef-
fectivity of progesterone. Most studies found a correlation 
between speedy dispensation of progesterone and favorable 
outcome. Wright et al. (2007) reports that the greatest benefit 
is gleaned when progesterone is administered within two hours 
of injury, but that there is still great advantage when it is given 
within 24 hours. Pan et al. (2007) and Shear et al. (2002) both 
started treatment within an hour of injury. It was noted that 
there is a consistent reduction in formation of cerebral edema 
when progesterone is given within 24 hours of injury (Shear, 
et al. 2002). There is a consensus that much of the success of 
progesterone is dependent upon the timing of its initiation. 
The duration of administration is slightly more controversial. 
One study, citing the contradictory effects of inflammatory cy-
tokines, limited the duration of progesterone to 24 hours. The 
researchers claimed that while immediately following an injury, 
inflammatory cytokines are neurotoxic, they are later neuropro-
tective. Seeking to block the initial harmful effect of inflammatory 
cytokines yet capitalize on their latent neuroprotective abilities, 
the study administered progesterone from 30 minutes to 24 
hours following injury, at which time they ceased administration 
of the treatment (Pan, et al. 2007). However, other studies noted 
that the greatest benefit was attained when progesterone was 
administered for five days (Shear, et al. 2002; Xiao, et al. 2008). In 
the experiment carried out by Shear, et al. (2002) on rodents, one 
group received progesterone for three days, while the other re-
ceived it for five. It was concluded that five days of progesterone 
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are necessary to achieve the desired results, namely an alleviation 
of the neuropathological and behavioral abnormalities which are 
caused by traumatic brain injury. This finding seems to contradict 
that of Pan’s. However, as harmful consequences of extending 
the progesterone treatment have not been found, it might be ad-
vantageous to forfeit the possible neuroprotective capabilities of 
inflammatory cytokines in favor of the documented benefits of an 
extended progesterone treatment. 
Decompressive Craniectomy
Craniectomy has long been used as a last resort in the treat-
ment of traumatic brain injury. It is only when indicators of 
incredibly high intracranial pressure manifest that craniectomy 
is considered. Such indicators include compression of cortical 
gyri and basal cisterns, signs of immediate herniation, and ce-
rebral swelling (Morgalla, et al. 2008). In the majority of studies 
analyzed, craniectomy was only used after standard protocols 
had failed to lower intracranial pressure sufficiently. As such, it 
is difficult to assess the efficacy of craniectomy, as it is generally 
used only on patients with severe injuries who have already 
undergone other treatments. Usually, by the time a craniectomy 
is performed, there has been a lapse of time between injury and 
the surgery (Morgalla, et al. 2008; Olivecrona, et al. 2007), limit-
ing its benefit. Another hindrance to the study of decompressive 
craniectomy is that due to the surgical nature of the procedure, 
a blinded study is impossible. 
While one study analyzed found decompressive craniectomy 
to lower intracranial pressure but hinder favorable outcome 
(Cooper, et al. 2012), four other studies found that long term 
results justify the surgery (Akyuz, et al. 2010; Morgalla, et al. 
2008; Olivecrona, et al. 2007; Qiu, et al. 2009). Cooper, et al.’s 
2012 study reports that patients who received a craniectomy 
along with standard treatment showed a less favorable outcome 
after six months. However, the mortality rate was the same in 
patients who had undergone the procedure and those who had 
not. In contrast, Olivecrona, et al. (2007) found a 10% difference 
in outcome, with those who received a decompressive craniec-
tomy having the more favorable outcomes when compared to 
patients who received only standard care. 
Patients who had undergone a decompressive craniectomy 
needed fewer interventions to lower intracranial pressure. They 
required a shorter period of time on mechanical ventilation, 
and they spent a shorter amount of time in the intensive care 
unit (Cooper, et al. 2012). There was a significant reduction in 
intracranial pressure directly after the surgery, which later sta-
bilized to manageable levels (Olivecrona, et al. 2007). One study 
found that 40% of patients who were otherwise likely to die had 
favorable results after undergoing a decompressive craniectomy 
(Morgalla, et al. 2008).
There are a number of caveats in regard to craniectomies. 
Firstly, patients who underwent the surgery had a higher in-
cidence of hydrocephalus (Cooper, et al. 2012), which neces-
sitates additional medical or surgical care. Secondly, unilateral 
craniectomies have been linked to delayed intracranial hema-
tomas and subdural effusion, both of which must be treated 
through surgical intervention (Qiu, et al. 2009). However, suc-
cess has been seen in bilateral craniectomies. A problem with 
all decompressive craniectomies seems to be an increase in 
transcapillary leakage. The point of a craniectomy is to allow 
room for swelling. The loss of resistance in the brain leads to 
transcapillary leakage due to an increase in the transcapillary 
hydrostatic pressure gradient. In order to counteract this effect 
of a craniectomy, the transcapillary pressure must be lowered 
by preventing an increase in arterial pressure and infusing albu-
min and packed red blood cells (Olivecrona, et al. 2007). These 
issues are all collateral damage of decompressive craniectomies, 
but the benefit of the surgery seems to outweigh the detriment. 
An important factor to consider is the timing of the procedure. 
While most craniectomies are performed after standard proto-
col has been tried and found unsuccessful, thus lengthening the 
amount of time between the injury and the surgery, this might 
not be the most advantageous use of craniectomies. Akyuz, et al. 
(2010) compared the results of craniectomies on patients who 
received the surgery following standard procedure to those 
who received the surgery immediately. The first group had their 
craniectomies around 35.7 hours after trauma, as compared to 
the second group, who underwent the procedure approximate-
ly 4 hours after trauma. It was found that early decompressive 
craniectomy resulted in a 48% decrease in intracranial pressure. 
The group which underwent standard protocols before receiv-
ing craniectomies yielded a 27.8% favorable outcome as com-
pared to the other group, which had a 50% favorable outcome 
after 12 months. While the best results were found when the 
procedure was performed within 4 hours of injury, performing 
the craniectomy within 48 hours still provides benefit (Qiu, et 
al. 2009). Using craniectomy as a second tier response hinders 
the positive effects of the procedure, as an extended amount of 
time with high intracranial pressure is detrimental to functional 
outcome.
The size of the decompressive craniectomy is also significant. If 
the craniectomy is too small, it will not allow the brain enough 
room to expand. The brain will then swell through the incision, 
causing external herniation. Bilateral craniectomies have the ad-
vantage of providing more space for the brain to expand (Akyuz, 
et al. 2010).
Age is also an integral consideration when determining the out-
come of decompressive craneictomy. In fact, the study done by 
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Cooper, et al. (2012), which found the least favorable results, 
was the study which included the oldest patients. It seems that 
the highest recommended age upon which a craniectomy for 
traumatic brain injury should be performed is 40, and that it is 
detrimental to those over 60 (Akyuz, et al. 2010; Morgalla, et al. 
2008; Olivecrona, et al. 2007). The greatest benefit is to younger 
patients. This might be due to a stronger immune system or to 
an elevated recovery ability in younger patients.
Conclusion
These three responses to traumatic brain injury are still being 
researched. From the studies analyzed, it is apparent that due to 
the negligible benefit and immense cost of using hypertonic sa-
line, it should be reserved for patients with injuries that indicate 
surgery. The status of hypertonic saline as a first tier response 
should be reevaluated. Progesterone, on the other hand, should 
be initiated into standard protocol. It shows no discernable 
harm and has been proven to do much good. It is essential that 
it be included in first tier response, as the immediacy of ad-
ministration bears effect on the amount of good it can do for 
the patient. Decompressive craniectomy should be considered 
immediately in a case of uncontrollable intracranial pressure in 
a relatively young patient, so as to capitalize on the efficacy of a 
rapid craniectomy. In such a case, the gains outweigh potential 
damage. However, all assessments must be made on an individ-
ual basis, as each patient presents a unique set of properties.
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Introduction: Neuroplasticity following blindness
Neuroplasticity describes the brain’s ability to change its struc-
ture and function throughout the course of a lifetime.  The 
largely differing conditions in the brain following early onset 
sensory impairments such as congenital blindness or deafness, 
allow for large scale changes that promote a full reorganization 
of the brain. This may result in a functional network remarkably 
different from the one seen in healthy individuals. Accordingly, 
in a congenitally blind person, despite the lack of visual input 
to the brain, the visual cortex does not degenerate, but rather 
it receives input from non-visual functions such as touch and 
audition (Bubic, et. al., 2010). Functional neuroimaging methods 
validate these findings by showing that the occipital cortex func-
tionally engages in perceptions such as audition (Gougoux, et al., 
2005; Kujala, et al., 2005) and tactile Braille readings (Gizewski, 
et al., 2003). Studies in which auditory (Collingnon, et al., 2006) 
and tactile processing (Merabet, et al., 2004) were disrupted via 
transcranial magnetic stimulation to the occipital cortex con-
firm the necessity of occipital engagement in these non-visual 
functions. Recently, anatomical studies in primates indicated the 
existence of projections from the auditory to the visual cortex 
(Chabot, et. al., 2007) Furthermore, it is important to realize 
that the involvement of unimodal brain regions (occipital cor-
tex) in cross modal perception (auditory and tactile stimuli pro-
cessed by the occipital cortex) is not only limited to individuals 
with sensory impairments, but can under specific circumstances 
be identified in the general population. The difference is that the 
cross modal involvement is much more pronounced in those 
with sensory impairments, perhaps due to increased neuroplas-
ticity, as sensory areas deprived from their customary sensory 
input become integrated into other neural circuits, affecting the 
entire system as a whole (Bubic, et. al., 2010).
Sensory substitution devices/ the human- 
machine interface:
Sensory substitution refers to the transformation of the char-
acteristics of one sensory modality into the stimuli of another 
modality. For example, it is possible to replace vision with touch 
or audition, and to replace audition or vestibular sense, with 
touch.  This paper will focus on sensory substitution devices 
(SSD’s) which replace vision with audition, otherwise known 
as auditory to visual sensory substitution devices.  In general, 
auditory to visual SSD’s capture visual information via a video 
camera, which then transforms the images into auditory input 
that is conveyed to the user using headphones or an earpiece 
(Bubic, et. al., 2010). (Figure 1) 
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The general concept of a sensory substitution device (SSD) and a typical 
visual to auditory setup. SSD’s typically include a visual capturing device, a 
computational device transforming the visual input into auditory input, and an 




Different auditory to visual SSD’s primarily differ in the conver-
sion algorithm the computer utilizes to transform the visual in-
formation into auditory input. To formulate an answer regarding 
the rehabilitative value of auditory to visual sensory substitution 
this paper takes into account the following selection of auditory 
to visual SSD’s which are used in the various studies cited later 
on. The first auditory SSD developed is the vOICe system. The 
capital letters conveniently stand for “Oh I See”. The vOICe 
utilizes a conversion algorithm in which for every image picked 
up by the camera, the vertical axis is represented by frequency, 
the horizontal axis is represented by time and stereo panning, 
and the brightness of the image is encoded by the amplitude of 
the sound (loudness). The resulting sound encoding the image 
is termed a “soundscape” (Bubic, et. al., 2010). (Figure 2) The 
voice can theoretically generate a resolution up to 25,344 pixels 
(Striem- Amit, et al., 2012).
Another more recently developed device is the Prosthesis for 
Substitution of Vision by Audition (PSVA). The algorithm is sim-
ilar to vOICe, except the PSVA uses a frequency mapping to 
map horizontal position as well as vertical position. Thus, the 
frequency associated to each pixel increases from left to right 
and from bottom to top. Furthermore, in order to enhance the 
similarity with the human visual system, the receptor field of 
the PSVA has a higher resolution in the center of the picture to 
simulate the human fovea (Hanneton, et al., 2010) In contrast, 
the PSVA has a maximal theoretical resolution of only 124 pixels 
(Striem- Amit, et al., 2012). Another device known as the Vibe 
converts a video stream into a stereophonic sound stream. It 
uses a virtual retina composed of two levels of “cells”; sensors 
and receptors. Each sensor corresponds to a particular pixel. 
The activity of the sensor is a function of the coded compo-
nents of the captured pixel. A receptor has a receptive field 
determined by a set of sensors. So, a receptor is concerned by 
a particular area of the captured video frames. Each receptor 
produces a signal that can be interpreted as a sound. The signals 
of all the receptors are mixed together to produce a stereo 
audio output that can be adequately adapted for human percep-
tion  (Hanneton, et al., 2010).  Lastly, Israeli Scientists have come 
up with a new device called EyeMusic which uses an algorithm 
that is similar to vOICe algorithm in most respects, except that 
it also conveys color. It distinguishes color by using different 
musical instruments for each of the four colors: white, blue, red, 
and green. Black is represented by silence. In order to increase 
the pleasantness of the sound the device was created with a rel-
atively low resolution of 24 by 40 pixels, is (Abboud, et. al., 2014)
Occipital Activation through the use of Sensory 
Substitution Devices
Recent neuroimaging studies have investigated the neural bases 
of sensory substitution, raising questions about the nature of sen-
sory substitution in blind versus blindfolded individuals. (Poirier, 
et. al., 2007a) Studies show Occipital activation in both blind and 
blindfolded sighted subjects while using auditory SSD’s. Using 
Positron Emission Tomography (PET), Arno and colleagues have 
shown that pattern recognition using the PSVA induced the re-
cruitment of extra-striate occipital areas (BA 18 and 19) in early 
blinded subjects, and to a lesser degree in blindfolded sighted 
control subjects (Arno, et. al., 2001). In another study PET was 
used to show activation of the visual cortex during depth per-
ception using an auditory SSD. In this study blindfolded sighted 
volunteers used the PSVA to determine depth based on the 
relative target size, the proximity of the target to the horizon, 
and the linear perspective. The exercise was found to involve 
the extra-striate area BA 19 (Renier, et. al., 2005).  A study using 
functional Magnetic Resonance Imaging (fMRI)  has shown that 
pattern recognition through an auditory to visual device can 
induce the recruitment of striate (BA 17) and extra-striate 
(BA 18 and 19) areas in blindfolded sighted subjects (Poirier 
et al., 2007b). These studies show similar occipital activation in 
the blind and sighted when using these devices, however the 
basis of the visual activation in each subject group is debated. 
In general, the use of SSD’s seems to induce visual brain areas 
via two processes: mental imagery and cross modality. Though 
cross modality, a function of the brain’s neuroplasticity, seems 
to be the primary basis of SSD use, mental imagery may play an 
important part in the process, especially for blindfolded sighted 
users. Both blind and sighted people can perform mental imag-
ery. The phenomenon of cross modality, though more significant 
in the blind, occurs in the sighted too. So, both processes can be 
performed by either group. In addition, both mental imagery and 
cross modality are known to activate the visual area of the brain. 
After reviewing the data a study by Poirier et al proposes that 











A schematic summary of the vOICe algorithm. Time and stereo 
panning constitute the horizontal axis in the sound representation of 
an image, tone frequency makes up the vertical axis, and loudness 
corresponds to pixel brightness (Bubic, et. al., 2010).
Figure 2
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cross-modality is predominant in blind subjects (Poirier, et. al., 
2007a). Both populations may fare better in different respects 
following this proposal. The sighted or for practical purposes 
late onset blind, who predominantly utilize mental imagery, will 
be able to better associate the cross-modal input to the proper-
ties of vision as they knew it. On the other hand, the early blind 
who lack such understandings of the visual world, and instead 
primarily utilize the cross modality of the brain, due to more 
highly developed cross modal networks and plasticity, seemingly 
have a larger potential in the realm of sensory substitution.( 
Bubic, et. al., 2010) In general, this paper will value this propos-
al, and when analyzing various studies which utilize blind and/
or blindfolded participants, it will acknowledge the discrepancy 
in their use of SSDs, and the effect that these differing modes 
of use have on the results when applicable, while still focusing 
on the broader picture. This approach will help when trying to 
determine an answer regarding the rehabilitation potential of 
these devices for the blind, as this paper is less concerned with 
the effects and potential of these devices in regard to sighted 
individuals.
Methods:
The information in this paper was obtained from Touro College’s 
online database and from various online medical journals. All of 
the data is experiment based, collected and analyzed to best 
answer the question of how effective SSD’s are and to analyze 
their potential to be incorporated into rehabilitation efforts for 
the blind.
Discussion:  Acuity
An important factor regarding the usefulness of SSD’s is the 
amount of detail resolvable to the user. To measure this, a study 
was conducted using the Snellen E- chart visual acuity test. This 
test, generally used by ophthalmologists, was adapted into an 
auditory version via the vOICe technology, and used to test the 
visual acuity of a group of eight congenitally blind, and one early 
onset blind individual. Each participant was trained for several 
months in a two hour weekly training session, by a single trainer, 
on a one by one basis.  The training program was composed of 
two features. One part focused on structured two dimensional 
training, in which the participants were taught how to process 
two dimensional static images such as letters, numbers, faces 
and houses using the vOICe. The second part, live view train-
ing, focused on visual depth- perception and training in hand 
“eye” coordination using the vOICe. The test was conducted by 
playing soundscape stimuli in a pseudo randomized order of E 
directions. Patients had to state the rotation of the letter E (up, 
down, left, right). (Figure 3)
The results, analyzed on both a group level and on an individual 
basis, showed that group performance differed statistically from 
chance level, and individual visual acuity scores varied between 
20/200 and 20/600. Five of the nine participants had visual acu-
ity that exceeded the visual acuity threshold for blindness of 
20/400 as defined by the World Health Organization (WHO). 
(Figure 4)
The study also showed that participants were able to identify 
and mimic the body posture of a person standing a few me-
ters away and navigate in crowded corridors while avoiding 
obstacles. One of the participants was able to identify live three 
dimensional emotional facial expressions. Capabilities such as 
these provide a basis for the device to be used in natural set-
tings, which are sufficiently more complex than those present 
in the study. (Striem-Amit et. al., 2012) Another study also in-
vestigated the acuity of users of the vOICe via the Snellen E 
Figure 3
 A blind participant perceiving an image of a large Snellen E and 
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Figure 4
The group performance on the Snellen acuity test, also displayed is 
the WHO Blindness Threshold (BT) (Striem-Amit et. al., 2012).
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test. This time, however, all the participants were blindfolded 
sighted vOICe users who received no training prior to experi-
mentation. In this way the study aimed to provide a benchmark 
measure of acuity, because in the previous study it is unclear 
whether the acuity levels achieved are due primarily to the 
resolution of the device, or rather the compensatory neural 
plasticity of the blind participants, combined with their exper-
tise in using the device. The participants included 26 adults all of 
whom reported normal vison. The participants completed two 
experimental procedures using the Snellen E test. In the first 
test scores of 20/2464 and 20/4682 (in comparison with normal 
vision: 20/20) were achieved by the highest number of partic-
ipants. In the second test a score of 20/2464 was achieved by 
the highest number of participants, showing a marked improve-
ment from the first test. In general, the acuity results from this 
study are much lower than those of the previous. However, the 
participants in this study received less than 1% of the training 
received by participants of the previous study. In addition, since 
all the participants of the previous study were blind this was 
probably a factor in their high performance. Nonetheless, these 
results are significant, because they show that very little training 
or explanation is required to carry out this task using an SSD 
(Haigh, et. al., 2013).  This study is important because it helps to 
define the minimum capability of the device. The participants 
were both blindfolded and received no training and still man-
aged to extrapolate results, showing the even greater potential 
of the device with blind users who will use the device after 
many hours, days or even years of practice, and who may also 
have developed compensatory neuroplasticity. In addition, these 
studies of acuity along with future studies of acuity using audito-
ry SSD’s, are important in providing a standard measure of acui-
ty for comparing sensory substitution algorithms, and individual 
differences in sensory substitution acquisition. Furthermore, a 
standard measure of acuity might be helpful to test the resolu-
tion and precision of synesthetic experiences described by long 
term users of SSD’s as described below.
Pattern Recognition
One of the most important developments in information tech-
nology is the graphic user interface (GUI). However, the GUI 
has presented a new challenge for blind people given its inher-
ent visual nature, with icons, multi windows, and mouse-based 
command structure. Similarly, in the current world of communi-
cation, graphics play an increasingly important role. Numerous 
graphs, charts, diagrams and other forms of visual communica-
tion are included in documents intended to be read by sighted 
people. Thus, blind people remain at a great disadvantage for 
graphical information access.  In a study by conducted pattern 
recognition in a computer environment was investigated in six 
early blind and six blindfolded sighted subjects using the PSVA. 
By comparing performance of both groups, the study aimed to 
investigate the effect of early visual deprivation on recognition 
of visual patterns. Subjects were trained during twelve, one hour 
sessions. During training the subjects learned how to recognize 
patterns displayed on a PC screen by exploring the graphics 
tablet with a pen. Subjects heard sounds related to their hand 
movements and had to recreate the pattern in a frame using 
aluminum dots and strips. At the end of training, learning was 
tested by having the subjects recreate patterns which they had 
encountered during training. Performance was evaluated on the 
basis of response accuracy and processing time needed to an-
swer. Accuracy was assessed by finding the number of common 
points between the subject’s recreated pattern and the actual 
pattern. The results showed that early blind and blindfolded 
sighted subjects are able to recognize patterns from auditory 
feedback related to hand movements, but the early blind scored 
better in both accuracy and processing time. This suggests that 
mental imagery is not a prerequisite for the development of 
these representations. The results are encouraging from a re-
habilitation point of view by showing that pattern recognition 
in a computer environment is possible using a vison to audition 
coding scheme without previous visual experience. (Arno, et. 
al., 2001)
Depth Perception
Sighted people use depth perception for many applications 
such as obstacle avoidance, navigation, object localization, and 
grasping. A study investigated how early blind subjects interpret 
visual depth cues and use them to locate objects using the PSVA 
SSD, and how sensory substitution can contribute to the de-
velopment of depth perception and visual perspective in early 
blind subjects through interactions with the environment. The 
participants included twenty blindfolded sighted volunteers and 
ten early blind individuals. All received training in recognizing 2D 
shapes with the device. None of the participants had previously 
used the SSD to localize objects, or to explore a 3D environ-
ment. The experiment was divided into a pre-test, a practicing 
session, and a post test. Results from the pre and post-test were 
compared to see the effect the practicing session had on each 
of the subjects groups. During the pre-test subjects explored a 
three dimensional set up via a head mounted camera. The set 
up consisted of a black table surrounded with six white poles 
with twenty preselected positions on the table for a white cube. 
(Figure 5).
The cube was placed pseudo randomly at different positions 
during the experiment. After exploring a specific set up, the 
PSVA was turned off, the cube was removed, and the subjects 
had to replace it by hand in its initial location. Scores were cal-
culated by finding the difference between the correct position 
and the position the subject placed it in. Each participant com-
pleted 20 set ups. In sighted subjects the mean error score was 
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about 11 cm for the depth and about 5.5 cm for the width. In 
early blind subjects, the error score was about 19 cm for the 
depth and 5 cm for the width. These results show better per-
formance in sighted subjects for the depth and little difference 
for the width. These results are explained due to the fact that 
sighted subjects used their knowledge about visual depth to 
perform the task with the PSVA, in other words using a form 
of mental imagery, while the early blind subjects were affected 
by their lack of visual experience. Then, during three 45 minute 
practicing sessions, subjects got to practice with the PSVA in 
the 3D display. All subjects had the same number of trials to 
practice with the PSVA. The post-test following the practicing 
session consisted of the same procedure as the pre-test.  When 
comparing the scores, significant improvement was seen in the 
early blind subjects for determining depth, while on a whole 
there was no significant improvement in the sighted subjects. 
Only those in the sighted group who were the least accurate 
in the pre-test showed an improvement in the post test, seem-
ingly representing a ceiling level for accuracy in sighted subjects. 
However, the improvement seen in the early blind was probably 
due to enhanced tactile and auditory abilities which contrib-
uted to an optimization of the learning process, thus enabling 
them to learn how to correctly use visual depth cues. With a 
longer practice period it is likely that early blind subjects would 
outperform the sighted subjects. These results suggest that vi-
sual experiences via an SSD can help blind people learn visual 
perspective and pictorial depth cues both of which are key for 
depth perception. (Renier, et. al., 2010) 
Fast accurate reaching movements with a visual 
to auditory SSD:
Previously this paper has discussed acuity, pattern recognition, 
and depth perception using auditory SSD’s. A further study dis-
cusses SSD’s in regard to sensorimotor integration, which is 
critical in the effort to make SSD’s relevant for everyday tasks, 
including making accurate reaching movements toward objects, 
and interacting with people and objects. The purpose of the 
study was to test the use of auditory SSD’s to guide a fast reach-
ing movement.  This study utilized the EyeMusic SSD device, and 
involved 18 sighted participants who were naïve to the use of 
SSD’s. The experiment consisted of a familiarization session and 
a test session. During the test session participants used a pen 
shaped stylus to perform 2D reaching movements with their 
dominant hand on top of a digitizing tablet. Movements were 
made from a center location to one of four 2 cm radius targets, 
represented by a white square located 6 cm from the center. In 
the testing session, participants performed two blocks of trials, 
which differed by the type of feedback provided: either auditory 
(SSD) or visual (VIS). During the SSD block participants were 
blindfolded, while during the VIS block, the participants’ arm was 
placed under an opaque cover, such that they did not have di-
rect visual feedback of their hand. (Figure 6)
Participants did not receive feedback on their movement path, 
but received feedback on the location of their hand at the end 
of each trial. If the endpoint location was within 2 cm of the 
center of the target the trial was considered successful and only 
feedback on the location of the endpoint was given in the form 
of a blue square. However, if the end location of the hand was 
farther than 2 cm away from the center of the target, feedback 
on the location of both the target square (white), and endpoint 
(blue) was given, such that participants could use their end 
position relative to the target to correct future movements. 
During the SSD block the participants did not see the squares 
when receiving feedback, but could distinguish between the 
Figure 5
View of the 3D display used in the experiment. The perceived size, 
height in the field view and the geometrical perspective induced by 
the poles can be used as depth cues to estimate the egocentric 
distance of the white cube. The arrows indicate the   width and depth 
axes of the scene. (Renier, et. al., 2010).
Figure 6
The experimental setup: A participant performing the SSD block 
blindfolded (on left). A participant performing the VIS block, with his 




target and the endpoint square because of special eye music 
algorithm which allows for color incorporation, piano for white 
and marimba for blue. The following measures were used to 
characterize participants reaching movements under the two 
feedback conditions; movement time: the time elapsed from the 
movement onset to termination, peak speed: the maximal hand 
speed during the movement, path length: the total displacement 
of the hand from the beginning to the end of the movement, and 
endpoint error: the distance between the hand’s final position 
and the target. Surprisingly, there were no significant differences 
between movements performed with SSD feedback compared 
to those performed with visual feedback in term of movement 
time, peak speed and path length. Average endpoint error in 
both types of movements was smaller than 0.5 cm. It is likely 
that with further practice participants will be able to perform 
movements with an even smaller endpoint error using the 
EyeMusic SSD. The main limit on the study is the fact that it did 
not include any blind subjects. As previously explored, because 
the subjects were sighted it is possible that rather than using 
auditory information directly to control movement, they “trans-
lated” it into a visual image of the target location, and acted 
based on this image. However, the study is strengthened by the 
fact that there was no visual information given of the target 
directly before or during the testing block, so there was no pos-
sibility to perform any vision based calibration between trials, 
which could help to improve subsequent trials (Levy-Tzedek 
et. al., 2012) Furthermore, the use of sighted subjects is auxil-
iary, because it allows for the movements using an SSD to be 
compared to the movements of the same individuals using sight. 
This helps to better define this capability using the device. With 
blind subjects there would be no comparison point, because the 
subjects can only reach out blindly. Nonetheless, a future exper-
iment with blind individuals would reveal the ability the ability 
of blind subjects to create a spatial representation, and act on it, 
without the possibility of mediation by visual imagery. Still these 
results are important since those obtained from the SSD block 
can be used in a future study as a comparison point for blind 
individuals using an SSD. Furthermore, if the blind can replicate 
the accuracy level reached in this study by the sighted subjects, 
then performing daily tasks with an SSD is feasible, and thus the 
prospects of the rehabilitative use of SSD’s are broadened.
Novel SSD’s what they offer to the world of 
rehabilitative techniques: Eye Music and The Vibe
Thus far, various experiments have demonstrated the ability 
of blind users to use SSD’s on various levels. However, most 
auditory SSD’s generate unpleasant sounds and also lack color 
information. For some this provides for a bland and somewhat 
irritating experience at times. Eyemusic was created to address 
these issues by using natural instruments to convey visual in-
formation in a pleasant manner, while also conveying color 
information. Different instruments represent different colors 
and the ceiling frequency was limited to 1568 Hz, because high 
frequency ranges have been linked with unpleasantness. A study 
was conducted to see if the device accomplished these goals. 
The study included twelve blind participants, and ten sighted 
blindfolded controls. Part of the study included a survey which 
asked the participants to compare the pleasantness of EyeMusic 
with the pleasantness of the vOICe, the leading algorithm for 
many auditory SSD’s. This was done by generating two second 
soundscapes using the vOICEe SSD and EyeMusic in their de-
fault modes with a two second break between them. All but two 
participants scored the soundscapes generated by the EyeMusic 
as more pleasant on average. Of these two participants one 
scored the vOICe soundscapes as equally pleasant on average, 
and the other found the vOICe soundscapes to be slightly more 
pleasant on average. On a whole these results are promising 
suggesting that EyeMusic could be a step forward in terms of 
user experience. Notwithstanding, the increased pleasantness 
and potential for prolonged use come at the expense of image 
resolution. Therefore, EyeMusic could be useful for tasks that 
that require prolonged use or when color is valuable to the 
user, while other devices, such as the vOICe, that offer higher 
resolution could be used for tasks demanding finer detail. One 
device does not have to replace the other; rather, each with 
its specific characteristics can be utilized at different points to 
augment the rehabilitative process. In addition, since the sounds 
generated by the device are relatively pleasant this may en-
courage users to use the system as pleasant sounds are said to 
induce positive emotions ( Abboud et. al., 2014) The Vibe is an-
other SSD developed that offers extra versatility, an important 
feature when trying to tailor the device for a specific user. The 
mechanism of the device is described above briefly. This unique 
format allows for several innovations.  The first is pre-filtering 
of the video stream.  A useful example of this is the application 
of a threshold to the captured pictures. The threshold can make 
a great number of receptors silent, and consequently can make 
the resulting audio signal less complicated and more comfort-
able for the user. A second example of pre-filtering is the use of 
a filter that computes as input to the Vibe a time difference of 
successive captured frames. With this kind of filtering, instead of 
producing a continuous and complex audio stream, the Vibe will 
generate sounds only if there are changes in the video stream. 
This functioning can also be more comfortable and less tiresome 
for the user than the static solution that continuously produces 
a complex sound.  One can imagine building filters that combine 
thresholds and time differences for an optimal user experience. 
Another adaption is sensor distribution which affects the pix-
els addressed by each sensor of each receptive field. Receptive 
fields can thus be large or small, identical or different, overlap-
ping or non- overlapping. The distribution of the sensors on the 
2D plane of captured pictures can affect the perceptive abilities 
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of the user. Thus, the sensor distribution can be modified for 
specific users and in specific situations when different effects 
are wanted. Finally, the Vibe also offers the possibility to enhance 
the binaural perception and differentiation by the listener of 
the sound by adding inter-aural disparity cues to the sound like 
inter aural time differences. This can be done by adding delays to 
the transfer functions of the receptors (Hanneton, et. al., 2010) 
The versatility of the Vibe, allows for extra capabilities, which 
enhance the user experience and customization, allowing it in 
these respects to serve as a better rehabilitative tool.
Long Term visual experiences in the blind 
induced by SSD’s
Ward and Meijer (2010) investigated the phenomenology of 
two late onset blind users of the vOICe system. The users both 
report detailed visual phenomenology that developed within 
months of immersive use and has continued to evolve over a 
period of years. In addition, their long term use of the device 
seems to have produced an acquired synesthesia. Synesthetic 
experiences are percept in nature and are elicited by a stimulus 
and occur involuntarily. Furthermore, the experienced sensa-
tion co-exists with the induced one rather than replacing it. So, 
for a synaesthete a sound is seen, but it is also heard. This effect 
may be due to different mechanisms of plasticity that emerge 
after long term use of the device. One is unmasking of existing 
cross modal connections, and another is a slower reorganiza-
tion perhaps associated with changes in synaptic connectivity. 
The two subjects in the study PF and CC both became blind 
at the ages of 21 and 33 respectively. PF currently has a small 
amount of light perception in the left eye, while CC has a low 
visual acuity that enables her to count fingers in front of her, 
and notice large objects in strong contrast. Both were asked a 
series of questions to understand their visual experience, how 
it developed, and the extent to which it comprises an acquired 
synesthesia. Initially, both were asked about perceiving edges, 
contrast and acuity. PF reports visual experience in terms of a 
non-detailed grey scale sketch. She says, “I cannot tell fine little 
tiny details. Rather my vision is based upon black and white and 
all the little gradients in between. The best way I try to describe 
this to people is : take a large black sheet of paper; now take a 
magical piece of white chalk and sketch me here on this stage 
in line drawing now make me three dimensional…”. CC, like PF 
also claims not to get enough visual detail to identify a person’s 
sex or age with the vOICe, but can sometimes differentiate sex 
based on clothing.  She says, “I could tell whether they had a 
long coat on or shorts…” Both PF and CC report being able 
to perceive depth, but that the ability occurred gradually, and 
only after having flat visual experiences of edges and shading. PF 
described the acquiring of depth perception as a sort of eureka 
moment that occurred while she was washing dishes as she 
looked down at the sink and realized with astonishment, “Oh 
I can see down. I can see depth.”  In addition, both were asked 
about perceiving movement. The vOICe software normally con-
verts one visual image per second into a soundscape and is not 
well suited for detecting fast moving objects. However, both PF 
and CC no longer report any subjective experience of jerkiness, 
nor is their experience a series of snapshots. PF describes it like 
using a flip book, “You don’t see the different breaks between 
images.” Likewise CC says at first it was like a very jerky movie, 
but now she experiences smooth movement.  As far as acquired 
synesthesia, both PF and CC claim to be able to ‘see sounds’ 
when not using the vOICe. Their brains have internalized the 
vOICe rules for mapping between hearing and vision, and the 
rules are applied, both, when the device is worn, and when it is 
not.  CC describes her synesthetic experience: “Monochrome 
artificially induced synesthesia, only in certain frequencies of 
sound. A small price to pay for very detailed vision, but the con-
sultant’s music next door sets me off as well (Bach Mass in B 
Minor)… It is not triggered by all sounds but by vOICe like 
sounds. It is almost as if you had a computer with two moni-
tors running simultaneously different pictures… and sometimes 
you switched your attention between both.” PF also gives visual 
descriptions, all monochrome, to a number of simple sounds. 
In addition, PF also believes her synesthetic experiences are 
stable, a hallmark feature of developmental synesthesia. On a 
whole, both the sound of human speech and the sound of most 
instrumental music do not elicit visual experiences. This study 
is enlightening, but also raises further questions. Would congen-
itally blind users acquire an altered sense of visual like space 
as a result of using the device, or is prior vision a prerequisite 
for these experiences that go beyond the scope of what the 
vOICe SSD delivers in most experiments? Furthermore, are the 
particular mappings used by the vOICe special in some way, or 
could any consistent mapping between vision and audition lead 
to these kinds of experiences? It is noteworthy that for both 
their phenomenology has developed over time. The length of 
time using the device may be the key to both of these questions, 
but further study on a larger sample size would be necessary.
Conclusion
The data from the studies supports the use of SSD devices in 
the rehabilitation for the blind. Most studies comparing the use 
of blind versus blindfolded volunteers showed increased po-
tential for blind users using these devices. However, more data 
should still be collected. The present studies are limited by the 
relatively small sample size of volunteers, and the lack of real 
data following long term use. Additionally, the testing set up of 
the experiments cannot parallel the real world which is fast 
paced and demanding, so it would have to be determined if the 
clear benefits as demonstrated under testing conditions could 
be utilized in a real world setting, when the subject has little 
room for error. In the long term, sensory substitution devices 
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seem to be both a promising and innovative addition to the 
rehabilitation of blind people.
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Influenza is a viral disease that routinely causes significant mor-
bidity and mortality. Influenza pandemics have been responsible 
for the deaths of tens of millions of people in the last century 
alone. Science has been desperately searching for any agent to 
mitigate the effects of this infectious disease. 
Tamiflu (a neuraminidase inhibitor) was brought to market in 
the last 20 years with great fanfare and hope.  During the 2009 
influenza pandemic government agencies and hospitals spent 
billions of dollars stockpiling the Tamiflu. It was widely touted 
by health professionals and the media as an effective “silver 
bullet” for the disease. In 2009 The Cochrane Report created 
a tremendous uproar with a British Medical Journal (BMJ) re-
port that concluded that Tamiflu was not effective. Despite the 
controversy, Tamiflu continues to be recommended for use at 
clinics and hospitals as first line defense for treatment as well as 
prophylaxis (Zachary 2015).
Like any medication, use of Tamiflu involves financial and other 
costs i.e. side effects. Given that it is not a benign drug, it be-
hooves us to explore the controversy in detail.
Methods
The information for this paper was obtained from many on-
line resources.  Many of the databases and journals used were 
accessed through the Touro library database and PubMed.gov. 
Much of the background information and pictures were ac-
cessed through Dr. Vincent Racaniello’s (College of Physicians 
and Surgeons of Columbia University) “Virology 101” blog.
Background
Influenza is a viral infection that attacks the respiratory system 
(the nose, throat and lungs). It is caused by one of the three 
types of influenza viruses A,B and C. Influenza viruses can be 
spread by airborne droplets(aerosols) person-to-person con-
tact, or contact with contaminated items (fomites). Airborne 
spread appears to be the most important mechanism. A single 
sneeze can generate up to 20,000 virus containing aerosol par-
ticles. Aerosolized particles produced by these activities are of 
different sizes. The largest droplets fall to the ground within a 
few meters and will transmit an infection only to those in the 
immediate vicinity. Smaller droplets can travel long distances 
determined by their size. 
Onset of symptoms ranges from 1 to 4 days with an average 
of about 48 hours. Symptoms include sudden onset of chills, 
fever, cough, and generalized aches and pains. Severe Headache 
is common. In mild cases, many symptoms are like those of a 
common cold e.g. sore throat, runny nose, and mild conjuncti-
vitis may also occur. After 2 to 3 days, acute symptoms rapidly 
subside, although fever may last up to 5 days. Cough, weakness, 
sweating, and fatigue may persist for several days or occasionally 
for weeks.
Influenza-related pneumonia is an important cause of increased 
morbidity or mortality in high-risk patients. Encephalitis, myo-
carditis, and myoglobinuria, sometimes with renal failure, de-
velop infrequently after influenza A or B infection. Patients at 
higher risk are those with: underlying illness, acute respiratory 
distress syndrome, primary influenza pneumonia, or secondary 
bacterial pneumonia .These include: Children under the age of 
4 years; adults over the age of 65 years; people with chronic 
medical disorders (e.g., cardiopulmonary disease, diabetes mel-
litus, renal or hepatic insufficiency, hemoglobinopathies, immu-
odeficiency); women in the 2nd or 3rd trimester of pregnancy 
and patients with disorders that impair handling of respiratory 
secretions (e.g., cognitive dysfunction, neuromuscular disorders, 
stroke, seizure disorders).
Aside from the use of antivirals such as Tamiflu treatment is 
symptomatic. This includes rest, hydration, and antipyretics 
as needed. Appropriate antibiotics are necessary for treating 
complicating bacterial infections. Antiviral drugs given with-
in 1 to 2 days of symptom onset may decrease the duration 
of fever, severity of symptoms, and time to return to normal 
activity. The two main drug types are the neuraminidase inhib-
itors Oseltamivir and Zanamivir, and the adamantane drugs, 
Amantadine and Rimantadine. Neuraminidase inhibitors inter-
fere with release of influenza virus from infected cells thereby 
halting the spread of infection. These will be discussed at length 
in this paper. Adamantanes block the M2 ion channel thereby 
interfering with viral uncoating inside the cell. They are effective 
only against influenza A viruses (influenza B viruses lack the M2 
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protein). Choice of antiviral drug is complicated by resistance 
of different influenza types and subtypes to different drugs 
(Pringle, 2014).
The influenza virus is unique in that it completely experienc-
es changes in the characteristic of the antigens on its surface. 
Typically, small changes occur from one year to the next. This 
is known as “antigenic drift”. Less frequently, there are signifi-
cant changes in the surface antigens. This is known as “antigenic 
shift.” Hosts who have been previously exposed to influenza 
generally have some residual immunity against viruses that have 
drifted antigenically. In contrast, there is little/no preexisting im-
munity against viruses that have shifted antigenically. The former 
is responsible for epidemics which tend to be milder in severity. 
The latter situation results in influenza pandemics, with high 
mortality e.g. The Spanish influenza of 1918 is thought to have 
caused 30-50 million deaths worldwide. 
Influenza Type A can cause pandemics and epidemics and is 
our main concern. Type B can only cause epidemics. Type C can 
cause mild illness but does not cause pandemics nor epidemics. 
Influenza is often confused with “Influenza-like- illness” which 
may be caused by other factors but has similar symptoms.
Influenza is most common in the winter months. This is because 
the winter conditions are optimal for the spread of influenza. 
The transmission of infection is most effective at a humidity 
level of 20-35 degrees and colder temperatures. At these con-
ditions virion particles are more stable and can travel further 
distances in droplets (Mubareka et al., 2009). Increasing levels of 
humidity of indoor air during the winter may be an effective way 
of decreasing the spread of influenza.
Pathophysiology
Influenza types
As noted above There are three types of Influenza A, B and C. 
Type A and type B cause the same spectrums of disease but 
type B can only infect humans and seals and therefore limits the 
reassortments in contrast to type A which has numerous hosts 
and numerous reassortments.
Influenza A Subtypes
Type A has 3 different membrane proteins, surface proteins 
hemagglutinin (HA), neuraminidase (NA). Matrix protein 2 
(M2) traverses the membrane. As shown in figure 1. (Type B has 
the HA and NA proteins but does not have the M2 protein). 
(Tscherne and Garcia-Satre, 2011). The subtypes of influenza A 
are classified based on the HA and NA proteins. There are 18 
HA types and 11 NA types. This means there are 198 possible 
combinations. The nomenclature of the virus describes the HA 
and NA subtypes for example a virus with HA type 11 and NA 
type 7 is called Influenza H11N7. Only a few types of influenza 
are pathogenic to humans. This depends on their ability to bind 
to Human sialic acid, as discussed later.
Antigenic drifts are minor mutations in preexisting HA and NA 
combinations resulting in new strains. This decreases the effec-
tiveness of antibodies to the Influenza. Antigenic Shifts are new 
combinations of HA and NA proteins. Such as a change from 
H1N1 to H1N2. Antibodies produced against previous influenza 
strains are generally ineffective, thereby increasing its ability to 
infect and cause illness. These shifts often occur when two dif-
ferent influenza types infect one cell. When the viruses replicate 
the RNA can then combine and form a new “reassortant” type 
(see picture 3 below (Ranciello, 2013)).
HA (bl ue), NA (red), and M2 (purple) proteins 
(Ranciello 2013)
Figure 1
Influenza reassortment (Ranciello, 2013)
Figure 2 
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NA Structure
NA is a tetramer of four identical polypeptides each contain-
ing approximately 470 Amino Acids. It has four sections: A cy-
toplasmic sequence, a transmembrane sequence, a stalk and a 
globular head. There are two phylogenetic groups of NA, NA 
group 1 and NA group 2. Group 1 contains N1, N4, N5 and 
N8. Group 2 contains N2, N3, N6, N7 and N9. Group 1 has 
an additional cavity “150 loop” that is not present in group 
2(Air, 2012).
Cell Invasion
Animal respiratory cell membranes contain Sialic acid mole-
cules. These molecules are the binding site receptors of the 
influenza virus. (Gamblin, and Skehel, 2010). When viral HA 
proteins bind to sialic acid receptors on the host cells a se-
quence of events is set in motion resulting in the virus entering 
the cell.
Types of Sialic Acid
Sialic acid is a glycoprotein. It is typically linked to a galactose 
molecule. As stated, Sialic acid is linked to galactose. There are 
2 main types of such linkages: 1. Alpha2, 3 linkage (pictured 
above), in which the carbon 2 of the acid is linked to the car-
bon 3 of galactose. 2. Alpha 2, 6 linkage, in which the carbon2 
of the acid is linked to carbon 6 of galactose. Humans primar-
ily have a2, 6 receptors. This means that viruses targeting this 
structure are more likely to infect these cells. The results of 
studies of early influenza virus isolates from the 1918, 1957, 
and 1968 pandemics suggest that these viruses preferentially 
recognized alpha (2, 6) linked sialic acids. In contrast, viruses 
targeting the a2, 3-linked structure are not very pathogenic 
for humans. In humans, these linkages are only found in ciliated 
epithelial cells, which are a minor population within the human 
respiratory tract. Nevertheless, these are the preferred recep-
tors for the avian flu (Matrosovich et al., 2000).
Mechanism of infection
First the viral HA protein binds to the sialic acid receptors 
on the cell membrane. The virus is then engulfed by the cell 
through endocytosis. This causes the pH of the endosomal ves-
icle to drop to 5 which activates a conformation change on the 
HA protein which exposes a fusion peptide. The fusion peptide 
enables the viral envelope to fuse with the vesicle membrane 
wall. The viral RNA is then released into the cytoplasm. Viral 
RNA travels to the nucleus to initiate protein synthesis and 
assemble new viruses. The newly formed viruses travel back to 
the cell membrane. The virus interacts with the cell membrane 
causing it to bud off. The virus is released to infect other cells. 
The mechanism of the virus leaving involves a potential problem. 
One would expect the viral HA protein to bind to the sialic acid 
receptors on the cell membrane as it leaves. This would result 
in the virus becoming trapped on the host cell. This is prevented 
by the NA protein which cleaves the sialic acid to allow the 
virus to escape (Wagner et al, 2002). NA also cleaves sialic acid 
molecules in mucus in the human respiratory tract (Cohen, et 
al., 2013). This increases viral infectivity.
Neuraminidase inhibitor drugs
In order to prevent viral infection the NA protein has been 
exploited by developing drugs that act as sialic acid analogs 
which bind to the NA active site. These are called NA inhibitors. 
These drugs disable the NA protein from cleaving sialic acid, 
leaving the virus trapped on the cell (Russel et al., 2006).Tamiflu 
(Oseltamivir) and Relenza (Zanamivir) are the two drugs which 
dominate the market. These have been stockpiled by govern-
ments and public health agencies (Jefferson et al., 2009) for the 
treatment of Flu and are recommended by the CDC.
Oseltamivir resistant strains
There have emerged strains of flu that are resistant to oseltami-
vir.  This is due to a point mutation of histidine being switched 
for tyrosine (H274Y) in NA. This leads to decreased binding of 
the drug. Nevertheless this change is also detrimental for the 
virus as it leads to a decrease of surface NA reducing the virus 
replicating abilities and infectivity.
During the 2008-09 flu season oseltamivir resistant influenza 
H1N1 viruses with the H274Y change became more prevalent, 
and within a year they were found in most seasonal isolates. Two 
amino acid changes were identified that even in the presence 
of H274Y restore surface levels of NA. These are V234M and 
R222Q. These secondary mutations seem to balance the dele-
terious effects of the H274Y mutation, thus enabling it to spread 
(Bloom et al., 2010). 
Discussion- The Tamiflu Controversy
Cochrane Report
At the height of the 2009 H1N1 influenza pandemic, the British 
Medical Journal (BMJ) released a Cochrane update (of a 2005 
Cochrane meta-review) which shook the medical world. The 
report cast serious doubt on the usefulness of neuraminidase 
inhibitors (Nis) in influenza. Specifically concluding that, at best, 
NIs reduce symptoms by approximately one day- a moderate 
benefit. 
They reviewed 1416 titles for neuraminidase inhibitors mostly 
on oseltamivir. They discarded all but 20 due to various prob-
lems. These included, variously, insufficient information, inac-
cessibility to data, poor description of methods, and issues of 
reliability. For example, some studies used a mixed population 
of healthy adults and those with comorbid complications. This 
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meant the studies weren’t effective in properly determining 
outcome in healthy populations. They noted that, even this data 
may not be accurate as up to 80 percent of the studies may have 
not been “pure” influenza, rather “influenza like illness”. This is 
because influenza was unconfirmed by laboratory tests. 
Most importantly, according to Cochrane, there is insufficient 
data as to whether NIs are effective in reducing complications 
of lower respiratory tract infection as indicated by antibiotic 
use or hospital admissions. They also note that there is a sig-
nificant risk of toxicity, especially of psychosis, in prophylactic 
treatment. They concluded “because of the moderate effective-
ness of neuraminidase inhibitors, we believe they should not be 
used in routine control of seasonal influenza.”
Kaiser et al (2003)published a meta-analysis of 10 studies of 
oseltamivir. They concluded that Oseltamivir was effective in re-
ducing lower respiratory tract infections (LRTIs). The Cochrane 
2005 report, which relied on this study also concluded that it 
was effective in reducing LRTIs. 
Hayashi (Jefferson, et al, 2009) pointed out that the 2005 
Cochrane report was flawed in that they didn’t actually re-
view the data of the individual studies themselves. In addition, 
he questioned the reliability of the Kaiser report as only 2 of 
these studies were actually published in peer reviewed journals 
(JAMA and Lancet).  The other eight were not and were not 
available for review. He also notes a conflict of interest in that 
the authors of the Kaiser report included four employees and 
one paid consultant of F. Hoffman-La Roche (the manufacturer 
of oseltamivir). Hayashi also noted that in the two published 
studies, there was no significant difference between Oseltamivir 
and placebo in the incidence of LRTIs. He suggests that the only 
way to rely on the report is by a rigid appraisal of the other 
eight trials-which were not released by the drug company La 
Roche.
Cochrane was unable to obtain the data of the 8 unpublished 
studies for further  analysis. This led Cochrane to conclude 
in 2009 that “paucity of good data has undermined previous 
findings for oseltamivir’s prevention of complications from in-
fluenza. Independent randomized trials to resolve these uncer-
tainties are needed.” The question of a publication bias was also 
raised by Cochrane due to the fact that these results weren’t 
published.
Doshi (2009), (a Cochrane author) goes so far as to suggest that os-
eltamivir is no better than NSAIDs, such as aspirin, in the treatment 
of influenza. He also notes the numerous contradictory reports in 
the clinical studies on the effectiveness of oseltamivir which casts 
doubts upon the reliability of the methods and information used 
to generate these reports. He criticizes the fact that government 
organizations have spent so much money on a drug before ascer-
taining the reliability of the data of its effectiveness.  He notes that 
the Centers for Dis¬ease Control and Prevention (CDC) based 
their recommendations on the problematic Kaiser report.
The US government also partly based its national pandemic pre-
paredness strategy on similar assumptions. As a result billions of 
dollars were spent building drug stockpiles, and oseltamivir was 
elevated to the status of a public health drug.
In 2014, Cochrane (published in BMJ 2014) released an update 
of a 5 year campaign it launched against Roche to obtain all the 
clinical study reports (CSRs)- which are extensive summaries of 
RCTs, on Tamiflu. Cochrane managed to pressure Roche into 
releasing all their data. They note that this is the first time all 
clinical study reports of trials in a manufacturer’s program have 
been made available to readers without any restriction. The im-
portance of this is the ability of researchers to assess the clinical 
trials for reliability, adherence to protocol, clarity of definitions 
and avoided reliance on conclusions of researchers who may 
have published biased material. It also allows for considerable 
more information on potential harms.
Cochrane notes that many discrepancies, problems and biases 
have been found in these trials. These include:  Lack of clear defi-
nitions. For example there are eight definitions for laboratory 
confirmed influenza and no clear definition for influenza-like ill-
ness. Lack of reliability of the placebo. In many cases the placebo 
capsule had a different colored cap than that of the active cap-
sule. This was not remarked on in the report. Many of the pla-
cebo capsules in oseltamivir trials contained dehydrocholic acid 
and dibasic calcium phosphate dihydrate. Both can cause gastro-
intestinal symptoms. Although the substances seemed to be in 
low doses, no discussion of their potential effects in people with 
fever was reported. Missing documents. This includes missing 
study protocols and amendments, study manuals of procedures 
and minutes of safety data monitoring committee meetings. 
Ghost authorship and lack of accountability. Authorship and ac-
countability for the writing of many of the clinical study reports 
remains unclear. Some names on studies were redacted and no 
one seemed to claim responsibility for assembling and writing 
the reports. Missing data on duration and durability of symptom 
relief. Data on relapse after the five day treatment period were 
not reported in the clinical study reports. 
There was also a mix-up with follow-up cards in a few of the 
trials which was not even reported in CSRs and only came to 
light from the FDA Summary Basis of Approval papers. There 
is ambiguity as to whether treatment of the flu shown through 
reduction of antibody titers was due to effectiveness of the viral 
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fighting activity of the drug or the immunosuppressant activity 
of the drug.
Cochrane 2014 concludes that oseltamivir is helpful for prophy-
laxis and modestly helpful in treatment (though they downplay 
its usefulness). In contrast to the assertion of various orga-
nizations Cochrane concludes that there is little evidence of 
significant benefits with regards to complications caused by 
influenza and viral transmission. Due to the above as well as 
the side effects, oseltamivir should be used cautiously. Due to all 
the discrepancies and poor quality of the studies, they question 
governmental sole reliance on this data to stockpile oseltamivir, 
its inclusion on the WHO list of essential drugs, and its use 
in clinical practice as an anti-influenza drug. This is especially 
true due to lack of sizeable benefits, and concerns of toxicity 
(Jefferson et al, 2014).
Cochrane study results
For Adults in Treatment trials: oseltamivir reduced the time to 
first alleviation of symptoms by 16.8 hours-from seven days to 
6.3 days. In treatment trials there was no difference in admissions 
to hospital. 
For Adults in prophylaxis pre-exposure: oseltamivir reduced 
symptomatic influenza in participants by 55%. There was no sig-
nificant effect on asymptomatic influenza (increase in antibody 
titers without symptoms). In post-exposure there are two com-
ponents to interrupting transmissions of the virus. The reduction 
of viral spreading from nasal shedding and the prevention of 
onset of influenza in contacts.
Roche claims that it is effective, but there were serious flaws 
in the methods of the studies. This includes giving paracetamol 
which may have reduced viral shedding, and not checking anti-
bodies in participants with potentially asymptomatic influenza. 
This leads to the conclusion that there is “no evidence of a re-
duction in transmission.” 
It is important to note that these studies specifically influenced 
WHO’s policy of recommending this drug. 
Harms for Treatment: increased the risk of nausea (risk differ-
ence 3.66%, 0.90% to 7.39%; number needed to treat to harm 
(NNTH) 28.) and vomiting (4.56%, 2.39% to 7.58%; 22, 14 to 42).
For Prophylaxis: oseltamivir increased the risk of psychiatric ad-
verse events during the combined “on-treatment” and “off-treat-
ment” periods (risk difference 1.06%, 0.07% to 2.76%; NNTH 94, 
36 to 1538) and there was a dose-response effect on psychiatric 
events in two “pivotal” treatment trials of oseltamivir, at 75 mg 
(standard dose) and150 mg (high dose) twice daily (P=0.038).
Oseltamivir increased the risk of headaches on-treatment (risk 
difference3.15%, 0.88% to 5.78%; NNTH 32, 18 to 115).It in-
creased renal events with treatment (0.67%,−0.01% to 2.93%), 
and increased nausea while receiving treatment (4.15%, 0.86% to 
9.51%; NNTH 25, 11 to 116).
For child treatment it reduced influenza for otherwise healthy 
children by 12 to 47 hours with a mean difference of 29 hours. 
There was no effect in children with asthma. There was no signifi-
cant difference in admissions to hospital. There was no significant 
effect on bronchitis, otitis media, sinusitis unverified pneumonia 
or any complication classified as serious or that led to study 
withdrawal. There was no significant difference in prophylaxis. 
In treatment of children, oseltamivir induced vomiting (5.34%, 
1.75% to 10.29%; 19, 10 to 57).
Cochrane’s call to governments
Compared with a placebo, taking Tamiflu led to a quicker allevia-
tion of influenza-like symptoms of just half a day (from 7 days to 
6.3 days) in adults, but the effect in children was more uncertain. 
There was no evidence of a reduction in hospitalizations or se-
rious influenza complications; confirmed pneumonia, bronchitis, 
sinusitis or ear infection in either adults or children. Although 
when used as a preventative treatment, the drug can reduce the 
risk of people suffering symptomatic influenza, it is unproven that 
it can stop people carrying the influenza virus from spreading it 
to others.  
Evidence from treatment trials confirms increased risk of suf-
fering from nausea and vomiting. And when Tamiflu was used in 
prevention trials, there was an increased risk of headaches, psy-
chiatric disturbances, and renal events. 
Evidence also suggests that Tamiflu prevented some people from pro-
ducing sufficient numbers of their own antibodies to fight infection.
Claims about the effectiveness of Tamiflu against complications 
were a key factor in decisions made by governments around the 
world to stockpile these drugs in case of a pandemic. The US 
has spent more than $1.3 billion buying a strategic reserve of 
antivirals, while in the UK the government has spent almost £424 
million  for a stockpile of about 40 million doses*.
It was initially believed that it would reduce hospital admissions 
and complications of influenza, such as pneumonia, during influ-
enza pandemics. However, the original evidence presented to 
government agencies around the world was incomplete.
Along with the evidence of harms from the medication, it raises 
the question of whether global stockpiling of the drugs is still jus-
tifiable given the lack of reliable evidence to support the original 
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claims of its benefits. The BMJ and Cochrane issued a joint call to 
government and health policy decision makers the world over 
asking, in light of the latest findings from the Cochrane Review, 
would you make the same recommendations today, choosing to 
stockpile Tamiflu? (Breeze and Burns 2014).
Criticisms against the Cochrane reports
There are many that criticized the BMJ/Cochrane reports. The 
study was done in collaboration with channel 4 TV station in Britain. 
This may have led to a conflict of interests in overdramatizing a 
story for viewers. As Revere notes (Revere 2009) “Doing this in 
tandem with a media outlet whose objectives are not science but 
snagging viewers is unseemly at best and borders on the unethical”.
An article in Nature (Noorden 2014) notes that it seems as 
if Cochrane, in their overzealousness to confront the big 
Pharmaceutical agencies have been ”cherry-picking” the results 
to make them look worse for antivirals. Some of their statements 
have contributed to media misinterpretation that the drugs are 
‘ineffective’ or ‘useless’.” For example: Cochrane writes ” (os-
eltamivir) reduces symptoms of influenza by half a day” instead 
of the more precisely stating 18 hours for adults and 29 hours 
in children. In the 2009 report they also neglect to mention the 
prophylactic benefits. The Cochrane article obscures the thera-
peutic effect on decreased risk of diarrhea and cardiac system 
events by sandwiching them among the harms of the drug. A 
Cochrane author takes the extreme approach-not supported 
by evidence- of suggesting that Oseltamivir is no more effective 
than paracetamol.
It is important to note that Cochrane hasn’t shown that antivi-
rals didn’t work for healthy people who got flu and were given 
a neuraminidase inhibitor to avoid more serious complications 
like pneumonia. It just alleged there was no “Cochrane-required-
level-of-evidence” that they did prevent complications.
Cochrane only uses Randomized Controlled Trials (RCTs). 
These are studies in which volunteers are randomly assigned to 
get a treatment or a placebo and are considered the gold stan-
dard of evidence. Observational Studies that observe outcomes 
in people who receive a treatment don’t make the cut because 
they are “unreliable for establishing treatment effects”. However, 
often the observational studies are better at concluding the ac-
tual facts on the ground as opposed to the theory. For example, 
an observational study (Muthuri, 2014) of 30,000 people hos-
pitalized during the 2009–10 swine-flu pandemic reported that 
neuraminidase inhibitors reduced mortality by 25%.
Although RCTs are considered the gold standard in of establish-
ing effectiveness of a drug, they lack sufficient statistical power to 
allow reliable conclusions to be drawn about the effects on flu 
complications and hospitalizations- which are the key outcomes 
of interest during a flu pandemic. This is especially true noting 
that these small clinical trials were carried out to gain regulatory 
approval for Tamiflu as treatment and prophylaxis for seasonal flu. 
The trials were not designed to test for the severe outcomes that 
are most relevant to pandemics.
Additionally, The Metro (Branswell 2009) notes, sometimes 
it isn’t possible to conduct randomized controlled trials. 
Sometimes observational data is the best evidence available.
For instance, it’s unlikely any researchers could get permission 
to test Tamiflu against a placebo in people severely ill with 
H1N1. It would be considered unethical to withhold the drug 
from severely ill H1N1 patients if observational data suggested 
the drug might help.
Researchers worry that the Cochranes recommendation “we 
believe they should not be used in routine control of seasonal 
influenza” and the ensuing media storm of overly negative pub-
licity risks undermining public confidence in this class of drug 
which will increase illness. Tamiflu is prescribed as the main 
treatment for serious cases of flu. Many experts say based on 
the observational data that these drugs work and have benefi-
cial effects on severity of illness and preventing death. They are 
worried that we risk losing one of the few weapons we have. 
This is especially true based on the timing of the release and the 
lack of conclusive evidence that it doesn’t work. “So here we 
are in the middle of a pandemic and the Cochrane folks, aided 
and abetted by the BMJ and television producers, are saying, 
“How do you know for sure that they will prevent pneumonia 
in an otherwise healthy person who gets flu?” There is evidence 
about this, even if the Cochrane zealots don’t recognize it”.
Evidence supporting the efficacy of Oseltamivir
It is hard to say that Oseltamivir is completely ineffective. One 
of the first human studies on the effectiveness of Tamiflu was 
published approximately fifteen years ago. In a 1999 study 
(Hayden et al) 117 healthy adult volunteers were inoculated 
with the influenza A virus. Two studies were conducted, one on 
prophylaxis where volunteers were given the drug 26 hours be-
fore inoculation and one on therapeutic treatment where they 
were given the drug 26 hours after inoculation. Treatment was 
continued for 5 days. In these trials, prophylaxis and early treat-
ment with oral oseltamivir were both associated with significant 
antiviral and clinical benefits in experimental human influenza.
Prophylactic
Among the 12 evaluable placebo recipients, 8 (67%) had labora-
tory-confirmed infection and 6 (50%) had recovery of the virus 
from nasal washings. In contrast, of the 21 receiving oseltamivir 
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only 8 (38%) had laboratory confirmed infection and none of 
the 21 evaluable oseltamivir recipients had virus isolated.
The total symptom score area under the curve value was lower in 
the combined oseltamivir groups (n=21) compared with placebo 
(n=12); P=.02. Fourteen symptoms related to influenza were in-
cluded in the score.
Therapeutic
Of the 69 with laboratory confirmed illness At 24 and 36 hours 
after initiating treatment, the median time to cessation of viral 
shedding was reduced from 107 hours in the placebo group to 58 
hours in the combined oseltamivir group as shown in the graph. 
No virus was detected by 60 hours after infection. Effect of Oral 
Oseltamivir Treatment on Illness Following Experimental Influenza 
A/Texas/36/91(H1N1) Infection The total symptom score area 
under the curve value was lower in the combined oseltamivir groups 
(n=56) compared with placebo (n=13);
The total symptom score area under the curve value was lower in 
the combined oseltamivir groups (n=56) compared with placebo 
(n=13);
Dobson et al, 2015
In 2015 the Lancet published a study by Dobson et al. which shows 
that oseltamivir in adults with influenza accelerates time to clinical 
symptom alleviation, reduces risk of lower respiratory tract compli-
cations, and admittance to hospital.
The Cochrane reviews were based on meta-analysis of clinical trial 
study reports alone and not on individual patient data. In the Lancet 
study, Dobson et al did a meta-analysis of all available randomized 
treatment trials of oseltamivir-which includes both published and un-
published data (thereby overcoming previous concerns regarding po-
tential publication bias). This analysis is first of its kind that reviewed 
individual patient data.
Nine trial studies were done between 1997 and 2001 involving 4328 
participants. Participants were labeled as laboratory confirmed in-
fluenza-infected (“intention to treat infected”) and Influenza-like 
(“intention to treat non- infected”).   Participants were within 36 
hours of feeling unwell- with a fever and at least two other influenza 
symptoms. They received 5 day regimens of Tamiflu with a 21 day 
follow up.
Limitations of these studies are that they weren’t set up to test for 
relieving of respiratory complications As such, specific diagnostic 
tests were not used. Instead, in order to enhance reliable reporting 
of complications they incorporated “antibiotic use” in the definition 
of LTRIs. These tests were also not set up to determine prophylactic 
effects.
Effectiveness
Included are data from nine trials including 4328 patients. In 
the Influenza confirmed population (intention-to-treat infected 
population), 
Alleviation of all symptoms for oseltamivir versus placebo recipi-
ents-21% shorter time of 25·2 h,
(The median times to alleviation were 97·5 h for oseltamivir and 
122·7 h for placebo)
An estimated 44% reduction in risk lower respiratory tract compli-
cations requiring antibiotics more than 48 h after receiving oseltami-
vir (65 of 1544 participants given oseltamivir and110 of 1263 partici-
pants given placebo. Components were 56 versus 87 bronchitis, nine 
versus 21 pneumonia, and one versus four lower respiratory tract 
infections, respectively)
An estimated 63% risk reduction of admittances to hospital for any 
cause In the intention-to-treat (nine of 1591 participants had to be 
admitted to hospital for any cause versus 22 of 1302 participants 
given placebo). Participants given Oseltamivir had significantly less 
diarrhea, infections and infestations, and respiratory, thoracic and 
mediastinal disorders and fewer cardiac disorders.  Regarding safe-
ty, increased the risk of nausea (9·9% oseltamivir vs 6·2% placebo), 
increased vomiting (8·0% oseltamivir vs3·3% placebo). No recorded 
effect on neurological or psychiatric disorders (although slightly high-
er with 150 mg). No serious adverse events.
Non-confirmed influenza (intention-to-treat non- infected 
population)
Oseltamivir was ineffective in non-confirmed influenza. This is 
consistent with the fact that Oseltamivir is an anti-viral. In some 
studies some researchers haven’t distinguished between con-
firmed and non-confirmed influenza population. This will skew 
the results of efficacy of the drug being that it is not meant to 
treat non-confirmed influenza. Nevertheless, these results will 
more clearly resemble the effectiveness in real world situations 
where there is mix of these populations.
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CDC rejection of Cochrane Report
The CDC (CDC 2015) continues to promote antivirals such as 
Oseltamivir for treatment of the flu. The CDC promotes the 
“Take 3” campaign to fight the flu. Step 1 is to get vaccinated. 
Step 2 is taking preventative action to stop the spread of germs. 
Step 3 of the campaign encourages people to “take flu antiviral 
drugs if your doctor prescribes them.” 
In CDC (2014) an article entitled ““Have You Heard?  CDC 
Recommendations for Influenza Antiviral Medications Remain 
Unchanged.” The CDC addresses their recommendations and 
the Cochrane’s criticism. Based on the observational studies 
published, the CDC says “treatment with a neuraminidase in-
hibitor antiviral drug was associated with a 25% reduction in the 
likelihood of death compared to no antiviral treatment. Early 
treatment with neuraminidase inhibitor antiviral drugs (i.e., 
within 48 hours of development of influenza illness) halved the 
risk of death compared to no antiviral treatment. This confirms 
findings from previous observational studies in hospitalized in-
fluenza patients that the clinical benefit of neuraminidase inhibi-
tor antiviral treatment is greatest when started within two days 
of influenza illness onset.”  
 The CDC states that their disregard for the Cochrane findings 
is because Cochrane did not consider any data from observa-
tional studies of oral oseltamivir. CDC adds that observational 
studies of antiviral treatment of seasonal influenza or influenza 
A (H1N1) pdm09 (2009 H1N1) have been conducted among 
hospitalized patients, including critically ill children and adults. 
Theses have consistently found that early oseltamivir treatment 
of influenza patients reduces the duration of hospitalization and 
risk of severe outcomes such as intensive care unit admission 
or death. CDC states that Cochrane RCT reviews of data on 
outpatients with clinically mild influenza-like illness is limited in 
by the narrow scope of participants. It is statistically underpow-
ered and not designed to assess the effects of the medications 
on more severe influenza illness outcomes, such as hospital-
izations, intensive care unit admissions, or deaths. RCT data 
is unavailable for those at highest risk for developing severe 
complications from influenza: hospitalized patients with severe 
influenza illness, the elderly, young children, pregnant women, 
and persons with underlying medical conditions such as chron-
ic obstructive pulmonary disease (COPD), asthma, congestive 
heart failure and diabetes. 
They conclude “available evidence for seasonal influenza and 
2009 pandemic H1N1 virus infections consistently indicates 
that antiviral treatment, when initiated as soon as possible, can 
have clinical and public health benefits in reducing severe out-
comes of influenza. Therefore, neuraminidase inhibitor antiviral 
medications continue to be recommended for treatment of 
influenza.”
BMJ/Cochrane response to CDC and Lancet
In a response article written by the BMJ’s Jeanne Lenzer “Why 
aren’t the US Centers for Disease Control and Food and Drug 
Administration speaking with one voice on flu? ” (BMJ 2015) 
Lenzer raises allegations regarding the reliability of CDC. She ac-
cusing them of being “more emotional than scientific” and notes 
that they are at odds with the FDA Who have said oseltamivir “has 
not been proven to have a positive impact on the potential conse-
quences (such as hospitalizations, mortality, or economic impact) 
of seasonal, avian, or pandemic influenza.” She considers the CDC’s 
reliance on the Lancet review as unreliable. This is because the au-
thors have not made their study protocol available for critique nor 
have they released an appraisal of the methodological quality of 
each study.  She concludes by raising the concerns that the policies 
of the CDC and Lancet review have been influenced by funding 
from the Pharmaceutical companies. The CDC Foundation con-
firmed to The BMJ that the CDC received a directed donation 
from Roche for the campaign, stating, “Roche provided a grant of 
$198 000 to CDC Foundation [which] has an administrative fee 
of 13.5%, so $174 800 was provided to [the CDC to] support 
qualitative research into influenza prevention and treatment mes-
saging.” The CDC Foundation also receives funding from the phar-
maceutical industry. A spokesperson said that over the past three 
years the foundation has received an average of around $6.3m 
annually from the industry, 21% of the foundation’s overall funding. 
Some of the companies who have provided funds include Gilead, 
which holds the patent on oseltamivir, as well as Genentech and 
Roche, the drug’s manufacturers. This greatly discredits the CDC’s 
credibility as a nonbiased party.
The Lancet’s Funding
The Lancet study itself was conducted through MUGAS which 
was funded by an open grant from Roche- as the study noted. 
Lancet asserts that neither they nor the study itself were influ-
enced in any way by Roche. Additionally, neither MUGAS nor 
Roche saw the results of the study before publication.
Also two of the researchers note that they have had ties in the 
past to Roche. A third researcher, Stuart Pocock didn’t list any 
conflict of interest on the research paper, but revealed to The 
BMJ that he has received funding from several drug companies for 
cardiovascular research, including Gilead and Genentech, but that 
none of his funding was related to the study of antivirals for flu.
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Paul Roblin in his BMJ blog notes Although the name Multiparty 
Group for Advice in Science ( MUGAS) might lead you to imag-
ine an independent body bringing together representatives of a 
number of organizations to consider a range of issues, MUGAS is 
funded by Roche and is led by four scientists, three of whom are 
advisers to Roche. It appears to have been set up specifically as 
part of the attempt to counter the Cochrane’s criticisms. He also 
notes that there is a complex set of inter-related organizations 
that supported the Lancet study and receive funding from Roche 
and Gilead. Also, one the Lancet authors and MUGAS have many 
more connections to the CDC, Roche and Gilead than they dis-
closed. One of the researchers for the Lancet article, Professor 
Richard J Whitley joined Gilead’s board of directors in 2008 and 
works with/for the CDC. 
Conclusion
All parties agree about the following: Oseltamivir is effective 
in reducing symptoms by at least 16 hours. Oseltamivir works 
reasonably well for prophylaxis. Oseltamivir has significant side 
effects including psychosis in prophylactic patients.
The main debate is whether it reduces secondary complications, 
hospitalizations and spread of disease. The debate also centers 
on whether it is justifiable to prescribe oseltamivir in the face of 
significant side effects.  Also questioned is the wisdom of govern-
mental stockpiling of billions of dollars of Tamiflu. The critics of 
oseltamivir, most prominently Cochrane/ BMJ point to the dearth 
of high quality evidence. Their opponents base their opinions on 
observational data, which is less rigorous, but compelling none-
theless. At the present, clinical practice favors action i.e. the use of 
oseltamivir for both prophylaxis and treatment. The clinical deci-
sion supporting resource “UpToDate” continues to recommend 
treatment with the anti-virals as per the recommendation of the 
CDC and the IDSA. This is based on the observational study data 
that shows its effectiveness. It seems that the current consen-
sus in Hospitals is to give Tamiflu as a first line defense both for 
prophylaxis and for treatment. Although evidence shows it may 
not be as effective as we once thought, this is basically our only 
defense against influenza. In hospitalized patients with preexisting 
complications we wish to take all possible precautions. This au-
thor wishes to point out that such an approach is defensible only 
in an environment in which cost of treatment (financial and side 
effect) is not prohibitive. We wonder whether this calculus would 
be different elsewhere.
Many things can be learned from the Tamiflu controversy. Firstly, 
as demonstrated by Cochrane, one may err in assuming that 
because a paper is published in a peer reviewed journal all the 
evidence is reliable. Especially when an important decision must 
be made the data should be reviewed for accuracy, reliability of 
methods and lack of bias. Secondly, as suggested by Cochrane, the 
trustworthiness of decision making by government bodies should 
be questioned. In any situation, conflict of interest may be present. 
Thirdly, as suggested by their critics, was the Cochrane disingen-
uous in completely ignoring observational data supporting use of 
Tamiflu?  And were the Cochrane writers sensationalists in their 
conclusions and media communications?
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Attention deficit hyperactivity disorder (ADHD) is a disorder 
most commonly seen in children and adolescents, but also may 
present or persist into adulthood. It is a neurocognitive behav-
ioral disorder that presents with symptoms of maladaptive be-
haviors such as impulsivity and or hyperactivity, the inability to 
pay attention and remain on task. ADHD is also associated with 
other maladies such as, mood disorders and learning disabilities 
(Journal of Attention Disorders, 2014). ADHD is costly because 
it is usually diagnosed in childhood and may become a lifelong 
disorder that causes a wide range of symptoms. In addition, chil-
dren with ADHD have been shown to be more likely to sustain 
major injuries and need both inpatient and outpatient emergen-
cy care. Median medical costs for children with ADHD were 
double those of children without the disorder when studied 
over a nine year period. 
Because of its prevalence amongst American children and 
adults and its high cost to the health care system, treatment 
of ADHD is important. Today, many treatments are available, 
these may include, behavioral as well as pharmaceutical ther-
apies. Medications available range from non-stimulant options 
to stimulants available in both extended release, long acting or 
traditional dosages (Journal of Attention Disorders, 2014). This 
paper will attempt to understand the causes of ADHD on a 
neurological level and evaluate possible treatment options, ana-
lyzing how physicians may be better able to match treatment to 
a patient lifestyle and disease. 
What is ADHD?
ADHD, attention deficit hyperactivity disorder, is a neurobiolog-
ical developmental disorder that is characterized by the inability 
to remain on task, difficulty to remain focused and the tendency 
to be overly energetic with impulsive behaviors. It is most com-
monly found in school-age children but can frequently continue 
into adulthood. ADHD is a widespread disease, having been 
found in all countries surveyed with a prevalence of about 7-8% 
of youths and 4-5% of adults. Furthermore, interestingly enough, 
ethnicity did not seem to be a factor in the frequency, however, 
social groups, were found to be most likely to play a role in the 
diagnosis (Journal of Attention Disorders, 2014). 
ADHD, attention deficit hyperactivity disorder, is broken up 
into three different categories, ADHD-I; ADHD, Predominantly 
Hyperactive-Impulsive Type; and ADHD, Combined Type: 
Inattentive and hyperactive/impulsive. ADD, attention deficit 
disorder, is an alternate name for ADHD-I, the first type of 
ADHD. ADHD is the broad term for the hyperactive, inattentive 
disease and ADD is a classification of ADHD. Firstly, ADHD-I, 
also known as ADD or ADHD-Inattentiveness, is diagnosed by 
the inability to keep on task or follow and understand instruc-
tions. Furthermore, children with ADD tend to make careless 
mistakes and use minimal effort in accomplishing difficult tasks. 
Additionally, the ADHD Predominantly Hyperactive-Impulsive 
Type is categorized by the individual suffering with the symp-
toms of hyperactivity, such as, fidgeting, squirming, trouble 
playing quietly or interrupting constantly. Lastly, the combined 
type of ADHD is characterized by a pattern of inattentiveness 
and over activity. Meaning, an individual with the combined type 
of ADHD will exhibit symptoms of fidgetiness, and inability to 
concentrate and remain seated, in addition to, signs of constant 
distraction and failure to remain on task (diffen.com). 
Causes of ADHD
Attention deficit hyperactive disorder can be triggered by many 
matters.  For instance, ADHD is mainly prompted by genetics, but, 
it can also be the result of the environment or specific brain inju-
ries. Firstly, many studies have proven hereditability to be the most 
common cause of ADHD. Genes can have the greatest impact on 
one’s children, whether it means passing down an advantageous 
trait, or passing down a disease, such as ADHD (myadhd.com). 
Family studies were performed in order to find the relationship 
between ADHD and genetics. Results have shown that 25% of 
closely-related family members with ADHD also have the disease. 
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Furthermore, adoption studies and twin studies were done in 
order to support the idea that ADHD is genetically related. If 
ADHD was not genetic, then adopted children should further 
resemble their adopted parents than their biological. However, 
reports have shown that adopted children are more similar to 
their biological parents, further supporting the point.  Twin stud-
ies, have shown similar results. Identical twins contain the same 
genetic materials as each other, and therefore, if one twin has the 
disease, the other twin does as well.  The last study that was done 
on ADHD patients, was molecular genetic research. Molecular 
genetic research focuses on the specific genes related to the 
transmission of ADHD. DAT1 and DRD4 are two dopamine 
genes that were discovered to have the biggest effect on ADHD 
gene transmission (myadhd.com).
Additionally, exposure to toxicity can be another cause of 
ADHD.  A relationship has been found between mothers who 
have smoked tobacco or intoxicated in alcohol during preg-
nancy, and the probability that learning disabilities and ADHD 
will develop in their child. Furthermore, lead exposure or poi-
soning in early years of childhood can have negative effects on 
the child’s progress and advancement.  The last, atypical, cause 
of ADHD can be a head or brain injury. Although somewhat 
unlikely, tumors, traumas, strokes or diseases can also result in 
ADHD as well (myadhd.com). 
ADHD and the Science of the Brain
Current research has proven that the causes of ADHD are high-
ly related to many dysfunctions of neurotransmitters and of re-
gions in the brain. A highly essential neurotransmitter, dopamine, 
has proven to have an effect in ADHD, as well as, the prefrontal 
cortex which requires high amounts of dopamine in order to 
function. Dopamine is a significant inhibiting neurotransmitter; 
meaning, that it plays a major role in preventing certain impuls-
es in the brain, and ultimately, preventing the causes of ADHD 
(dnalc.org). Dopamine transporters are found to be responsible 
for the lack of dopamine in the brain since they absorb too 
much dopamine, disabling it to transfer from one brain cell to 
another, thereby causing a dopamine deficiency in the brain. 
The basal ganglia, a collection of nuclei located throughout the 
brain, also suffer from the lack of dopamine, DA, present in the 
brain. The basal ganglia are responsible for motion or normal 
voluntary movement and are excited by dopamine transmitters. 
Therefore, a lack of dopamine also effects the role of the basal 
ganglia, causing ADHD. When the levels of dopamine are low, 
there are high risks for attention deficit hyperactivity disorder 
because the main neurotransmitter which inhibits impulses is 
lacking (dnalc.org). 
Therefore, the ADHD drugs are specially designed and intended 
to bind to a dopamine transporter with their nitrogen, oxygen 
or carbon atom, enabling it to transfer the dopamine to the 
brain. The nitrogen and oxygen atoms are surrounded by at 
least one lone pair which assists in the formation of a hydro-
gen bond to the dopamine transporter. However, although the 
carbon atom is lacking such a lone pair, it has interestingly been 
discovered that it too can form a bond to the dopamine carriers 
(dnalc.org).  
The question still remains, however, how do the ADHD drugs 
increase the levels of dopamine in the brain by binding to the 
dopamine transporters? There are three known mechanisms 
that ultimately inhibit the rise of dopamine in the brain. The 
dopamine rapidly diffuses into the synapse causing the dopa-
mine transporters to bind to the dopamine and positioning it 
throughout the nerve cell membrane. Then, extracellular action 
of dopamine on the auto receptors of the neuron, consequent-
ly inhibit the further release of dopamine. Thus, the dopamine 
stimulating drugs are aimed to prevent the uptake of dopamine 
by the neurons so that extracellular action will not occur. 
Furthermore, the drugs can promote additional dopamine re-
lease. For example, either the drug can bind to the dopamine 
transporters hindering it from bringing the dopamine into the 
neuron. Or, other forms of the drug can excite the release of 
more dopamine (Molecular Psychiatry, 1998). 
Additionally, the prefrontal cortex and its association with fur-
ther brain regions, such as the striatum, cerebellum are found to 
be slightly smaller or less active in ADHD victims.  Furthermore, 
the frontal lobe, basal ganglia, and the caudate nucleus, are also 
related to ADHD and they too play a significant role in regulat-
ing behavior.  Studies of animals have shown that the prefrontal 
cortex has a responsibility in regulating behavior and attention, 
as well as, understanding representational data (sciencedaily.
com). Researchers were not surprised to find a smaller pre-
frontal cortex in patients with ADHD due to the fact that the 
prefrontal cortex is critical in providing and dividing attention, 
and inhibiting distractions. Therefore, it was understood why 
the MRI’s of ADHD victims exhibited significantly smaller pre-
frontal cortexes.
Treatment of ADHD: Stimulant vs.  
Non-Stimulant Drugs
Treatments for attention deficit hyperactive disorder include 
pharmacological approaches, as well as, non-pharmacological 
care. When treated pharmacologically, the patients are cared for 
using specific prescriptions of drugs that provide them relief 
from their symptoms. Most often, stimulant drugs, drugs that 
arouse activity in the brain, are used as pharmacological treat-
ments. However, non-stimulant medications can be used as well 
(Journal of Attention Disorders, 2014).
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Psychostimulants are stimulant drugs that are psychoactive, 
meaning, they temporarily generate mental and physical func-
tions in the brain such as increased awareness and attentive-
ness (Molecular Psychiatry, 1998).   Current psychostimulants 
include D-amphetamine, D, L-amphetamine, Magnesium pemo-
line, Methylphenidate, dexmethylphenidate, mixed amphetamine 
salts and lisdexamfetamine dimesylate (LDX). Surprisingly, the 
structural composition of these molecules are all different, 
however, share a common backbone of phenyl-ethylamine with 
endogenous catecholamines, such as, norepinephrine and do-
pamine. Uptake of the psychostimulant drugs provide the brain 
with significant dopamine, thereby enabling the inhibition of 
impulses (Molecular Psychiatry, 1998).  
Methylphenidate, is an example of a short acting, central ner-
vous system, stimulant drug for children and adults. They have 
an onset of approximately 30-60 minutes and remain in action 
for about 2-5 hours. Methylphenidate regularizes certain brain 
functions, specifically in the frontal lobe, prefrontal cortex, the 
basal ganglia and cerebellum, by stimulating the brain chemicals 
dopamine and norepinephrine (Molecular Psychiatry, 1998). 
Dopamine and norepinephrine are important neurotransmitters 
in the brain, and, a lack of them can cause dysfunction in brain 
activity. Drugs that increase the dopamine or norepinephrine 
levels will, therefore, provide a short-lasting relief to individuals 
with ADHD. Methylphenidate binds to the dopamine transport-
ers, and blocks them from transporting to the neurons. In this 
way, the extracellular action in the neurons will not take place 
and further production of dopamine will not stop (L.E Arnold).
Methylphenidate also provides a therapeutic effect due to the 
slow and steady increases of the stimulants. In addition to the 
physical effect, methylphenidate also provides an emotional 
relief by increasing the child’s self-esteem and bettering their 
interactions with others.  Therefore, stimulant medications are 
usually given gradually until a beneficial, relaxing effect comes 
about (Molecular Psychiatry). Also, when treated with the sus-
tained-release preparations, they can have longer lasting effects of 
8-12 hours. Evidence to the efficacy of the drug can come from 
functional magnetic resonance imaging tests (fMRI) on ADHD pa-
tients, which have shown that after a dosage of methylphenidate, 
there was increased activations in the brain, verifying the efficacy 
of this drug. The medication has been continuously proven to 
positively affect many ADHD victims (L.E Arnold).  
Ritalin, Concerta, Quillivant XR, Daytrana, Focalin, Medikinet, 
Equasym XL and Methylin are all derivatives of methylphenidate 
and all have similar effects. Firstly, the main byproduct of meth-
ylphenidate, Ritalin, is a short-lasting drug providing immediate 
release of dopamine and norepinephrine in the body (psychcen-
tral.com). Hence, those patients in need of immediate relief will 
benefit from Ritalin. On the other hand, Concerta, is a long acting 
stimulant which increases dopamine levels gradually. Thus, one 
may not need to take more than one dose a day, due to its all-day 
symptom relief. Depending on the severity, time and frequency, 
different patience may have a preference for either the short-act-
ing Ritalin or the long lasting Concerta (healthline.com).
Furthermore, Quillivant XR may be an option to some ADHD 
patients. Quillivant XR is the only liquid long lasting medication, 
thereby, attracting young children who cannot swallow pills. In 
addition, since it is a liquid, it is easily measurable, and, there-
fore, those patients who only need a small dosage will tend to 
choose Quillivant XR. Daytrana, has an unusual advantage of ex-
isting in patch form. Meaning, a specific dosage of medication is 
located in a patch that is worn somewhere on the body usually 
the hip. Throughout the day, the Daytrana is released into the 
blood. Consequently, the effects on the patient will have a lon-
ger duration, usually lasting throughout the entire day.  Children 
typically are the most common ones to use this drug, being that 
it makes life simpler (adhd-treatment-options 2009). The next 
drug, Focalin, is also a drug that offers extended-release, and is 
found to more effective than Concerta. Focalin has proven to 
offer immediate relief first thing in the morning, and then provide 
continuous effects throughout the day, thereby allowing children 
to focus during the day in school. Therefore, Focalin has been a 
first choice drug option for school-age children (drugs.com). 
Another methylphenidate drug, Medikinet, grants immediate-re-
lief and short lasting results. Therefore, it would need to be 
taken several times a day. However, Medikinet XL is a new ver-
sion of the drug which splits up the dosage, releasing 50% im-
mediately and holding back the other 50% to be released later 
on in the day. The latter form of the drug is most probably more 
beneficial to most people, not needing to retake the medica-
tion multiple times a day (netdoctor.co.uk). Similar to Medikinet 
XL, Equasym XL, is also a pill that releases 30% immediately 
and stores the other 70% to be released hourly throughout 
the course of the day. In this case, as well, one morning capsule 
is enough to last the child the whole day. Lastly, Methylin, is 
short-lasting pills and requires multiple doses during the course 
of the day. Additionally, it has many side effects so it is not the 
best option of an ADHD drug (netdoctor.co.uk).
The second most common type of ADHD stimulant drug, 
Amphetamine, is similar to Methylphenidate, except that vari-
ants of this drug are usually intermediate-acting. For example, 
D, L-amphetamine, has a slightly longer duration of 4-6 hours. A 
blend of four amphetamine salts, amphetamine aspartate mono-
hydrate, amphetamine sulfate, dextroamphetamine sulfate and 
dextroamphetamine saccharate, produce Adderall, which is an 
equally effective drug (progressivehealth.com). Being that the 
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two main drugs are especially similar, differences between meth-
ylphenidate and amphetamine are not so distinct. However, the 
chemical activity is different. Ritalin, travels into the brain cells 
and prohibits them from continuous absorption of dopamine 
(learn.genetics). On the contrary, Adderall, not only stops the 
brain cells from absorbing the dopamine, but, also, forces the 
cells to drain the already absorbed dopamine, thereby, directly 
increasing the dopamine levels in the brain.  Furthermore, when 
methylphenidate binds to the dopamine transporters, it merely 
inhibits the uptake of dopamine by the neurons, thereby stop-
ping the inhibition of dopamine. Amphetamine furtherly differs 
from methylphenidate in that along with the immediate release 
formulation of the drug, it can provide extensive release as well. 
Therefore, less dosages per day are needed of Adderall than of 
methylphenidate. Furthermore, even though Adderall is more 
powerful than Ritalin, some people react better to Ritalin, some 
react better to Adderall and some react equally to both drugs 
(LE Arnold).  
Being that stimulant ADHD drugs are similar to cocaine and mor-
phine, many risks and side effects exist. People think that being 
that many children use it, the drug is harmless and mild. However, 
being that methylphenidate is highly addictive, many dangers are 
present. The FDA requires all Ritalin boxes to contain the fol-
lowing notification, “Ritalin is a federally controlled substance 
because it can be abused or lead to dependence. Keep Ritalin 
in a safe place to prevent misuse and abuse.” The above warning 
states that the effects Ritalin can be abused and harmful if not 
used in the correct manner. The use of this drug can also lead to 
anxiety, agitation, trouble sleeping, decreased appetite, headaches, 
stomachaches etc. More serious side effects include the chance 
for seizures, and blurred vision (ritalinsideeffects.net). The main 
concern with these stimulant drugs is its potential for physical 
and emotional abuse. Addiction to the drugs can be caused by 
increasing dosages due to a buildup of tolerance to the drugs. 
The higher dosages, may then cause the patient’s body to become 
solely dependent on the drug, craving it and eventually being un-
able to live life without it. Withdrawal from the medication can 
lead to panic attacks, depression and hunger. Therefore, limita-
tions to this drug are extremely important to prevent addiction 
and abuse (drugabuse.gov). Side effects of both medications in-
clude vomiting, nausea, anxiety, insomnia, skin rashes, headaches, 
dry mouth and agitation. Furthermore, Adderall has an additional 
side effect of increasing the risk of certain heart diseases, such 
as, heart palpitations, increased heart rates and increased blood 
pressure. 
Although stimulant medication is usually the most effective for 
treatment of ADHD, these drugs are not for everyone. Whether 
it being the intolerable side effects, or the ineffectiveness of stim-
ulants, some patients prefer the non-stimulant option remedy. 
Strattera, Clonidine, Guanfacine, Intuniv, and Kapvay, are some 
of the most popular non-stimulant possibilities.   Furthermore, 
Bupropion SR and XL, The tricyclic antidepressants, The Selective 
Serotonin Reuptake Inhibitors (SSRIs), and Effexor can also be 
used as non-stimulant relief (ncpamd.com). 
The first approved ADHD non-stimulant medication for chil-
dren and adults, Strattera, also called Atomoxetine, increases 
the amount of norepinephrine in the brain, thereby increasing 
a child’s attention span and moderating their impulsive behav-
ior (ncpamd.com). Strattera does not directly influence the 
dopamine levels as do the stimulant medications. Strattera is 
effective in decreasing the ADHD symptoms, however, it is not 
controlled and it is less likely to be abused and cause addiction. 
The clinical effects last throughout the day and therefore, more 
than one dosage a day is not necessary. Although there are some 
side effects, they are minimal and tolerable, such as, fatigue, diz-
ziness and nausea (my.clevelandclinic.org). 
Clonidine and Guanfacine, have been used in adults mainly 
to control high blood pressure but has been further used to 
control ADHD mainly in adults with impulsivity and aggression. 
Due to its painkilling and soothing characteristics, Guanfacine, 
is commonly used to help individuals fall asleep. However, due 
to the major side effects of these drugs including high blood 
pressure and heart rate, it is important to monitor one’s blood 
pressure with frequent EKG’s, electrocardiograms, tests that 
check the electrical activity of the heart.   Guanfacine lasts lon-
ger than Clonidine and only one or two dosages are needed 
per day. Furthermore, these drugs mainly relieve over activity as 
opposed to inattentiveness.     
Intuniv and Kapvay are other non-stimulating drugs approved 
by the FDA in September 2009-2010 for individuals ages 6-17. 
Both drugs can be used independently or simultaneously with 
a stimulant. They also tend to take longer than stimulants to 
show results. It may take up to a month to see their effects. 
Furthermore, just like Guanfacine and Clonidine, Kapvay may 
cause a rise in blood pressure and it therefore should be mon-
itored (ncpamd.com). 
Antidepressant drugs can also be used to cure ADHD that is 
linked to depression. Although its results are not as beneficial 
to helping children with attentiveness and remaining on task, 
children who are depressed due to their disease, commonly 
lead towards anti-depressants for help. The first, most popular, 
category of anti-depressants are The Tricyclic Antidepressants 
which include, Pamelor, Norpremine, Aventyl, and Tofranil. They 
are long-lasting so do not require frequent dosages (ncbi.nlm.
nih.gov). Tricyclics, however, can cause dry mouth, blurred vi-
sion, constipation, dizziness and sedation. Other antidepressants 
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such as Wellbutrin, Effexor, Effexor XR, and MAO inhibitors, are 
mainly used as antidepressants but can be used to treat ADHD 
by increasing serotonin in the brain, thereby, increasing concen-
tration in the child. MAO inhibitors are usually a last choice 
for ADHD patients because of their dangerous side effects 
including high blood pressure when taken with certain foods. 
Antidepressants are sometimes mixed with stimulant drugs 
when the individual is suffering from symptoms of anxiety in 
addition to their hyperactivity and inattentiveness (Journal of 
Attention Disorders, 2014). In conclusion, the use of antide-
pressants to relieve the symptoms of ADHD may be beneficial 
if monitored by a health professional. 
What is Cognitive Behavioral Therapy for 
children or adults with ADHD?
Patients diagnosed with ADHD need to manage their symptoms 
of hyperactivity, impulsivity and inability to focus their atten-
tion. CBT, cognitive behavioral therapy, consists of teaching skills 
to control these symptoms. There are two different arms to 
this strategy. One is to teach ways of staying focused and orga-
nized while the other’s goal is to minimize disruptive behaviors 
that interfere with social and academic growth. CBT is used 
both alone and in conjunction with pharmaceutical treatment 
consisting of stimulant and non-stimulant medication (Miller- 
Behavioral Treatments for Kids with ADHD). CBT is important 
as, unlike medication, it teaches life skills that can serve the pa-
tient even after medication is stopped.
For children with behavior problems that detracts from their 
academic progress and causes conflict both at home and in 
school, parent-child interaction therapy, PCIT, may be beneficial. 
It involves 14-17 week sessions in which parent-child interaction 
is viewed through a one way mirror and the parent is coached 
by a phycologist using an ear bud. Parents are encouraged to use 
positive reinforcement in conjunction with strict consequences 
for inappropriate behaviors. These techniques are meant to be 
continued at home and in school. Teacher involvement is en-
couraged and essential.  Goals are set, such as following specific 
classroom rules with a prize following each positive behavior. 
Over time, he child learns to control behavior and therefore, 
have more beneficial interactions with parents, teachers, and 
peers (Miller, Child Mind Institute). 
Another form of behavior therapy involves the attention aspect 
of the disorder. These include techniques to establish routines 
to allow the ADHD patient to organize himself, allowing him to 
stay on task and accomplish his goals. It also focuses on transi-
tioning techniques to allow for less distraction. Everyday tasks 
such as homework or bed time are broken down into smaller 
achievable steps (Miller, Child Mind Institute). In general, both 
methods of CBT have been shown to be more effective the 
younger the child is, and less benefit has been seen by those 
children who have reached adolescence. 
Cognitive Behavioral Therapy as a viable 
treatment for ADHD
Because the use of pharmacological treatments of ADHD may 
not be acceptable to some parents of affected children or the 
affected individuals themselves, cognitive behavioral therapy, 
CBT, has been an alternative to the use of these medications. 
CBT has long been used to treat ADHD both in conjunction 
with medication or on its own. However, not many studies are 
available comparing CBT applied on its own, to medication 
alone, to a combination of CBT and pharmaceutical options 
(Journal of Attention Disorders, 2014). A study by Susan Young 
and J. Myanthi Amarasinghe view these possible treatment op-
tions through the lifespan of the ADHD patient uncovering ev-
idence which suggests different approaches to treatment are 
more effective during different periods in the patient’s life. 
The young preschool child, who is still cognitively immature, 
cannot yet put into practice skills that are taught directly. He 
responds best to parental training to enforce positive behav-
ior control such as tangible consequences along with positive 
support to reinforce good behavior. It has been noted that 
preschoolers that do not meet criteria for diagnosis and there-
fore do not receive early treatment were further affected into 
their school years and beyond than those children treated early 
(Young and Amarasinghe). In addition, parent-child relationships 
are strained during these early years creating stress that lingers 
into adulthood. Because the focus of a child’s life at this time 
is his home and parents, parent training is the most effective 
treatment yielding the most benefits throughout the patient’s 
lifetime. Parenting techniques and interventions include teaching 
parents about ADHD and addressing and targeting behavioral 
problems associated with it. Reward and positive reinforce-
ments for appropriate social behaviors are stressed in conjunc-
tion with consequences for negative and socially inappropriate 
behaviors. Parents may also be offered support groups to deal 
with their own reactions to their child’s difficulties (Young and 
Amarasinghe). 
Older, school age children, are cognitively capable of learning 
skills and techniques to aid in social and academic situations. 
They appreciate being involved in their care at this stage in their 
development. This type of behavior therapy can be developed to 
aid in treatment of older adolescence as well as adult patients. 
These patients exist in two basic environments: at home and at 
school, therefore treatment must be tailored to these situations. 
Home-school connections must be fostered and communica-
tion between the two is imperative. Parent training is similar to 
that of younger children as described above while teachers are 
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coached to set achievable academic and social goals in addition 
to positive reinforcement along with tangible consequences for 
behavioral issues or impulsivity (Miller, Child Mind Institute). 
As children move past their elementary school year, a child is 
able to be more involved in his behavioral therapy. He is able to 
be involved in role playing to advance social skills and improve 
communication with eye contact and body language. An adoles-
cent can be taught how to give compliments, accept construc-
tive criticism, take turns and resolve conflicts. He can be taught 
to actively listen to and follow directions and monitor his own 
attention All of these will improve the patient’s relationships and 
academic achievement improving self-esteem. As an adolescent 
enters adulthood, all of these techniques can be furthered, set-
ting direct treatment goals such as dealing with procrastination 
and developing strategies to aid in memory and impulsivity con-
trol (Miller, Child Mind Institute). 
There are ongoing discussions in the medical and psychiatric 
communities on which avenues of treatment to choose as the 
optimal way to treat ADHD. Depending on the age of the child, 
the first line of defense may be different. The ADHD NICE 
Clinical Guideline advises that parent training be the initial 
treatment in preschool children and young school age children 
with behavioral issues.  Parent training is not as effective in older 
children. Parent training has also been shown to be less effec-
tive in cases where the parents themselves exhibit symptoms of 
ADHD (Young and Amarasinghe). 
In a Multimodal Treatment study, four treatment possibilities 
were compared. Firstly, medication, in the form of methylpheni-
date. Second, CBT including parent training, summer treatment 
programs and school based treatment. Third, A combined treat-
ment including medication and behavior therapy. And, lastly, a 
control group of community care consisting of children, many of 
whom were medicated, but did not receive treatment from the 
researchers. Results found that the medication and combined 
tracks were more effective than behavioral therapy alone or 
the community care.  The combined treatment which consisted 
of medication and CBT in combination was more effective for 
symptoms reported by parents then medication alone. In ad-
dition, CBT, with or without medication was very effective for 
those patients from poorer socioeconomic groups who were 
receiving public assistance. The combination treatment was 
more effective and less costly for patients with many comor-
bid symptoms. In addition, it is important to note that children 
in the combination treatment were able to control symptoms 
with lower doses of medication (JAMA Psychiatry). 
As patients enter adolescence, boys and girls may present with 
different symptoms and, therefore, may need different courses 
of treatment. Boys have a tendency to be more aggressive and 
the need for behavior control is more pressing while girls may 
have more social and emotional symptoms requiring social and 
mood altering treatments. It is for this reason that at this stage, 
teens must be made an integral part of their own treatments. 
Parent training at this stage includes the same basic premise 
as younger children with positive reinforcements becoming 
more age appropriate. For example, positive reinforcement in-
cludes more time with friends or more computer time while 
consequences for negative behavior may be losing privileges 
(Miller, Child Mind Institute). Working closely with teachers 
and counselors at this stage is most important as difficulties 
in school is a major concern. It seems that CBT and parent 
training alone is not as effective in the adolescent group as in 
younger children and a combined regimen including medication 
and behavior intervention is more effective than either alone 
(JAMA Psychiatry). More studies on adolescents need to be un-
dertaken, however, since most assume that their problems may 
be successfully addressed using similar methods as those used 
for their younger counterparts.
Conclusion
ADHD is a developmental and neuropsychological disease 
caused by low levels of dopamine release that presents with 
symptoms including behavioral impulsivity and inability to focus, 
along with the possibility of comorbid conditions of depression 
and behavioral defiance. It is a disease which may present at any 
time throughout a lifespan, but treatment is most effective when 
diagnosed and treated earlier in life. There are many treatment 
options available to the ADHD patient including stimulant and 
non-stimulant medications which may be administered in many 
modalities and doses to fit many different lifestyles. Non phar-
macological approaches include cognitive behavior therapies, 
including parent and teacher training, student workshops and 
summer training programs. Individualized approaches to treat-
ments seem to be the most effective based on a patient’s age, 
symptoms, socio-economic group, and sex. In general, combined 
medication therapy with different forms of CBT tailored to pa-
tient lifestyle as he grows is the most effective treatment. 
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In recent years, probiotic supplements and probiotic yogurt 
have become increasingly popular pharmacy and grocery items. 
Proponents posit that these live cultures of beneficial bacteria 
counteract the negative effects of antibiotics and decreased mi-
crobial exposure of modern life, while others are skeptical of 
these relatively new products and claims. 
Every human gut contains millions of bacteria from hundreds of 
species which aid in digestion and promote health. These bac-
teria are healthy bacteria and are very important to one’s well-
being. Western, developed countries successfully controlled in-
fectious diseases during the last century by improving sanitation 
and using antibiotics and vaccines. At the same time, a rise in dis-
eases such as allergies, autoimmune disorders, and inflammato-
ry bowel disease has been observed in both adults and children, 
and it is hypothesized that improvements in hygiene, decreased 
microbial exposure in childhood, and decreased maintenance of 
microflora are responsible for this increase. In 1907, the Russian 
zoologist Élie Metchnikoff was the first one to suggest that gut 
microbes may influence human health (Britannica). 
Recent studies show that ingesting oral probiotics can promote 
health and counteract some negative effects of antibiotics, but 
only in specific ways. It is necessary to understand the mecha-
nisms and limitations of probiotic supplements in order to be 
an informed consumer.
Methods
This subject was researched using Touro College’s online library 
database as well as Google Scholar. Additionally, ProQuest, 
EBSCO, MEDLINE, and PubMed were used to search for arti-
cles. The author had free access to these search engines through 
the Touro College Library. The method of research entailed 
reviewing published articles and studies that have been peer 
reviewed. Key words such as “gut bacteria”, “probiotic bacteria”, 
“health promoting bacteria”, “probiotic yogurt”, “human micro-
biome”, and “microbiota” were used to find appropriate articles.
Background: Development of gut microbiome
Babies born via vaginal births are colonized by bacteria as they 
pass through the birth canal. The vaginal microbial communities 
appear to change during pregnancy to provide newborns with 
beneficial microbes; at the time of delivery, the vagina is domi-
nated by Lactobacillus and Prevotella spp (Krajmalnik-Brown et 
al 2012). Breast milk also populates the baby’s gut with additional 
health promoting bacteria from the Bifidobacterium family. 
According to very recent research, babies acquire stomach bac-
teria from their mothers even before birth. In healthy human fe-
tuses, bacteria have been detected in umbilical cord blood, fetal 
membranes, and amniotic fluid, supporting the notion of bac-
terial transmission through the placental barrier. Furthermore, 
the meconium (ingested amniotic fluid) from newborns has 
been shown to be non-sterile, home to a complex community 
of microbes, including Enterococci and Escherichia, commonly 
found in the adult GI tract. Therefore, even babies born by cae-
sarean section are born with microbiomes, despite lacking the 
vaginal exposure (Funkhouser and Bordenstein 2013). 
Diversity between ethnic groups
While 90% of all people’s gut biome is similar, the bacteria spe-
cies and proportions vary between races and ethnic groups. A 
study published in 2010 comparing rural children of Burkina 
Faso, Africa, with children in the modern and developed city 
of Florence, Italy, showed that Bacteroidetes and Spirochaetes 
were abundant in the microbiota of the African children and that 
the specific types that were increased were well suited to ex-
tract nutrition from their herbal-rich diet. These bacteria were 
from the genus Prevotella and Xylanibacter (Bacteroidetes) and 
Treponema (Spirochaetes), which are known for their skill at 
cellulose and xylan hydrolysis. The diet of the rural village in 
Burkina Faso is low in animal protein and fat but rich in starch, 
fiber, and plant polysaccharides from local herbs and vegeta-
bles. These bacteria were completely lacking in the European 
children whose diet was high in fat, animal protein, sugars, and 
nutrient-rich but thoroughly cleansed foods (De Filippo et al 
2010). 
A recent study has shown that the Japanese possess unique 
bacteria in their intestines which allow them to digest red 
algae, commonly used to wrap fish in sushi. Japanese have a sea-
weed-rich diet, eating on average of 14.2 grams of sushi a day. 
Red algae, used in sushi, contain the polysaccharide porphyran 
in their cell walls. It is broken down specifically by an enzyme 
called porphyranase. This enzymatic activity is unique to select 
marine bacteria such as Zobellia galactanivorans, the bacteria 
that populate the gut of the Japanese, giving them the machinery 
they need to digest these nutritional sea plants (Hehemann et 
al 2010).
A similar phenomena has been detected in the guts of rodents. 
Desert woodrats (Neotoma lepida) of the Mojave and Great 
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Basin deserts have special toxin-degrading gut microbes to di-
gest the toxic creosote and juniper bushes (Kohl et al 2014). 
This diversity between ethnic groups adds a dimension of com-
plexity to understanding the workings of the microbiome. This 
variation may impact the manner in which the gut responds to 
introduced probiotic bacteria and may result in probiotic treat-
ments being beneficial for some people but not others.
How gut microbes affect autrient absorption and 
energy regulation
In a way similar to how rhizoidal fungi allow plant roots to ab-
sorb soil nutrition, the biofilm structure of the many mucosal 
microbiota adhering to gut epithelium facilitates benefits for the 
host, including nutrient exchange and stimulation of immunity 
(Sonnenburg et al 2004). For example, Bacteroides thetaiotao-
micron is a major symbiont of the human adult gut (Hayashi 
et al 2013). This organism makes an important contribution 
to human digestion by breaking down complex plant material 
that innate human enzymes cannot digest. The human body can 
produce amylase and sucrase which break down starch, glyco-
gen, and sucrose respectively, yet it cannot independently digest 
complex plant material (Microbewiki). Using the plant and fungus 
polysaccharides ingested by the human host as its food source, 
B. thetaiotaomicron is able create small sugars with its glycoside 
hydrolases which  hydrolyze glycosidic bonds in complex sugars. 
It produces mucus that allows it to attach to the gut epithelial 
cells, avoiding washout from the microecosystem. The mucus 
sticks to epithelial lining as well as to undigested food particles. 
These aggregations serve to promote the assembly of more 
microbes and allow their syntrophic relationship with the gut.. 
Other gut bacterial species such as harmless strains of E. Coli 
benefit from the small sugars provided by B. thetaiotaomicron, 
which the E. Coli cannot produce independently. Methanogens, 
another family of the microbiome, use the short-chain fatty acid 
products of the fermentation of carbohydrates. These symbiotic 
relationships add productivity to the human gut (Sonnenburg 
et al 2004). It is clear that the many interactions between gut 
bacteria are extremely complex and to date only a fraction of 
this organization is understood. Much research is needed to 
fully understand the way in which introduced probiotic bacteria 
interrelate and network with the host gut microbiome.
Vitamins
Vitamin B12 is required for metabolism in cells and for the 
formation of red blood cells. The human body cannot produce 
vitamin B12. Only bacteria and archaea are capable of manu-
facturing this vitamin. Species of Pseudomonas and Klebsiella, 
normal residents of the human small intestine, have been shown 
to produce vitamin B12 (Albert et al 1980). E. coli in the large 
intestine produce Vitamin K2 (Bentley and Meganathan 1982). 
Biotin (vitamin B7), a vitamin required for production of fatty 
acids and cell growth, is synthesized in significant quantities by 
the intestinal flora (Scheinfeld et al 2015)..
Gut bacteria help prevent pathogenic infections
Lactic acid bacteria are found naturally in acidic foods such as 
pickles, olives, and yogurt, preventing spoilage by maintaining a 
low pH. In the same way, many pathogenic bacteria are deterred 
from growing in the human intestines due to the unfriendly 
acidic environment created by members of lactic acid bacteria 
family, Lactobacillales. Furthermore, by merely colonizing the 
gut, the healthy bacteria leave little real estate for pathogenic 
bacteria to occupy (Nester).
Having established the presence and functions of gut microbes, 
a question of concern is how the common use of antibiotics 
affects this microbiome and the life functions dependent upon it.
What happens to the bacteria when antibiotics 
are taken?
Studies on isolated cultured colonies of gut bacteria in a labo-
ratory setting have shown how antibiotics impact them. In one 
study, 14 common gut bacterial species from the Clostridium, 
Bifidobacterium, and Bacteroides genera were treated in vitro 
with ampicillin and metronidazole, clinically prescribed anti-
biotics. Effects on bacterial physiology and metabolism were 
monitored over a 48 hour period. Bacteroides and some 
Clostridium species were substantially reduced by Ampicillin. 
On bifidobacterial species ampicillin only had a bacteriostatic 
effect. Metronidazole strongly affected bacteroides communi-
ties, reduced some clostridium species, but had no effect on 
bifidobacterial communities. This study showed that the antibi-
otics ampicillin and metronidazole have a real inhibitory effect 
on some intestinal bacteria species but not others (Newton F 
et al 2013). 
 Modeling tests have been conducted on mice as well to bet-
ter understand the relationship between antibiotics and intes-
tinal bacteria. Mice have similar gut bacterial composition to 
humans. Oral intake of antibiotics, streptomycin and vancomy-
cin, was used to agitate the intestinal microbiota of the mice. 
Thereafter, the mice were infected with Salmonella enterica se-
rovar Typhimurium to gauge the results of antibiotic treatment. 
Analysis showed that the number of intestinal bacteria was not 
altered significantly by the antibiotic regimen, but the microbio-
ta composition was affected. Both vancomycin and streptomycin 
treatments significantly decreased lactobacilli and enterococci/
group D streptococci populations and promoted the over-
growth of Enterobacteriaceae. These perturbations in the mi-
crobiota caused the mice to be more susceptible to Salmonella 
serovar Typhimurium intestinal colonization and infection than 
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before antibiotic treatment. This study demonstrates the impor-
tance of a healthy microbiota in limiting susceptibility to enteric 
pathogens. This study showed that the antibiotics vancomycin 
and streptomycin can have a detrimental effect on intestinal 
bacteria species, limiting host immunity (Sekirov et al 2008). 
A leading expert in this field, David Relman M.D., investigated 
the gut bacterial communities of three healthy humans before 
and after treatment with ciprofloxacin, a commonly prescribed 
broad spectrum antibiotic of the fluoroquinolone family, by 
comparing stool samples before and after treatment. He mon-
itored them for a period of ten months. Ciprofloxacin treat-
ment eliminated about a third of the bacterial taxa in the gut, 
decreasing the diversity of the community. Faecalibacterium, 
Lachnospiraceae, Bacteroides and Alistipes are names of several 
genera that were reduced by ciprofloxacin. The magnitude of 
this effect varied to some degree between individuals. However, 
by 4 weeks after the end of treatment, the makeup of the com-
munity closely resembled its pretreatment state in all three indi-
viduals with the exception of several taxa which failed to recov-
er even 6 months later. During the four week recovery period, 
the participants reported normal intestinal function. The rapid 
resurgence of the pretreatment community indicates strong 
bacterial community resilience. However, the fact that several 
bacterial species did not recover tells that even a short course 
of antibiotics may cause minor permanent changes to gut com-
munity flora. Though the participants did not experience any 
immediate obvious stomach problems from the medication, this 
cannot predict the possibility of long term impacts such as in-
creased susceptibility to allergies or skin irritations (Modi S et al 
2014). Relman found that a second exposure to ciprofloxacin a 
half year after the first treatment causes similar effects but was 
accompanied by incomplete recovery (Dethlefsen and Relman 
2010).
Similar studies using clindamycin showed that the gut Bacteroides 
community never returned to its original composition even two 
years after antibiotic treatment (Jernberg et al 2010). Clearly 
antibiotics impact the bacterial gut population with possible ef-
fects on host wellness.
Which diseases result from antibiotic use?
Campylobacteriosis (stomach ulcer) has been linked with in-
take of antibiotics up to one year before the onset of disease 
(Folkhälsomyndigheten 2014). Candida glabrata, an opportunis-
tic pathogen of the urogenital tract and bloodstream in immu-
nocompromised persons, has been associated with taking of 
specific antibiotics (Ben-Ami 2012). In one large study, fluoro-
quinolones were found responsible for over 55% of cases of 
Clostridium difficile-associated diarrhea, an often fatal disease 
(Pepin et al 2005). Studies have demonstrated using mouse 
models that the two antibiotic-associated pathogens, Salmonella 
typhimurium and Clostridium difficile, infect their host by catab-
olizing mucosal carbohydrates liberated from microbiota by the 
antibiotic streptomycin (Katharine et al 2013). Use of antibiot-
ics in children was significantly associated with Crohn’s disease 
even if 6 months had elapsed between diagnosis and the latest 
intake of antibiotics (Virta et al 2012).  
Aside for the infection of Salmonella typhimurium and 
Clostridium difficile, the exact biological mechanism for most 
of these epidemiological associations is currently unknown. 
However, it is logical to assume that killing off good bacteria 
is causative because we don’t know of any other lasting effects 
of antibiotics, but we did see from the studies  of Modi et al 
(2014)  and Dethlefsen and Relman (2010)  that some of the 
good bacteria decrease and don’t ever reestablish themselves.
Results: Probiotic theory
To counter the adverse effects of antibiotics many have con-
sidered consuming probiotics. The theory behind probiotics is 
that swallowing new live bacteria will replenish the lost bacterial 
communities diminished by the antibiotics. Because a healthy 
gut microbiome is believed to promote and maintain health, 
probiotic yogurt and dietary supplements have been suggested 
even for individuals who have not taken antibiotics. First, though, 
it must be determined that probiotic bacteria are alive and can 
reach the gut when consumed orally.
Do probiotic bacteria die in the acidic pH of the 
stomach before they reach the intestine? 
Critics of probiotics question whether the majority of the bac-
terial communities housed in a probiotic pill survive the acidic 
environment of the stomach on their journey to the intes-
tine. Research has been done to determine the effects of the 
stomach’s acidic environment on probiotic bacteria. It is worth 
noting that Lactobacilli, which are native gut bacteria and are 
included in most probiotic formulations, are acidophilic and are 
not adversely affected by stomach acid (Tannock 2004).  
De Campo et al (2005) performed a double-blind study with 
114 healthy volunteers. After 15 days of yogurt consumption, 
the participants’ feces were analyzed by culture, specific PCR, 
and DNA hybridization for presence of the yogurt organisms 
L. delbrueckii and Streptococcus thermophilus. Detection of 
yogurt lactic acid bacteria in total fecal DNA by bacterial cul-
ture and PCR assay was consistently negative indicating that 
the strong acidic environment of the stomach killed microbes. 
However, Marina Elli et al (2006) showed that the De Campo 
et al’s analytical detection methods were poorly set up. Elli’s 
studies in turn confirmed that yogurt bacteria, especially L. del-
brueckii subsp. bulgaricus, can be retrieved from feces of healthy 
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individuals after a few days of ingestion of commercial yogurt. 
Thus, Marina Elli’s research established that many strains of 
probiotic bacteria do indeed survive transit through the gastro-
intestinal tract. It still is a possibility that though the low pH of 
the stomach does not destroy the entire probiotic population, 
it may limit the number of live bacteria that reach the intestine, 
reducing the effectiveness of the probiotic administration. 
To overcome the possibility that a portion of the probiotic bac-
teria die in the stomach acid, new delivery technology has been 
developed to protect the strains from stomach acid. Scientists 
have constructed a coating for susceptible probiotics to avoid 
this possibility. Bifidobacterium breve, a model probiotic, was 
encapsulated into a multilayer alternating alginate-chitosan 
coating. This construction improved the endurance of B. breve 
during contact with stomach acid. During exposure to in vitro 
gastric conditions, a tremendous increase in viability from that 
seen in free cells was demonstrated (Cook et al 2013). Other 
studies have shown that capsules made of alginate, xanthan gum, 
and carrageenan gum increased the survival of probiotic bac-
teria in acidic stomach conditions (Ding and Shah 2009). Many 
probiotic supplements sold today include protective coatings. 
Though probiotic bacteria in yogurt has no such coating, the 
study of Marina Elli et al (2006) confirms that much of the bac-
teria do survive the acidic stomach environment.
Ancillary support for the survival of probiotic bacteria comes 
from the animal world. Coprophagy is the norm in an over-
whelming number of vertebrae. Rodents, rabbits, pigs, foals and 
gorillas and chimpanzees all eat their feces regularly (Soave and 
Brand 1991). The young of elephants, pandas and hippos eat 
their maternal feces and thereby obtain the bacteria required 
to properly digest and obtain nutrition from vegetation in their 
diet. They are born without these necessary bacteria in their in-
testines (Zilber-Rosenberg 2013). The idea of sharing gut micro-
biota via feces has made its way to human medicine. Fecal bacte-
riotherapy or stool transplants have a well-entrenched place in 
the history of medicine of many ancient cultures. Recent studies 
have shown that C. difficile can be effectively treated with fecal 
transplants (Shultz 2014). The idea behind the consumption of 
feces is very similar to the reason to eat probiotics. It replenish-
es the microbiome with friendly bacteria.
Viability of organisms in capsules
Skeptics have questioned whether probiotic bacteria are alive 
and viable in their capsules or whether they die during pro-
duction or storage. Many studies have been conducted proving 
that the bacteria are indeed alive. This is the general manufac-
turing process of probiotic pills as described by the Lallemand 
Health Solutions probiotic producer (2015): Chosen bacteria 
are inoculated onto a culture media and multiply. Live bacteria 
are then separated from the culture medium by centrifugation; 
they are mixed with a cryoprotectant, to help them survive the 
freeze-drying process. Alternatively, they are vacuum dried or 
spray dried. The dried bacteria form a solid cake which is milled 
into a fine homogeneous powder, each grain of which contains 
approximately 1 billion bacteria. Bacteria powders are blended 
with other carrier and diluent ingredients for the desired bacte-
rial concentrations and then encapsulated and packaged.
Studies into the storage stability of spray-dried (Ananta E et 
al 2005), and freeze dried (Kurtmann L et al 2009) probiotics 
are positive. The bacteria remain alive, although dormant, and 
start to grow again after they reach the moist gut environment. 
Even higher storage stability has been found for vacuum-dried 
probiotic cells. Vacuum-dried cells show much higher stabilities 
than the freeze-dried cells (Foerst P et al 2012). 
Effects of temperature on probiotic quality
Temperature has been shown to play a role in the stability of 
probiotics. Warmth and moisture are the ideal growing condi-
tions for probiotic and gut bacteria. The growth and reactivation 
of these dormant organisms is inhibited in the presence of cold 
air, which holds less moisture and is not in the ideal temperature 
range for these bacteria to thrive. Cold air is therefore optimal 
for storage of probiotics as it keeps the bacteria from activating 
and hence dying before they have a chance to reach the human 
body. High heat can also degrade the viability of these organ-
isms and care should be taken to keep them away from high 
temperatures. A thorough study on the effects of temperature 
on vacuum-dried probiotic bacteria revealed that after three 
months of storage at 4°C cells remained stable with a survival 
rate of 70%. At non-refrigerated temperatures (~37°C) only 
54% of the cells survived (Foerst P et al 2012). Similarly, a study 
of freeze-dried common probiotic lactobacteria strains showed 
that stored at 4°C for three months, the survival rate was 76%, 
while storage at 23°C for the same length of time had only a 37% 
survival rate (Jalali M et al 2012). Similar effects of temperature 
on probiotic bacteria were determined for cells produced by 
spray-drying (Corcoran BM et al 2004). Based on this it would 
be best to store probiotics at refrigerated temperatures. Ideally, 
they should be kept at such temperatures in warehouses, ship-
ment, and stores as well, though this is not currently standard.
It should be noted that as an extra measure, many manufac-
turers add an overage of bacteria to their probiotic products 
to compensate for the expected decline in numbers over time 
(NowFoods).
Probiotics and health
To date there has been insufficient research to prove whether 
probiotics counteract the many adverse effects of antibiotics 
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mentioned above, besides for treating antibiotic-associated diar-
rhea. However, a large number of studies have demonstrated the 
benefits of prophylactic probiotic treatment for general health 
benefits, preventing a variety of ailments, and curing other dis-
eases not associated with antibiotics.
Probiotics as treatment for antibiotic-associated 
diarrhea
In 2012, researchers (Hempel S et al 2012) conducted an ana-
lytical search of hundreds of earlier studies and reviews about 
the effects of probiotics on antibiotic-associated diarrhea. This 
systematic review found that using the lactic acid-producing 
bacteria such as Lactobacillus rhamnosus, or L. casei as well as 
Saccharomyces boulardii [cerevisiae] may be helpful in preventing 
and curing antibiotic-associated diarrhea. The number-needed-to-
treat value (NNT) was found to be 13. This means that statisti-
cally on average out of thirteen susceptible patients being treated 
with probiotics for antibiotic-associated diarrhea, one will bene-
fit. Due to overall poor documentation of the probiotic strains, 
it was not clear if the efficacy of treatment was strain specific. 
Furthermore, the studies were spread over a vast population so 
more research needs to be performed to determine whether 
the elderly, middle-aged, or children would benefit most from 
adjunct probiotics therapy. Another question that requires clarity 
is which specific antibiotics are more likely to cause diarrhea and 
which probiotic strains best combat those particular antibiotics. 
However, the studies analyzed included patients taking a variety of 
antibiotics or did not specify the antibiotics used, limiting any con-
clusive correlation (Hempel S). Because the overall results from 
these studies are promising, many medical experts see no reason 
not to suggest probiotics when prescribing antibiotics (Kligler and 
Cohrssen 2008). 
A more recent (2013) large study targeting 2,941 inpatients over 
65 years of age exposed to broad-spectrum antibiotics found no 
supporting evidence that multi-strain lactobacilli or bifidobacteria 
probiotics were effective in prevention of antibiotic associated 
diarrhea in that group (Allen S et al 2013). 
Studies on the effects of probiotics on the particularly dangerous 
condition, Clostridium difficile colitis, often caused by an impaired 
microbiome due to antibiotics, provide insufficient evidence to 
recommend probiotic therapy even merely as an adjunct treat-
ment (Pillai A and Nelson R 2008). 
Probiotics may shorten the duration of infectious 
diarrhea
Infectious diarrhea is often caused by shigella, E. coli, salmonella, 
and clostridium bacteria.  A meta-analysis of almost 2000 patients 
from 23 studies of infectious diarrhea in both adults and children 
indicates that the duration of symptoms may be shortened by 
the use of probiotics by a mean of 30 hours (Allen SJ et al 2004). 
The majority of the probiotics tested in these studies were lactic 
acid bacteria; two studies used Saccharomyces boulardii. Though 
infectious diarrhea is not necessarily a result of antibiotic treat-
ment, infectious diarrhea from Salmonella often is associated with 
antibiotic use. Thus, in this way probiotics may be considered to 
be counteracting the effects of antibiotics.
Bifidobacterium infantis 35624 reduced 
symptoms of irritable bowel syndrome (IBS)
In a review analyzing 16 randomized clinical trials of irritable 
bowel syndrome (IBS) patients who received either placebo 
or probiotic supplements, Bifidobacterium infantis 35624 was 
effective in reducing irritable bowel syndrome symptoms, such 
as intestinal gas, abdominal pain, bloating, and bowel function 
(Brenner DM et al 2009). There was no evidence of adverse 
results. No other probiotic, including isolated Lactobacillus spe-
cies, showed significant improvement in IBS symptoms in appro-
priately designed randomized clinical trials. 
Another systematic review of the literature revealed that pro-
biotics succeeded in reducing irritable bowel syndrome symp-
toms with a number needed to treat (NNT) of 4 (Moayyedi 
P et al 2010). Almost all probiotic combinations contained 
Bifidobacteria species (Verna 2010). 
Probiotics for constipation
Dr. Mary Morgan, an immunologist and researcher for probi-
otics companies, conducted a meta-analysis to uncover which 
probiotics have the best results for constipation. She found 
the following five are best: Bifidobacterium lactis DN-173 010, 
VSL#3 formula (a probiotic mix), Bifidobacterium lactis Bb-
12, Lactobacillus casei Shirota, and Bifidobacterium longum 
(Morgan 2013).
Probiotics may prevent hepatic encephalopathy 
development from cirrhosis
A recent study shows that probiotics are effective in prevent-
ing the progression of liver cirrhosis to hepatic encephalopathy 
(Lunia MK et al 2013). Cirrhosis is an advanced liver disease 
characterized by replacement of healthy liver tissue with scar 
tissue, leading to progressive loss of liver function. It is usually 
caused by alcoholism, Hepatitis A or Hepatitis B. As cirrhosis is 
irreversible, treatment of cirrhosis focuses on preventing pro-
gression. In a progressed state, cirrhosis may lead to hepatic 
encephalopathy, in which an over accumulation of toxic ammo-
nia in the blood due to loss of liver function brings the patient 
to an altered level of consciousness or coma. Natural members 
of gut flora such as Eubacterium aerofa-ciens, E. lentum, and 
Peptostreptococcus productus produce urease, which hydrolyz-
es urea into ammonia (Suzuki K et al 1979). In a healthy body, 
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this ammonia is absorbed from the intestine into the blood-
stream then filtered out by a functioning healthy liver. Hepatic 
encephalopathy, the result of poor liver function, is commonly 
treated with the sugar, lactulose, which reduces the absorption 
of ammonia from the gut into the bloodstream. The usefulness 
of lactulose is limited by side effects such as diarrhea, bloating, 
and flatulence. The Lunia MK, et al study found that intake of 
a specific set of probiotics will alter the intestinal microbiota, 
preventing development of hepatic encephalopathy in patients 
with cirrhosis. By recolonizing the gut with non-urease produc-
ing bacteria such as those in the supplements used in this study, 
a buildup of ammonia is avoided, thus preventing hepatic coma.
The 86 patients in the treatment group received a regimen of 
probiotics which contained Bifidobacterium breve, B. longum, 
B. infantis, Lactobacillus acidophilus, L. plantarum, L. paracasei, 
L. bulgaricus, and Streptococcus thermophilus, 110 billion col-
ony-forming units in all, in one capsule 3 times per day. The 
control group included 74 patients. Patients were told to re-
frain from eating any commercial probiotic yogurt. The patients 
were followed up on each month for six months to ascertain 
that they were keeping to their probiotic treatment plan and 
to track the development of any hepatic encephalopathy symp-
toms. The researchers observed that the incidence of hepatic 
encephalopathy was significantly lower in patients treated with 
probiotics. No adverse effects were detected from the probiot-
ics. These results offer a more comfortable and better-tolerated 
alternative to current lactulose treatments (Lunia MK).
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leading to progressive loss of liver function. It is usually caused by 
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B. infantis, Lactobacillus acidophilus, L. plantarum, L. paracasei, 
L. bulgaricus, and Streptococcus thermophilus, 110 billion col-
ony-forming units in all, in one capsule 3 times per day. The 
control group included 74 patients. Patients were told to re-
frain from eating any commercial probiotic yogurt. The patients 
were followed up on each month for six months to ascertain 
that they were keeping to their probiotic treatment plan and 
to track the development of any hepatic encephalopathy symp-
toms. The researchers observed that the incidence of hepatic 
encephalopathy was significantly lower in patients treated with 
probiotics. No adverse effects were detected from the probiot-
ics. These results offer a more comfortable and better-tolerated 
alternative to current lactulose treatments (Lunia MK).
Probiotics as bowel movement and nutrition 
enhancer in the elderly
Hilla Zaharoni et al (2011) conducted a study to determine 
the preventive impact of probiotics on problems with bowel 
movement and malnutrition in the elderly (Zaharoni H et al 
2011). The study included 215 elderly patients at an orthopedic 
rehabilitation center (107 as control, 108 as probiotic recipi-
ents), age 65 and over. Each participant received a daily dose 
of commercially sold probiotic bacteria. The dosage consisted 
of four strains of Lactobacillus – L. planturum, L. paracasei, L. 
bulgaris, L. acidophilus; three strains of Bifidobacterium – B. 
breve, B.longum, B. infantis; and one strain of Streptococcus, S. 
thermophiles. The control group received a daily placebo packet 
looking exactly like the probiotic complement. After being fed 
daily probiotics or placebo pills for 45 consecutive days in a 
randomized, double-blind, placebo-controlled trial, the patients 
were monitored for 45 follow-up days. The incidences of diar-
rhea were significantly lower among the study group (HR=0.42, 
p=0.04) with a more significant difference among participants 
age 80 and older (HR=0.32, p=0.026). The necessity to use lax-
atives, an indicator of constipation, also showed significant de-
crease in the probiotic group compared with the control group 
(HR=0.74, p=0.032). 
Additionally, healthier levels of transthyretin, reflecting a pos-
itive nutritional intake status, and increased serum albumin 
levels, necessary for proper distribution of body fluids, were de-
tected in the octogenarians of the treatment group compared 
with the control group (P=0.047, p=0.07, p=0.03 respectively) 
but not in the younger age group (between 65 and 80 years 
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of age). This study strongly indicates that the studied bacterial 
strains in commercial probiotics have a positive effect on the 
bowel movements of elderly patients in orthopedic rehabilita-
tion (Zaharoni H et al 2011).
Bifidobacterium lactis (BB-12), Lactobacillus 
reuteri prevents occurrence of infantile fever 
and diarrhea, though not respiratory illness
An important study led by Weitzman Z et al (2005) shows ex-
cellent results for probiotics’ prophylactic effect against fever 
and diarrhea in infants. A placebo-controlled, double-blind 
trial was conducted at 14 child care centers on healthy in-
fants four to ten months old. Infants were assigned randomly 
to either no probiotics or baby formula supplemented with 
Bifidobacterium lactis (BB-12) and Lactobacillus reuteri 55730 
for a period of 12 weeks.  The infants were not breastfed prior 
to the study, and were fed only the assigned formula. The par-
ents agreed not to administer any other probiotic or prebi-
otic supplements. The number of episodes of fever (>100.5 
degrees F), diarrhea, and respiratory illness and the days of 
duration were measured for both groups.
Of 201 participating infants who were similar in gestational 
age, birth weight, and prior breastfeeding, 60 infants were con-
trols, 73 were fed B. lactis, and 68 were fed L. reuteri. Febrile 
outbreaks and diarrheal episodes were nearly double in the 
control group compared to the recipients of B. lactis. The du-
ration of diarrhea was also protracted in the control group. 
Results from the 68 infants of the L. reuteri group were even 
more encouraging. Compared with the controls and even B. 
lactis infants, the L. reuteri group had a substantial decrease 
in number of days with fever, doctor visits, nursery absences, 
and antibiotic medication prescriptions. The probiotic sup-
plements showed no effect on the incidents of respiratory 
illnesses between the groups. 
Bifidobacteria infantis, Streptococcus 
thermophilus, and Bifidobacteria bifidus for 
necrotizing enterocolitis
Prophylactic use of the probiotics, Bifidobacteria infantis, 
Streptococcus thermophilus, and Bifidobacteria bifidus, were 
tested by Alona Bin-Nun et al (2005) to determine their ef-
fect on the incidence and severity of necrotizing enterocoli-
tis. Necrotizing Eterocolitis is a postnatal medical condition 
where portions of the bowel undergo necrosis. Primarily seen 
in premature infants, it is among the most common causes of 
mortality in premature infants. Neonates were randomized to 
either receive a daily feeding supplementation with a probiotic 
mix of 109 colony-forming units per day or to receive no pro-
biotic supplements.
For 72 study and 73 control infants, respectively, birth weight, 
gestational age, and time to reach full feeds were nearly equal. 
The incidence of necrotizing enterocolitis was reduced in the 
study group (4% vs 16.4%). Additionally, necrotizing enterocoli-
tis was less severe in the probiotic-supplemented infants. Three 
of 15 babies who developed necrotizing enterocolitis died, all 
three from the control group. 
Discussion and future study
Over the past two decades there has been significant advance-
ment in the field of probiotics since it has been first suggested in 
1907 by Elie Metchnikoff. These studies have used random undi-
rected criteria for choosing which bacteria from amongst thou-
sands of species and strains to test for potential health benefits. 
They often chose strains occurring in various fermenting foods. 
Each trial has been like a shot in the dark hoping to find a cure. 
The author suggests that future studies focus on the strains 
unique to the gut of residents of the rural village in Burkina 
Faso in the De Filippo et al (2010) study and of other remote 
non-westernized locales for their potential probiotic qualities. 
Epidemiological evidence tells that the improved sanitation, 
sterile industrial foods, and antibiotics of westernized civiliza-
tion has controlled infectious diseases but also has increased the 
incidence of allergic, autoimmune disorders, and inflammatory 
bowel disease (IBD). By selecting gut bacteria unique to isolated 
populations living with an environment and diet of the pre-mod-
ern era, we may discover probiotic beneficial bacteria which can 
restore and implant the health benefits of those primeval and 
rustic lifestyles into the modern urbane world. The De Filippo 
et al study identified bacteria from the genus Prevotella and 
Xylanibacter (Bacteroidetes) and Treponema (Spirochaetes) ex-
clusive to the Burkina Faso population. These results should be 
verified and similar investigations should be made into the gut 
bacteria of other traditional societies such as remote Tibetan 
villages and Northern Okinawa farm towns. New randomized 
clinical trials for probiotic efficacy should be designed utilizing 
the bacterial findings of these remote searches. 
Practical consumer implications; Considerations 
for choosing probiotic supplements
There are hundreds of probiotic supplements available on the 
market. Many of these products have no claim to any support-
ing studies. As probiotics are considered dietary supplements 
and not medications, they do not require certification from 
the Federal Department of Agriculture (FDA). There are great 
variations in the strains of bacteria they contain. It is best to 
buy products that are backed by clinical research. The wise 
consumer will examine the labels of the product to be certain 
that it contains the particular research-backed strains he or she 
desires. If one hopes for a particular cure or health benefit, the 
supplement one chooses should contain strains shown to be 
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Condition Probiotic Bacterial Species Population*
antibiotic-associated diarrhea Lactobacillus rhamnosus, L. casei,   Saccharomyces 
boulardii [cerevisiae]
people younger than 65 years
infectious diarrhea caused by shigella, E. 
coli,  and salmonella
Lactic acid bacteria species, Saccharomyces 
boulardii
adults and children
irritable bowel syndrome (IBS) Bifidobacterium infantis 35624 adults
promoting bowel movements and 
better nutrition intake
Lactobacillus planturum, L. paracasei, L. bulgaris, L. 
acidophilus, Bifidobacterium breve, B.longum, B. 
infantis, Streptococcus  thermophiles
individuals of 65 years and older
fever and diarrhea (prophylactic treat-
ment)
Bifidobacterium lactis (BB-12), Lactobacillus 
reuteri 55730
infants
constipation Bifidobacterium lactis DN-173 010, VSL#3® 
formula (a probiotic mix), Bifidobacterium lactis 
BB-12, Lactobacillus casei Shirota, Bifidobacterium 
longum
adults
necrotizing enterocolitis Bifidobacteria infantis, Streptococcus thermophi-
lus,  Bifidobacteria bifidus
infants
 hepatic encephalopathy 
(prophylactic treatment)
Bifidobacterium breve, B. longum, B. infantis, Lac-
tobacillus acidophilus, L. plantarum, L. paracasei, L. 
bulgaricus, Streptococcus thermophilus
cirrhosis patients
*These particular populations were studied. Effects on other populations are not included unless indicated.
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beneficial to that end. Table 1 summarizes researched bacterial 
strains and the conditions they benefit.
Probiotic Yogurt
Many yogurt products claim to be probiotic. Again, these claims 
are not backed by the FDA. Some bacterial strains in yogurt 
have more scientific support than others. According to the 
Dairy Reporter (August 2, 2013), Dannon, Yoplait, Chobani, and 
Stonyfield rank among the most popular brands in the United 
States. Table 2 lists the strains included in commonly available 
yogurts.
Starter bacteria
Most of the brands use Lactobacillus bulgaricus and 
Streptococcus thermophilus as yogurt culture starters to turn 
milk into yogurt.  The only researched health benefits of these two 
species is that they boost the immune system in anorexia patients 
(Nova E et al 2006) and help lactose absorption those who are 
lactose-intolerant (Riskalla SW et al 2000).
Other added strains
Bifidobacterium animalis lactis BB-12 (LaYogurt)
The precise bacteria combination found in La Yogurt hasn’t been 
scientifically researched. However, there have been many trials 
using the strain Bifidobacterium animalis lactis BB-12, which all 
La Yogurt probiotic products contain (*personal communication). 
Studies have shown BB-12 reduces incidences of fever and need 
for antibiotic treatment in infants (Weitzman Z et al 2005). Also, 
it has been demonstrated that negative immune-related effects of 
non-breastfed infants can be significantly reduced by including B. 
animalis lactis BB-12  in their diet (Holscher HD et al 2012).
Bifidobacterium lactis DN-173 010 (Activia®)
On the yogurt ingredient panel this strain is known as Bifidus 
regularis. This strain is well suited to treating intestinal inflamma-
tions such as colitis (Veiga P et al 2010). Studies showed that it 
can reduce symptoms of irritable bowel syndrome (Agrawal A et 
al 2009) and improve digestive comfort and symptom experience 
of adults from the general population (Guyonnet D et al 2009) 
and well as help improve constipation in children (Tabbers MM 
et al 2009).
Lactobacillus casei DN-114 001 (DanActive®)
L. casei DN-114 001, also known as L. casei immunitas, used in 
DanActive®, has great study results. Daily consumption of a prod-
uct containing Lactobacillus casei DN-114 00 has been shown to 
reduce the risk of gastrointestinal and respiratory common infec-
tious diseases in shift workers (Guillemard E et al 2010).
Lactobacillus casei Shirota (Yakult)
The yogurt drink Yakult’s live Lactobacillus casei Shirota has been 
tested for effect on constipation with excellent results. Chronic 
constipation patients experienced a sharp reduction in symptoms 
after only two weeks of drinking Yakult (Koebnick C et al 2003) 
(Cassani E et al 2011).
Yogurt Certification
In the USA,  a ‘Live Active Culture Seal’ (image 1) was introduced 
by the National Yogurt Association to identify refrigerated or fro-
zen yoghurt products which contained at least 108 or 107 viable 
bacteria per gram at the time of manufacture (AboutYogurt.com). 
In heat-treated yogurt, a process done to prolong shelf life or de-
crease yogurt’s natural tartness, these cultures are killed during 
heating after fermentation.
However, because these counts do not differentiate between 
true scientifically proven probiotic strains and mere starter cul-
tures, the National Yoghurt Association’s certification emblem is 
still not reflective of true probiotic value (Senok AC et al 2005). 
One must also check that the strains inside the yogurt are the 
well-researched bacteria discussed above.
Conclusions
While it is true that many strains of bacteria confer positive 
health benefits when taken orally, these bacterial strains demon-
strate great specificity. Precise subspecies and strains have been 
shown to cure certain ailments but not others, to benefit only a 
particular age group, and to provide these advantages only when 
taken on a regular basis. The research in this paper is important 
because it shows the specific ways in which probiotic bacteria 
are effective. The widely spread beliefs about benefits of probi-
otic products are not ensured by any governing body. Research 
indicates that the functions and mechanisms of gut bacteria 
are very complex and therefore there is no reason to assume 
that random “probiotic” bacteria will offer any health benefit. 
In addition, considerations for form and storage of probiotics 
were discussed: namely that alginate coating may aid in probiotic 
colonization and that probiotic supplements should be stored at 
or below 4°C. Consumers should note that the positive results 
in the studies were generally observed after 2-4 weeks or more 
of daily probiotic consumption. Additionally, suggestions for 
future studies utilizing gut bacteria unique to non-modernized 
traditional societies have been made. This paper aids the gener-
al population by providing the necessary knowledge needed in 
order to be an educated consumer of probiotic products.
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Introduction
Acronyms: UC-ulcerative colitis IBD-inflamitory bowel disease
Ulcerative colitis (UC), a subdivision of inflammatory bowel 
disease (IBD), affects 1 to 2 million people in the United 
States each year. The reason for ulcerative colitis is not quite 
understood. However, the condition appears to be related to 
a combination of genetic and environmental factors. Minor 
symptoms include unformed stools, abdominal cramping, and 
diarrhea (Lichteger et al.,1994). As the severity of the disease 
increases, patients experience fatigue, loss of appetite, weight 
loss mucus present in the stool, intense rectal bleeding in 
addition to fever and anemia. UC can ensue at any time yet it is 
usually diagnosed in a person’s teenage years.  Roughly around 
20% of people with UC have a close relative with IBD.  (CCFA.
org, 2015).
UC is normally a lifelong chronic illness with times of intense 
flairs and remission. A severe attack which can be a potential-
ly fatal condition, is sometimes the first manifestation and is 
observed in about 15% of the patients with this disease. The 
introduction of corticosteroids sharply reduced the death rate. 
Corticosteroids remain as a pillar in the treatment of a severe 
attack of ulcerative colitis. The importance of achieving remis-
sion is undermined by the fact that the long-term colectomy 
rate in patients with a severe attack who achieve clinical and 
endoscopic remission after steroids is similar to those with a 
moderately severe or mild attack.  The dependence on corti-
costeroid is a continuous problem. Steroid dependent patients 
may develop osteoporosis as they get older, in addition to deal-
ing with weight gain, moon face, increase in appetite, as well as, 
acne and joint pain. Furthermore, the likelihood of a colectomy 
within the first five years from diagnosis ranges from  9% in pa-
tients with distal colitis to 35% in patients with complete colitis, 
normally because of unsuccessful medical therapy. The risk of 
recurring inflammatory bowel disease in the form of pouchitis 
ranges from 15.5% 1 year after the procedure to 45.5% 10 years 
after the procedure.  Accordingly, new treatments for ulcerative 
colitis are needed (CCFA.org, 2015).
In recent years biological therapy has been the new method of 
treatment for those who are steroid dependent and or failing 
to respond to other treatments. Tumor necrosis factor α (TNF-
α) is a key pro-inflammatory cytokine in patients with Crohn’s 
disease, but is also found in amplified amounts in the intestinal 
tissue, stools, blood and urine of patients with ulcerative coli-
tis.  Infliximab, also known as Remicade, is an IgG1 monoclonal 
antibody that binds with intense strength to TNF-α, neutralizing 
its biologic activity (Simmons & Jewell, 2002). The question now 
becomes; will biological therapy be the answer to help induce 
clinical remission in those suffering from UC? 
Material and methods
In order to answer the question proposed above, many re-
search articles with relation to this topic have been read. Touro 
College’s library database, the national website of Pubmed and 
Google Scholar were all used to obtain information for this 
paper. All of the articles and information that was accumulated 
through this research have been used in an attempt to conclu-
sively determine if biological therapy will induce a remission in 
patients living with active state of ulcerative colitis.
Different types of ulcerative colitis
The symptoms present for a person with ulcerative colitis will 
vary based on the amount and severity of inflammation present 
and the site of the disease in the large intestines. Ulcerative 
proctitis, the mildest form of ulcerative colitis, is limited to the 
rectum (about 6 inches or less).  Proctosigmoiditis is colitis that 
affects the rectum and sigmoid colon-which is located superior 
to the rectum. Proctosigmoiditis can be determined sometimes 
by the symptom of tenesmus (straining to have a bowel move-
ment.)  In addition, moderate pain on the lower left side of 
the abdomen may occur while the disease is present. The third 
version of colitis is known as left sided colitis. This presents as 
continuous inflammation that begins at the rectum and goes 
up as far as the splenic flexure (a bend in the colon near the 
spleen in the upper left abdomen). Symptoms for left side colitis 
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include severe pain on the left side of the abdomen,  in addition 
to loss of appetite. Lastly, the most severe form of ulcerative 
colitis is pancolitis. Pancolitis affects the entire colon causing 
terrible abdominal pain, weight loss and complete loss of appe-
tite (CCFA.org, 2015).
Climbing the medical ladder
Today, there are very effective treatments on the market to help 
control the disease with the goal of putting it into remission. The 
main aim of the different treatments is designed to decrease in-
flammation. This not only allows the colon to heal, but also re-
lieves the symptoms of diarrhea, rectal bleeding and abdominal 
pain accompanied by the flare. Unfortunately, there is no “one size 
fits all” treatment plan for everyone suffering with this disease. 
One person may do just fine with the most minor suppository 
and live fine the rest of his life, while another may require more 
invasive treatment or need a complete colectomy. Therefore, the 
approach must be customized for each individual person because 
each person’s disease is different. With the correct medical treat-
ment, a patient can achieve remission with the hope of  the state 
of remission lasting for months or even years.  Nonetheless, ul-
cerative colitis may flare up at times from the reappearance of 
inflammation or from a specific trigger. Reoccurrence of a flare 
usually indicates the need to change the medication regimen for 
the patient. The choice of drugs to treat a patient is dependent 
upon the severity of the disease.  The most commonly prescribed 
drugs fall into three basic categories:
Aminosalicylates: This class of drugs encompass 5-aminosa-
licylic acid commonly known as the 5-ASA . This class of drug 
is available in an oral form in addition to a suppository or an 
enema. The goal of the 5-ASA is to line the GI tract with the 
hope to decrease inflammation. In addition, Aminosalicylates are 
beneficial as a maintenance treatment in order to prevent a re-
lapse of the disease (Colombel et al., 2010).
Corticosteroids: The job of steroids is to prevent the body 
from launching an inflammatory cascade. Additionally, cortico-
steroids work to keep the immune system properly balanced. 
Steroids are effective for short-term control of flare-ups. This 
class of drugs is known to help “put out the fire”. Yet, corti-
costeroids are not recommended for long term use or as a 
maintenance drug for UC because of their tremendous amount 
of side effects. The goal of steroids is to buy the patient time, 
not fix the problem.  A person who is unable to come off ste-
roids without experiencing a relapse of the disease will then be 
prescribed a higher class of drugs to help manage the disease 
(Colombel et al., 2010). 
Immunomodulators: Immunosuppressants work to con-
trol the body’s immune system response in order to prevent 
ongoing inflammation. Immunomodulators are mostly used in 
people who have failed to respond to the 5-ASA and steroids 
have not been effective or have been minimally effective in 
controlling the disease. Furthermore, immunosuppressants are 
geared to allow people who are steroid dependent to eliminate 
the use of them (Sood et al., 2002). 
Though these three possibilities of treatments have been shown 
to be effective, there are always patients who fail to respond to 
the three treatment options. These patients were left with no 
choice but to have surgery to rid them of the disease leaving 
them without a colon and remaining with a pouch for the rest 
of their lives. It had become evident that there was a need to 
help prevent patients from undergoing a complete colectomy.
TNF-a and inflammation
All humans have a large gastrointestinal mucosal surface that 
is continually being exposed to billions of potentially harmful 
antigens from our food, bacteria and the environment. However, 
the mucosal surface of the GI tract possesses an immune sys-
tem that strongly controls the balance between immunogenic 
responsiveness and non-responsiveness-tolerance. Response to 
luminal antigens provokes “controlled” inflammation that is rap-
idly down regulated after eradication of the pathogen. However, 
this is not the case for someone with ulcerative colitis. In this 
disease this state of equilibrium is disturbed resulting in a state 
of chronic inflammation. During the start of the inflammation, 
antigen presenting cells, such as macrophages, cause the acti-
vation of T lymphocytes. T lymphocyte cells divide into two T 
helper T1 and T2 cells. T1 cells secrete interferon gamma (IFNy) 
which then enables macrophages to produces TNFa (Simmons 
& Jewell, 2002). 
 TNFa is an inflammatory mechanism that has been shown to 
play a vital role in the pathogenesis of IBD. The transcribing of 
the TNFa gene in stimulated macrophages, platelets, mono-
cytes, adipocytes and T cells results in the secretion of TNFa. 
Circulating TNFa binds to 2 TNFa receptors facilitating numer-
ous biological effects including activation of other macrophages, 
further expansion of the T cell response, and initiation of granu-
loma formation. TNFa also lengthens inflammation by triggering 
NF-kB dependent pathways, which contribute to ulceration and 
degradation of the mucosa through the release of MMP (matrix 
metalloproteins). TNFa triggers other inflammatory mediators, 
such as, IL6 therefore strengthening the early sequence of the 
inflammatory cascade. Increased TNFa production and NFKb 
have been shown to be abundant in lamina propria mononucle-
ar cells derived from UC patients with ulcerative colitis through 
stool, urine and blood tests (Hassan et al., 2007).
Recent advancement in bio-technology have thankfully led to 
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the development of a large array of new therapeutic agents 
intended to target the exact site in the multifaceted cascade 
of cytokine and chemokine effector molecules involved in UC 
pathogenesis. In particular, the introduction of the chimeric 
monoclonal antibody to TNFa has deeply affected the clinical 
treatment of moderate to severe ulcerative colitis, opening the 
door to a new era in the treatment of this disease. 
Infliximab
Infliximab is the first and most widely studied biological agent 
for ulcerative colitis.  As of 2006, Infliximab has been approved 
by the FDA for the treatment of ulcerative colitis. “This bio-
logic is a chimeric monoclonal antibody to TNFa composed 
of a “human” IgGI constant region (75%) and murine-derived 
antigen binding variable region (25%)” (Sands & Kaplan, 2007 
). Infliximab is able to bind powerfully to both soluble and 
membrane-bound TNFa receptors.  The actual mechanism of 
Infliximab is not completely understood, direct neutralization 
of TNFa does not entirely explain its effect. Infliximab has 
been found to apply a proapoptotic effect on monocytes and 
T cells in the lamina propria of the gut. The proapoptotic ef-
fect in infliximab may be exerted, preventing the production of 
granulocyte macrophage colony-stimulating factor, which is a 
growth factor that stimulates granulocyte growth and differen-
tiation and activates neutrophils with greater adhesion (Sands 
& Kaplan, 2007).  
Patients were eager to try this treatment option hoping to get 
their disease under control. A study was conducted in March 
2002 testing the safety and efficacy of Infliximab.  This study 
consisted of two large double-blind, placebo controlled trials 
known as the Active Ulcerative Colitis Trials 1 and 2 (ACT 1 
and ACT 2). Both trails were done on 364 patients with mod-
erate to severe ulcerative colitis. All participants in ACT 1 who 
were considered eligible were screened for a confirmed diag-
nosis of ulcerative colitis via biopsy and endoscopies. Eligible 
patients had active colitis with a Mayo score of 6 to 12 points 
(scores range from 0-12 with higher scores indicating more 
severe disease activity).  Additionally, eligible patients also had 
active disease on the sigmoidoscopy exam results (despite si-
multaneous treatment with steroids alone or in combination 
with immunosuppressant’s, aza or 6mp). ACT 2 allowed study 
participants who had only failed 5 ASA’s to participate. Patients 
formerly exposed to infliximab or any other anti-TNF agents 
were omitted. Patients who were eligible were randomly as-
signed to be administered intravenous infusions or infliximab 
at a dose of 5mg or 10mg per kilogram of weight or a placebo 
at weeks 0, 2, and 6 and then every 8 weeks. Patients were 
monitored through week 54 in ACT 1 and week 30 in ACT 2 
(Rutgeerts et al., 2005). 
The main end point was a clinical response at week 8. Secondary 
end points included a clinical response or remission with stop-
page of corticosteroids at week 30 in both studies and at week 
54 in ACT 1.
Of the 364 patients in ACT 1,   121 were given a placebo, 121 
received 5 mg of infliximab, and 122 to received 10 mg of inflix-
imab. Treatment was stopped early by 74 patients in the placebo 
group, 45 patients in the group receiving 5 mg of infliximab, and 
49 patients in the group getting 10 mg. Of the 364 patients in 
ACT 2, 123 were given a placebo, 121 received 5 mg of inflix-
imab, and 120 were administered 10 mg.  At week 8, in ACT 1, 
clinical remission was achieved in 69.4% of patients receiving 5 
mg of infliximab and 61.5 % of patients in the group receiving 
10 mg of infliximab. However, in the placebo group only 37.2 
percent of patients achieved clinical response. In ACT 2, at week 
8, 64.5 % of the patients in the group receiving 5 mg of infliximab 
and 69.2 % of patients receiving 10 mg of infliximab exhibited 
a clinical response, in comparison to the 29.3 % of patients in 
the placebo group.  Additionally, at the end of weeks 54 and 30 
significantly higher percentage of patients receiving Infliximab 
as opposed to the placebo went into complete remission and 
were able to discontinue the use of steroids (Rutgeers et al., 
2005).
Antibodies against Infliximab
A common concern when starting biologics is the possibility 
of a buildup of antibodies towards the drug.  One study tested 
serum samples from participants to check for a buildup of anti-
bodies to the drug. At week 54, 229 patients in ACT 1 had serum 
samples available for testing of antibody build up to Infliximab. Only 
14 patients had a positive test after the first infusion, 36 presented 
negative tests and 179 patients had inconclusive tests. In ACT 2 
from the 188 patients who had serum samples available for testing, 
12 presented a positive test for antibodies, 34 negative, and 142 in-
conclusive. Furthermore, in ACT 2 a clinical response still occurred 
in 11 patients who tested positive for antibodies.
The study further tested the safety of this drug. In both studies, 
the proportions of patients with adverse events were similar in 
the placebo group and the two Infliximab groups. In ACT 1, serious 
adverse events occurred in 25.6% of patients in the placebo group, 
21.5% of patients receiving 5 mg of Infliximab, and 23.8% percent 
of patients receiving 10 mg of infliximab. In ACT 2, the percent-
ages of serious adverse events were 19.5% in the placebo group, 
10.7% in the 5mg group, and 9.2% in the 10mg group. Based on 
these numbers, it was concluded that adverse events were more 
common in the placebo group showing that the medication was 
effective. Serious adverse events were most commonly related to 
the gastrointestinal system.
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Among adverse events in ACT 1, basal-cell carcinoma developed in 
one patient treated with 10 mg of infliximab. In ACT 2, basal-cell 
carcinoma developed in one patient who received placebo, and 
rectal adenocarcinoma developed in one patient treated with 5 
mg of infliximab. Three neurologic events occurred only in patients 
treated with infliximab. One patient in ACT 2 (receiving 5mg of 
infliximab) presented   a lupus-like reaction (Rutgeers et al.,2005).
The incidence of infections was similar among the groups in 
both studies. In ACT 1,   infections occurred in five patients in 
the placebo group, three patients in the group receiving 5 mg 
of infliximab, and eight patients in the group receiving 10 mg of 
infliximab. In ACT 2, severe infections occurred in one patient 
in the placebo group, two patients in the group receiving 5 mg 
of infliximab, and three patients in the group receiving 10 mg 
of Infliximab. In ACT 1, tuberculosis developed in one patient 
treated with 10 mg of infliximab (Rutgeers et al., 2005). 
This study proves that Infliximab is twice as likely two induce 
clinical remission in patients with moderate to severe ulcerative 
colitis in comparison to a placebo. Because the results of the 
study proved to be positive for adult patients put on Infliximab 
doctors wanted to use this drug to treat young children failing 
to respond to other medical therapy as well. Consequently, a 
study was done to test the safety and efficacy of the use of 
Remicade in pediatric patients with a moderate to severe form 
of the disease. A total of 60 pediatric patients ranging from ages 
6-17 years old who had active ulcerative colitis and had not re-
sponded to or tolerated other treatment options like immuno-
suppressants, steroids or 5ASA, were given 5 mg/ of infliximab 
at weeks 0, 2, and 6. The primary end point was response at 
week 8. At week 8, those whose responded well to the drug 
were randomly assigned to groups given Infliximab every 8 or 
12 weeks and were monitored through week 54 (Hyams et al., 
2012). 
Results
The study done proved Remicade to be highly effective in 
treating children with moderate to severe form of the disease. 
At week 8, Infliximab induced a response in 73.3% of patients. 
Additionally, 68.3% of patients achieved mucosal healing at week 
8. Those who achieved remission at week 8, were randomly as-
signed to receive Infliximab, 5mg every 8 weeks through week 
46 or every 12 weeks through week 42. At week 54, twice as 
many patients in the group that received Remicade every 8 
weeks achieved remission compared with the group that re-
ceived Remicade every 12 weeks.  Serious unfortunate events 
and infusion reactions occurred in comparable quantities in the 
8 and 12 week groups. No deaths, cancers, serious infections, 
or tuberculosis were reported in either group given Remicade. 
Infliximab was safe and effective, inducing a response at week 
8 in 73.3% of pediatric patients with moderate to severely ac-
tive ulcerative colitis who did not respond to other medical 
intervention. Those given the every 8 week infusion ended up 
with a higher clinical remission rate than those who were given 
infusion every 12 weeks (Hyams., 2012) . 
Today, Remicade is approved for children and adults. It is known 
to be one of the most effective methods of treatment for those 
suffering with an active state of the disease. Remicade is known 
to save people form undergoing a complete colectomy in addi-
tion to giving them a new lease on life. The studies above help 
strengthen this point showing how effective this biologic can be. 
Adalimumab
Another biologic on the rise is known as Humira has been ap-
proved by the FDA in 2012. Humira is a   treatment method 
for moderate to severe active ulcerative colitis in adult patients 
who have failed to respond to conventional therapy. Humira 
is a fully humanized monoclonal antibody against TNFa. Unlike 
Remicade, Humira is administered subcutaneously. Because 
Adalimumab is fairly new on the market it is still being test-
ed today. The main studies that assessed the effectiveness of 
Adalimumab in UC are the induction and maintenance trials, 
known as ULTRA 1 and ULTRA 2 (Ammuzi et al., 2013).
ULTRA 1 was an 8 week  randomized, double-blind, placebo 
controlled trial studying the use of Humira as an induction 
therapy in patients with moderate- severe UC despite the 
use of conventional therapy. In the ULTRA 1 trial 576 patients 
were randomly selected to receive either placebo or one of 
two different regimens of Adalimumab. The first regimen was 
160/80mg. patients were given 160mg at week  0 followed by 
80mg at week 2 and 40mg at weeks 4 and 6. The second regimen 
was   80/40mg. 80mg were given at week 0, 40mg were given at 
week 2, 4, 6. At the same time patients were still receiving stable 
treatment with oral corticoid steroids or immunosuppressants 
(Sandborn et al., 2013). 
The primary endpoint of the trail was clinical remission at week 
8. The patients who participated had moderately to severely 
active UC, with a Mayo score of 6–12 and simultaneous treat-
ment with at least oral corticosteroids, mercaptopurine/AZA 
or did not respond or could not endure prior corticosteroids 
or immunomodulators.
The primary endpoint of clinical remission was achieved with 
the higher dose of Adalimumab 160/80mg showing results of 
18.5% percent response and 9.2% placebo.  The amount of pa-
tients who achieved clinical remission at week 8 in the placebo 
group compared to the group receiving Humira at a regimen 
of 80/40mgand 80/40mg was a difference of point .6%. These 
96
Tzipora Glanzman
results show that Humira is much more effective when given 
to patients at a higher regimen. Additionally, Adalimumab treat-
ment was tolerated  well at both doses.  The safety profile was 
comparable to that of placebo. Ulcerative colitis was the most 
common adverse event which led to discontinuation of 4% of 
the placebo group, 3.8% of the 80/40mg group and 3.6% of the 
160/80mg group (Sandborn et al., 2013). 
ULTRA 2 was a 52 week study evaluating the efficacy of 
Humira as a maintenance therapy in UC patients. The ULTRA 
2 trial included 494 patients displaying moderate-severe ulcer-
ative colitis and failed to respond to conventional treatment. 
ULTRA 2 evaluated patients through week 52 but did not have 
an open-label phase after induction like in ULTRA 1.ULTRA 
2 included two treatment possibilities: 248 patients received 
Adalimumab 160/80mg (160 mg at week 0, 80 mg at week 2, 
and 40 mg every other week starting at week 4) and a placebo 
group consisting of 246 patients. Participants were randomly 
assigned to treatment groups. The two primary endpoints were 
remission at week 8 and 52 (Sandborn et al., 2013). 
Overall, clinical remission at week 8 was achieved in 16.5% of 
patients on Humira compared to 9.3% on placebo. The results 
for week 52 for the Adalimumab and placebo groups were 
17.3% and 8.5%. Secondary endpoints encompassed clinical 
response and mucosal healing.  The differences between adalim-
umab and placebo were substantial at weeks 8 and 52 in favor 
of adalimumab (Ammuzi et al., 2013).
A subclass analysis of ULTRA 2 evaluated the one-year main-
tenance outcomes in patients who responded to therapy with 
Adalimumab. Patients who attained clinical response at week 8 
were evaluated at week 52 to determine if they achieved several 
outcomes such as clinical remission, clinical response and muco-
sal healing. At week 8, approximately half of the Humira treated 
patients achieved clinical response. Of those, 30.9% from the 
placebo, 49.6% for the 160/80mg and 43.1% for the 80/40mg 
achieved clinical remission, clinical response and mucosal healing 
at week 52. Furthermore, of the week 8 responders who were 
dependent on corticosteroids, 21.1% achieved steroid-free re-
mission and 37.8%  were able to discontinue steroids at week 
52 (Sandborn et al., 2013).   
Aside from the ULTRA trials, there is further clinical experience 
on the use of Adalimumab for UC. Data from a study on a small 
group of 30 patients from Spain validated that Adalimumab in-
duction and maintenance therapy was effective in patients who 
previously failed other therapies including infliximab. At weeks 
4 and 12, clinical response was achieved in 16 (53%) and 18 
(60%) of patients, and clinical remission was achieved in 3(10%) 
and 8 (27%) of the patients. Adalimumab was continued in 50% 
of the patients after the 48week follow-up. Total colectomy was 
necessary in six (20%) of patients. Nevertheless, patients who 
reached clinical response at week 12 evaded colectomy over 
the long term (Denese et al., 2013). 
Adalimumab vs. Infliximab
Real-life data on the use of anti-TNF agents in UC was obtained 
from a Canadian group. This was a forthcoming study with a long-
term follow-up of 53 patients treated with either Remicade or 
Humira. Effectiveness was evaluated using physician’s worldwide 
assessment focusing on stabilization of bowel frequency, nonap-
pearance of blood with defecation and tapering of corticosteroids 
until it can be discontinued. Responses to induction therapy were 
96.4% for infliximab and 80% for Adalimumab. Responses to main-
tenance therapy were similar: infliximab 77.8% and Adalimumab 
70.0% (Denses et al.,2013).
Based on research present above, Remicade tends to produce bet-
ter results when given to patients with active disease. There haven’t 
been any studies found showing that Remicade does not induce 
remission to those experiencing moderate to severe ulcerative 
colitis. 
Administering biologics
However, due to the way the two biologics are administered may 
be enough of a reason for a patient to prefer one over the other. 
Remicade is administered as a 2-hour IV infusion so that it goes 
right into the bloodstream and starts to work. Doctors will nor-
mally give a patient 5mg per infusion. Some adult patients who at 
first respond to treatment or completely fail to respond to 5mg/kg 
may do well if their dose is increased to 10mg/kg.  Remicade is first 
given at weeks 0, 2, and 6.  Patients will then stay on maintenance 
therapy, which is every 8 weeks, which could be as few as 6times 
per year (REMICADE.com, 2014).  
Humira, on the other hand, is given via self-injection under the 
skin, typically every other week (after the initial starting doses). 
Humira needs to be kept in a refrigerator in its original bottle and 
protected from light until it’s ready to be used. The recommended 
dose regimen for adult patients taking Humira is 160 mg initially on 
Day 1 (given as four 40 mg injections in one day or as two 40 mg 
injections per day for two sequential days), followed by 80 mg two 
weeks later. When this is completed patients continue two weeks 
later with a dose of 40 mg every other week (HUMIRA.com, 2013).
Possible side effects
As always, all drugs come along with side effects. The usual side 
effects of biologics are nausea, headaches and fatigue. However, 
with time these side effects usually subside. More serious side ef-
fects have been experienced by patients especially those 65 years 
and older. Patients have had serious infections caused by viruses, 
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fungi or bacteria that have spread all through the body, including 
tuberculosis (TB) and histoplasmosis. Some of these infections 
have been deadly. Rare cancers have been reported in children and 
teenage patients taking TNF-blocker medicines. T-cell lymphoma, an 
uncommon form of deadly lymphoma, has transpired typically in 
teenage or young adult males with ulcerative colitis who were tak-
ing Remicade or Humira. (REMICADE.com, 2014; HUMIRA.com, 
2013). To help prevent serious side effects, patients are required to 
go for blood work initially every other week and then monthly in 
order to monitor their blood count. Though the side effects listed 
above are scary, a patient needs to weigh the benefits and the risks 
together. Prolonged, untreated inflammation is the number one 
cause of colon cancer a number one leading death in the United 
States today.
Immunosuppressants + Biologics
Seeing the results biologics produce on their own, doctors ques-
tioned if combining immunosuppressants with biologics to treat 
patients would have an even greater outcome than just using bio-
logics alone. Their thought process was as follows; the job of im-
munosuppressants is to stop the production of white blood cells 
by interfering with transcribing DNA and preventing the division 
and multiplying of many more white blood cells. Biologics on the 
other hand, are geared to stop an inflammatory response by bind-
ing with TNFa. Therefore, it was thought by combining these two 
drugs the likelihood of the patient achieving a remission is two 
times more likely than just treating them with one drug. 
Initial data is available from a UC study that had a similar de-
sign to SONIC (which was a study designed to test the same 
combination in Crohn’s patients) (Colombel et al., 2012).  The 
study included 239 patients with moderate-severe UC who 
were unexperienced to biologics, were failing corticosteroids 
and were either unexperienced to AZA or had stopped AZA 
three months before entering the study. Patients were randomly 
assigned to receive AZA 2.5 mg/kg, infliximab 5 mg/kg or inflix-
imab 5 mg/kg plus AZA 2.5 mg/kg for 16 weeks. The primary 
endpoint was steroid-free remission at week 16 and secondary 
endpoints included response and mucosal healing both at week 
16.  Preliminary results showed that the primary endpoint was 
achieved in the infliximab plus AZA group compared with the 
AZA alone. Additionally, infliximab plus AZA was greater to 
AZA or infliximab monotherapy in inducing steroid-free remis-
sion in patients. Patients treated with an infliximab plan of action 
were more likely to achieve response and mucosal healing than 
those treated with AZA monotherapy.  What does this study 
mean for anti-TNF therapy moving forward? It is tough to make 
any precise conclusions and more data is needed. Nonetheless, 
the limited data (only from infliximab experience) point that an-
ti-TNF therapy in combination with immunosuppressants may 
be more effective in early UC compared with monotherapy at 
16 weeks. Though remission is achieved in a greater percentage 
when the two classes of drugs are combined, it is not recom-
mended to combine the two because of increased risk of side 
effects (Denese et al., 2013). 
Conclusion
Recent advancement in bio-technology have thankfully led to 
the development of a large array of new therapeutic agents 
intended to target the exact site in the multifaceted cascade 
of cytokine and chemokine effector molecules involved in UC 
pathogenesis. In particular, the introduction of the chimeric 
monoclonal antibody to TNFa has deeply affected the clinical 
treatment of moderate to severe ulcerative colitis, opening the 
door to a new era in the treatment of this disease. Studies dis-
cussed in this paper show the effectiveness of both Remicade 
and Humira given to patients with an active state of this dis-
ease. Additionally, doctors tested the possibility of combining 
a biologic with an immunosupressent. Though remission nearly 
doubled, side effects were likely to double as well. Therefore, 
doctors are not pushing the combination of the two drugs un-
less there is no other option. 
With the recent introduction to biologics, patients suffering 
with ulcerative colitis in an unmanageable state are able to 
try a new treatment option with the hope of avoiding surgery. 
Remicade and Humira have both been proven to put patients 
with an active state of the disease into full remission.
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Introduction
Autism Spectrum Disorder (ASD) is a neurological impairment 
where the child has a problem interacting with others, has trou-
ble communicating verbally and non-verbally, and exhibits odd 
behaviors such as repeating certain actions over and over again 
and acting out if something does not go according to routine 
(Block et. al., 2006).  A child with ASD will have trouble making 
eye contact with those interacting with him and will be unable 
to understand what others are thinking or feeling because they 
have trouble picking up on social cues (“What is Autism”, 2009) 
ASD is predicted to occur in three to six children for every 
1000 who are born.  It is 5 times more likely for a male to get 
autism than a female, however if a female does have autism her 
symptoms are more severe.  Autism Spectrum Disorder is cat-
egorized as a pervasive developmental disorder because there 
are many different symptoms and behaviors for people with 
autism.  Someone who has severe symptoms of autism can be 
placed on one end of the spectrum, while someone with a mild-
er case can be on the opposite end of the spectrum.  Different 
forms of ASD include Rett’s disorder, childhood disintegrative 
disorder, and Asperger’s syndrome. (Block et. al., 2006).
Methods
The information that was collected for this research paper was 
obtained through Proquest, Ebsco, Pubmed, and the NIH web-
site.  These resources were provided from the Touro College 
Library.  Key words included autism, ASD, vaccinations, genetics, 
and environmental factors.
Discussion: Diagnosing Autism
There is no specific test done to determine if a child has ASD 
because the symptoms and behaviors are so broad and can vary 
significantly between each child.  Although children can start 
showing symptoms between 15-18 months of age, the aver-
age age of diagnosing is four to five years old.  Diagnosis for 
ASD should be done by gathering developmental history of 
the child, and by direct observation of the behaviors of the 
child.  There should be a team of different professionals who 
can assess symptoms and behaviors of the child.  The team 
should include a pediatrician, a child psychiatrist, and a speech 
and language therapist, and a child psychologist.  Behavior of 
the child should be observed in different settings such as in 
his home and in his school.  The team should be looking for 
different behaviors that are prevalent in children with ASD. 
Prognosis of each case is done on an individual basis because 
the behaviors of the child can vary greatly, and the behaviors 
can even change over time.  Some people with autism can lead 
productive lives, such as those with high functioning Asperger’s 
syndrome, while others will need assistance all through their 
lives (Yates et. al., 2013). 
MMR Vaccine and Autism
There has been much talk over the years about a possible 
link between the Mumps, Measles and Rubella (MMR) vaccine 
and autism.  The supposed link caused major panic because 
vaccines are needed to prevent, in this case, mumps measles 
and rubella from spreading.  Vaccines were a vital discovery 
which prevented many infectious diseases from recurring over 
and over again around the world.  
The link between the vaccine and autism was introduced by 
Andrew Wakefield in 1998 (cited in Richards, 2011), when 
he conducted an experiment using twelve children to prove 
the link.  It came out later, while his experiment was under 
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investigation, that he altered many of the details of the chil-
dren’s previous symptoms and behaviors. Therefore his study 
had no scientific basis to prove a link.  Many studies have been 
done since then to disprove the supposed link between the 
MMR vaccine and autism (Richards, 2011).
One reason why people may think there is a link between 
the MMR vaccine and ASD is because children start show-
ing signs of autism right around the time that they get the 
vaccine.  The explanation for this is that the vaccine is given 
to children only after they are a year old, which is when 
children start showing symptoms and unusual behavior.  Just 
because these events happen around the same time does not 
mean that there is any basis for a connection.  Many studies 
were done to try to prove a link between the vaccine and 
autism but none of them have been successful (‘Autism and 
the MMR Vaccine’, 2001).
Investigations done to disprove the link
In 2000, the Institute of Medicine at the National Academy of 
Science, under the request of the CDC and NIH conducted 
a review of all the evidence linking the MMR vaccine to ASD. 
They took under consideration all the studies and conclud-
ed that the evidence did not support an association between 
the vaccine and autism.  Furthermore in 2000, the American 
Academy of Pediatrics held a conference to review the infor-
mation and found no evidence in support of a linkage (‘Autism 
and the MMR Vaccine’, 2001).  
In 1999, Taylor and colleagues published a study to determine 
a connection between the MMR vaccine and autism (‘Autism 
and the MMR Vaccine’, 2001). He took all the known cases of 
ASD in children living in certain districts in London who were 
born in 1979 or later and matched the ASD patients with an 
independent registry of vaccinations.  His results were: 1. the 
number of ASD cases had increased steadily since 1979 but 
there was no steep incline in cases after doctors started using 
the MMR vaccine.  2. Children showed symptoms and were 
diagnosed with ASD all at around the same age, regardless if 
they got the vaccine before or after 18 months of age.  This 
is important because if the children were vaccinated they 
would have shown signs of ASD earlier than those children 
who were not vaccinated.  3.  Lastly, by age two the number 
of children who got the vaccine and showed signs for ASD 
was almost the same amount as children who got the vaccine 
but did not show any symptoms.  If there was a connection 
between the MMR vaccine and autism more children should 
have shown symptoms for ASD (NICHD, 2001).  Although the 
MMR vaccine was a popular theory concerning the causes of 
autism, many later studies failed to show a connection.  This 
still remains controversial and continues to be studied. 
Genetic factors that may cause ASD
possible genetic mutations that cause autism
Another possible cause of autism is genetic mutations in the 
genome of the affected person.  Mutations in genes that are 
responsible for encoding proteins which are involved in molec-
ular machinery regulating synaptic protein synthesis is strongly 
connected to autism.  Autism possibly can be caused due to 
mutations known as Fragile X Syndrome and tuberous sclerosis 
(TS).  Both of these syndromes are caused by abnormal mRNA 
translation, resulting in excess protein synthesis. 
Fragile X Syndrome (FXS) is caused by an unstable expansion of 
the CGG repeat in the FMR1 gene.  The prevalence of autism in 
the FXS mutation is 30%.  This gene mutation causes abnormal 
methylation production, FMR1 transcription silencing, and de-
creased FMRP protein levels in the brain.  ASD in FXS is mainly 
characterized by deficits in peer interaction.  Tuberous sclerosis 
is an autosomal dominant disease that is caused by a mutation on 
either the TSC1 or TSC2 gene.  Clinical manifestations of tuberous 
sclerosis included epilepsy, learning difficulties, and behavioral prob-
lems.  There are a variety of mutations that cause tuberous sclero-
sis including nonsense, missense, insertion, and deletion mutations. 
Autism is significantly more frequent among TS patients than in the 
general population.  Because there is a large phenotypic variability 
in FXS and TS with patients who have autism, research is being 
done to make a clear correlation (Perisco et. al., 2013).
Using Whole-Exome Sequencing (WES) to 
determine possible genetic links to ASD
Whole-Exome Sequencing (WES) is a technique which captures 
and sequences the exons in the genome to reveal all de novo 
and low frequenting alleles that contribute to genetic risk for dis-
ease.  This method is cheaper than Whole-Genome Sequencing, 
because instead of searching through the entire genome, it only 
goes through the exons in the genome, which only takes up 2-3% 
of the genome.  This technique is better than the previously used 
technique of Genome Wide Association Studies (GWAS) be-
cause GWAS only reveals risk factors that are common in the 
population (Icahn School of Medicine, 2012).  WES is particularly 
good for finding the cause of ASD because ASD can be caused 
from different genes in many different locations with a weak gen-
otype and phenotype correlation (Perisco et. al., 2013).
A study was done applying WES on families where the spouses 
were related and on families where cousins shared the same 
disease.  This way it is easier to identify specific mutations that 
cause ASD.  The mutations that were identified on the genes 
were hypomorphic mutations, meaning that the altered gene 
product has a reduced level of activity, which can explain the 
wide spectrum of ASD.  This analysis was done on three families. 
In this paper the first family will be discussed.
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The first family had three children with ASD and two unaffected 
children.  The parents were first cousins.  WES was performed 
and it showed a single linkage peak in a large homozygous in-
terval, and suggested a 900:1 likelihood that the responsible mu-
tation was found in this homozygous interval.  Then WES was 
performed on one of the affected children.  The linked interval 
showed only a single rare change that was absent in the known 
databases and population matched controls. 
This mutation was on a gene that is responsible for the produc-
tion of the enzyme AMT, aminomethyltransferase.  This enzyme 
is needed for the breakdown of glycine.  Sanger Validation con-
firmed that the mutation was heterozygous in both parents, ho-
mozygous in the affected children, and absent or heterozygous in 
the unaffected children. 
Mutations in AMT cause nonketotic hyperglycemia (NKH), which 
is a neonatal syndrome that causes lethargy, hypotonia, several 
seizures and death within the first year.  Rarer, atypical forms of 
NKH have been described in association with hypomorphic mis-
sense AMT mutations.  This manifests at a later age and causes 
delay in expressive language, behavioral problems and seizures. 
While individually non diagnostic, when all three children were 
tested they exhibited a range of neurological symptoms that 
were strongly suggestive of NKH (Yu et. al., 2013).
The amygdala theory of autism
There is a network of neural regions that comprise the “social 
brain”: the orbit-frontal cortex, the superior frontal sulcus, and 
the amygdala.  This region of the brain is responsible for social 
intelligence, a quality which ASD patients are known to be lack-
ing.  The Neuroscience and Behavioral Reviews has come up 
with The Amygdala Theory of Autism, where they hypothesize 
that patients with ASD have an amygdala deficit which causes 
the deficit in social skills.  
An experiment was done on rhesus monkeys which showed 
that ibotenic acid lesions of the amygdala affect the social be-
havior of the monkeys and they also became socially isolated. 
When the amygdala-lesioned monkeys were sent into the wild, 
they were unresponsive to group members, failed to display ap-
propriate social signals and they withdrew from other animals. 
When another study was done, where lesions were made to the 
monkeys’ anterior temporal lobe, which included the amygdala, 
the monkeys showed specific symptoms, for example they had a 
tendency to overreact to all objects, they were hyperemotional, 
they had a loss of fear, and they started to investigate objects 
with their mouth instead of their hands. 
Then a study conducted with humans was done.  They used 
single photon emission computed tomography that showed that 
patients with ASD show significant reductions in the temporal 
lobe blood flow.  The study was done in fuller depth where an 
fMRI (functional MRI) was done on adults with ASD that showed 
significantly less amygdala activation during a mentalizing task 
called “Judging the Mind in the Eye” task.  In this experiment, six 
people with autism were matched for mean age, handedness, IQ, 
socioeconomic status and educational level with twelve people 
in the normal group.  
In the fMRI scanner a blocked periodic ABA design was used. 
There were two tasks.  The first task, Task A, was supposed to 
induce periodic MR signal changes, with signal maximum in brain 
regions relatively specialized from gender recognition from fa-
cial stimuli.  In this task, the subjects were visually presented 
with pictures of eyes and were asked to indicate by right button 
pressing if the picture was a male or female.  
The second task, Task B, was checking the periodic MR signal 
change with signal maximum in brain regions relatively special-
ized in mental state recognition from facial stimuli.  In this task, a 
response involved choosing between two words that described 
the mental state of the photographed person.
The key difference between the two tasks was seeing the sub-
ject’s judgement between the two pictures.  Social intelligence is 
about picking up social cues, such as the expression of people’s 
faces to understand what the person is thinking.
The subjects who had ASD had a hard time doing task B.  The 
fMRI data was analyzed in two stages.  First, generic brain ac-
tivation maps were constructed separately for the control 
and autistic groups.  By doing so, they were able to determine 
which voxels were activated in each group by each of the two 
tasks.  Secondly, ANOVA was used to determine the voxels that 
demonstrated a significant difference between groups in mean 
power of response to each task.
The autistic group activated the frontal components less ex-
tensively than the control group, and they did not activate the 
amygdala at all.  The control group demonstrated significantly 
greater power of response in their bilateral superior temporal 
gyrus.  The autistic group seems not to use the amygdala for the 
task, and compensated by using a greater processing load on 
temporal lobe structures, which specializes in verbally labeling 
complex visual stimuli.  This may be because of compensation 
for an amygdala abnormality (Baron-Cohen et. al., 2000).
Maternal diabetes and autism
A study was done to investigate if Gestational Diabetes Mellitus 
(GDM) in the mother may result in the child having ASD. 
Specifically, researchers were determining if the timing of when 
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the mother developed GDM had any significance whether the 
child would develop ASD.  
This study included children who were born at 28-44 weeks 
gestation.  Women who had type 1 diabetes and congenital 
anomalies were excluded from the study.  The primary variable 
was maternal type 2 diabetes or maternal GDM during preg-
nancy.  Exposures were broken up into three categories- 1. No 
exposure to maternal diabetes, 2. Exposure to maternal type 2 
diabetes, and 3. Exposure to maternal GDM.  Other variables 
that were included were maternal age at delivery, education, 
self-reported maternal race/ethnicity, and the gender of the 
child.  For the GDM exposed group, the different methods that 
were used to diagnose were also recorded.  The gestational 
weeks were also split up into three categories- 1. Diagnosed 
26 weeks or earlier, 2. Diagnosed after 26 weeks but before 30 
weeks, 3. Diagnosed at 30 weeks or later.  
The primary data analysis was collected from 322,323 chil-
dren.  The children were checked up on approximately five 
and a half years after birth.  During this time, 3,388 children 
were diagnosed with ASD.  A large amount of mothers who 
got GDM during the first 26 weeks of pregnancy gave birth 
to a child with ASD.  It is also interesting to note that among 
the children who had ASD, 121 of them had older siblings who 
also had ASD.
To summarize, mothers with pre-existing type 2 diabetes were 
not significantly associated with risk of ASD, but mothers who 
got GDM earlier than 26 weeks of pregnancy were significantly 
associated with risk of ASD (Xiang et. al., 2015).
De Novo Mutations
De novo mutation is an alteration of a gene that was present for 
the first time in one family member as a result of a mutation in a 
germ cell (egg or sperm) of one of the parents or in the fertilized 
egg itself (Genetics Home Reference, 2015).  De novo mutations 
are important in finding the cause of ASD.  
Studies show that the majority of de novo mutations do not 
cause the disease, they only increase the risk of getting the dis-
ease.  There may be several genes in which a high risk of de novo 
mutations can occur from.  Through these studies many de novo 
mutations were found that predicted that these mutations would 
disrupt the gene function in a child with ASD, however these mu-
tation are not necessarily what causes the disease.  Two studies 
also found that de novo mutations are caused from the paternal 
side and are age dependent.  There is a detectable increase in au-
tism risk with children who were born to older fathers (Perisco 
et. al., 2013). 
Advancing parental age and autism
There are a number of studies which are trying to determine if 
the age at which the parents conceived the child increases the 
risk of the child being born with ASD.  Whole-Exome Sequencing 
links older fathers to de novo mutations and increased risk of 
having a child with ASD.  The linkage of older mothers having a 
child with ASD follows different pathways.
Prevalence of ASD has increased from 5 cases per 10,000 peo-
ple in the 1980’s to the latest CDC’s estimate of 1 case in every 
68 people.  This may be due to a variety of reasons, including 
changes in diagnostic practice, heightened awareness, or even 
an actual increase in the disorder.  One factor that might cause 
ASD is parental age, since there is a tendency in recent years for 
people to become parents later in life.  In Spain and England the 
proportion of mothers who had children after 35 years old in 
1980 was 14% and 25% respectively.  In 2007, the proportion of 
mothers who had children after 35 years old increased to 25% 
and 40% respectively.  
There are more than forty studies being done trying to link age 
of parents when they had kids to ASD.  While individual studies 
are not consistent with their findings, this can be because of a 
number of factors.  The discrepancies can be caused by incon-
sistent sample sizes and characteristics, or missing data.  The 
studies did conclude an increased risk of ASD from both older 
parents, an older father but not older mother, and older mother 
but not older father, and neither an old mother or old father. 
Inconsistencies could have also been affected by the fact that 
these studies did not take into account socioeconomic status 
of the families or co-parental age.
The general consensus is that advancing paternal age (APA) and 
advancing maternal age (AMA) are independent factors that can 
increase the risk of having children with ASD.
In 2012 meta-analysis focused on advancing maternal age and a 
link to autism, using data from over 25,000 ASD patients, and 
eight million controls aggregated from 10 studies.  The results 
were that mothers who were 35 years or older when they had 
the child had a 1.5 fold increased likelihood of having a child with 
ASD compared to mothers who had children at 25-29 years of 
age.  In 2010, a study was done to test the theory of advancing 
paternal age and its link to autism.  Meta-analysis was done on 
eleven studies and found that fathers who were 40-49 years old 
when they had children, had a 1.8 fold increased likelihood of 
having a child with ASD, compared to fathers who were 29 years 
old or younger.
APA effects on ASD
At this point the question is how APA and AMA are associated 
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with a child being born with ASD.  One possibility of why age 
affects ASD is age- related mutagenesis in the male germ cell. 
While a female germ cell undergoes 22 mitotic cell divisions in 
utero, male germ cells undergo 30 mitotic cell divisions in em-
bryogenesis, and then divide every 16 days from puberty and on. 
Because the male germ cell undergoes many more cell divisions 
during his reproductive age, there is more of a possibility of gene 
copying errors, which can lead to de novo mutations in the male’s 
child, which can cause ASD.
Multiple studies that are using Whole-Exome or Genome 
Sequencing found that higher numbers of de novo loss-of-
function single nucleotide variants are seen in fathers of in-
creasing age.  While it is fine for a new born to have between 
30-100 de novo point mutations, there is an increase of about 
one to two mutations for each increasing year of a father’s 
age.  If the mother is also older, it increases the likelihood of 
more de novo mutations, because AMA and APA can be linked 
together.
Two studies were conducted to disentangle APA effects from 
AMA effects on the child.  The studies used multiple regression 
which was adjusted so that both parental ages were entered 
as predicators.  It was found that APA remained a significant 
predicator in de novo mutations while AMA effects were neg-
ligible.  Two thousand, five hundred families who had one child 
with ASD were analyzed and found that a majority of the de 
novo mutations originated from the father.  It should be point-
ed out that although de novo mutations can affect any biolog-
ical system, there is reason to believe that de novo mutations 
differentially impact brain development because the brain may 
have fewer redundancy mechanisms that are needed to inhibit 
mutations (Lee et. al., 2015).
They hypothesized that if mutations in germ cells result in a 
slightly faster rate of cell division, then cells with these mu-
tations will expand within the testes and logically they will 
contribute to the larger proportion of sperm.  This process is 
known as “selfish spermatogonial selection”.  This mechanism 
can favor the propagation of germ cells which are carrying mu-
tations that prefer to impact certain cellular signal pathways. 
(Lee et. al., 2015).
AMA effects on ASD
One possible correlation between AMA and ASD would be 
assisted reproductive technologies which are used by couples 
more commonly with increasing age.  A Swedish study was 
done which involved 2.5 million infants.  The results were that 
in vitro fertilization procedures had no association with risk 
of ASD, while a specific procedure called “Intracytoplasmic 
Sperm Injection (ICSI)” has a slightly increased risk of having 
children with ASD.  ICSI is done when there is paternal infer-
tility.  The reason why ICSI can increase risk of ASD is because 
the injection process can damage the egg which can increase 
the risk of adverse outcomes.
Another possible correlation can be the fact that a person 
accumulates more and more environmental toxins with in-
creasing age.  Environmental factors such as pesticides, heavy 
metal, and organic pollutions have been linked with increased 
risk of ASD.  Human brain samples were examined and found 
that exposure to polychlorinated biphenyl 95 strongly predict-
ed maternal 15q11-q13 duplication, which is one of the most 
common CNV findings in ASD cases (Lee et. al., 2015).
Other factors that effect advancing parental age 
and autism
A study was done using 1,251 ASD cases occurring in over 
250,000 births throughout the United States.  This study found 
a connection between parental age and birth order with in-
creasing risk of ASD.  Younger parents (mother younger than 
35, father younger than 40), on their first birth, had a 1.7 fold 
increased odds of having a child with ASD compared to other 
young parents on their third birth and later.  Regardless of the 
age of the parents, the risk of ASD is increased in first born 
children.  Older parents (mother older than 35, father older 
than 40) on their third child or later had a 1.8 fold increase 
on the likelihood of having a child with ASD.  Older parents on 
their first child had a 3.1 fold increase on the odds of having a 
child with ASD.  To conclude, the effect of parental age on ASD 
is amplified if it is their first birth (Lee et. al., 2015).
Environmental chemical exposures and autism 
spectrum disorder
Autism can be caused by a mixture of genetic and environ-
mental influences, and studies are being done to understand 
the interplay of both contributions.  These contributions can 
be different from one person to the next.  A study in Sweden 
was done which included 14,000 children with autism.  The 
study showed that heritability contributed to 50% of a possi-
ble cause of autism while environmental factors contributed 
an equally strong role.  Genetic and environmental factors may 
work together to disrupt the normal process of nervous sys-
tem development, interfering with neuron formation and mi-
gration, synapse formation, or neurological connectivity which 
can cause ASD.
In this study, the chemical exposures that were included are 
ones that can be reduced in exposure, which opens up possibil-
ity for prevention of autism.  Of course it can only be reduced 
because not all exposure can be controlled, such as air pollution 
and any toxic chemical that are unknown to the patients. 
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Maternal smoking in pregnancy and ASD 
diagnosis
Seven studies were included which were done in the United 
States, Canada, Sweden, Norway, Finland, and England/Whales. 
These studies showed no association between maternal smok-
ing during pregnancy and ASD diagnosis.  Some of the studies 
focused on the spectrum of autism.  There was an elevation in 
two of the studies between maternal smoking during pregnan-
cy and higher functioning autism, such as Asperger’s syndrome, 
compared to lower functioning autism.  Overall, there is no 
conclusive evidence that maternal smoking or tobacco expo-
sure to a fetus has any effect on a child being born with autism 
(Kalkbrenner et. al., 2014).
Regulated and traffic related air pollutants 
exposure and ASD
Air pollutants include hundreds of chemicals which can be 
categorized into three categories: 1. Point pollutants arising 
from spatially separated large buildings, for example factories 
and power plants. 2. Area pollutants associated with popu-
lation density, for example gas stations and dry cleaners. 3. 
Mobile pollutants associated with vehicles.  In this paper we 
will be discussing the third category.  When these pollutants 
enter the atmosphere they undergo reactions that create new 
pollutants.  Specific chemicals that arise from traffic that will 
be discussed here are particulate matter (PM), NO2; nitrogen 
dioxide, and O3; ozone.  
Air pollutants enter the body through inhalation and direct 
transportation from the nose to the brain via the olfactory 
bulb.  Some chemical pollutants are known to induce oxida-
tive stress and cause a systemic inflammatory reaction, which 
can alter normal neurodevelopment.  Fetuses itself can come 
in contact with chemicals from air pollutants or they can be 
exposed to them from the elevated levels of inflammatory cy-
tokines in the maternal circulation.  
Seven studies were done in the United States with adequate 
sample sizes ranging from 284 to 7,594 children with autism. 
The studies also had controls under consideration such as ma-
ternal age and the parent’s level of education.  Season of birth 
is also important to take under consideration because occur-
rence of autism varies by season of conception for unknown 
reasons.  It is also important because certain air pollutants 
have a stronger concentration in some seasons over other 
season, such as influenza infection and vitamin D levels.
Results for this study concluded that exposure to pollutants 
such as PM2.5, PM10, and NO2, were associated with the risk 
of getting autism.  For almost every pollutant in every study, as-
sociations were stronger for exposures in the third trimester 
of pregnancy and the first year of life compared to earlier 
on in the pregnancy.  All of these studies estimated exposure 
to outside levels of these air pollutants using historical data 
that could be related geographically to the home residence 
of the pregnant woman or infant, because retroactive direct 
person-based air sampling was not possible (Kalkbrenner et 
al 2014).
Metal (Ethylmercury) from vaccinations  
and ASD
Connecting this discussion back to vaccinations, thimerosal 
was thought to be a toxic compound that increased the risk 
of autism.  Thimerosal is a vaccine preservative that contains 
ethylmercury which is considered a less toxic form of mercury 
compared to methylmercury. 
 Although the Institute of Medicine already stated that there 
is no concrete evidence that the MMR vaccine causes autism, 
people are still skeptical.  No one suspected thimerosal to be 
toxic, seeing as it was found in such small doses in vaccines. 
In the 1970’s it was known that large doses of mercury were 
harmful.  It was only in the late 1990’s that scientists suggested 
that even relatively low exposure to organic mercury could be 
dangerous to fetuses and young infants (Baker, 2008).  The U.S. 
Food and Drug Administration suggested removing thimerosal 
from vaccines in 2001, because of the biological plausibility that 
thimerosal may pose as a neurotoxic harm.  However, trace 
amounts of thimerosal are present in influenza vaccines which 
infants and pregnant women may be exposed to.  Six studies 
were included, testing for a link between thimerosal-containing 
vaccines and autism.  The results of the studies suggested that 
there is no connection between thimerosal and increased risk 
of autism (Kalkbrenner et. al., 2014).
Conclusion
The causes of autism are still vague.  Because it is characterized 
as a spectrum disorder there can be many different variables 
that can play a role in causing different levels of it.  The theo-
ry that vaccinations cause autism has become a popular idea, 
therefore much research has been done to make a correct con-
clusion.  Until the causes of autism are confirmed research is 
still being done to see what role vaccinations have on autism, 
however the research that has been done until now has con-
cluded that vaccinations do not have a link to ASD.  Another 
highly researched cause of autism is a genetic cause, be it a 
genetic mutation or a number of other different genetic vari-
ables.  In this paper the idea that different genetic mutations 
that can cause autism has been discussed, and while some stud-
ies have brought optimistic results, further studies have to be 
conducted.  Other genetic factors that have been discussed are 
the effect of maternal diabetes on the fetus, and parental age 
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when the child was conceived.  While further research is need-
ed to confirm these factors, the studies that have been done 
have given additional insight into what causes autism.  Another 
possible cause for ASD that was discussed was a mixture of 
genetic and environmental factors that the child was exposed 
to either as a fetus or as an infant.  While some environmental 
factors that have been tested had no correlation to ASD, other 
environmental factors did show a correlation, although more 
research is required.  
Many studies are constantly being done, and researchers are 
discovering more factors that might be a cause for ASD.  The 
closer they come to finding a cause, the closer they get to trying 
to find a way to prevent autism from becoming more prevalent, 
and maybe even closer to finding a possible cure for Autism 
Spectrum Disorder.
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Introduction
Modern views on the experience of hypnosis are largely domi-
nated by the belief that the ‘‘hypnotist’’ possesses the ability to 
generate a  ‘‘sleep-like state’’ within the individual being hypno-
tized. It is then presumed that the hypnotist possesses a super-
natural control over the person’s mind, causing him to behave in 
an irrational manner. In actuality, hypnosis is a highly complicated 
component of neuroscience related to the intrinsic workings of 
the human brain. Neurobiologically, the induction of a hypnotic 
trance can be viewed as an alternate state of consciousness due 
to the modulation of brain activity critically related to areas in the 
brain that oversee the regulation of the conscious state of being 
(Kihlstrom, 2013). Hypnosis is also characterized as an increase 
in mental relaxation and mental absorption mainly related to 
changes in the anterior cingulate cortex (ACC), various areas of 
the prefrontal cortex and frontal lobes, cortical and sub-cortical 
areas, the ponto-mesencephalic brainstem, and changes of region-
al cerebral blood flow (rCBF) in these areas (Rainville et al., 2002). 
Contemporary scientific theories of hypnosis emphasize changes 
in the engagement or disengagement of specific neurocognitive 
processes, and their effect on performance and psychophysiolog-
ical activity such as executive control and attention. Additionally, 
there are individual psychological characteristics, partially relat-
ing to genetic brain structure, predicting hypnotic susceptibility. 
Moreover, scientific experiments have proven that hypnosis can 
be effective as an analgesic. Hypnosis can reduce acute pain as-
sociated with invasive medical procedures, burn care pain, labor 
pain, as well as reduce chemotherapy side affects. Hypnosis can 
also decrease chronic pain such headaches, backaches, and fibro-
myalgia. The study of hypnosis and its clinical applications is an 
ever-evolving field that can greatly advance the understanding of 
the conscious versus the subconscious mind and the complex 
structure of the human brain.
History of Hypnosis
In the 1770’s Anton Mesmer wrote his doctoral thesis titled: ‘De 
influxu planetarum in corpus humanum’ (On the Influence of the 
Planets on the Human Body), in which he revisited the ancient 
belief that the solar system emits invisible rays that affect our 
bodies. Mesmer called this idea the “animal magnetism” effect. 
He practiced his healing through animal magnetism, capturing 
the “magnetic fluid” through pieces of iron and conductive met-
als that he fixed upon the diseased areas on the patients´ bodies. 
He concluded that one could attain “magnetic” effects through 
the laying of hands, or even simply by speaking to the patient. 
His teaching became known as mesmerism. This theory was ac-
cepted until the mid-1800’s.  James Braid disproved this idea of 
mesmerism in 1840 (Gauld, 1992). Braid demonstrated, through 
various experiments, that hypnosis was nothing more than a 
fixation of attention rather than an occult shadow of mesmer-
ism. Braid concluded that there is a biological and physical basis 
to what was previously known as “mesmerism”, and coined the 
term “hypnosis”, which comes from the Greek word “Hypnos”, 
which means sleep (due to the trance-like state of the sub-
ject). Subsequently, many famous psychologists such as Milton 
Erickson, who introduced the Neuro-Linguistic Programming 
via hypnosis, used hypnosis to cure clients of psychological ail-
ments (Gauld, 1992). The trance-like state of hypnosis is now 
known to be a reflection of biological circuitry and a form of 
focused attention as proposed by Braid. The future of hypnosis 
will be to uncover fully all the underlying neurological compo-
nents of hypnosis and discover its many clinical applications.
Materials and Methods
In researching the neurological underpinnings of hypnosis and 
its clinical advantages, many articles and journals were compiled 
to properly explore and present this topic. References were 
obtained through PubMed, and Touro College’s Database, in ad-
dition to Google scholar and EBSCO multisearch. Key words, 
such as; hypnosis, hypnotic susceptibility, clinical benefits of 
hypnosis, and hypnotic analgesia were used to find pertaining 
articles that are cited throughout this paper.
Contemporary rendition of hypnosis
Succeeding the Braidian definition of hypnosis, research-
ers argued regarding the exact definition of hypnosis and its 
causes. Hypnosis refers to a change in mental activity follow-
ing an induction, which usually results in increased attention, 
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dissociation, and an increased absorption in pertaining stimuli 
(Spiegel, 2007). Typical hypnosis includes alterations in sensory 
experiences, motor control, and even amnesia. During a hyp-
notic induction, specific neural synaptic circuits are activated to 
express one’s character, and personality in relation with his/her 
character traits specifically portrayed during hypnosis. Herbert 
Spiegel (2007), an American psychiatrist who popularized hyp-
nosis as a treatment for pain and other disorders, identified 
three characteristics of hypnotized individuals:
1. Dissociation is the conscious versus unconscious separation 
of memory, perception, and motor response from one’s main 
awareness. The capacity to dissociate is biologically deter-
mined and is reflected in the Eye Roll (ER) movements con-
trolled by the external ocular muscles (as explained below). 
2. Absorption is the decrease in peripheral awareness to facili-
tate greater focal attention. The intensity and duration of this 
absorption is influenced by bio-psychological components 
of intelligence and motivation. Absorption is diminished by 
attention deficit disorders, impaired concentration, and some 
medications. 
3. Suggestibility is characterized by how prone an individual is 
to accept new information as fact with a relative suspension 
of critical judgment. 
Rainville et al. (2002) described hypnosis as a state of mental 
relaxation and mental absorption, which are both associated 
with the instructions used to induce a hypnotic state. Hypnotic 
relaxation results from the direct instruction to relax prior 
to a hypnotic induction, which leads to positive bodily feeling, 
drowsiness and mental ease. Mental absorption, otherwise 
known as fixed attention, as  “total attention that fully engages 
one’s representational resources and results in imperviousness 
to distracting events” (Rainville et al., 2002).
Individuals who were hypnotized reported having been in an al-
tered state of consciousness, describing this state as an increase 
in mental relaxation, automatic response, slight disorientation 
of time, increased imagery, focused attention, dissociation of ir-
relevant stimuli, and a disorientation toward their sense of self 
(Oakley and Halligan, 2009).
Hypnosis susceptibility
Hypnotic susceptibility is unique to each individual. Some peo-
ple are easily hypnotizable while others are virtually unaffected 
by hypnotic induction. Hypnotic suggestibility scales are the pri-
mary way to measure hypnotic susceptibility. Two such scales 
include the Stanford Hypnotic Susceptibility Scale (SHSS) and 
the Harvard Group Scale of Hypnotic Susceptibility (HGSHS). 
These tests are constructed for standardized group adminis-
tration and are scored by self-report. They consist of a record-
ed verbatim hypnotic induction, which is scored according to 
how similar the subjects responses are in relation to previously 
measured highly susceptible individuals. There are many other 
ways to measure hypnotic susceptibility, but these two scales 
are most commonly used in scientific experiments. 
Hypnosis is thought to be a state of fixed attention and absorp-
tion. It can therefore be postulated that that the individuals who 
have the highest score in hypnotic susceptibility are more able 
to focus intently on one specific stimulus, disregarding other 
competing “noise”(Galbraith et al., 1970). There is much con-
troversy as to whether or not hypnotic susceptibility depends 
on the individual’s ability to selectively attend to the hypnotist’s 
instructions, or whether it has to do with the ability to shut off 
distracting stimuli, creating a mental state where the subject is 
more able to capture the hypnotist’s commands. A study was 
done to measure hypnotic susceptibility via an electroenceph-
alogram (EEG). Subjects were asked to focus intently on a dim 
light. The EEG showed that those who scored highest on hyp-
notic susceptibility were more able to fix their attention on the 
dim light, which directly led to their ability to ignore all other 
stimuli (Galbraith et al., 1970). This discovery discounts the find-
ings that hypnosis is an inhibitory response and lends credence 
to the fact that hypnosis is a result of fixed attention.
To further research this phenomenon, a case study was done 
to determine the differences in cortical activity in “high” and 
“low” individuals (in regard to hypnotic susceptibility).  The EEG 
showed greater theta activity (4-8 Hz) in highly susceptible indi-
viduals in the anterior frontal cortex, as well as in the occipital 
cortices. Theta waves in the frontal lobes and occipital cortices 
are associated with vivid visualizations, and great imagination. 
This shows a pattern of EEG dimensionality more consistent 
with imagery processes, which are controlled by various parts 
of the frontal, occipital and parietal regions of the brain.  Low 
susceptible individuals exhibited a pattern more consistent with 
cognitive activity such as mental math (Blai et al., 1998).  This 
study was done in conjunction with another study involving 
neuropsychological tests. These tests were administered to both 
“high” and “low” individuals. The tests were selected to examine 
potential differences in tasks using the prefrontal cortex, as well 
as verbal and visual-spatial modalities. The WCST (Wisconsin 
Card Sort Test) tests the ability to detect relevant information 
by dissociating the irrelevant. Overall, a faster performance was 
observed in the highly susceptible individuals, which indicated 
that highly suggestive participants are more flexible in their abil-
ity to shift cognitive sets, which is consistent with the results of 
the EEG (shifting cognitive sets more easily insinuates a greater 
imaginative ability) (Blai et al., 1998).
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In 1992, Herbert Spiegel presented three different personality 
styles based on the way an individual related to the self and to 
the world. Those who score high on hypnotic ability tend to 
be more trusting, have a higher degree of malleability, and an 
extreme propensity to dissociate. This lends to total absorption 
with a complete abandonment of peripheral awareness. Those 
who are not susceptible tend to place logic at highest priority 
and have a limited experience of dissociation, having constant 
peripheral awareness. Those in midrange exhibit trends toward 
oscillating between relative periods of action and inaction. They 
tend to fluctuate between feeling and thinking and have a mod-
erate ability to express dissociation.
 In a study conducted by Herbert Spiegel in 2006, the measure 
of what was referred to the “eye roll” determined hypnotic sus-
ceptibility. This proved that there was a discernable biological 
component in the ability to experience a hypnotic state. The eye 
roll is the distance between the lower eyelid and the bottom 
of the cornea. Spiegel hypothesized that hypnotic susceptibility 
was based on the amount of sclera seen in the eye while hyp-
notized. Consequently, experiments showed that his hypothesis 
was correct. When he asked his patients to look up during the 
induction phase of hypnosis, he found that if the eye roll was 
so high that nothing but the sclera was showing, that individual 
has a higher neurological capacity for dissociation and focused 
attention, thereby having the potential to be highly hypnotizable. 
This is attributed to the basic biological circuitry of the brain 
unique to each individual. This complex circuitry involves spinal 
cord pathways, the trigeminal nerve that includes the ocular 
motor muscles (which explains the ER phenomena), as well as 
the vagus complex and many other nuclei and neural circuits. 
Conversely, if little sclera is seen between the lower lid and 
the cornea, that individual has a lower biological dissociative 
ability and is therefore only capable of low hypnotic capacity. 
This study was further proven in conjunction with the Hypnotic 
induction profile, which provides an assessment for mental con-
centration, the ability to internalize new ideas, disassociation, 
and the capacity to experience sensory alteration. This proves 
that the ER can be regarded as a surface indicator of underlying 
synaptic circuitry.
To enable those who have low hypnotic susceptibility to ben-
efit from hypnotherapy, studies have been done to determine 
whether hypnotic susceptibility can be increased. A study 
done by Kinny and Sachs (1974) demonstrated that hypnotic 
susceptibility could indeed be increased in some individuals. 
Additionally, this experiment determined whether the permu-
tation in hypnotic susceptibility is attributed to actual cogni-
tive and perceptual changes or to a response alteration due to 
expected behaviors. The experiment included training that was 
found to improve hypnotic susceptibility in past experiments. 
Participants were taught how to imagine certain sensations so 
acutely until the perception of the sensory explanation was 
perceived as being genuine.  The goal of this learning process 
was to teach participants how to feel the sensation that was 
imagined, in addition to blocking out other competing variables. 
Therefore, it can be inferred that the more imaginative a person 
is, the more susceptible they are to hypnosis. The SHSS was 
given after each training session to measure the progress of 
the participants.  The result of this experiment proved to be 
exceedingly intriguing. Overall there was an increase in hypnotic 
susceptibility among most of the subjects. Researchers postu-
late that the reason for this change can be attributed to three 
variables: learning, attitude and motivation. This can essentially 
be positively correlated to the learning process of all other skills. 
Subjects practiced attending to specific sensations and blocking 
out others. Moreover, subjects were allowed to advance at their 
own pace to ensure optimal results. There were also changes 
in the attitude previously attributed to hypnosis. Many subjects 
were originally skeptical regarding the legitimacy of hypnosis. 
Once they accepted the fact, for example, that their hand could 
be lowered involuntarily, they were more willing to capitulate to 
the hypnotic induction.  Subjects then reported that they were 
better able to concentrate, and believed that they had greater 
autonomy over their actions during hypnosis. The subjects who 
originally portrayed controlling, rigid and/or fearful personalities 
failed to show large improvements in their ability to be hypno-
tized. They were afraid of losing control and were concerned 
that their mind would betray them during the hypnotic stage 
(Kinny and Sachs, 1974).  Furthermore, hypnotic susceptibility 
has been shown to be a stable trait due to studies that tested 
the hypnotic susceptibility of the same individuals at different 
ages. Therefore, it can be deduced that hypnotic susceptibility 
can be attributed to personality traits that are inherent in each 
individual, which also control their ability to imagine, focus at-
tention, and absorb internal stimuli.
Neurological underpinnings of hypnosis
There is much controversy regarding the neurological basis of 
hypnosis. This is attributed to the fact that much remains un-
known regarding the various structures and networks present in 
the brain. Although many studies show conflicting results, there 
are some conclusions that can be deduced from the many studies 
that examined this topic. The following comprehensive study was 
done by Rainville et al. in 1999 and was later repeated in 2002, 
attaining similar results. Therefore, it can be assumed that the in-
formation presented in these studies can be considered rather 
factual, as opposed too purely theoretical. The effects of hypnosis 
on regional cerebral blood flow (rCBF) were measured using 
positron emission tomography (PET), which gauges the rCBF in 
the brain.  “Pure” hypnosis (hypnosis without suggestion) was 
accompanied by a considerable increase in rCBF in the following 
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regions: the occipital region, the right anterior cingulate cortex, 
and bilaterally in the inferior frontal gyri. Decreases in rCBF were 
found in the right inferior parietal lobe, the posterior cingulate 
gyrus, and the left precuneus. Hypnosis with suggestion showed 
additional increases in rCBF in the frontal cortices, chiefly in 
the left side of the brain (Rainville et al., 1999). This is attributed 
to the fact that the proposal for an altered perception reflects 
the verbal arbitration of suggestion and top-down processing 
involved in the reinterpretation of the perceptual experience 
(Kihlstrom, 2013). An increase in delta rhythms shown in the EEG 
performed along with the PET, supports the theory that hypnosis 
reflects an altered state of consciousness which is associated with 
decreased arousal. Moreover, findings show a great increase in 
occipital rCBF, which supports the theory that hypnosis facilitates 
visual imagery.
rCBF differences in “pure” hypnosis
Hypnotic induced relaxation showed a wide-spread increase in 
rCBF bilaterally in the occipital lobes (Figure 1). Interestingly, 
comparable effects have been reported during visual imagery. 
In this study, subjects were not encouraged to engage in imag-
inative thinking, but spontaneous visual imagery was reported 
in many subjects. This phenomenon could be attributed to the 
establishment of deep relaxation, which has been proven to 
facilitate visual imagery processes (Brann et al., 2012). Other 
areas associated with an increase in rCBF included: the inferi-
or frontal gyri, which are associated with prepotent respons-
es, and the right anterior cingulate cortex (ACC), as seen in 
Figure 1. The ACC is an area in the brain that is connected to 
functions related to conscious experiences and the emotional 
interpretation of pain. Greater rCBF in the ACC was present 
in more emotionally aware females (Lane et al., 1998). Many 
studies have found that the ACC is involved in functions such as 
anticipation tasks, attention, and motivation (Bush et al., 1999). 
Moreover, focus of attention is associated with the anterior cin-
gulate gyrus, which is consistent with the definition of hypnosis 
as being a state of focal attention and increased concentration.
Decreases in rCBF were associated with the inferior parietal 
lobule, which involves language and mathematical operations. It 
is remarkable to note that individuals with low hypnotic sus-
ceptibility tend to exhibit a greater preference to cognitive ac-
tivities such as mental math (as aforementioned). Specific parts 
of the posterior parietal cortex also showed a significant de-
crease in rCBF (Figure 1). The posterior parietal cortex attends 
to processes involving spatial attention, orientation to external 
stimuli, and self-representation. A decrease in rCBF in this area 
reflects the decreased orientation to extrapersonal and so-
matic stimuli observed in individuals under hypnotic influence. 
Additional decreases in rCBF were found in the medial precu-
neus, which is involved in self-processing operations, and is part 
of the network of the neural correlates of self-consciousness 
and self-related mental representation (Cavanna and Trimble, 
2006).  A reduction in rCBF was observed in the left posterior 
cingulate gyrus, which has been proven to become deactivated 
during effortless mind wandering, while controlled awareness 
corresponded to activation in the posterior cingulate (Garrison 
et al., 2013), the left medial superior frontal gyrus, which is in-
volved in self -awareness in conjunction with sensory system, 
and left posterior middle temporal gyrus, whose function re-
mains unknown (Rainville et al., 1999). 
rCBF differences in suggestion related hypnosis
Increases in rCBF were seen predominantly within the medial 
superior and left dorsolateral regions of the frontal lobes, in 
addition to the right dorsolateral frontal lobule (Figure 2). This 
can reflect the verbal mediation of hypnotic suggestions, work-
ing memory processing, and top-down mechanisms involved in 
the reinterpretation of the sensory experience sometimes used 
Statistical (t) maps of hypnosis-related increases in rCBF, across 
stimulation conditions, in occipital (A), right anterior cingulate 
(B), left frontal (arrow in C), right frontal and right temporal 
cortices (arrows in E). Decreases in blood flow were found in right 
lateral and medial posterior parietal cortices (D). When analyzed 
separately in each stimulation condition, the hypnosis-related 
increase in occipital rCBF was observed mainly in the neutral 




in the induction of hypnosis. Similar effects have been found in 
subjects who were asked to listen and list words that include 
verbal lexical-sematic processing (Oakley and Halligan, 2009). 
Therefore, it was postulated that the left anterior lobes are 
largely involved in the internally generated reinterpretation of 
stimuli, which can lead to an alteration in perception known to 
affect hypnotized individuals (Rainville et al., 2002). Significant 
increases were also seen in the left medial parietal and bilateral 
posterior parietal cortices (Figure 2). This can be attributed to 
the specific content of the suggestion, which may cause specific 
somatic interpretation of perception. Decreases were found in 
the right uncus, bilateral in posterior orbitofrontal regions, and 
the left lateral cerebellum (Rainville et al., 1999).
Hypnotically induced changes in neural 
oscillations as measured by EEG
When searching for neurological changes in the brain due to 
hypnosis, Electroencephalography (EEG) can directly measure the 
electrical activation of the various parts of the brain. An EEG re-
cords the frequency (measured in Hz) and amplitude (measured 
in microvolts) of waves produced by electrical brain activity.  Four 
simple periodic rhythms are recorded in the EEG: alpha, beta, delta, 
and theta. These rhythms are associated with the frequency of the 
waves. Alpha waves are typically 8-13 Hz. Alpha rhythms are usually 
prominent in adults who are awake, but in a very relaxed state 
(e.g. eyes closed). These alpha waves diminish when subjects tune 
into external stimuli and are usually observed to be of the greatest 
amplitude in the parietal and occipital regions of the cerebral cor-
tex. In contrast, Beta rhythms (13-30 Hz) occur in individuals who 
are attentive to external stimuli, or who exhibit specific mental 
stimulation. In essence, Beta waves represent the arousal of the 
cerebral cortex to higher degrees of alertness and attention. Delta 
waves (1-5 Hz) are generated in deep meditation, and suspend ex-
ternal awareness. It has been proven that healing and regeneration 
occur in this state as well. Theta waves (4-8 Hz) are low-frequency 
rhythms that are dominant in deep meditative sleep. Senses in this 
state ignore external stimuli and focus on the subconscious. Vivid 
imagination beyond normal conscious awareness is present in this 
stage as well (Lee et al., 2007). Not surprisingly, these rhythms di-
rectly correspond to the EEG brain waves associated with different 
stages in hypnosis.
 A case study was done to determine whether an EEG during 
“pure” hypnosis (hypnosis without suggestion) would differ from 
a normal non-hypnotic EEG. Pure hypnosis can be categorized 
as a state of heightened attention and increased alertness, re-
flected in neuronal activation (Rainville et al., 1999). These neural 
changes account for the susceptibility to suggestion after a hyp-
notic induction. This study concluded that hypnosis affected all 
of the EEG electrodes. Occipital and frontal EEG channels were 
most affected by hypnosis. There was up to an 89% increase in 
Spectral Pattern (SP) from baseline to hypnotic state in the frontal 
lobes. Right parietal and mid-frontal EEG channels increased 11%. 
Comparative analysis demonstrated that hypnotic conditions 
caused a large increase in delta, beta, and theta rhythmic segments 
in various areas of the brain when compared to the non-hypnot-
ic state EEG. Although all EEG channels were affected by hyp-
nosis, the prefrontal cortex (Fp1 and Fp2 electrodes) and the 
right occipital electrode (O2) showed the greatest percentage 
increase (Fingelkurtz et al., 2007). This data is consistent with the 
knowledge that many neural changes in these areas occur during 
hypnosis. Hypnosis increased beta activity and decreased delta 
activity in the frontal lobes. This is an interesting phenomenon, for 
delta rhythms should increase during hypnosis while beta rhythms 
should technically decrease when measured in accordance to the 
mental states that they represent. However, it can be inferred 
that the EEG measured hypnotic state after induction, which can 
account for the increase in beta waves due to heightened atten-
tion, while an increase in delta waves may have been observed 
during the induction, but decreased thereafter. A majority of beta 
rhythmic conditions appeared in the EEG only after the induction 
of hypnosis. This unique composition in brain oscillation in the 
prefrontal cortex during hypnosis reinforces the premise that this 
area is of major import in the hypnotic state (Fingelkurts et al., 
2007).  In addition, these findings disprove previous views that 
hypnosis constitutes a sleep-like state. This study further demon-
strates that in actuality, hypnosis is a state of increased alertness 
and heightened attention to internal stimuli, as proven by the 
increase in beta waves.  Moreover, this confirms the theory that 
the frontal lobes are extensively involved in attention networks. 
To further elucidate the notion that suggestion for specific per-
ception under hypnotic induction facilitates the same response 
in cortical activity as reality, a study was done by Kosslyn et al. 
(2000) in which color perception in the brain was recorded.  A 
grey-scale image was shown to hypnotically induce participants 
Statistical (t) maps of suggestion-related changes in rCBF show 
increases in medial (A) and dorsolateral frontal cortices (C, D, and 
E), and in medial and lateral posterior parietal cortices (arrows in 
B). Arrow in D shows significant subcortical increase in left nucleus 




with a suggestion to perceive a colored image.  There was modu-
lation of activity in the fusiform gyrus that is responsible for color 
processing in the brain, thereby proving that when hypnotically 
induced, the brain interprets perception as authenticity.
Hypnotic Analgesia
The mechanism through which hypnosis reduces pain is still 
quite obscure; however, there is a plethora of scientific evidence 
proving the effectiveness of pain amelioration via hypnosis.  Pain 
is a spinal nociceptive reflex. Once the nociceptive signal reaches 
the brain, a sensory and affective discriminative neural network 
acts to facilitate the conscious perception of pain (Perl, 2011). 
Structures in the brain that compromise these networks include 
the primary and secondary somatosensory cortices (S1 and S2), 
thalamus, insula, and the ACC (Rainville, 1998).  Hypnotic analge-
sia is thought to be attention based in that incoming stimuli are 
inhibited while awareness is simultaneously deployed elsewhere 
(Eimer, 2000).  The inhibition of afferent nociceptors can be at-
tributed to the decrease in thalmic activity when hypnotically 
induced (Faymonville et al., 2003).  Miron, Ducanan, and Bushnell 
(1989) conducted a study in which subjects were instructed to 
attend to a painful stimulus or divide their attention between 
the painful stimulus and a visual stimulus.  Pain reduction was 
reported in subjects who were asked to divide their attention 
between two simultaneous stimuli.  These results support the 
hypothesis that when faced with competing processes, attention 
is directed to other processes, thereby inhibiting the conscious 
perception of pain.  This process depends on a supervisory at-
tention control system that operates to relocate thalamocorti-
cal activities.  Incoming painful stimuli are suppressed at cortical 
levels and do not enter conscious awareness, thereby reducing 
the degree of perceived pain by invoking physiological inhibitory 
processes of the brain (Faymonville et al., 2003).
Although most studies attribute the reduction in pain to cor-
tical activity, a study was conducted to monitor nociception 
at the spinal cord level and how it is affected by hypnosis.  A 
study done in 1998 demonstrated that a suggestion for analge-
sia directly correlates with the spinal nociceptive (R-III) reflex. 
Subjects showed strong inhibition of the R-III reflex at the spinal 
cord level in response to hypnotic induction (Danziger et al., 
1998).  These results are rather intriguing because they intro-
duce a new aspect of hypnosis, independent of the cognitive 
model.  There is no recorded scientific basis for these findings, 
but they do insinuate that there may be mechanisms in the pe-
ripheral nervous system that are directly influenced by hypnosis.
There has been much research as to whether hypnotic analgesia 
affects the sensory or affective processing of pain.  Researchers 
speculated that hypnosis has a greater affect on the affective 
system because that system has a greater cognitive evaluation, 
while the sensory system is modulated by nociceptive inputs 
from the peripheral nervous system.  Studies have shown that 
both are affected by hypnosis.  Hypnotic analgesia produces 
both a modulation of pain effect by producing changes in the 
anterior cingulate cortex, and inhibition of afferent nociceptive 
signals arriving at the somatosensory cortex.  Hypnotic sug-
gestion for altering pain unpleasantness affected rCBF flow to 
the ACC, but not to the S1 Cortex, proving the role of the 
ACC in pain affect.  Suggestion for modulating pain intensity 
affected rCBF mainly in the S1 and S2 cortices and had little 
affect on the ACC.  These results are consistent with the role 
of the somatosensory cortex in the sensory dimensions of pain. 
Interestingly, the context of the suggestion that facilitated the 
analgesia determined to what degree the affective and sensory 
systems were affected (Rainville, 1998). 
 Researchers at the University of Iowa conducted a case study 
in 2004 to determine the difference in pain perception in hyp-
notically induced individuals.  fMRI (functional magnetic reso-
nance imaging) was used to measure brain activity.  A painful 
thermal stimulus was applied to the participants’ left hand. The 
subjects were then hypnotized, and their brain activity was 
recorded by the fMRI.  The hypnotic state was then broken 
and the procedure was repeated.  Hypnosis was successful in 
reducing perceived pain in all of the individuals.  Participants 
reported a significant pain reduction or feeling no pain.  The 
fMRI reported decreased activity in the primary sensory cortex, 
which is involved in pain perception.  Increased activation was 
seen in the basal ganglia and the anterior cingulate cortex.  The 
increase in brain activity in these two regions could be attribut-
ed to their involvement in the inhibition pathway that blocks 
pain signals from reaching higher cortical areas responsible for 
pain perception (Schulz‐Stübner et al., 2004).
The induction of hypnotic analgesia, simply known as the reduc-
tion of pain via hypnosis, can offer amelioration of pain intensity 
and offer an alternative to drugs that have various negative side 
effects.  By utilizing direct suggestion such as suggesting numb-
ness (glove anesthesia), direct suggestion for turning down pain, 
physical dissociation from painful areas of the body, pain relief 
imagery, or cognitive reframing while in an hypnotic state, pain 
reduction is possible (Eimer, 2000).
A study was conducted to ascertain whether pain modulation 
requires a hypnotic suggestion for pain reduction, or if pure 
hypnosis affects the ratings for pain unpleasantness.  Participants 
were expected to submerge their left hand in painfully hot 
water (470C) during pure hypnosis and then again in response 
to a suggestion for pain reduction while hypnotized.  The rela-
tionship between pain effect and cerebral activity was recorded 
via PET.  An increase in rCBF was seen in the insular cortex, 
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where a person imagines pain while looking at painful images 
and feels sensation of pain and its intensity.  Increases were also 
found in the ACC, which mediates affective response to noxious 
stimuli, and the primary and secondary somatosensory cortical 
areas (S1 and S2), which are believed to involve the sensory 
discriminating processing of pain.  Comparing hypnosis related 
changes in rCBF in neutral and painful stimuli conditions tested 
the effect of hypnotism on pain reduction.  A strong lateral-
ization increase in rCBF in the right ACC has been shown in 
conjunction with the experimental painful stimuli.  Furthermore, 
although pain and hypnosis related ACC sites were anatomically 
close within broadmann area 24 (which is part of the cingulate 
gyrus), the pain related peak was medial along the cingulate 
gyrus and the hypnosis related peak was more lateralized in the 
cingulate sulcus.  Occipital rCBF was less when a pain modulatin 
suggestion was proposed in relation to occipital rCBF without 
suggestion.  Additionally the amount of pain reduction and pain 
unpleasantness was directly correlated with the participant’s 
level of hypnotic susceptibility (Rainville et al., 1999). 
Hypnosis in treating acute pain
Acute pain is defined as pain that gradually resolves as the in-
jured tissue heals.  Many studies have been done to uncover 
the effects of hypnosis on the reduction of acute pain.  A study 
was performed in 1991 to determine the effects of hypnosis 
in treating invasive medical procedure pain.  This study com-
pared participants who received pre-surgery hypnosis prior to 
angioplasty surgery with participants who received standard 
care.  The hypnotically induced patients showed a 25% increase 
in the amount of time they allowed the cardiologist to keep the 
balloon catheter inflated, and showed a substantial reduction 
in opioid analgesics that are vital during the procedure.  The 
hypnotically induced group also showed a significant decrease 
in catecholamine blood levels relative to the control group 
(Weinstein and Au, 1991).  Another study done in 1996 pro-
duced similar results.  Sixteen patients received hypnosis with a 
suggestion for relaxation and pain relief imagery while fourteen 
patients were treated with the standard procedure.  Hypnotized 
patients reported less pain, used less pain medication, and 
showed more physiological stability during the diagnostic ar-
teriogram procedure.  No statistically significant differences in 
heart rate or blood pressure were recorded (Lang et al., 2000).
Bone marrow transplant patients often receive supralethal 
doses of chemotherapy prior to the procedure.  This treatment 
often results in severe nausea, pain from oral mucositis, and 
vomiting.  Patients were hypnotically induced and were given 
suggestion for pain control and relaxation.  Most patients re-
ported a significant reduction in pain; however, no significant 
differences emerged regarding nausea and vomiting (Syrjala et 
al., 1992).  Burn care patients who were treated with hypnosis 
reported a reduction in burn-related pain and even facilitated 
wound healing (Patterson et al., 2003).  Additionally, burn pa-
tients who received hypnosis used significantly less analgesic 
drugs than the control group (Wakeman and Kaplan, 1978). 
Labor pain is also a good candidate for hypnosis.  There have 
been many clinical benefits recorded in using hypnosis to reduce 
labor pains.  Women who were given sessions of posthypnotic 
suggestions for pain relief and relaxation during labor showed 
shorter stage 1 labor and reported less labor pain (Davidson, 
1962).  Freeman et al. (1986) conducted another study in which 
women received hypnosis before labor.  Hypnosis involved 
suggestion for pain relief and for transferring anesthesia from 
the hand to the abdomen.   No differences were reported in 
pain relief during labor; however, highly susceptible individuals 
reported that hypnosis helped reduce their anxiety during labor, 
thereby helping them cope effectively with the pain.
Hypnosis in treating chronic pain
Chronic pain is defined as pain that persists beyond the healing 
time needed for a specific injury.  Many psychological factors, 
such as patient coping responses, patient cognition, and envi-
ronmental factors play an important role in the expression and 
experience of chronic pain, while acute pain is directly related 
to the injury itself.  Therefore, different techniques in hypnosis 
must be used in the treatment of chronic pain as opposed to 
acute pain.  The difficulty in treating chronic pain with hypnosis 
can be maintaining reduced pain awareness for an extended pe-
riod of time (Patterson et al., 2003).  Many studies have been 
performed to determine the effectiveness of hypnosis on head-
aches, fibromyalgia, and back pain.  Other etiologies of chronic 
pain have not been extensively researched. Hypnosis treatment 
was given to 47 subjects suffering from migraine headaches. The 
control groups consisted of participants who were not given 
any treatment as well as subjects who were given prochlor-
perazine.  Suggestion was given for visual imagery techniques, 
pain reduction, and for the aversion to migraine headaches.  The 
patients who received hypnotherapy reported fewer headaches 
per month, a higher frequency for remission, and fewer Grade 
4 headaches (Anderson et al., 1975).  Hypnosis was also prov-
en to be more effective than physical therapy in the treatment 
of fibromyalgia.  Muscle pain, fatigue, and sleep disturbances 
caused by fibromyalgia were improved via hypnosis (Haanan et 
al., 1991).  Back pain was also shown to improve when treated 
with hypnosis.  A study done among 22 patients suffering from 
spinal cord injury related pain showed an 86% decrease in pain 
following a hypnotic induction (Jensen et al., 2001). 
Conclusion
Although there is still much obscurity surrounding the intriguing 
phenomena of hypnosis, much research has been done to eluci-
date the underlying mechanisms and benefits of this remarkable 
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phenomenon.  Hypnosis has matured to become both a worth-
while treatment option for many medical conditions as well as 
a significant research tool in the quest to understand human 
cognition. The actual benefits of hypnosis can be seen through 
various experiments, both cognitively and clinically, disputing re-
searchers who term hypnosis as being one giant placebo effect. 
The clinical applications of hypnosis are numerous, and more 
study is being done to discover viable hypnotic treatments for 
various illnesses. By understanding of the neurophysiological 
mechanisms underlying the hypnotic modulation of conscious 
experience, and its specific patterns of cerebral activation, one 
can appreciate, and potentially benefit, from the many advantag-
es of hypnosis both in research and in practice.
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Epigenetics literally means “above” the gene and is a new 
study of research in biology that explains how environmental 
factors impact one’s biology. Epigenetic mechanism explains 
how there are over 220 different cell types in an adult organ-
ism even though they all have the same DNA. All cells in each 
organism contains the same DNA, but their cell function dif-
fers in different cells, based on “qualitative and quantitative 
differences in gene expression.” (Gibney, Nolan, 2010). Bone 
cells, skin cells, heart cells, all have the same DNA, but their 
functions are completely different. This cell differentiation is 
a specific pattern of gene expression where certain parts 
of the DNA are turned on or off in each type of cell. This 
specific pattern of gene expression is passed down from 
cell to cell. Epigenetics is defined as “the study of mitotically 
(and potentially meiotically) heritable alterations in gene ex-
pression that are not caused by changes in DNA sequence 
(Gibney, Nolan, 2010). One researcher compares genes and 
epigenetics to a computer, where genes are the hardware and 
epigenetics is the software telling the hardware how to func-
tion. There is a certain balance of epigenetics that is normal 
and healthy for the cell, but when these balances are changed 
and the epigenetic mechanisms become unregulated there 
may be alterations in gene expression, and can ultimately 
lead to cell transformation and malignant outgrowths. There 
are three major types of epigenetic changes; DNA methyl-
ation, Covalent Posttranslational Histone Modification, and 
Small Inhibitory RNA-mediated signaling Pathways. Mainly, 
Epigenetic processes, including DNA methylation and histone 
modification, influence gene expression at the transcription 
level. 
DNA methylation is the most studied epigenetic factor and 
that is what will be discussed in this paper. DNA methyla-
tion occurs through the covalent addition of a methyl group 
(CH3) to the 5 position of a cytosine generating 5-methyl-
cytosine (Stein, Davis, 2012). Methyl groups protrude into 
the major groove of DNA and change the biophysical char-
acteristics of the DNA. Cells can methylate and demethylate 
DNA, which effects specific gene expression. These epigene-
tic changes can experience multigenerational inheritance; not 
only does it change the phenotype of the first individual, but 
the methylation can pass onto further generations.
Materials and Methods
In order to understand how epigenetics can be a potential cure 
for cancer, many journals and articles were retrieved from Touro 
College’s library database.  Those articles and the references 
they listed formed the basis for exploring this topic.
Correlation between DNA methylation and gene 
silencing
An experiment with mice and coat color phenotype and body 
weight measurement exposed the correlation between methyl 
groups and silencing of gene expression. A group of pregnant 
mice that were genetically identical were assembled, half the 
group were fed a diet rich in methyl groups (here soy), and the 
control half their regular diet.  All these mice had the agouti 
gene, which when expressed gives the mouse a yellow color 
and causes obesity. The offspring of the mice that had the methyl 
rich diet were thin and brown, whereas the offspring of the 
mice that did not eat the methyl groups remained yellow and 
fat. They both have the agouti gene, but the brown mice had a 
methyl group attached to the agouti gene which shut it down. 
Bisulfite sequencing methylation analysis of CpG sites in the 
promoter region of the agouti gene (Avy IAP) showed a statisti-
cal increased average percentage of cells methylated of the mice 
given the methyl rich diet.  This was a simple experiment to see 
how DNA methylation affects gene expression because it was 
easy to see when the gene was on and off based on the pheno-
type color switch and body measurement. Also, this epigenetic 
tag was passed down to the offspring’s of these mice, and con-
tinued until they ate a diet without enough methyl groups. Soy 
has an active ingredient that methylates DNA. This research may 
explain why there is a lower incidence of cancer among Asians 
compared to Westerners, because Asians eat diets rich in soy 
and may explain why Asians who emigrate to America are more 
likely to develop cancer than their family back home. (Dolinoy, 
et. al. 2006)
DNA methylation causes gene silencing
Although a correlation was noted between gene activation and 
methylation, the authors wanted to prove conclusively that 
DNA methylation is the cause of the gene silencing. They were 
not positive yet which was the cause and which was the effect, 
they though that it might be possible for the gene inactivation 
to cause the DNA methylation. An experiment was carried 
Abstract
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out that proved that DNA methylation caused gene inactiva-
tion. The experiment was conducted on the E2a region of Ad2 
DNA. The region was cloned, and then half of the gene was 
methylated in vitro with HpaII DNA methyltransferase and then 
microinjected into the nuclei of X. laevis oocytes. The key is that 
the scientists ensured that the methylated DNA only remained 
methylated for 24 hours after microinjection. There was no syn-
thesis of Ad2 specific RNA in the methylated DNA cells until 24 
hours after injection. The control did however readily express 
the Ad2 specific RNA. The experiment results demonstrate that 
methylation plays an actual role in causing genome inactivation 
because at the end of the 24 hour period, there is no genome 
expression, yet that does not cause the methylation to contin-
ue, which proves that methylation is not a consequence of a 
lack of gene expression. The gene expression inactivation only 
occurred in the narrow window that the Gene was methylated 
(Doerfler, 1981).
How it causes gene silencing
Cytosine methylation inhibits the transcription of genes. When 
there is an extra methyl group on the DNA, it becomes inacces-
sible for protein binding for gene expression.  The methyl group 
interferes with the binding of the protein to its specific DNA 
to transcribe it.
Cancer
Typically, it was believed that cancer was caused by genetic de-
fects such as, mutations, amplifications, deletions and translo-
cations, which affected the cancer cell and provided it with the 
advantage to survive and metastasize. However, today, it is clear 
that there is another system of equal importance that is liable in 
causing cancer, and that is epigenetic marks. Today cancer is con-
sidered a genetic and epigenetic disease. This epigenetic alter-
ations which can cause cancer have been termed epimutations. 
This is extremely important because damage to a cell’s DNA 
is permanent, whereas epigenetic change is reversible. (Stein, 
Davis, 2012).
Proof that epigenetic changes can cause cancer
Take arsenic which is known to cause cancer of the skin, liver, lung, 
and bladder, but actually does not cause DNA mutations, as demon-
strated in standard mutagenic assays. However in 2010, researchers 
found that arsenic caused cancer by epigenetic mechanisms. This 
was a groundbreaking epigenetic mechanism that cause cancer, 
and that is a major breakthrough in terms of finding a cure. One 
group of researchers studied CpG islands of over 14000 genes 
in people who were exposed to high levels of arsenic, verified by 
their urinary arsenic levels. It was found that these genes were 
epigenetically modified from the arsenic exposure, and researchers 
found that a tumor suppressor gene was silenced. This is called 
a “tumor suppresorome,” which is a group of 17 confirmed or 
recognized tumor suppressor genes that are silenced in human 
cancers, most of these through abnormal methylation patterns. 
(Stein, Davis, 2012)
Two ways that DNA Methylation can have an 
impact on carcinogenesis
One is by hypomethylation and one is by hypermethylation. 
Hypomethylation is a decrease in the normal amount of meth-
ylation on DNA. Hypomethylation usually occurs at repetitive 
chromosomal sequences where DNA is normally methylated. 
Researchers found that four out of five cancer patients had 
significant hypomethylation in their cancer cells as compared 
to their neighboring cancer free cells. Hypomethylation, in 
decreasing the normal amount of methylation of the gene, 
decreases the normal amount of gene silencing, i.e. increases 
gene expression. This can result in an activation of genes with 
growth and tumor promoting functions (Lund, Lohuizen, 2004). 
Additionally, hypermethylation, or the increase in the amount 
of DNA methylation can cause a negative impact on the cells, 
and can lead to carcinogenesis. This hypermethylation is found 
at CpG islands, which are most likely found in the 5’ regulatory 
region of the gene, which are not methylated. Here the extra 
methylation causes gene silencing, and tumor suppressor genes 
are being silenced (Feinberg, 2001).  In one experiment, it was 
revealed that the mRNA for RL7NX3, a tumor suppressor gene 
involved in several cancers, is suppressed in primary cutaneous 
melanoma and in metastatic tumors. CpG Island, which are usu-
ally not methylated and transcriptionally active, have been found 
to be abnormally hypermethylated during the development of 
cancer, particularly in tumor suppressor genes. Genes involved 
in cell cycle regulation, DNA repair, (to name two) are very 
epigenetically susceptible (Stein, Davis, 2012).
Hypermethylation of GSTP1 and prostate cancer
Methylation of GSTP1 is the most common epigenetic alteration 
described in several tumors, such as prostate cancer, endometrial 
cancers, and breast cancers. GSTP1 catalyzes the s conjugation 
of GSH, which protects the cell from cytoxic and carcinogenic 
agents. Methylation of GTSP1 gene occurred in 90% of prostate 
cancer tissue from surgical specimens. In this experiment, the 
tissue samples from 144 patients who were having a prostate 
biopsy were examined. Forty two out of the 144 patients were 
diagnosed with prostate cancer. Additionally, there was hyper-
methylation of the GTSP1 gene in 31 out of those 42 patients, 
and only in 2 out of the 102 patients who did not have cancer. 
Since epigenetics is a cause of carcinogenesis, and, therefore, cells 
will exhibit hypermethylation at the onset of the cancer, there is 
potential for using hypermethylation as a biomarker to detect 
the cancer. These genes, and other genes that exhibit hypermeth-
ylation in the early onset of cancer, may eventually be useful as 
a biomarker to detect prostate cancer. However, methylation of 
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the GTSP1 gene may indicate another cancer, and does not indi-
cate prostate cancer, specifically. However there is potential for 
mapping out hypermethylation of other genes and using a multi 
gene profile to improve specificity for cancers. Azacytidine has 
been found to reverse the hypermethylation of the GTSP1 gene, 
and reactivate transcription (Miano et. al. 2007).
Epigenetic tests on identical twins
The best way to study epigenetics is on monozygotic twins 
because they have the same genetic material, but still have dif-
ference in cell expression and their phenotype. There is a high 
discordance rate between identical twins for many diseases, 
even those thought to be genetic. Epigenetic changes through 
environmental variances can be the answer to the phenotypic 
differences of identical twins. Researchers in Madrid studied 80 
identical twins in a range of 3 to 74 years old.  Thirty five per-
cent of the twin pairs had significantly different methylcytosine 
genomic content. Researchers observed that the difference in the 
methylcytosine pattern for the twins increased with the age of 
the twins. The youngest twin pair had their epigenetic pattern 
the most similar, whereas the oldest pair’s epigenetic pattern was 
very different.  Also, they found that twins who had not grown up 
together had the greatest difference of 5’ methyl cytosine levels. 
These differences in methylation of their cells is what causes the 
gene expression and phenotype of monozygotic twins to differ. 
This study indicates that methylation patterns are one reason 
why twins with the same DNA may have different phenotypes. 
Additionally, the fact that the epigenetic differences were more 
distinct in twins who spent less of their lives together indicates 
that major role the environment plays into translating a general 
genotype into different phenotypes detectable.  External factors 
play a great role in gene expression by changing the pattern of 
epigenetic modifications (Fraga, et. al. 2005).
Epigenetics and age correlation
For every cell division there is a potential for epigenetic damage. 
As a person ages, their cells are forced to divide again and again 
to replenish any tissue damage that may have occurred. Each time 
this happens there is a chance for epigenetic damage through an 
altering of the normal methylation pattern of the cell.  Scientists 
can take tissues from an older person and can estimate by looking 
at the epigenetic patterns of the DNA in a particular tissue how 
old the person is, because these epigenetic changes accumulate as 
a person ages. For a cell, aging is counted by how many times the 
cell has divided.  The more damage a cell has, the more times it is 
forced to divide and replenish, and the more chances that there 
is going to be an abnormal pattern of methylation in this cell.  For 
example, smoking and sun exposure can cause skin tissue injury. 
When a person’s skin peels from a sunburn its cells repair that 
damage by dividing and replenishing those cells. In these cases, 
the sun and cigarette exposure can cause actual DNA damage, 
but they also just damage the tissue which leads to cellular repair 
of that injury through cell division, and leads to a gradual accu-
mulation of epigenetic damage. Lungs of heavy smokers can look 
20 times older than nonsmokers. This can explain why there is a 
higher incidence of cancer among older individuals.  With age, the 
amount of exposure he or she has had to environmental toxins 
increases, which can ultimately lead to an abnormal methylation 
pattern (Nova, 2007).
Epigenetic therapy
Epigenetic therapy works to repair the normal methylation pat-
tern of the cell. This is done through DNA methylation inhibition. 
5’Azacytidine and 5-aza-2’-deozycytidine (Decitabine/DAC), the 
two most advanced drugs for epigenetic therapies for cancer. 
Both are in clinical use (Silverman, et. al. 2006). They are DNA 
methyltransferase inhibitors and work by trapping DNA meth-
yl transferases thereby inhibiting methylation, and restoring the 
gene’s normal expression. DNA methyl transferases, known as 
DMTAs, are the enzymes that are responsible for DNA meth-
ylation. DAC incorporates into DNA and forces the methyl 
transferases to form irreversible covalent bonds to DNA. These 
methyl transferases are then targeted for deletion in the prote-
asome. Then, cells divide, without DMTA and there is now DNA 
hypomethylation and reactivation of genes that were silenced 
from the extra methyl groups. However, DAC can also cause cy-
totoxicity when given in high doses, and therefore dosage must 
be monitored.  A positive side to epigenetic therapy of cancer is 
the minimal side effects which is due to the fact that scientist can 
give low doses of the medication with successful results. Whereas 
for cancer drugs scientist have to give the highest dose possible 
of the medication to kill all the harmful cells, epigenetic therapy, 
does not necessitate high doses of the drug because it is not 
aiming to kill all the cells, but rather just to change the abnormal 
methylation patterns of the cancer cells. DAC was not tested 
Table 1 shows a list of that when hypermethylated become 
cancerous. This means that it may be possible to use 
hypermethylation as a biomarker to detect cancer early on.
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on young children or on pregnant women. The drug does not 
target normal methyl tags for two reasons. Firstly, drugs target 
the area of the most cellular divisions, and in this case, they are 
going to target the cancer cells and leave the normal cells alone. 
Additionally, modification of epigenetic patterns has a large ef-
fect on cancer cells but will hardly have any long term effect on 
the behavior of normal cells. When the drug was stopped the 
normal cells returned to their normal epigenetic pattern, while 
the cancer cells, now healthy cells with normal methylation pat-
terns, did not revert to tumorigenesis. There is potential for all 
other cancers that have an epigenetic origin. Myelodysplastic syn-
drome, also known as MDS, and Acute Myelogenous Leukemia, 
also known as ALS are easier targets for these drugs because the 
cancer cells are in the blood and have easy access to drugs. (Issa, 
2013) These drugs do not work with solid tumors yet. A reason 
that is likely is because it is much harder to incorporate the drugs 
into these cells, which are multiplying much more slowly than 
hematological cancers. Right now, these drugs are being tested 
with solid state tumors and the results have been promising. In 
the laboratory the scientists have been able to adjust the abnor-
mal epigenetic pattern of the solid state tumor with these drugs, 
and are working to mimic these results in the body. The catch is 
that these drugs that prevent methylation can reactivate expres-
sion of multiple silenced genes, even genes that we want silenced, 
like oncogenes, which are genes that have the potential to cause 
cancer. Therefore, the demethylation can be harmful as well as 
helpful. For example, oncogene NT5E is transcriptionally silenced 
by methylation in breast cancer. Therefore hypomethylating that 
area would activate that oncogene and not be helpful. This is why 
in the future it is important to have some sort of epigonomic 
profiling- to identify potentially deleterious silenced genes before 
using epigenetic therapy to pharmacologically reverse resistance 
(Hatzmichael, Crook, 2013).
MDS, AML and other lymphomas
Myelodysplastic syndrome, or MDS, and Acute Myelogenous 
Leukemia, are cancers of the bone marrow.  MDSs are hema-
tological disorders that usually progresses into AML. Years ago, 
patients diagnosed with MDS were basically given a death sen-
tence, there was no cure, and no hope for any remission. It was 
soon realized that MDS was epigenetic in origin. Researchers 
thought to study the epigenetic pattern in patients with MDS 
because of the fact that the patients with the disease have an 
average age of 70. Diseases that target older individuals likely 
have an epigenetic component in it. MDS patients have aberrant 
methylation of their CpG loci and silencing of multiple genes. 
MDS was therefore an ideal candidate for epigenetic therapy, 
and indeed results were positive.  Decitabine was given to over 
100 patients for Acute Myelogenous Leukemia. In fifty percent 
of the patients the disease disappeared fully. Twenty five percent 
achieved some improvements. However, another 25% did not 
respond to the drug, or the drug worked for a short amount of 
time but then stopped working (Nova, 2007).
Conclusion
All in all, the discovery that many cancers have an epigenetic 
origin, has opened a new path for potential cures for cancer. This 
was possible because epigenetic abnormalities are reversible.  It 
is integral to realize that everything one does affects his or her 
health, and the health of future generations. One’s diet and what 
one is exposed to can affect his epigenome and subsequently his 
future generation’s phenotype. We are not just the product of 
our biology, we are also its cause. 
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Laron Syndrome, eponymously named after the scientist Zvi 
Laron who first discovered the syndrome, is a growth hormone 
insensitivity syndrome. People with Laron Syndrome have a ge-
netic mutation in the growth hormone receptor. These patients 
have a normal level of growth hormone but a reduced level of 
Insulin-like Growth Factor 1 (IGF-1) and are characterized by 
dwarfism and other physical deformities. Remarkably, patients 
with this condition have been proven to be immune to cancer. 
Through research on Laron Syndrome scientist have found a 
link between a key growth hormone and resistance to cancer.
Methods and Materials
Information was compiled from various articles that were ob-
tained through Touro College’s library database and Pubmed. 
The information was narrowed down to those directly related 
to the topic. The information extracted and synthesized was 
used to hypothesize why Laron Syndrome patients are immune 
to cancer.
Background information
Data shows that Laron Syndrome (LS) patients have normal lev-
els of, and a normal, GH molecule, but a defect in the Growth 
Hormone Receptor gene (GHR). Patients with LS have either a 
gene deletion or a point mutation in this gene (Wood & Savage, 
1996).
Mutations in the growth hormone receptor interrupts the JAK- 
STAT signaling pathway which stimulates the production of 
IGF-1. The JAK-STAT signaling pathway brings information from 
chemical signals outside the cell, through the cell membrane, 
and into the cell where gene promoters on the DNA in the cell 
nucleus can causes DNA transcription and activity in the cell. 
The mutation in the Growth Hormone Receptor, leads to an 
inability of the extracellular domain to bind growth hormone 
and stimulate the production of IGF-1 (Gastier et al., 2000).
Cited from Rosenbloom and Guevara-Aguirre that in 1966, 
Laron, Pertzelan and Mannheimer did research on the high 
levels of growth hormones in patients with clinical and labo-
ratory signs of growth hormone deficiency (Rosenbloom and 
Guevare-Aguirre, 1998). There are ~251 reported people with 
this syndrome. One hundred and forty eight are known to have 
Semitic origin. One third of the people with this syndrome live 
in Loja, Ecuador which is where most of the genetic studies take 
place. The people in Loja, Ecuador are said to have ancestors 
who converted to Christianity during the Spanish Inquisition 
(Wood & Savage, 1996).
Laron syndrome is a congenital autosomal recessive disorder. The 
parents of an individual with Laron syndrome must each have a 
copy of the mutated gene while displaying no signs of the syn-
drome. People with Laron Syndrome have postnatal growth fail-
ure; it begins with “subnormal birth length, retarded brain growth, 
acromicria, also of the facial bone, defective and crowded teeth, 
sparse hair, small gonads and genitalia, obesity, retarded skeletal 
maturation, delayed puberty, hypoglycemia. As these patients get 
older they have obesity, muscle underdevelopment and weak-
ness, osteoporosis, hypercholesterolemia, hyperinsulinemia, and 
various degrees of glucose intolerance (Yamamoto et al, 2007).” 
There is wide phenotypic variability among patients with this 
syndrome. With that said, there is uncanny similarity between 
patients with LS even with variability in genotype and even if they 
are from different places. In the image below of two men with 
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Laron Syndrome, it is evident that there is a similarity in physical 
features. 
The man in figure A and C is 21 years old with a height of 126.6 
cm. The man in B and D is 28 years old and has a height of 115 
cm. Analysis of the faces indicate different craniofacial pheno-
type, but still both men with Laron Syndrome have an uncanny 
resemblance (Rosenbloom and Guevare-Aguirre, 1998).
Patients with LS have extremely low levels of insulin-like growth 
factors, below the 0.1st percentile for age, such as IGF-I which 
is the major hormone responsible for growth and it is under the 
control of GH. Patients with GHD also have a low level of IGF-I 
but those patients responded well to exogenously administered 
GH, whereas patients with LS did not which is a characteristic 
of LS. This is the primary difference between GHD and GHRD. 
LS patients also have extremely low levels of Insulin-like growth 
factor binding proteins (IGFBPs). Specifically, IGFBP-3 levels are 
decreased in LS patients (Wood & Savage, 1996).
Insulin-like growth factor 1 (IGF-1)
IGF-1 is a 70 amino acid polypeptide hormone involved in en-
docrine, paracrine, and autocrine functions. An original name for 
this hormone was somatomedin C because it was under the 
control and mediates the effect of the growth hormone. The 
name was changed to Insulin-like because it shared a similarity 
to proinsulin. Also, it mimics insulin activity such as stimulating 
glucose uptake in the cells. Additionally, IGF-1 has mitogenic ca-
pabilities (Puche & Castille-Cortazar, 2012).
Synthesis and Circulation
Growth hormone is secreted by the pituitary gland and it stim-
ulates the production of IGF-1 by acting on the liver where 
it is made. The pituitary gland releases GH and it works 
together with the liver in a negative feedback mechanism to 
stimulate the secretion of IGF-1; increased levels of IGF-1 
cause a decrease in production of GH which stimulates the 
production of less IGF-1 (Puche & Castille-Cortazar, 2012).
Recent research by Puche and Castille-Cortazar is uncov-
ering IGF-1 as an independent and self-sufficient peptide, 
separate from GH. IGF-1 is produced mainly by the liver 
in response to the endocrine GH stimulus, but it is also 
secreted by multiple tissues for autocrine and paracrine 
purposes.  In tissues throughout the body it is evident that 
IGF-1 expression is regulated and stimulated by other fac-
tors besides GH, such as estrogen in the uterus (Puche & 
Castille-Cortazar, 2012). 
The stimulatory role of IGF-1 on intrauterine growth is 
GH-independent. Regardless of the levels of GH, IGF-1 
deficiency is the main determinant of a reduced birth size. 
(Puche & Castille-Cortazar, 2012). 
Research done on the effects of GH to stimulate skeletal 
growth has proven that GH directly stimulates bone growth. 
Additionally, GH stimulates the production of IGF-1 which 
will then promote bone growth. This proves, along with 
other findings, that IGF-1 and GH work independently and 
synergistically to promote postnatal body growth (Puche & 
Castille-Cortazar, 2012).
Central nervous system development
IGF-1 binds to IGF-1R a cell surface receptor. When IGF-1 
binds to the receptor intracellular signaling is initiated. The 
AKT signaling pathway, which is a stimulator of cell growth 
and proliferation, and a potent inhibitor of programmed cell 
death, is activated.
IGF-1 production coincides with periods of neuron progenitor 
proliferation and differentiation. The role of IGF-1 in the brain 
is not only neuronal produced IGF-1. Systemic IGFs (mainly 
produced by the liver) can cross the blood-brain-barrier and 
are also involved in these processes. Labeled IGFs were placed 
in the carotid arteries of rats and were later on detected in 
the choroid plexus, median eminence, brain arterioles, and 
parenchyma. This coincides with the data that confirmed the 
presence of IGF-1 receptors in the brain capillary endothelial 
cells which constitutes the BBB, and the role in internalizing 
IGFs from circulation to the CNS. There is evidence that 
growth factors, GH, basic fibroblast growth factor; nutrition; 
and injury influence and regulate IGF-1 expression in the brain. 
All of the growth abnormalities that are attributed to LS pa-
tients (see above), indicate that IGF-1 plays a critical role on 
brain development and function. 
Current therapeutic options and limitations
In 1980, Recombinant Human IGF-1 (rhIGF-1), Mecasermin 
became available for experimental therapy for people with se-
vere primary IGF-1 deficiency. An average of 8.5 cm in height 
was grown the first year. Besides for an increase in height, pa-
tients with rhIGF-1 treatment had an increase in testosterone 
levels, testicular size and stretched penile length. This shows 
the effect of IGF-1 on sex hormones and organs in male pa-
tients (Puche & Castile-Cortazar, 2012).  
Another treatment that the FDA approved was a combination 
of IGF-1 and IGFBP-3, Mecasermin Rinfabate. This was thought 
to have been a smarter alternative to Recombinant human 
insulin growth factor 1 (rhigf-1) because it was supposed to 
extend the duration of IGF-1 in the body. Interestingly enough, 
when the combination of IGF-1 and IGFBP-3 were used to 
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treat patients compared to a control group who only were 
treated with IGF-1, those treated with IGF-1 alone had better 
results (Puche & Castile-Cortazar, 2012). 
Dosing guidelines for rhIGF-1 are still being debated. The in-
ternational Congress of Endocrinology has stated that both 
one and two injections of rhIGF-1 is safe and efficient. One 
or two injections regimen have the same growth velocity. By 
carefully monitoring the IGF-1 serum levels the negative side ef-
fects can be avoided. Long-term rhIGF-1 has reported negative 
side effects. These side-effects, namely tachycardia were easily 
managed without treatment discontinuation (Puche & Castile-
Cortazar, 2012). 
A novel and efficient method for hormone replacement therapy 
is being developed using Sertoli cells. Sertoli cells are original-
ly from the male testis, and they can ameliorate development 
and survival and function of different cell types. In the “Laron 
mouse” it was successfully reported that pre-pubertal sertoli 
cells in microcapsules can successfully promote growth. There 
was a significant increase in body weight and body length com-
pared with the control “Laron mouse” treated with empty cap-
sules.  IGF-1 serum levels were noticeably increased in mice 
treated with Sertoli cells microcapsules.  The reduction in side 
effects, the increase in growth, and the fact that sertoli cells 
do not require intramuscular daily injections are all reasons 
that sertoli cell treatment is preferred over rhigf-1 treatment 
(Kinam Park, 2012).
Puche and Castille-Cortazar cite a study done by Steuerman R, 
Shevah O, Laron Z. on the prevalence of cancer in people with 
Laron Syndrome compared to their family members. This study 
proved that IGF-1 deficiency provides protection against cancer. 
Interestingly, this study reported that Laron Syndrome patients 
are protected against future cancer development, even when 
treated with rhIGF-1. (Puche & Castile-Cortazar,  2012).
The positive results of exogenously administered IGF-1 in sub-
jects without  IGF-1 deficiency, to use its anti-inflammatory, 
hematopoietic, antioxidant, metabolic or anabolic properties,  is 
not clearly determined (Puche & Castile-Cortazar,  2012).
Discussion
Studies have shown that patients with overexpression of IGF-I 
are more susceptible to tumors. Laron set out to determine 
if patients with IGF-I deficiency (LS) are less likely to develop 
cancer. Two hundred and twenty eight patients with IGF-1 defi-
ciency and 338 of first and second degree family members were 
surveyed. Cancer was not a cause of death in GHRD patients of 
any age. Ten to twenty four percent of the family members had a 
history of malignancies. Only one GHRD subject monitored had 
cancer, papillary serous epithelial tumor in the ovary. The table 
below shows the prevalence of the malignancies in patients and 
family members.  Because of the results of this and further stud-
ies, IGF-I receptor blockers are being developed as drugs for 
cancer therapy (Shevah & Laron, 2006)
What is the link between GH and cancer? 
Data suggest that the GH/IGF-1 axis shows an important role 
in cancer.
Growth Hormone does not have the ability to induce cancer, 
but it has cancer-enhancing properties. There are many differ-
ent factors that influence the different effects of the IGF-1. The 
powerful effects of IGF-1 on the stages of cancer development 
and behavior include “cellular proliferation and apoptosis, an-
giogenesis and metastasis…” Additionally, IGF-1 is a powerful 
antiapoptotic agent. These opposing effects relate strongly to 
cancer. Firstly, there is increased proliferation causing epithe-
lial cell turnover within tissues. Secondly, there is an imbalance 
in the control between proliferation and cell death because of 
the anti-apoptotic effects which leads to hyperproliferation. 
This is the first stage of development of many cancers. Thirdly, 
this imbalance between cell proliferation and cell death causes 
the favoring of cell survival even in damaged cells. This could 
Prevalence of malignancy in the surveyed subjects
Diagnosis Patients Malignacy Relatives Malignacy
Israeli Cohort
Laron syndrom n=40a 0 n=99 n=24(24.2%)
M:F 18:22 2:49:00 15:08
Age Range 3–75 19–91 42–81
Mean age 32.3 55.4 51
Other diagnosis n=22 0 n=83 n=7(10%)
M:F 13:09 19:40:00 3:04
Age Range 3–56 5–93 32–80
Mean Age 27 51.4 64.8
Other Countries
Laron syndrom n=129 0 n=151 n=17(11.2%)
M:F 59:70 78:73 8:09
Age Range 6–78 27–68 45–85
Mean Age 16 50 68
Other diagnosis n=31 0 n=5 n=3
M:F 19:12 3:02 2:01
Age Range 2.5–50 40–80 68–80
Mean Age 16.8 60 65
(Laron & Shevah, 2006)
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accelerate carcinogenesis. Both the second and third point are 
ways that cancer is accelerated not initiated (Puche & Castile-
Cortazar, 2012).
Research in epidemiological studies have shown a correlation 
between the role of GH and carcinogenesis. People with more 
growth hormone are naturally taller.  The Boyd-Orr study 
showed an SD of 1 inch height to be linked with a 42% higher 
risk of cancer later in life in boys. High birth weight, high stature 
at 14, low body mass index, and peak growth at early age were 
independent risk factors for breast cancer. (Jenkins et. al., 2005) 
Epidemiological date found a correlation between adult height 
and cancer. An increase in breast cancer by 22 % was noted with 
increased height. These studies suggest that the GH/IGF-1 axis 
plays an important role in cancer development and behavior 
(Jenkins et. al., 2005). Many pharmaceutical companies are creat-
ing drugs that inhibit the IGF-1 signaling to inhibit breast cancer 
proliferation and block the mitogenic effects of exogenous IGF-
1. They are also experimenting with Inhibitors of the IGF-IR as a 
chemotherapeutic (Jenkins et. al., 2005).
Studies on mice were done to provide evidence to this rela-
tionship. Transgenic mice with human GH and agonist for the 
IGF-1 receptor have increased incidence of breast tumor de-
velopment. On the other hand, mice with a non-functioning GH 
receptor (serum GH/IGH-1 levels of ten percent the normal), 
showed inhibition of growth of transplanted breast cancer cells. 
Even the serum was less mitogenic to breast cancer cells in 
vitro than a control serum, this changed once IGF-1 was added 
to the serum. Recent studies have shown that mice transfected 
with growth hormone receptor antagonists have less incidences 
of carcinogenesis (Guevara-Aguirre et. al., 2011). 
Another study done on mice was used to prove the influen-
tial effects IGF-1 exerts on the metastatic power of cancers 
(Guevara-Aguirre et. al., 2011). This is an extremely important 
aspect of cancer as the metastatic spread of cancer is usually 
what causes mortality. A cell from the LCC6 metastatic breast 
cancer cell line was transfected with a truncated IGF-1 receptor 
that silenced the expression of IGF-1 receptor and inhibited 
IGF-1 signaling. These cells were transplanted into mice and the 
metastatic spread was measured. Mice that were transplanted 
with wild type cells had multiple pulmonary metastases, but the 
mice transplanted with the transfected cells were completely 
absent of any metastases (Guevara-Aguirre et. al., 2011).  
Another reason how the GH/IGF-1 axis can cause cancer is 
by promoting an increased DNA damage. Experiments on 
Saccharomyces cerevisiae yeast indicate that mammalian growth 
signaling pathway genes promote an increase in DNA muta-
tions by elevating superoxide production and increasing DNA 
damage. This is particularly important because it hypothesizes 
that, in addition to the possibility that the GH/IGF-1 axis may 
promote cancer by preventing apoptosis of the damaged cells, 
it can increase DNA damage in cells that can ultimately lead 
to cancer. To test this hypothesis, human mammary epithelial 
cells (HMECs) were placed in a medium that contained 15% 
serum from either Laron syndrome subjects or their relatives. 
The cells were then treated with H2O2 followed by comet anal-
ysis to detect DNA strand breaks. The comet analysis indicated 
that cells incubated in serum from GHRD patients had fewer 
DNA breaks after treatment in comparison to cells incubated in 
serum from relatives. This teaches that serum from GHRD sub-
jects can protect against oxidative DNA damage independently 
of cell division. It was determined that that IGF-1 signaling was 
responsible for the sensitization of cells to oxidative damage via 
analysis of DNA damage in MEF cells lacking the IGF-R or over-
expressing the human IGF-1R cell (R+ cells). R+ cells had more 
DNA damage than did R-cells. (Guevara-Aguirre et. al., 2011).
A study done by Wang and colleagues on rats explains that 
down-regulation of GH signaling could block carcinogenesis in 
rats. Human prostate cancer cell lines express GH receptors 
at levels greater than normal.  A rat that does not have GH 
because of a mutation was crossed with the Probasin/Tag rat, 
a rat which develops prostate carcinomas at 100% incidence 
rate. The rats that were homozygous for the GH deficiency had 
prostrate tumor incidence and tumor latency reduced relative 
to wild type rats. At 25 weeks of age, the rats with no GHR 
resulted in a 20% and 80% decrease of carcinoma in the dorsal 
and lateral lobes, respectively. At 52 weeks of age, invasive pros-
tate adenocarcinomas were observed in all Probasin/ Tag rats 
positive for the Growth Hormone. Conversely, majority of the 
Tag rats with the mutation that makes them GH deficient did 
not develop invasive tumors (Wang et. al. 2008).
The potent antiapoptotic and mitogenic properties of IGF-1 
is linked to an increased risk in developing cancer. It is docu-
mented that IGF-1 can promote carcinogenesis at the cellular 
(Svensson et. al., 2012)
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level, but evidence is accumulating that circulating IGF-1 can 
also promote carcinogenesis. For example, reduction of IGF-1 
by dietary restriction slows tumor progression and increase 
apoptosis in tumor cells of animal models. And when these 
models were treated with recombinant IGF-1 the effects were 
reversed. Additionally, IGF-1 gene deletion in mice is linked to 
a 75% decrease in circulating IGF-1 levels. Tumor growth and 
development was much higher in the control group than trans-
genic mice. 
Biological interactions among insulin, IGF-1 and 
IGFPBS
As stated above there are many clinical studies that suggest that 
high serum IGF-1 levels associate with increased risk of cancer. 
Increasing clinical evidence suggests that low IGF-1 levels are as-
sociated with cancer mortality in older men. In numerous stud-
ies, the association between circulating IGF-1 levels and cancer 
mortality was U-shaped with increased levels of mortality at 
both the low and high serum IGF-1 levels.
Serum IGF-1 was extracted from the blood of a large cohort of 
elderly men from Sweden. The measurements of serum IGF-1 
levels were obtained. The reason for mortality was documented 
on the death certificate of the subjects and then used in the 
study. Cox proportional hazards was used to analyze the associ-
ation between serum IGF-1 levels and mortality by cancer. Cox 
regression analysis showed that both low and high serum IGF-1 
concentration was associated with increased cancer mortality. 
The patients with a history of cancer were excluding from the 
analysis (Svensson et al, 2012).
IGF-1R Inhibitors as an Anti-Cancer
Because of the role that IGF signaling plays in the promotion 
of cell growth and inhibition of apoptosis, IGF blocking is being 
developed as a therapeutic potential to protect against cancer. 
Currently there are many clinical studies targeting and inhib-
iting the IGF pathway to promote anti-tumor activities. There 
are three main classes of IGF/IGF-1R inhibitor antibodies being 
studied in clinical trials; each class inhibits IGF-1R signaling 
but through different mechanisms. There has been some small 
success in treating patients with select tumor types, but many 
trials have been unsuccessful. Researchers are trying to identify 
patient selection markers to attain future success in IGF-1R in-
hibitor development (Chen & Sharon, 2013).
IGF blocking is also being used to overcome chemotherapy 
sensitivity. Resistance to chemotherapy is common nowadays. 
IGF is implicated in chemotherapy resistance because it pro-
motes proliferation and inhibits apoptosis.  Researchers have 
tested this hypothesis and have found that IGF-1R inhibitors 
have caused significant tumor growth inhibition. Currently, 
researchers are testing the combined effect of IGF-1R inhibitors 
with a chemotherapeutic (Weroha & Haluska, 2008).
Conclusion
Laron Syndrome subjects participate in groundbreaking genetic 
studies to explore the relationship between the deficiency in 
the growth hormone receptor and immunity to cancer. This 
syndrome is providing insight to, and revolutionizing, the way 
cancer is treated and prevented. Because Laron Syndrome sub-
jects have decreased levels of IGF-1 they are protected against 
numerous and potentially harmful effects of IGF-1 including cel-
lular proliferation, apoptosis, angiogenesis, and metastasis. The 
increased proliferation and decreased apoptosis causes survival 
of damaged cells that then spread easily throughout the body, 
which could lead to the development of cancer. Because Laron 
Syndrome subjects have decreased levels of IGF-1 they are 
immune to cancer.  The implications of IGF/IGF-1R in cancer 
development, maintenance, and progression, is what led to rep-
licating the IGF-1 levels of LS patients to use as an anti-cancer 
target. IGF-1 has been successfully inhibited in animal models to 
prevent cancer cell growth. Now researchers are beginning to 
use IGF-1 reducing agents and blockers as a chemotherapeutic 
to prevent cancer.
Abbreviations
IGF-1 Insulin Growth Factor 1
LS Laron Syndrome
GH Growth Hormone
GHR Growth Hormone Receptor
GHD Growth Hormone Deficiency
GHRD Growth Hormone Receptor Deficiency
CNS Central Nervous System
rhIGF-1 Recombinant Human Insulin Growth Factor 1
IGFBP Insulin Growth Factor Binding Proteins
HMEC Human Mammary Epithelial Cells
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